1AYJ is a 50-amino acid peptide with the sequence QKLCERPSGTWSGVCGNNNACKNQCINLEKARHGSCNYVFPAHKCICYFPC. This peptide contains multiple cysteine residues suggesting a complex disulfide bond structure that likely contributes to its stability and biological activity. Based on its sequence characteristics and structural features, 1AYJ appears to be a research peptide that may have therapeutic potential. The presence of multiple cysteine residues and specific amino acid motifs suggests it could interact with various biological targets and pathways. Currently, this peptide appears to be in early research phases with limited published data available. The peptide's structure indicates it may have applications in tissue repair, wound healing, or other regenerative processes, though comprehensive clinical studies are needed to establish its efficacy and safety profile. As with many research peptides, 1AYJ requires further investigation to fully understand its mechanisms of action and therapeutic potential.
Key Benefits
Overview
1AYJ is a 50-amino acid peptide with the sequence QKLCERPSGTWSGVCGNNNACKNQCINLEKARHGSCNYVFPAHKCICYFPC. This peptide contains multiple cysteine residues suggesting a complex disulfide bond structure that likely contributes to its stability and biological activity. Based on its sequence characteristics and structural features, 1AYJ appears to be a research peptide that may have therapeutic potential. The presence of multiple cysteine residues and specific amino acid motifs suggests it could interact with various biological targets and pathways. Currently, this peptide appears to be in early research phases with limited published data available. The peptide's structure indicates it may have applications in tissue repair, wound healing, or other regenerative processes, though comprehensive clinical studies are needed to establish its efficacy and safety profile. As with many research peptides, 1AYJ requires further investigation to fully understand its mechanisms of action and therapeutic potential.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 1AYJ likely functions through multiple disulfide bond formations due to its high cysteine content, which creates a stable three-dimensional structure essential for biological activity. The peptide may interact with specific cell surface receptors or intracellular targets to modulate cellular signaling pathways. The presence of basic amino acids like lysine and arginine suggests potential for cell membrane interaction and cellular uptake. The peptide's structure may enable it to influence protein-protein interactions, enzyme activity, or gene expression. Without specific research data, the exact molecular targets and signaling cascades remain to be elucidated through further biochemical and pharmacological studies.
Risks & Safety
Legal Status
1B1I is a research peptide with a complex 128-amino acid sequence containing multiple functional domains. Based on its structural characteristics, including the presence of cysteine residues that likely form disulfide bonds and various charged amino acid clusters, this peptide appears to have potential biological activity. The sequence suggests possible interactions with cellular receptors or enzymatic pathways, though specific mechanisms remain to be fully elucidated. Currently in early research phases, 1B1I represents an investigational compound that may have applications in various therapeutic areas. The peptide's relatively long sequence and complex structure indicate it could function as a bioactive molecule with multiple targets. Without extensive published research data, the full therapeutic potential and safety profile of 1B1I remain under investigation. As with many research peptides, 1B1I is primarily of interest to researchers studying novel therapeutic approaches and is not approved for human therapeutic use. Further studies are needed to determine its specific biological functions, optimal dosing, and clinical applications.
Key Benefits
Overview
1B1I is a research peptide with a complex 128-amino acid sequence containing multiple functional domains. Based on its structural characteristics, including the presence of cysteine residues that likely form disulfide bonds and various charged amino acid clusters, this peptide appears to have potential biological activity. The sequence suggests possible interactions with cellular receptors or enzymatic pathways, though specific mechanisms remain to be fully elucidated. Currently in early research phases, 1B1I represents an investigational compound that may have applications in various therapeutic areas. The peptide's relatively long sequence and complex structure indicate it could function as a bioactive molecule with multiple targets. Without extensive published research data, the full therapeutic potential and safety profile of 1B1I remain under investigation. As with many research peptides, 1B1I is primarily of interest to researchers studying novel therapeutic approaches and is not approved for human therapeutic use. Further studies are needed to determine its specific biological functions, optimal dosing, and clinical applications.
Potential Benefits
Mechanism of Action
The mechanism of action for 1B1I is not well-established in current literature. Based on its amino acid sequence analysis, the peptide contains multiple functional domains that suggest potential interactions with cellular receptors or signaling pathways. The presence of cysteine residues indicates possible disulfide bond formation, which could stabilize the peptide's three-dimensional structure and enhance its biological activity. The sequence contains charged amino acid clusters that may facilitate binding to specific cellular targets. The peptide may modulate intracellular signaling cascades, though the specific pathways involved require further investigation. Potential mechanisms could include receptor binding, enzyme modulation, or direct cellular membrane interactions, but these remain speculative without detailed experimental validation.
Risks & Safety
Legal Status
1BBC is a research peptide with a complex 127-amino acid sequence containing multiple cysteine residues that likely form disulfide bonds, suggesting a structured protein with potential biological activity. The peptide sequence includes regions that may interact with cellular receptors or signaling pathways. Currently classified as a research chemical, 1BBC appears to be in early investigational phases with limited published clinical data. The peptide's structure suggests potential applications in tissue repair and cellular regeneration processes, though comprehensive studies are needed to establish its therapeutic profile. As with many research peptides, 1BBC represents an emerging compound in the peptide research landscape, requiring further investigation to determine its full biological potential and safety profile. The complex structure indicates possible multi-target activity, which could provide diverse therapeutic applications but also necessitates careful evaluation of its pharmacological properties.
Key Benefits
Overview
1BBC is a research peptide with a complex 127-amino acid sequence containing multiple cysteine residues that likely form disulfide bonds, suggesting a structured protein with potential biological activity. The peptide sequence includes regions that may interact with cellular receptors or signaling pathways. Currently classified as a research chemical, 1BBC appears to be in early investigational phases with limited published clinical data. The peptide's structure suggests potential applications in tissue repair and cellular regeneration processes, though comprehensive studies are needed to establish its therapeutic profile. As with many research peptides, 1BBC represents an emerging compound in the peptide research landscape, requiring further investigation to determine its full biological potential and safety profile. The complex structure indicates possible multi-target activity, which could provide diverse therapeutic applications but also necessitates careful evaluation of its pharmacological properties.
Potential Benefits
Mechanism of Action
Based on the peptide's complex structure containing multiple cysteine residues and potential disulfide bonds, 1BBC likely functions through receptor-mediated signaling pathways. The structured nature of the peptide suggests it may interact with specific cellular receptors to modulate intracellular signaling cascades. The presence of charged amino acids and hydrophobic regions indicates potential membrane interactions and cellular uptake mechanisms. The peptide may influence protein synthesis, cellular repair processes, or growth factor signaling pathways, though specific receptor targets and downstream effects require further characterization through detailed biochemical studies.
Risks & Safety
Legal Status
1BH4, also known as Circulin A, is a 30-residue natural plant polypeptide derived from Chassalia parvifolia with the sequence GIPCGESCVWIPCISAALGCSCKNKVCYRN. This cyclotide belongs to a class of naturally occurring circular peptides that serve as plant defensive compounds. Circulin A demonstrates dual antimicrobial and antiviral properties, showing particular promise as an inhibitor of human immunodeficiency virus (HIV) replication through its cytopathic effects. The peptide's unique circular structure, stabilized by disulfide bonds, makes it an attractive scaffold for therapeutic peptide design. Current research focuses on its structural stability and potential as a template for developing antimicrobial and antiviral drugs. Computational studies have evaluated its molecular dynamics, including parameters such as root mean square deviation, hydrogen bonding patterns, and membrane-associated interactions. While Circulin A shows therapeutic potential, comparative studies suggest that related peptides like Circulin B may offer superior stability profiles. The peptide represents an important example of how natural plant defense mechanisms can be harnessed for pharmaceutical applications, particularly in the development of novel antimicrobial and antiviral therapeutics.
Key Benefits
Overview
1BH4, also known as Circulin A, is a 30-residue natural plant polypeptide derived from Chassalia parvifolia with the sequence GIPCGESCVWIPCISAALGCSCKNKVCYRN. This cyclotide belongs to a class of naturally occurring circular peptides that serve as plant defensive compounds. Circulin A demonstrates dual antimicrobial and antiviral properties, showing particular promise as an inhibitor of human immunodeficiency virus (HIV) replication through its cytopathic effects. The peptide's unique circular structure, stabilized by disulfide bonds, makes it an attractive scaffold for therapeutic peptide design. Current research focuses on its structural stability and potential as a template for developing antimicrobial and antiviral drugs. Computational studies have evaluated its molecular dynamics, including parameters such as root mean square deviation, hydrogen bonding patterns, and membrane-associated interactions. While Circulin A shows therapeutic potential, comparative studies suggest that related peptides like Circulin B may offer superior stability profiles. The peptide represents an important example of how natural plant defense mechanisms can be harnessed for pharmaceutical applications, particularly in the development of novel antimicrobial and antiviral therapeutics.
Potential Benefits
Mechanism of Action
Circulin A operates through multiple molecular mechanisms primarily centered on its unique cyclotide structure stabilized by disulfide bonds. The peptide exerts antimicrobial activity through membrane interactions, with computational studies showing membrane-associated free energy values that facilitate cellular penetration. Its antiviral mechanism against HIV involves inhibitory cytopathic effects on viral replication, likely through interference with viral entry or replication machinery. The circular peptide structure provides exceptional stability through intramolecular interactions, with studies documenting specific hydrogen bond distributions and disulfide bond distances that maintain structural integrity. The peptide's hydrophobic regions (approximately 67% hydrophobicity) enable membrane association and penetration, while polar regions facilitate specific molecular interactions. Secondary structure elements contribute to its biological activity through conformational stability and target recognition. The mechanism involves both direct antimicrobial effects through membrane disruption and specific antiviral activity through interference with HIV replication cycles.
Risks & Safety
Legal Status
1BHP is a synthetic peptide with the sequence KSCCKSTLGRNCYNLCRARGAQKLCANVCRCKLTSGLSCPKDFPK, characterized by multiple cysteine residues that likely form disulfide bonds creating a stable, constrained structure. Based on its amino acid composition and structural features, this peptide appears to be designed for potential therapeutic applications, though specific research data is currently limited. The presence of multiple cysteine residues suggests it may have antimicrobial or tissue-protective properties, as many cysteine-rich peptides exhibit such activities. The peptide contains basic residues (lysine and arginine) which may facilitate cellular uptake or membrane interactions. Current research status appears to be in early phases, with minimal published data available. The peptide's structure suggests potential applications in wound healing, antimicrobial therapy, or tissue repair, though comprehensive clinical studies are needed to establish efficacy and safety profiles. Further research is required to fully characterize its biological activities and therapeutic potential.
Key Benefits
Overview
1BHP is a synthetic peptide with the sequence KSCCKSTLGRNCYNLCRARGAQKLCANVCRCKLTSGLSCPKDFPK, characterized by multiple cysteine residues that likely form disulfide bonds creating a stable, constrained structure. Based on its amino acid composition and structural features, this peptide appears to be designed for potential therapeutic applications, though specific research data is currently limited. The presence of multiple cysteine residues suggests it may have antimicrobial or tissue-protective properties, as many cysteine-rich peptides exhibit such activities. The peptide contains basic residues (lysine and arginine) which may facilitate cellular uptake or membrane interactions. Current research status appears to be in early phases, with minimal published data available. The peptide's structure suggests potential applications in wound healing, antimicrobial therapy, or tissue repair, though comprehensive clinical studies are needed to establish efficacy and safety profiles. Further research is required to fully characterize its biological activities and therapeutic potential.
Potential Benefits
Mechanism of Action
Based on the peptide's structure containing multiple cysteine residues, 1BHP likely functions through disulfide bond formation creating a stable tertiary structure that may interact with specific cellular targets. The presence of positively charged residues (lysine and arginine) suggests potential electrostatic interactions with negatively charged cell membranes or proteins. The constrained structure formed by disulfide bonds may enable specific receptor binding or enzyme inhibition. Cysteine-rich peptides often exhibit antimicrobial activity by disrupting bacterial cell membranes or interfering with essential cellular processes. The peptide may also modulate inflammatory pathways or promote tissue repair through growth factor-like activities, though specific molecular targets and signaling pathways remain to be fully elucidated through detailed biochemical studies.
Risks & Safety
Legal Status
1BRZ is a 54-amino acid peptide with the sequence QDKCKKVYENYPVSKCQLANQCNYDCKLDKHARSGECFYDEKRNLQCICDYCEY. Based on its structural characteristics, this peptide contains multiple cysteine residues that likely form disulfide bonds, creating a stable, compact structure typical of bioactive peptides. The presence of charged residues (lysine, aspartic acid) and aromatic amino acids (tyrosine, phenylalanine) suggests potential for receptor binding and biological activity. While specific research data is limited, the peptide's structure indicates it may function as a signaling molecule or have therapeutic applications. The multiple cysteine residues and overall composition are characteristic of peptides involved in cellular communication, tissue repair, or immune modulation. Further research is needed to fully characterize its biological functions, safety profile, and therapeutic potential. The peptide appears to be in early research phases, with its specific mechanisms and clinical applications still under investigation.
Key Benefits
Overview
1BRZ is a 54-amino acid peptide with the sequence QDKCKKVYENYPVSKCQLANQCNYDCKLDKHARSGECFYDEKRNLQCICDYCEY. Based on its structural characteristics, this peptide contains multiple cysteine residues that likely form disulfide bonds, creating a stable, compact structure typical of bioactive peptides. The presence of charged residues (lysine, aspartic acid) and aromatic amino acids (tyrosine, phenylalanine) suggests potential for receptor binding and biological activity. While specific research data is limited, the peptide's structure indicates it may function as a signaling molecule or have therapeutic applications. The multiple cysteine residues and overall composition are characteristic of peptides involved in cellular communication, tissue repair, or immune modulation. Further research is needed to fully characterize its biological functions, safety profile, and therapeutic potential. The peptide appears to be in early research phases, with its specific mechanisms and clinical applications still under investigation.
Potential Benefits
Mechanism of Action
Based on the peptide's amino acid composition and structure, 1BRZ likely functions through receptor-mediated signaling pathways. The multiple cysteine residues suggest formation of disulfide bonds that create a stable three-dimensional structure necessary for specific receptor binding. The presence of charged amino acids (lysine and aspartic acid) may facilitate electrostatic interactions with target receptors, while aromatic residues (tyrosine and phenylalanine) could contribute to hydrophobic binding interactions. The peptide may activate intracellular signaling cascades upon receptor binding, potentially involving protein kinase pathways, cyclic nucleotide systems, or calcium-dependent mechanisms. The specific sequence suggests it could modulate cellular processes such as proliferation, differentiation, or inflammatory responses through downstream signaling events.
Risks & Safety
Legal Status
1C01 is a 75-amino acid peptide with the sequence SAFTVWSGPGCNNRAERYSKCGCSAIHQKGGYDFSYTGQTAALYNQAGCSGVAHTRFGSSARACNPFGWKSIFIQC. This peptide contains multiple cysteine residues suggesting potential disulfide bond formation and structural complexity. Currently in Phase 1 minimal catalog extraction, limited research data is available specifically for this peptide. The provided research context primarily focuses on epidemiological modeling rather than direct peptide research. The peptide's structure suggests it may have bioactive properties typical of cysteine-rich peptides, which often exhibit antimicrobial, wound healing, or tissue repair functions. Further research is needed to establish its specific biological activities, mechanism of action, and therapeutic potential. The presence of multiple functional amino acid residues including aromatic residues (tryptophan, tyrosine, phenylalanine) and charged residues suggests potential for protein-protein interactions and biological activity.
Key Benefits
Overview
1C01 is a 75-amino acid peptide with the sequence SAFTVWSGPGCNNRAERYSKCGCSAIHQKGGYDFSYTGQTAALYNQAGCSGVAHTRFGSSARACNPFGWKSIFIQC. This peptide contains multiple cysteine residues suggesting potential disulfide bond formation and structural complexity. Currently in Phase 1 minimal catalog extraction, limited research data is available specifically for this peptide. The provided research context primarily focuses on epidemiological modeling rather than direct peptide research. The peptide's structure suggests it may have bioactive properties typical of cysteine-rich peptides, which often exhibit antimicrobial, wound healing, or tissue repair functions. Further research is needed to establish its specific biological activities, mechanism of action, and therapeutic potential. The presence of multiple functional amino acid residues including aromatic residues (tryptophan, tyrosine, phenylalanine) and charged residues suggests potential for protein-protein interactions and biological activity.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 1C01 likely functions through protein-protein interactions facilitated by its cysteine-rich structure. The multiple cysteine residues suggest formation of disulfide bonds that stabilize the peptide's tertiary structure, potentially creating binding sites for cellular receptors. The aromatic amino acids (tryptophan, tyrosine, phenylalanine) may facilitate hydrophobic interactions with membrane proteins or intracellular targets. The presence of charged residues (arginine, lysine, glutamic acid) suggests potential for electrostatic interactions with negatively charged cellular components. However, specific receptor targets, signaling pathways, and downstream biological effects remain to be characterized through dedicated research studies.
Risks & Safety
Legal Status
1CW5 is a synthetic peptide with the sequence VNYGNGVSCSKTKCSVNWGQAFQERYTAGINSFVSGVASGAGSIGRRP. This peptide appears to be a research compound that is currently in early-phase investigation. Based on its structural characteristics and sequence composition, 1CW5 contains multiple cysteine residues which suggest potential disulfide bond formation and structural stability. The peptide includes various amino acid motifs that may interact with biological receptors or cellular pathways. Currently classified as a Phase 1 minimal catalog extraction compound, indicating limited published research data is available. The peptide's specific biological targets and therapeutic applications remain under investigation. Its complex sequence suggests potential applications in tissue repair, cellular signaling, or regenerative medicine, though comprehensive clinical data is not yet available. Further research is needed to fully characterize its pharmacological properties, safety profile, and therapeutic potential.
Key Benefits
Overview
1CW5 is a synthetic peptide with the sequence VNYGNGVSCSKTKCSVNWGQAFQERYTAGINSFVSGVASGAGSIGRRP. This peptide appears to be a research compound that is currently in early-phase investigation. Based on its structural characteristics and sequence composition, 1CW5 contains multiple cysteine residues which suggest potential disulfide bond formation and structural stability. The peptide includes various amino acid motifs that may interact with biological receptors or cellular pathways. Currently classified as a Phase 1 minimal catalog extraction compound, indicating limited published research data is available. The peptide's specific biological targets and therapeutic applications remain under investigation. Its complex sequence suggests potential applications in tissue repair, cellular signaling, or regenerative medicine, though comprehensive clinical data is not yet available. Further research is needed to fully characterize its pharmacological properties, safety profile, and therapeutic potential.
Potential Benefits
Mechanism of Action
The mechanism of action for 1CW5 is not fully characterized due to limited research data. Based on its amino acid sequence, the peptide likely interacts with specific cellular receptors or signaling pathways. The presence of cysteine residues suggests the formation of disulfide bonds, which may contribute to structural stability and receptor binding affinity. The peptide may modulate cellular processes through receptor-mediated signaling cascades, potentially affecting gene expression, protein synthesis, or cellular metabolism. Without specific research data, the exact molecular targets and biological pathways remain to be determined through further investigation.
Risks & Safety
Legal Status
1D6X is a synthetic peptide with the sequence VRRFPWWWPFLRR, characterized by multiple tryptophan residues and basic amino acids. This peptide appears to be in early research phases with limited published data available. The sequence suggests potential antimicrobial properties due to its cationic nature and tryptophan content, which are common features in antimicrobial peptides. The presence of multiple arginine residues may facilitate cellular uptake and membrane interaction. Currently, 1D6X exists primarily as a research compound with minimal clinical data. Its specific biological targets and therapeutic applications remain under investigation. The peptide's structure suggests it may interact with cellular membranes or specific protein targets, though comprehensive mechanistic studies are lacking. Given the limited research data available, most information about 1D6X remains theoretical based on its amino acid composition and structural predictions. Further research is needed to establish its safety profile, efficacy, and potential therapeutic applications. The peptide represents an area of ongoing scientific interest but requires substantial additional study before any clinical applications can be considered.
Key Benefits
Overview
1D6X is a synthetic peptide with the sequence VRRFPWWWPFLRR, characterized by multiple tryptophan residues and basic amino acids. This peptide appears to be in early research phases with limited published data available. The sequence suggests potential antimicrobial properties due to its cationic nature and tryptophan content, which are common features in antimicrobial peptides. The presence of multiple arginine residues may facilitate cellular uptake and membrane interaction. Currently, 1D6X exists primarily as a research compound with minimal clinical data. Its specific biological targets and therapeutic applications remain under investigation. The peptide's structure suggests it may interact with cellular membranes or specific protein targets, though comprehensive mechanistic studies are lacking. Given the limited research data available, most information about 1D6X remains theoretical based on its amino acid composition and structural predictions. Further research is needed to establish its safety profile, efficacy, and potential therapeutic applications. The peptide represents an area of ongoing scientific interest but requires substantial additional study before any clinical applications can be considered.
Potential Benefits
Mechanism of Action
Based on the peptide sequence VRRFPWWWPFLRR, 1D6X likely functions through membrane interaction mechanisms. The multiple arginine residues provide positive charge that may facilitate binding to negatively charged cell membranes or specific receptor sites. The tryptophan residues can insert into lipid bilayers and may contribute to membrane disruption or stabilization depending on the target. The peptide may act through cell-penetrating mechanisms due to its cationic nature, potentially allowing intracellular delivery of therapeutic effects. However, specific receptor interactions, signaling pathways, and downstream biological processes have not been well-characterized in available literature. The mechanism likely involves direct membrane contact and possible internalization, though detailed molecular pathways remain to be elucidated through further research.
Risks & Safety
Legal Status
1DKC is a 38-amino acid peptide with the sequence AGCIKNGGRCNASAGPPYCCSSYCFQIAGQSYGVCKNR. Based on its structural characteristics, this peptide contains multiple cysteine residues that likely form disulfide bonds, creating a stable, compact structure typical of bioactive peptides. The presence of multiple cysteine residues suggests it may belong to a family of cysteine-rich peptides that often exhibit antimicrobial, wound healing, or tissue repair properties. Currently in Phase 1 minimal catalog extraction, limited research data is available regarding its specific biological functions and therapeutic applications. The peptide's structure suggests potential roles in cellular signaling, tissue regeneration, or antimicrobial activity, though comprehensive studies are needed to establish its precise mechanisms and clinical efficacy. Further research is required to fully characterize its pharmacological properties and therapeutic potential.
Key Benefits
Overview
1DKC is a 38-amino acid peptide with the sequence AGCIKNGGRCNASAGPPYCCSSYCFQIAGQSYGVCKNR. Based on its structural characteristics, this peptide contains multiple cysteine residues that likely form disulfide bonds, creating a stable, compact structure typical of bioactive peptides. The presence of multiple cysteine residues suggests it may belong to a family of cysteine-rich peptides that often exhibit antimicrobial, wound healing, or tissue repair properties. Currently in Phase 1 minimal catalog extraction, limited research data is available regarding its specific biological functions and therapeutic applications. The peptide's structure suggests potential roles in cellular signaling, tissue regeneration, or antimicrobial activity, though comprehensive studies are needed to establish its precise mechanisms and clinical efficacy. Further research is required to fully characterize its pharmacological properties and therapeutic potential.
Potential Benefits
Mechanism of Action
Based on the peptide's cysteine-rich structure, 1DKC likely functions through disulfide bond formation that creates a stable three-dimensional conformation essential for biological activity. The multiple cysteine residues in the sequence suggest the peptide may interact with specific cellular receptors or membrane components. The presence of charged amino acids like lysine and arginine indicates potential electrostatic interactions with negatively charged cell surfaces or receptor binding sites. The peptide may modulate cellular signaling pathways involved in tissue repair, immune responses, or antimicrobial defense mechanisms. Without specific research data, the exact molecular targets and signaling cascades remain to be determined through further investigation.
Risks & Safety
Legal Status
1E4S is a synthetic peptide with the sequence DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK, containing 35 amino acids with multiple cysteine residues that likely form disulfide bonds creating a stable tertiary structure. Based on its structural characteristics, this peptide appears to be designed for research applications, though specific clinical data is currently limited. The presence of multiple cysteine residues suggests it may have antimicrobial or tissue-protective properties similar to other cysteine-rich peptides. The peptide's unique sequence and structure indicate potential applications in wound healing, tissue repair, and possibly immune modulation. Current research status appears to be in early investigational phases, with limited published clinical data available. The peptide's design suggests it may interact with cellular receptors or have direct antimicrobial effects, though specific mechanisms require further investigation. As with many synthetic peptides, 1E4S represents an area of active research interest for potential therapeutic applications, particularly in regenerative medicine and tissue repair applications.
Key Benefits
Overview
1E4S is a synthetic peptide with the sequence DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK, containing 35 amino acids with multiple cysteine residues that likely form disulfide bonds creating a stable tertiary structure. Based on its structural characteristics, this peptide appears to be designed for research applications, though specific clinical data is currently limited. The presence of multiple cysteine residues suggests it may have antimicrobial or tissue-protective properties similar to other cysteine-rich peptides. The peptide's unique sequence and structure indicate potential applications in wound healing, tissue repair, and possibly immune modulation. Current research status appears to be in early investigational phases, with limited published clinical data available. The peptide's design suggests it may interact with cellular receptors or have direct antimicrobial effects, though specific mechanisms require further investigation. As with many synthetic peptides, 1E4S represents an area of active research interest for potential therapeutic applications, particularly in regenerative medicine and tissue repair applications.
Potential Benefits
Mechanism of Action
Based on the structural characteristics of 1E4S, the peptide likely functions through multiple disulfide bond formation due to its high cysteine content, creating a stable three-dimensional structure that may interact with specific cellular receptors or membrane components. The peptide may exert its effects through direct binding to cell surface receptors, potentially modulating intracellular signaling pathways involved in tissue repair and regeneration. The presence of charged amino acids suggests possible electrostatic interactions with cellular membranes or proteins. The peptide may also function through antimicrobial mechanisms, disrupting bacterial cell walls or interfering with pathogen cellular processes. Additionally, the structured nature of the peptide suggests it could modulate immune responses by interacting with immune cell receptors or cytokine pathways, though specific receptor targets and downstream signaling cascades require further characterization through detailed biochemical studies.
Risks & Safety
Legal Status
1FD3 is a synthetic peptide with the sequence GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP, containing 39 amino acids with multiple cysteine residues that likely form disulfide bonds for structural stability. Based on its sequence characteristics and structural features, this peptide appears to be designed for research applications, though specific clinical data is currently limited. The presence of multiple cysteine residues suggests it may have a stable, constrained structure typical of bioactive peptides. The peptide's composition includes charged residues and hydrophobic regions that could facilitate cellular interactions and biological activity. Currently classified as being in Phase 1 minimal catalog extraction, indicating early-stage research status. The peptide's structure suggests potential applications in various biological processes, though comprehensive clinical studies are needed to fully characterize its therapeutic potential. Research into similar structured peptides indicates possible roles in cellular signaling, tissue repair, or immune modulation, but specific mechanisms for 1FD3 require further investigation. The peptide represents an area of ongoing research interest in the field of therapeutic peptides.
Key Benefits
Overview
1FD3 is a synthetic peptide with the sequence GIGDPVTCLKSGAICHPVFCPRRYKQIGTCGLPGTKCCKKP, containing 39 amino acids with multiple cysteine residues that likely form disulfide bonds for structural stability. Based on its sequence characteristics and structural features, this peptide appears to be designed for research applications, though specific clinical data is currently limited. The presence of multiple cysteine residues suggests it may have a stable, constrained structure typical of bioactive peptides. The peptide's composition includes charged residues and hydrophobic regions that could facilitate cellular interactions and biological activity. Currently classified as being in Phase 1 minimal catalog extraction, indicating early-stage research status. The peptide's structure suggests potential applications in various biological processes, though comprehensive clinical studies are needed to fully characterize its therapeutic potential. Research into similar structured peptides indicates possible roles in cellular signaling, tissue repair, or immune modulation, but specific mechanisms for 1FD3 require further investigation. The peptide represents an area of ongoing research interest in the field of therapeutic peptides.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 1FD3 likely functions through receptor-mediated signaling pathways. The multiple cysteine residues (8 total) suggest formation of disulfide bonds that create a constrained, stable three-dimensional structure essential for biological activity. The presence of charged amino acids (lysine, arginine) may facilitate electrostatic interactions with cell surface receptors or membrane components. The hydrophobic regions could enable membrane penetration or protein-protein interactions. The peptide's structure suggests it may modulate cellular signaling cascades, potentially affecting gene expression, protein synthesis, or enzymatic activities. The specific arrangement of amino acids may allow binding to particular receptor subtypes, triggering downstream signaling events that influence cellular metabolism, growth factors, or inflammatory mediators.
Risks & Safety
Legal Status
1FJN is a synthetic peptide with the sequence GFGCPNNYQCHRHCKSIPGRCGGYCGGWHRLPCTCYRCG, containing multiple cysteine residues that likely form disulfide bonds creating a stable, constrained structure. Based on its amino acid composition and structural characteristics, this peptide appears to be designed as a research compound for investigating peptide-protein interactions or as a potential therapeutic scaffold. The presence of multiple cysteine residues suggests it may have antimicrobial properties, as many cysteine-rich peptides exhibit activity against bacteria and fungi. The peptide's compact, cyclic-like structure due to disulfide bonding may provide enhanced stability and resistance to proteolytic degradation. Currently, 1FJN appears to be in early research phases with limited published data available. Its specific biological targets and mechanisms remain to be fully characterized through ongoing research efforts. The peptide may serve as a template for drug development or as a tool compound for studying specific biological pathways.
Key Benefits
Overview
1FJN is a synthetic peptide with the sequence GFGCPNNYQCHRHCKSIPGRCGGYCGGWHRLPCTCYRCG, containing multiple cysteine residues that likely form disulfide bonds creating a stable, constrained structure. Based on its amino acid composition and structural characteristics, this peptide appears to be designed as a research compound for investigating peptide-protein interactions or as a potential therapeutic scaffold. The presence of multiple cysteine residues suggests it may have antimicrobial properties, as many cysteine-rich peptides exhibit activity against bacteria and fungi. The peptide's compact, cyclic-like structure due to disulfide bonding may provide enhanced stability and resistance to proteolytic degradation. Currently, 1FJN appears to be in early research phases with limited published data available. Its specific biological targets and mechanisms remain to be fully characterized through ongoing research efforts. The peptide may serve as a template for drug development or as a tool compound for studying specific biological pathways.
Potential Benefits
Mechanism of Action
Based on the structural characteristics of 1FJN, the peptide likely functions through its cysteine-rich framework that forms multiple disulfide bonds, creating a stable three-dimensional structure. This constrained conformation may allow for specific binding to target proteins or receptors. The peptide's mechanism may involve interaction with cell surface receptors or intracellular targets, potentially modulating signaling pathways. The presence of charged residues like arginine and histidine suggests possible electrostatic interactions with negatively charged cellular components. If antimicrobial activity is present, the mechanism may involve membrane disruption or interference with essential bacterial processes. The stable disulfide-bonded structure likely provides resistance to enzymatic degradation, allowing for sustained biological activity.
Risks & Safety
Legal Status
1FRY is a synthetic peptide with the sequence RGLRRLGRKIAHGVKKYGPTVLRIIRIAG, consisting of 28 amino acids. This peptide appears to be in early research phases with limited published data available. The sequence contains multiple arginine and lysine residues, suggesting potential for cell membrane interaction and penetration capabilities. The presence of glycine residues may provide structural flexibility, while hydrophobic amino acids like valine, isoleucine, and alanine could facilitate membrane association. Based on its amino acid composition and structural characteristics, 1FRY may have applications in cellular delivery, antimicrobial activity, or tissue repair processes. However, comprehensive research data is currently limited, and the peptide's specific biological targets and therapeutic applications require further investigation. The current research status indicates this is primarily a research-grade compound with potential for various biomedical applications pending additional studies and clinical validation.
Key Benefits
Overview
1FRY is a synthetic peptide with the sequence RGLRRLGRKIAHGVKKYGPTVLRIIRIAG, consisting of 28 amino acids. This peptide appears to be in early research phases with limited published data available. The sequence contains multiple arginine and lysine residues, suggesting potential for cell membrane interaction and penetration capabilities. The presence of glycine residues may provide structural flexibility, while hydrophobic amino acids like valine, isoleucine, and alanine could facilitate membrane association. Based on its amino acid composition and structural characteristics, 1FRY may have applications in cellular delivery, antimicrobial activity, or tissue repair processes. However, comprehensive research data is currently limited, and the peptide's specific biological targets and therapeutic applications require further investigation. The current research status indicates this is primarily a research-grade compound with potential for various biomedical applications pending additional studies and clinical validation.
Potential Benefits
Mechanism of Action
Based on the amino acid sequence analysis, 1FRY likely functions through electrostatic interactions with cell membranes due to its high content of positively charged residues (arginine and lysine). These cationic properties may enable the peptide to interact with negatively charged cell surface components, potentially facilitating cellular uptake or membrane disruption. The peptide may work through direct membrane interaction, possibly forming pores or disrupting membrane integrity in target cells. The presence of hydrophobic residues suggests potential for membrane insertion and stabilization of peptide-membrane complexes. Without specific research data, the exact molecular targets and signaling pathways remain to be determined through future studies.
Risks & Safety
Legal Status
1G2T is a research peptide with a 67-amino acid sequence that appears to be in early-stage investigation. Based on its structural characteristics and sequence composition, this peptide contains multiple functional domains including cysteine residues that may form disulfide bonds, contributing to its structural stability. The presence of basic amino acids like lysine and arginine suggests potential for cellular uptake and membrane interactions. Currently classified as a research compound, 1G2T lacks extensive published clinical data, making it primarily of interest for experimental applications. The peptide's complex structure indicates it may have multiple biological targets and pathways of action. Without comprehensive clinical trials or established therapeutic protocols, its safety profile and optimal dosing remain undefined. Research into this peptide is still in preliminary phases, with limited peer-reviewed studies available to establish definitive mechanisms of action or clinical efficacy. As with many research peptides, 1G2T represents an area of ongoing scientific investigation where future studies may reveal specific therapeutic applications and biological functions.
Key Benefits
Overview
1G2T is a research peptide with a 67-amino acid sequence that appears to be in early-stage investigation. Based on its structural characteristics and sequence composition, this peptide contains multiple functional domains including cysteine residues that may form disulfide bonds, contributing to its structural stability. The presence of basic amino acids like lysine and arginine suggests potential for cellular uptake and membrane interactions. Currently classified as a research compound, 1G2T lacks extensive published clinical data, making it primarily of interest for experimental applications. The peptide's complex structure indicates it may have multiple biological targets and pathways of action. Without comprehensive clinical trials or established therapeutic protocols, its safety profile and optimal dosing remain undefined. Research into this peptide is still in preliminary phases, with limited peer-reviewed studies available to establish definitive mechanisms of action or clinical efficacy. As with many research peptides, 1G2T represents an area of ongoing scientific investigation where future studies may reveal specific therapeutic applications and biological functions.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 1G2T likely functions through multiple molecular pathways. The presence of cysteine residues suggests the formation of disulfide bonds that stabilize the peptide structure and may facilitate receptor binding. The basic amino acid clusters (lysine and arginine) indicate potential for electrostatic interactions with cell membranes and negatively charged cellular components. The peptide may modulate cellular signaling cascades through direct receptor interactions or by influencing protein-protein interactions within cells. The structural complexity suggests it could act as a signaling molecule that affects gene expression, protein synthesis, or enzymatic activities. Without specific binding studies, the exact molecular targets remain speculative, but the peptide's composition suggests it may interact with growth factor receptors, ion channels, or intracellular signaling proteins.
Risks & Safety
Legal Status
1G89 is a synthetic antimicrobial peptide with the sequence ILPWKWPWWPWRR, characterized by its high content of tryptophan and arginine residues. This peptide belongs to a class of cationic antimicrobial peptides that are designed to combat bacterial infections through membrane disruption mechanisms. The peptide's structure features multiple tryptophan residues, which are known to facilitate membrane insertion and interaction, along with positively charged arginine residues that enable electrostatic interactions with negatively charged bacterial membranes. Currently, 1G89 appears to be in early research phases, with limited clinical data available. The peptide's design suggests it may have potential applications in treating antibiotic-resistant bacterial infections, though comprehensive safety and efficacy studies are needed. As with many antimicrobial peptides, 1G89 represents a promising alternative to traditional antibiotics, particularly in an era of increasing antimicrobial resistance. However, the current research status indicates this peptide remains primarily an experimental compound requiring further investigation to establish its therapeutic potential, optimal dosing, and safety profile.
Key Benefits
Overview
1G89 is a synthetic antimicrobial peptide with the sequence ILPWKWPWWPWRR, characterized by its high content of tryptophan and arginine residues. This peptide belongs to a class of cationic antimicrobial peptides that are designed to combat bacterial infections through membrane disruption mechanisms. The peptide's structure features multiple tryptophan residues, which are known to facilitate membrane insertion and interaction, along with positively charged arginine residues that enable electrostatic interactions with negatively charged bacterial membranes. Currently, 1G89 appears to be in early research phases, with limited clinical data available. The peptide's design suggests it may have potential applications in treating antibiotic-resistant bacterial infections, though comprehensive safety and efficacy studies are needed. As with many antimicrobial peptides, 1G89 represents a promising alternative to traditional antibiotics, particularly in an era of increasing antimicrobial resistance. However, the current research status indicates this peptide remains primarily an experimental compound requiring further investigation to establish its therapeutic potential, optimal dosing, and safety profile.
Potential Benefits
Mechanism of Action
1G89 functions as a cationic antimicrobial peptide that targets bacterial cell membranes through electrostatic and hydrophobic interactions. The peptide's mechanism involves initial binding to negatively charged components of bacterial cell walls, such as lipopolysaccharides in gram-negative bacteria or teichoic acids in gram-positive bacteria. The multiple tryptophan residues facilitate insertion into the lipid bilayer of bacterial membranes, while the arginine residues provide the positive charge necessary for initial attraction to the bacterial surface. Once inserted, the peptide likely forms pores or causes membrane destabilization, leading to cell lysis and bacterial death. This membrane-disrupting mechanism makes it difficult for bacteria to develop resistance, as they would need to fundamentally alter their membrane composition.
Risks & Safety
Legal Status
1HU5 is a synthetic peptide with the sequence KNLRRIIRKIIHIIKKYG, consisting of 18 amino acids. This peptide appears to be a research compound that is currently in early phases of investigation. The sequence contains multiple basic amino acids (lysine, arginine) and hydrophobic residues, suggesting potential membrane-interacting or cell-penetrating properties. Based on its composition and structure, 1HU5 may have applications in cellular research, potentially involving membrane permeabilization or intracellular delivery mechanisms. The peptide's high content of positively charged residues could facilitate interactions with negatively charged cellular components such as cell membranes or nucleic acids. Current research status appears to be in preliminary stages with limited published data available. Further investigation is needed to fully characterize its biological activities, therapeutic potential, and safety profile. The peptide represents an area of ongoing research interest in the field of bioactive peptides and their potential applications in various therapeutic areas.
Key Benefits
Overview
1HU5 is a synthetic peptide with the sequence KNLRRIIRKIIHIIKKYG, consisting of 18 amino acids. This peptide appears to be a research compound that is currently in early phases of investigation. The sequence contains multiple basic amino acids (lysine, arginine) and hydrophobic residues, suggesting potential membrane-interacting or cell-penetrating properties. Based on its composition and structure, 1HU5 may have applications in cellular research, potentially involving membrane permeabilization or intracellular delivery mechanisms. The peptide's high content of positively charged residues could facilitate interactions with negatively charged cellular components such as cell membranes or nucleic acids. Current research status appears to be in preliminary stages with limited published data available. Further investigation is needed to fully characterize its biological activities, therapeutic potential, and safety profile. The peptide represents an area of ongoing research interest in the field of bioactive peptides and their potential applications in various therapeutic areas.
Potential Benefits
Mechanism of Action
Based on the amino acid sequence of 1HU5 (KNLRRIIRKIIHIIKKYG), the peptide likely functions through electrostatic interactions with cellular membranes due to its high content of positively charged residues (lysine and arginine). The mechanism may involve membrane permeabilization or cell-penetrating activities, allowing the peptide to interact with intracellular targets. The hydrophobic amino acids present in the sequence could facilitate insertion into lipid bilayers, while the charged residues may interact with phospholipid head groups. This dual nature suggests the peptide might function as a membrane-active compound, potentially disrupting membrane integrity or facilitating translocation across cellular barriers. The specific arrangement of amino acids may also allow for interactions with specific cellular receptors or binding sites, though the exact molecular targets remain to be fully characterized through detailed biochemical studies.
Risks & Safety
Legal Status
1i2u is a peptide with the sequence DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANVNCWCET that appears to contain multiple cysteine residues suggesting a structured, disulfide-bonded conformation. Based on its sequence characteristics and structural features, this peptide likely belongs to a family of bioactive compounds with potential therapeutic applications. The presence of multiple cysteine residues indicates it may form a stable, compact structure typical of peptides with antimicrobial, wound healing, or tissue repair properties. Currently, this peptide appears to be in early research phases with limited published data available. The sequence suggests it may interact with cellular receptors or have direct effects on tissue regeneration processes. Further research is needed to fully characterize its biological activities, safety profile, and therapeutic potential. The peptide's structure indicates it may have applications in regenerative medicine, wound healing, or as an antimicrobial agent, though comprehensive clinical studies are required to validate these potential uses.
Key Benefits
Overview
1i2u is a peptide with the sequence DKLIGSCVWGAVNYTSDCNGECKRRGYKGGHCGSFANVNCWCET that appears to contain multiple cysteine residues suggesting a structured, disulfide-bonded conformation. Based on its sequence characteristics and structural features, this peptide likely belongs to a family of bioactive compounds with potential therapeutic applications. The presence of multiple cysteine residues indicates it may form a stable, compact structure typical of peptides with antimicrobial, wound healing, or tissue repair properties. Currently, this peptide appears to be in early research phases with limited published data available. The sequence suggests it may interact with cellular receptors or have direct effects on tissue regeneration processes. Further research is needed to fully characterize its biological activities, safety profile, and therapeutic potential. The peptide's structure indicates it may have applications in regenerative medicine, wound healing, or as an antimicrobial agent, though comprehensive clinical studies are required to validate these potential uses.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 1i2u likely functions through direct interaction with cellular receptors or extracellular matrix components. The multiple cysteine residues suggest formation of disulfide bonds creating a stable tertiary structure that may mimic natural signaling molecules. The peptide may activate cellular signaling pathways involved in tissue repair, potentially through growth factor receptor binding or direct modulation of inflammatory cascades. The structured conformation likely allows for specific binding to target proteins or cell surface receptors, initiating downstream signaling events that promote cellular regeneration, wound healing, or antimicrobial activity. Without specific research data, the exact molecular targets and pathways remain to be fully elucidated.
Risks & Safety
Legal Status
1JKZ is a synthetic peptide with the sequence KTCEHLADTYRGVCFTNASCDDHCKNKAHLISGTCHNWKCFCTQNC, containing multiple cysteine residues that likely form disulfide bonds creating a stable cyclic or constrained structure. Based on its complex sequence and structural characteristics, this peptide appears to be designed for research applications, potentially targeting specific biological pathways or receptors. The presence of multiple cysteine residues suggests it may have enhanced stability and bioactivity compared to linear peptides. Currently classified as a research compound, 1JKZ is likely being investigated for various therapeutic applications, though specific clinical data is limited. The peptide's unique sequence and structure indicate it may have been designed through rational drug design approaches to target specific biological functions. Further research is needed to fully characterize its biological activities, safety profile, and therapeutic potential. As with many research peptides, its applications may span multiple therapeutic areas including tissue repair, neuroprotection, or metabolic regulation, though specific mechanisms and clinical efficacy remain to be fully established through comprehensive studies.
Key Benefits
Overview
1JKZ is a synthetic peptide with the sequence KTCEHLADTYRGVCFTNASCDDHCKNKAHLISGTCHNWKCFCTQNC, containing multiple cysteine residues that likely form disulfide bonds creating a stable cyclic or constrained structure. Based on its complex sequence and structural characteristics, this peptide appears to be designed for research applications, potentially targeting specific biological pathways or receptors. The presence of multiple cysteine residues suggests it may have enhanced stability and bioactivity compared to linear peptides. Currently classified as a research compound, 1JKZ is likely being investigated for various therapeutic applications, though specific clinical data is limited. The peptide's unique sequence and structure indicate it may have been designed through rational drug design approaches to target specific biological functions. Further research is needed to fully characterize its biological activities, safety profile, and therapeutic potential. As with many research peptides, its applications may span multiple therapeutic areas including tissue repair, neuroprotection, or metabolic regulation, though specific mechanisms and clinical efficacy remain to be fully established through comprehensive studies.
Potential Benefits
Mechanism of Action
The mechanism of action for peptide 1JKZ is not fully characterized based on available data. However, its structure containing multiple cysteine residues suggests it likely forms disulfide bonds that create a constrained, stable conformation. This structural stability may allow for specific receptor binding or enzyme interactions. The peptide may function through binding to cell surface receptors, modulating intracellular signaling pathways, or acting as an enzyme inhibitor or activator. The specific amino acid sequence suggests potential interactions with biological targets involved in cellular regulation, tissue repair, or metabolic processes. Further research is needed to elucidate the exact molecular targets and signaling pathways involved in its biological activity.
Risks & Safety
Legal Status
1JNJ is a peptide sequence consisting of 100 amino acids with the sequence IQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM. Currently classified as a research compound in Phase 1 minimal catalog extraction, this peptide represents an experimental therapeutic agent under investigation. The peptide's relatively long sequence suggests it may function as a protein fragment or engineered therapeutic construct. Given its research status and complex amino acid composition, 1JNJ likely targets specific biological pathways or receptor systems, though detailed mechanistic studies are still ongoing. The peptide appears to be in early-stage research and development, with limited publicly available data regarding its specific therapeutic applications or clinical outcomes. As with many investigational peptides, 1JNJ may have potential applications in areas such as tissue repair, immune modulation, or metabolic regulation, though comprehensive studies are needed to establish its safety profile and therapeutic efficacy. The current research phase indicates that this compound is being evaluated for its biological activity and potential therapeutic benefits before advancing to more extensive preclinical and clinical studies.
Key Benefits
Overview
1JNJ is a peptide sequence consisting of 100 amino acids with the sequence IQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM. Currently classified as a research compound in Phase 1 minimal catalog extraction, this peptide represents an experimental therapeutic agent under investigation. The peptide's relatively long sequence suggests it may function as a protein fragment or engineered therapeutic construct. Given its research status and complex amino acid composition, 1JNJ likely targets specific biological pathways or receptor systems, though detailed mechanistic studies are still ongoing. The peptide appears to be in early-stage research and development, with limited publicly available data regarding its specific therapeutic applications or clinical outcomes. As with many investigational peptides, 1JNJ may have potential applications in areas such as tissue repair, immune modulation, or metabolic regulation, though comprehensive studies are needed to establish its safety profile and therapeutic efficacy. The current research phase indicates that this compound is being evaluated for its biological activity and potential therapeutic benefits before advancing to more extensive preclinical and clinical studies.
Potential Benefits
Mechanism of Action
Based on the peptide's amino acid sequence and research classification, 1JNJ likely exerts its biological effects through specific receptor binding or enzymatic interactions. The peptide's 100-amino acid length suggests it may function as a bioactive protein fragment that could modulate cellular signaling pathways. The sequence contains multiple charged residues and hydrophobic regions that may facilitate membrane interactions or protein-protein binding. Given its research status, the peptide may target specific cell surface receptors, intracellular signaling cascades, or enzymatic processes. The presence of cysteine residues in the sequence suggests potential for disulfide bond formation, which could stabilize the peptide's three-dimensional structure and enhance its binding affinity to target proteins. The mechanism likely involves modulation of downstream signaling pathways that could affect cellular proliferation, differentiation, or metabolic processes, though specific molecular targets require further investigation.
Risks & Safety
Legal Status
1KJ6 is a synthetic peptide with the sequence GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK. This peptide appears to be a research compound that is currently in early-phase investigation. The peptide contains multiple cysteine residues suggesting potential disulfide bond formation, which may contribute to its structural stability and biological activity. Based on its sequence characteristics and the presence of basic amino acids, 1KJ6 may have antimicrobial properties and potential therapeutic applications. However, comprehensive research data is limited, and the peptide remains primarily in experimental stages. The specific mechanism of action and therapeutic targets are not yet fully characterized, requiring further investigation to determine its clinical potential and safety profile.
Key Benefits
Overview
1KJ6 is a synthetic peptide with the sequence GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK. This peptide appears to be a research compound that is currently in early-phase investigation. The peptide contains multiple cysteine residues suggesting potential disulfide bond formation, which may contribute to its structural stability and biological activity. Based on its sequence characteristics and the presence of basic amino acids, 1KJ6 may have antimicrobial properties and potential therapeutic applications. However, comprehensive research data is limited, and the peptide remains primarily in experimental stages. The specific mechanism of action and therapeutic targets are not yet fully characterized, requiring further investigation to determine its clinical potential and safety profile.
Potential Benefits
Mechanism of Action
The mechanism of action for 1KJ6 is not well-established due to limited research data. Based on its amino acid sequence, which contains multiple cysteine residues and basic amino acids, the peptide may interact with cellular membranes or specific protein targets. The presence of disulfide bonds likely contributes to structural stability, while the basic residues may facilitate binding to negatively charged cellular components. Further research is needed to elucidate the specific molecular pathways and receptor interactions involved in its biological activity.
Risks & Safety
Legal Status
1LFC is a synthetic peptide with the sequence FKCRRWQWRMKKLGAPSITCVRRAF that is currently in early research phases. Limited published research data is available for this specific peptide, indicating it may be an experimental compound under investigation. The peptide appears to be designed with specific amino acid sequences that could potentially interact with cellular receptors or signaling pathways. As with many research peptides, 1LFC is likely being studied for its potential therapeutic applications, though comprehensive clinical data is not yet available. The peptide's structure suggests it may have bioactive properties that warrant further investigation. Current research status appears to be in preliminary stages, with minimal catalog extraction completed. Without extensive published studies, the full therapeutic potential and safety profile of 1LFC remains to be established through rigorous scientific investigation. Researchers and clinicians should await peer-reviewed publications before drawing conclusions about its efficacy or safety for any specific applications.
Key Benefits
Overview
1LFC is a synthetic peptide with the sequence FKCRRWQWRMKKLGAPSITCVRRAF that is currently in early research phases. Limited published research data is available for this specific peptide, indicating it may be an experimental compound under investigation. The peptide appears to be designed with specific amino acid sequences that could potentially interact with cellular receptors or signaling pathways. As with many research peptides, 1LFC is likely being studied for its potential therapeutic applications, though comprehensive clinical data is not yet available. The peptide's structure suggests it may have bioactive properties that warrant further investigation. Current research status appears to be in preliminary stages, with minimal catalog extraction completed. Without extensive published studies, the full therapeutic potential and safety profile of 1LFC remains to be established through rigorous scientific investigation. Researchers and clinicians should await peer-reviewed publications before drawing conclusions about its efficacy or safety for any specific applications.
Potential Benefits
Mechanism of Action
The mechanism of action for 1LFC is not well-established due to limited available research data. Based on its peptide structure containing specific amino acid sequences including cysteine residues, it may potentially interact with cellular receptors or influence protein-protein interactions. The presence of positively charged amino acids like lysine and arginine in the sequence suggests possible interactions with negatively charged cellular components or membrane structures. However, without specific receptor binding studies or pathway analysis from published research, the exact molecular mechanisms remain speculative. Further research is needed to elucidate the specific biological targets and signaling cascades that 1LFC may influence.
Risks & Safety
Legal Status
1LYP is a synthetic peptide with the sequence GLRKRLRKFRNKIKEKLKKIGQKIQGFVPKLAPRTDY, consisting of 38 amino acids. Based on its amino acid composition, this peptide contains multiple lysine and arginine residues, giving it a highly cationic (positively charged) nature. The presence of these basic amino acids suggests potential cell-penetrating properties, which could facilitate cellular uptake and intracellular delivery. The peptide's structure includes hydrophobic residues like phenylalanine and leucine, balanced with charged residues, indicating it may interact with cell membranes or specific protein targets. Currently classified as a research-phase compound, 1LYP appears to be in early stages of investigation with minimal published data available. The peptide's design suggests it may have been developed for therapeutic applications requiring cellular penetration or membrane interaction. Without extensive clinical data, its primary functions and therapeutic potential remain under investigation. The current research status indicates this is an experimental peptide that requires further study to establish its biological activity, safety profile, and potential therapeutic applications.
Key Benefits
Overview
1LYP is a synthetic peptide with the sequence GLRKRLRKFRNKIKEKLKKIGQKIQGFVPKLAPRTDY, consisting of 38 amino acids. Based on its amino acid composition, this peptide contains multiple lysine and arginine residues, giving it a highly cationic (positively charged) nature. The presence of these basic amino acids suggests potential cell-penetrating properties, which could facilitate cellular uptake and intracellular delivery. The peptide's structure includes hydrophobic residues like phenylalanine and leucine, balanced with charged residues, indicating it may interact with cell membranes or specific protein targets. Currently classified as a research-phase compound, 1LYP appears to be in early stages of investigation with minimal published data available. The peptide's design suggests it may have been developed for therapeutic applications requiring cellular penetration or membrane interaction. Without extensive clinical data, its primary functions and therapeutic potential remain under investigation. The current research status indicates this is an experimental peptide that requires further study to establish its biological activity, safety profile, and potential therapeutic applications.
Potential Benefits
Mechanism of Action
Based on the peptide's amino acid sequence, 1LYP likely functions through electrostatic interactions with negatively charged cell membranes due to its high content of positively charged lysine and arginine residues. The cationic nature of the peptide may facilitate binding to cell surface proteoglycans and subsequent cellular internalization through endocytic pathways. The presence of hydrophobic amino acids suggests the peptide may undergo conformational changes upon membrane contact, potentially allowing membrane penetration or pore formation. The peptide may interact with specific cellular receptors or transport proteins, though the exact molecular targets remain to be characterized. Once internalized, the peptide could modulate intracellular signaling pathways, protein-protein interactions, or gene expression, depending on its specific design purpose and target localization.
Risks & Safety
Legal Status
1M4E is a synthetic peptide with the sequence ICIFCCGCCHRSKCGMCCKT, characterized by multiple cysteine residues that likely form disulfide bonds creating a stable cyclic or constrained structure. This peptide appears to be in early research phases with limited published data available. The high cysteine content suggests it may have antimicrobial properties, as many cysteine-rich peptides demonstrate activity against bacteria, fungi, or other pathogens. The specific sequence and structure may confer unique biological activities, though comprehensive research is needed to fully characterize its mechanisms and therapeutic potential. Currently classified as a research chemical, 1M4E requires further investigation to determine its safety profile, efficacy, and potential clinical applications. The peptide's structural characteristics suggest it may have applications in areas such as antimicrobial therapy, wound healing, or immune modulation, but these potential uses remain speculative pending rigorous scientific validation through preclinical and clinical studies.
Key Benefits
Overview
1M4E is a synthetic peptide with the sequence ICIFCCGCCHRSKCGMCCKT, characterized by multiple cysteine residues that likely form disulfide bonds creating a stable cyclic or constrained structure. This peptide appears to be in early research phases with limited published data available. The high cysteine content suggests it may have antimicrobial properties, as many cysteine-rich peptides demonstrate activity against bacteria, fungi, or other pathogens. The specific sequence and structure may confer unique biological activities, though comprehensive research is needed to fully characterize its mechanisms and therapeutic potential. Currently classified as a research chemical, 1M4E requires further investigation to determine its safety profile, efficacy, and potential clinical applications. The peptide's structural characteristics suggest it may have applications in areas such as antimicrobial therapy, wound healing, or immune modulation, but these potential uses remain speculative pending rigorous scientific validation through preclinical and clinical studies.
Potential Benefits
Mechanism of Action
The mechanism of action for 1M4E is not well-established due to limited research data. Based on its cysteine-rich structure with the sequence ICIFCCGCCHRSKCGMCCKT, the peptide likely forms multiple disulfide bonds that create a stable, constrained conformation. This structural feature is common among antimicrobial peptides that interact with microbial cell membranes, potentially disrupting membrane integrity or interfering with cellular processes. The peptide may exert its effects through direct membrane interaction, receptor binding, or modulation of immune responses, though specific molecular targets and signaling pathways have not been definitively characterized.
Risks & Safety
Legal Status
1M8A is a 67-amino acid peptide with the sequence SNFDCCLGYTDRILHPKFIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM. Based on its structural characteristics and amino acid composition, this peptide appears to be a research compound currently in early investigational phases. The presence of cysteine residues suggests potential for disulfide bond formation, which may contribute to structural stability and biological activity. The peptide contains several hydrophobic and charged residues that could facilitate membrane interactions or protein-protein binding. Given its length and complexity, 1M8A may function as a bioactive peptide with potential therapeutic applications, though comprehensive research data is currently limited. The peptide's designation suggests it may be part of a structural biology study or protein database entry. Further research is needed to fully characterize its biological functions, therapeutic potential, and safety profile. Current understanding is based primarily on sequence analysis and structural predictions rather than extensive clinical or preclinical studies.
Key Benefits
Overview
1M8A is a 67-amino acid peptide with the sequence SNFDCCLGYTDRILHPKFIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKKVKNM. Based on its structural characteristics and amino acid composition, this peptide appears to be a research compound currently in early investigational phases. The presence of cysteine residues suggests potential for disulfide bond formation, which may contribute to structural stability and biological activity. The peptide contains several hydrophobic and charged residues that could facilitate membrane interactions or protein-protein binding. Given its length and complexity, 1M8A may function as a bioactive peptide with potential therapeutic applications, though comprehensive research data is currently limited. The peptide's designation suggests it may be part of a structural biology study or protein database entry. Further research is needed to fully characterize its biological functions, therapeutic potential, and safety profile. Current understanding is based primarily on sequence analysis and structural predictions rather than extensive clinical or preclinical studies.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 1M8A likely functions through protein-protein interactions facilitated by its diverse amino acid composition. The presence of cysteine residues at positions 6 and 7 suggests potential for intramolecular or intermolecular disulfide bond formation, which could stabilize secondary structure or enable binding to target proteins. The peptide contains multiple charged residues (lysine, arginine, aspartic acid) that may facilitate electrostatic interactions with cellular receptors or membrane components. Hydrophobic regions within the sequence could enable membrane penetration or hydrophobic pocket binding. The peptide may modulate cellular signaling pathways through receptor binding, enzyme inhibition, or protein complex formation, though specific molecular targets remain to be characterized through detailed biochemical studies.
Risks & Safety
Legal Status
1MIJ is a synthetic peptide with the sequence GLGKAQCAALWLQCASGGTIGCGGGAVACQNYRQFCR, containing 38 amino acids. Based on its structural characteristics, this peptide appears to contain multiple cysteine residues that likely form disulfide bonds, suggesting a stable, folded structure typical of bioactive peptides. The presence of hydrophobic amino acids like leucine and tryptophan, combined with charged residues, indicates potential membrane interactions or receptor binding capabilities. Currently, limited research data is available for this specific peptide, placing it in early-stage research or experimental phases. The peptide's structure suggests it may have biological activity related to cellular signaling or tissue interactions, though specific mechanisms and therapeutic applications require further investigation. As with many research peptides, 1MIJ represents a compound of interest for potential therapeutic development, but comprehensive clinical data regarding its efficacy, safety profile, and optimal applications remains to be established through rigorous scientific study.
Key Benefits
Overview
1MIJ is a synthetic peptide with the sequence GLGKAQCAALWLQCASGGTIGCGGGAVACQNYRQFCR, containing 38 amino acids. Based on its structural characteristics, this peptide appears to contain multiple cysteine residues that likely form disulfide bonds, suggesting a stable, folded structure typical of bioactive peptides. The presence of hydrophobic amino acids like leucine and tryptophan, combined with charged residues, indicates potential membrane interactions or receptor binding capabilities. Currently, limited research data is available for this specific peptide, placing it in early-stage research or experimental phases. The peptide's structure suggests it may have biological activity related to cellular signaling or tissue interactions, though specific mechanisms and therapeutic applications require further investigation. As with many research peptides, 1MIJ represents a compound of interest for potential therapeutic development, but comprehensive clinical data regarding its efficacy, safety profile, and optimal applications remains to be established through rigorous scientific study.
Potential Benefits
Mechanism of Action
Based on the peptide's amino acid composition and structure, 1MIJ likely functions through receptor-mediated signaling pathways. The presence of multiple cysteine residues suggests the formation of disulfide bonds, creating a stable three-dimensional structure that may interact with specific cellular receptors. The hydrophobic regions containing leucine and tryptophan residues may facilitate membrane binding or protein-protein interactions. The peptide's structure indicates potential modulation of cellular signaling cascades, possibly involving G-protein coupled receptors or growth factor pathways. However, without specific research data, the exact molecular targets and downstream signaling mechanisms remain to be elucidated through detailed biochemical and pharmacological studies.
Risks & Safety
Legal Status
1mr4 is a 47-amino acid peptide with the sequence RECKTESNTFPGICITKPPCRKACISEKFTDGHCSKILRRCLCTKPC. This peptide contains multiple cysteine residues, suggesting it likely forms disulfide bonds that create a stable, structured conformation. The presence of these structural features indicates it may function as a bioactive peptide with potential therapeutic applications. Currently classified as a research peptide, 1mr4 appears to be in early investigational phases with limited published data available. The peptide's complex structure with multiple potential disulfide linkages suggests it may interact with specific biological targets or receptors. Without extensive published research, the exact mechanisms and applications remain to be fully elucidated through ongoing studies. The peptide's designation as '1mr4' may relate to its structural classification or research identification code. Given its amino acid composition and structural characteristics, it may have applications in areas requiring stable peptide therapeutics. Further research is needed to establish its safety profile, efficacy, and optimal therapeutic applications. The peptide represents part of the expanding field of synthetic peptide therapeutics that are being investigated for various medical conditions.
Key Benefits
Overview
1mr4 is a 47-amino acid peptide with the sequence RECKTESNTFPGICITKPPCRKACISEKFTDGHCSKILRRCLCTKPC. This peptide contains multiple cysteine residues, suggesting it likely forms disulfide bonds that create a stable, structured conformation. The presence of these structural features indicates it may function as a bioactive peptide with potential therapeutic applications. Currently classified as a research peptide, 1mr4 appears to be in early investigational phases with limited published data available. The peptide's complex structure with multiple potential disulfide linkages suggests it may interact with specific biological targets or receptors. Without extensive published research, the exact mechanisms and applications remain to be fully elucidated through ongoing studies. The peptide's designation as '1mr4' may relate to its structural classification or research identification code. Given its amino acid composition and structural characteristics, it may have applications in areas requiring stable peptide therapeutics. Further research is needed to establish its safety profile, efficacy, and optimal therapeutic applications. The peptide represents part of the expanding field of synthetic peptide therapeutics that are being investigated for various medical conditions.
Potential Benefits
Mechanism of Action
Based on the structural analysis of 1mr4's amino acid sequence, this peptide likely functions through specific receptor binding interactions facilitated by its disulfide-bonded structure. The multiple cysteine residues (C) in the sequence suggest formation of intramolecular disulfide bridges that create a stable three-dimensional conformation necessary for biological activity. The presence of charged residues like arginine (R), lysine (K), and glutamic acid (E) indicates potential for electrostatic interactions with target proteins or cell surface receptors. The peptide may modulate cellular signaling pathways through binding to specific receptor sites, potentially influencing downstream cascades involving protein kinases or other signaling molecules. The structured nature of the peptide, stabilized by disulfide bonds, would allow for precise molecular recognition and binding specificity. Without specific research data, the exact molecular targets and pathways remain to be determined through detailed pharmacological studies.
Risks & Safety
Legal Status
1MSH appears to be a synthetic peptide with a 70-amino acid sequence containing multiple functional domains. Based on its structural characteristics, including the presence of cysteine residues that may form disulfide bonds and various charged amino acid regions, this peptide likely has biological activity related to cellular signaling or regulatory functions. The sequence contains motifs that suggest potential interactions with cellular receptors or involvement in protein-protein interactions. However, comprehensive research data on this specific peptide is currently limited, indicating it may be in early research phases or represent a novel synthetic construct. The peptide's length and complexity suggest it could have multiple biological targets or functions, potentially making it of interest for therapeutic applications pending further investigation.
Key Benefits
Overview
1MSH appears to be a synthetic peptide with a 70-amino acid sequence containing multiple functional domains. Based on its structural characteristics, including the presence of cysteine residues that may form disulfide bonds and various charged amino acid regions, this peptide likely has biological activity related to cellular signaling or regulatory functions. The sequence contains motifs that suggest potential interactions with cellular receptors or involvement in protein-protein interactions. However, comprehensive research data on this specific peptide is currently limited, indicating it may be in early research phases or represent a novel synthetic construct. The peptide's length and complexity suggest it could have multiple biological targets or functions, potentially making it of interest for therapeutic applications pending further investigation.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 1MSH likely functions through receptor-mediated signaling pathways. The presence of multiple cysteine residues suggests the formation of disulfide bonds that stabilize the peptide structure, potentially creating specific binding domains for target receptors. The sequence contains both hydrophobic and hydrophilic regions, indicating it may interact with membrane-bound receptors or intracellular signaling proteins. The peptide may modulate cellular responses through activation of secondary messenger systems, though specific receptor targets and downstream signaling cascades require further characterization through experimental studies.
Risks & Safety
Legal Status
1NAP (1-Hydroxynaphthalene) is a monohydroxy polycyclic aromatic hydrocarbon (PAH) metabolite that serves as a biomarker for environmental exposure to naphthalene and other PAH compounds. This peptide-like compound is primarily studied in the context of environmental health and toxicology rather than as a therapeutic agent. 1NAP is commonly found in human urine as a result of exposure to cigarette smoke, vehicle exhaust, grilled foods, and urban air pollution. Recent research has established significant associations between elevated 1NAP levels and various health conditions including psoriasis, anxiety disorders, viral infections (HPV and HSV-2), and chronic respiratory symptoms. The compound appears to have neurotoxic properties and may influence inflammatory pathways and immune system function. Current research focuses on understanding its role as an environmental health risk factor rather than exploring therapeutic applications. Studies utilizing data from the National Health and Nutrition Examination Survey (NHANES) have consistently demonstrated dose-dependent relationships between 1NAP exposure levels and adverse health outcomes, with particularly strong associations observed in younger populations and non-smokers. The research status remains primarily observational, with ongoing investigations into its mechanisms of toxicity and potential for contributing to autoimmune and inflammatory conditions.
Key Benefits
Overview
1NAP (1-Hydroxynaphthalene) is a monohydroxy polycyclic aromatic hydrocarbon (PAH) metabolite that serves as a biomarker for environmental exposure to naphthalene and other PAH compounds. This peptide-like compound is primarily studied in the context of environmental health and toxicology rather than as a therapeutic agent. 1NAP is commonly found in human urine as a result of exposure to cigarette smoke, vehicle exhaust, grilled foods, and urban air pollution. Recent research has established significant associations between elevated 1NAP levels and various health conditions including psoriasis, anxiety disorders, viral infections (HPV and HSV-2), and chronic respiratory symptoms. The compound appears to have neurotoxic properties and may influence inflammatory pathways and immune system function. Current research focuses on understanding its role as an environmental health risk factor rather than exploring therapeutic applications. Studies utilizing data from the National Health and Nutrition Examination Survey (NHANES) have consistently demonstrated dose-dependent relationships between 1NAP exposure levels and adverse health outcomes, with particularly strong associations observed in younger populations and non-smokers. The research status remains primarily observational, with ongoing investigations into its mechanisms of toxicity and potential for contributing to autoimmune and inflammatory conditions.
Potential Benefits
Mechanism of Action
1NAP functions as a toxic metabolite that disrupts normal cellular processes through multiple pathways. As a PAH metabolite, it can interfere with cellular signaling mechanisms and promote inflammatory responses. The compound appears to activate inflammatory cascades that increase expression of psoriasis-related inflammatory factors in keratinocytes (HaCaT cells). Its neurotoxic properties suggest interaction with neural signaling pathways, potentially affecting neurotransmitter systems and contributing to anxiety-related symptoms. The mechanism likely involves oxidative stress generation and disruption of normal cellular homeostasis. 1NAP may also compromise immune system function, creating conditions that increase susceptibility to viral infections such as HPV and HSV-2. The compound's effects on respiratory tissues suggest it may trigger inflammatory responses in lung epithelial cells, leading to chronic cough and respiratory symptoms. The dose-dependent relationships observed in studies indicate that 1NAP accumulation overwhelms normal detoxification pathways, leading to progressive cellular damage and inflammatory responses.
Risks & Safety
Legal Status
1NKL is a 76-amino acid peptide with the sequence GLICESCRKIIQKLEDMVGPQPNEDTVTQAASRVCDKMKILRGVCKKIMRTFLRRISKDILTGKKPQAICVDIKICKE. Based on its structural characteristics, this peptide appears to contain multiple cysteine residues that likely form disulfide bonds, suggesting a stable, structured conformation. The presence of basic amino acids (lysine and arginine) throughout the sequence indicates potential for protein-protein interactions or membrane binding properties. The peptide's length and composition suggest it may function as a bioactive molecule with potential therapeutic applications. Currently, detailed research on 1NKL's specific biological functions and clinical applications appears limited in the available literature. The peptide's structural features suggest it may have roles in cellular signaling, protein interactions, or tissue-specific functions. Further research is needed to fully characterize its mechanism of action, therapeutic potential, and safety profile. The peptide represents an area of ongoing investigation in peptide therapeutics, where understanding of structure-function relationships continues to evolve.
Key Benefits
Overview
1NKL is a 76-amino acid peptide with the sequence GLICESCRKIIQKLEDMVGPQPNEDTVTQAASRVCDKMKILRGVCKKIMRTFLRRISKDILTGKKPQAICVDIKICKE. Based on its structural characteristics, this peptide appears to contain multiple cysteine residues that likely form disulfide bonds, suggesting a stable, structured conformation. The presence of basic amino acids (lysine and arginine) throughout the sequence indicates potential for protein-protein interactions or membrane binding properties. The peptide's length and composition suggest it may function as a bioactive molecule with potential therapeutic applications. Currently, detailed research on 1NKL's specific biological functions and clinical applications appears limited in the available literature. The peptide's structural features suggest it may have roles in cellular signaling, protein interactions, or tissue-specific functions. Further research is needed to fully characterize its mechanism of action, therapeutic potential, and safety profile. The peptide represents an area of ongoing investigation in peptide therapeutics, where understanding of structure-function relationships continues to evolve.
Potential Benefits
Mechanism of Action
Based on the amino acid sequence analysis, 1NKL likely functions through protein-protein interactions facilitated by its multiple basic residues (lysine and arginine). The presence of cysteine residues suggests the formation of disulfide bonds that stabilize the peptide's three-dimensional structure, which is crucial for biological activity. The peptide may interact with specific cellular receptors or binding proteins through its charged regions. The sequence contains potential binding domains that could facilitate interactions with cell surface receptors or intracellular targets. The molecular mechanism likely involves conformational changes upon target binding, leading to downstream signaling cascades. The peptide's structure suggests it may modulate cellular processes through direct protein interactions or by influencing membrane dynamics due to its amphipathic properties.
Risks & Safety
Legal Status
1O80 is a 75-amino acid peptide with the sequence VPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKERSKRSP. Based on its structural characteristics, this peptide contains multiple cysteine residues suggesting potential disulfide bond formation and structural stability. The sequence includes several lysine and arginine residues, indicating possible cell-penetrating properties or membrane interactions. The peptide appears to be in early research phases with limited published data available. Its relatively long sequence and complex structure suggest it may function as a bioactive peptide with potential therapeutic applications. The presence of multiple charged residues and the overall composition indicate it could interact with cellular receptors or membrane systems. Current research status appears to be in preliminary stages, with the peptide requiring further investigation to fully characterize its biological activities, safety profile, and therapeutic potential. Without extensive published research, the peptide's specific mechanisms and clinical applications remain to be fully elucidated through future studies.
Key Benefits
Overview
1O80 is a 75-amino acid peptide with the sequence VPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKERSKRSP. Based on its structural characteristics, this peptide contains multiple cysteine residues suggesting potential disulfide bond formation and structural stability. The sequence includes several lysine and arginine residues, indicating possible cell-penetrating properties or membrane interactions. The peptide appears to be in early research phases with limited published data available. Its relatively long sequence and complex structure suggest it may function as a bioactive peptide with potential therapeutic applications. The presence of multiple charged residues and the overall composition indicate it could interact with cellular receptors or membrane systems. Current research status appears to be in preliminary stages, with the peptide requiring further investigation to fully characterize its biological activities, safety profile, and therapeutic potential. Without extensive published research, the peptide's specific mechanisms and clinical applications remain to be fully elucidated through future studies.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 1O80 likely functions through multiple potential mechanisms. The presence of cysteine residues suggests the formation of disulfide bonds that could stabilize its three-dimensional structure, enabling specific receptor binding. The high content of positively charged amino acids (lysine and arginine) indicates potential cell membrane interactions or cell-penetrating capabilities. The peptide may interact with cellular receptors through its structured domains, potentially activating intracellular signaling cascades. The sequence composition suggests it could modulate protein-protein interactions or serve as a signaling molecule. However, without specific research data, the exact molecular targets, receptor interactions, and downstream signaling pathways remain to be characterized through detailed biochemical and pharmacological studies.
Risks & Safety
Legal Status
1PG1 is a disulfide-bridged peptide with the sequence RGGRLCYCRRRFCVCVGR that has been primarily studied in computational structural biology research. This peptide contains multiple cysteine residues that form disulfide bonds, which are critical for its three-dimensional structure and stability. Research has focused on understanding how disulfide constraints affect protein folding and structural prediction. The peptide has been used as a model system to evaluate computational methods for predicting protein structures, particularly those containing disulfide bridges. Studies have demonstrated that 1PG1 adopts its native conformation only when disulfide bond constraints are properly incorporated into molecular simulations, highlighting the importance of these structural elements. The peptide appears to have β-sheet secondary structure characteristics and serves as a valuable tool for developing improved computational approaches to protein structure prediction. While current research is primarily focused on its structural properties and computational modeling applications, the presence of disulfide bonds suggests potential stability advantages that could be relevant for therapeutic applications. However, comprehensive biological activity studies and clinical applications remain limited in the available literature.
Key Benefits
Overview
1PG1 is a disulfide-bridged peptide with the sequence RGGRLCYCRRRFCVCVGR that has been primarily studied in computational structural biology research. This peptide contains multiple cysteine residues that form disulfide bonds, which are critical for its three-dimensional structure and stability. Research has focused on understanding how disulfide constraints affect protein folding and structural prediction. The peptide has been used as a model system to evaluate computational methods for predicting protein structures, particularly those containing disulfide bridges. Studies have demonstrated that 1PG1 adopts its native conformation only when disulfide bond constraints are properly incorporated into molecular simulations, highlighting the importance of these structural elements. The peptide appears to have β-sheet secondary structure characteristics and serves as a valuable tool for developing improved computational approaches to protein structure prediction. While current research is primarily focused on its structural properties and computational modeling applications, the presence of disulfide bonds suggests potential stability advantages that could be relevant for therapeutic applications. However, comprehensive biological activity studies and clinical applications remain limited in the available literature.
Potential Benefits
Mechanism of Action
The mechanism of action for 1PG1 is primarily understood through its structural characteristics rather than specific biological pathways. The peptide's function is heavily dependent on disulfide bond formation between cysteine residues, which constrains the peptide into a specific three-dimensional conformation. These disulfide bridges are essential for maintaining structural integrity and achieving the native folded state. The peptide exhibits β-sheet secondary structure, which is stabilized by the disulfide constraints. Without proper disulfide bond formation, the peptide cannot achieve its native conformation, suggesting that the biological activity is structure-dependent. The computational studies indicate that the peptide requires specific constraining potentials, particularly Morse potential interactions, to fold correctly. The arginine residues in the sequence may contribute to electrostatic interactions and binding properties, while the cysteine-rich regions provide structural stability through covalent disulfide linkages.
Risks & Safety
Legal Status
1RJT is a 70-amino acid peptide with the sequence FPMFKRGRCLCIGPGVKAVKVADIEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIIKKVERKNF. Based on its structural characteristics, this peptide contains multiple cysteine residues suggesting potential disulfide bond formation and structural stability. The presence of basic amino acids like arginine and lysine indicates possible cell-penetrating or membrane-interacting properties. The peptide appears to be in early research phases with minimal published data available. Its sequence suggests it may have antimicrobial properties given the presence of cationic residues and potential amphipathic structure. The peptide's length and composition indicate it could function as a bioactive molecule with potential therapeutic applications, though comprehensive research data is currently limited. Further investigation is needed to fully characterize its biological activities, safety profile, and therapeutic potential.
Key Benefits
Overview
1RJT is a 70-amino acid peptide with the sequence FPMFKRGRCLCIGPGVKAVKVADIEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIIKKVERKNF. Based on its structural characteristics, this peptide contains multiple cysteine residues suggesting potential disulfide bond formation and structural stability. The presence of basic amino acids like arginine and lysine indicates possible cell-penetrating or membrane-interacting properties. The peptide appears to be in early research phases with minimal published data available. Its sequence suggests it may have antimicrobial properties given the presence of cationic residues and potential amphipathic structure. The peptide's length and composition indicate it could function as a bioactive molecule with potential therapeutic applications, though comprehensive research data is currently limited. Further investigation is needed to fully characterize its biological activities, safety profile, and therapeutic potential.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 1RJT likely functions through electrostatic interactions with negatively charged cellular components due to its high content of positively charged residues (arginine and lysine). The presence of cysteine residues suggests the formation of disulfide bonds that may stabilize its three-dimensional structure and enhance biological activity. The peptide may interact with cell membranes through its amphipathic properties, potentially disrupting membrane integrity in target cells. The specific arrangement of hydrophobic and hydrophilic residues could facilitate membrane penetration or receptor binding. Without specific research data, the exact molecular targets and signaling pathways remain to be elucidated through future studies.
Risks & Safety
Legal Status
1RON is a synthetic peptide with the sequence YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY, consisting of 36 amino acids. Currently classified as a research chemical, this peptide is in early-stage investigation with limited published data available. The peptide's name suggests potential involvement in iron-related biological processes, though specific mechanisms remain under investigation. Initial research indicates possible applications in cellular metabolism and tissue function, but comprehensive clinical studies are lacking. The peptide appears to be primarily used in laboratory settings for research purposes, with its therapeutic potential still being explored. Current evidence suggests it may have roles in cellular signaling pathways, though the exact molecular targets and biological effects require further characterization. As with many research peptides, 1RON represents an area of ongoing scientific inquiry where preliminary findings suggest potential therapeutic applications, but robust clinical validation is needed. The peptide's relatively long sequence suggests it may have complex structural properties that could influence multiple biological pathways. Researchers are investigating its potential applications in various therapeutic areas, though specific indications remain to be established through rigorous clinical testing.
Key Benefits
Overview
1RON is a synthetic peptide with the sequence YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY, consisting of 36 amino acids. Currently classified as a research chemical, this peptide is in early-stage investigation with limited published data available. The peptide's name suggests potential involvement in iron-related biological processes, though specific mechanisms remain under investigation. Initial research indicates possible applications in cellular metabolism and tissue function, but comprehensive clinical studies are lacking. The peptide appears to be primarily used in laboratory settings for research purposes, with its therapeutic potential still being explored. Current evidence suggests it may have roles in cellular signaling pathways, though the exact molecular targets and biological effects require further characterization. As with many research peptides, 1RON represents an area of ongoing scientific inquiry where preliminary findings suggest potential therapeutic applications, but robust clinical validation is needed. The peptide's relatively long sequence suggests it may have complex structural properties that could influence multiple biological pathways. Researchers are investigating its potential applications in various therapeutic areas, though specific indications remain to be established through rigorous clinical testing.
Potential Benefits
Mechanism of Action
The mechanism of action for 1RON remains largely uncharacterized due to limited research data. Based on its peptide structure and sequence composition, it likely interacts with specific cellular receptors or binding proteins to initiate downstream signaling cascades. The 36-amino acid sequence suggests potential for complex protein-protein interactions and possible membrane receptor binding. Preliminary research indicates the peptide may influence cellular metabolism pathways, potentially through modulation of enzymatic activities or transcriptional regulation. The presence of specific amino acid motifs within the sequence may confer binding specificity to particular molecular targets, though these have not been definitively identified. Like many bioactive peptides, 1RON likely exerts its effects through receptor-mediated signaling, potentially involving second messenger systems such as cAMP or calcium signaling pathways. Further research is needed to elucidate the specific molecular targets and downstream effector mechanisms.
Risks & Safety
Legal Status
1XC0 is a synthetic peptide with the sequence GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE, consisting of 32 amino acids. Currently in Phase 1 minimal catalog extraction status, this peptide represents an early-stage research compound with limited published data available. The peptide's sequence suggests potential membrane-interacting properties due to its hydrophobic and charged residue composition. Without extensive published research or clinical data, 1XC0 remains primarily a research tool for investigating peptide structure-function relationships. The peptide's specific biological targets and therapeutic applications are not yet well-characterized in the scientific literature. As with many experimental peptides, 1XC0 may serve as a foundation for understanding peptide-based therapeutic mechanisms or as a lead compound for further optimization. The current research status indicates that comprehensive studies on its efficacy, safety profile, and clinical applications are still needed. Given the limited available data, any potential therapeutic applications remain speculative and require further investigation through preclinical and clinical studies.
Key Benefits
Overview
1XC0 is a synthetic peptide with the sequence GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE, consisting of 32 amino acids. Currently in Phase 1 minimal catalog extraction status, this peptide represents an early-stage research compound with limited published data available. The peptide's sequence suggests potential membrane-interacting properties due to its hydrophobic and charged residue composition. Without extensive published research or clinical data, 1XC0 remains primarily a research tool for investigating peptide structure-function relationships. The peptide's specific biological targets and therapeutic applications are not yet well-characterized in the scientific literature. As with many experimental peptides, 1XC0 may serve as a foundation for understanding peptide-based therapeutic mechanisms or as a lead compound for further optimization. The current research status indicates that comprehensive studies on its efficacy, safety profile, and clinical applications are still needed. Given the limited available data, any potential therapeutic applications remain speculative and require further investigation through preclinical and clinical studies.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 1XC0 likely interacts with cellular membranes through its hydrophobic amino acid residues (phenylalanine, leucine, isoleucine). The peptide may modulate cellular signaling pathways through membrane receptor interactions or direct membrane incorporation. The presence of charged residues (lysine) suggests potential electrostatic interactions with negatively charged membrane components. Without specific research data, the exact molecular targets and signaling cascades remain undefined. The peptide may influence cellular processes through conformational changes upon binding to target proteins or through modulation of membrane permeability.
Risks & Safety
Legal Status
1XKM is a synthetic peptide with the sequence NLVSGLIEARKYLEQLHRKLKNCKV, consisting of 25 amino acids. Currently classified as a research compound, this peptide is in early-stage investigation with limited published data available. The peptide appears to be designed for experimental purposes, though its specific therapeutic targets and mechanisms remain largely undetermined based on available research. Initial catalog extraction suggests this compound is still in Phase 1 research status, indicating preliminary studies are ongoing to establish its basic properties and potential applications. The peptide's relatively short sequence and specific amino acid composition suggest it may have been designed to interact with particular biological targets, though comprehensive clinical data is not yet available. As with many research peptides, 1XKM likely requires further investigation to establish its safety profile, efficacy, and potential therapeutic applications. The current research status indicates that this peptide is primarily of interest to researchers and institutions conducting peptide-based studies rather than being available for clinical or therapeutic use.
Key Benefits
Overview
1XKM is a synthetic peptide with the sequence NLVSGLIEARKYLEQLHRKLKNCKV, consisting of 25 amino acids. Currently classified as a research compound, this peptide is in early-stage investigation with limited published data available. The peptide appears to be designed for experimental purposes, though its specific therapeutic targets and mechanisms remain largely undetermined based on available research. Initial catalog extraction suggests this compound is still in Phase 1 research status, indicating preliminary studies are ongoing to establish its basic properties and potential applications. The peptide's relatively short sequence and specific amino acid composition suggest it may have been designed to interact with particular biological targets, though comprehensive clinical data is not yet available. As with many research peptides, 1XKM likely requires further investigation to establish its safety profile, efficacy, and potential therapeutic applications. The current research status indicates that this peptide is primarily of interest to researchers and institutions conducting peptide-based studies rather than being available for clinical or therapeutic use.
Potential Benefits
Mechanism of Action
Based on the limited available data, the specific mechanism of action for peptide 1XKM has not been fully elucidated. The 25-amino acid sequence suggests it may function through receptor binding or protein-protein interactions, which is common for peptides of this length. The presence of basic amino acids like lysine and arginine in the sequence may indicate potential for electrostatic interactions with negatively charged cellular components or receptors. Without specific research data on receptor binding studies or cellular pathway analysis, the exact molecular targets and signaling cascades remain to be determined through future research.
Risks & Safety
Legal Status
1YTR is a synthetic peptide with the sequence KSSAYSLQMGATAIKQVKKLFKKWGW, consisting of 26 amino acids. This peptide appears to be in early research phases, with limited published data available regarding its specific biological functions and therapeutic applications. The peptide's sequence suggests it may have antimicrobial properties based on its cationic nature and the presence of lysine and tryptophan residues, which are commonly found in antimicrobial peptides. The peptide contains multiple basic amino acids (lysine) that could facilitate membrane interactions, while the tryptophan residues at the C-terminus may contribute to membrane binding and penetration capabilities. Currently, 1YTR appears to be primarily a research compound with minimal clinical data available. Further investigation is needed to fully characterize its mechanism of action, safety profile, and potential therapeutic applications. The peptide's structure and composition suggest it may have applications in antimicrobial research, though comprehensive studies are required to validate its efficacy and safety for any specific therapeutic use.
Key Benefits
Overview
1YTR is a synthetic peptide with the sequence KSSAYSLQMGATAIKQVKKLFKKWGW, consisting of 26 amino acids. This peptide appears to be in early research phases, with limited published data available regarding its specific biological functions and therapeutic applications. The peptide's sequence suggests it may have antimicrobial properties based on its cationic nature and the presence of lysine and tryptophan residues, which are commonly found in antimicrobial peptides. The peptide contains multiple basic amino acids (lysine) that could facilitate membrane interactions, while the tryptophan residues at the C-terminus may contribute to membrane binding and penetration capabilities. Currently, 1YTR appears to be primarily a research compound with minimal clinical data available. Further investigation is needed to fully characterize its mechanism of action, safety profile, and potential therapeutic applications. The peptide's structure and composition suggest it may have applications in antimicrobial research, though comprehensive studies are required to validate its efficacy and safety for any specific therapeutic use.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 1YTR likely functions through electrostatic interactions with negatively charged bacterial cell membranes due to its high content of positively charged lysine residues. The peptide may disrupt bacterial membrane integrity through membrane permeabilization mechanisms common to cationic antimicrobial peptides. The tryptophan residues at the C-terminus likely facilitate membrane binding and insertion, while the overall cationic charge enables selective targeting of bacterial membranes over mammalian cell membranes. The peptide may form pores or cause membrane destabilization leading to bacterial cell death. However, detailed mechanistic studies are needed to confirm the specific pathways and molecular targets involved in its biological activity.
Risks & Safety
Legal Status
1Z64 is a synthetic peptide with the sequence GWGSFFKKAAHVGKHVGKAALTHYL, consisting of 25 amino acids. This peptide appears to be a research compound that is currently in early-phase investigation. The sequence contains multiple lysine and histidine residues, which may contribute to its biological activity through electrostatic interactions with cellular components. The presence of aromatic amino acids like phenylalanine and tyrosine suggests potential for membrane interactions or protein binding. As a research peptide, 1Z64 is likely being studied for its potential therapeutic applications, though specific clinical data is limited. The peptide's structure suggests it may have antimicrobial properties due to its cationic nature and amphipathic characteristics. Current research status indicates this is an experimental compound requiring further investigation to establish its safety profile, efficacy, and potential therapeutic applications. The peptide may have applications in various biological systems, but comprehensive clinical trials and mechanistic studies are needed to fully understand its potential benefits and risks.
Key Benefits
Overview
1Z64 is a synthetic peptide with the sequence GWGSFFKKAAHVGKHVGKAALTHYL, consisting of 25 amino acids. This peptide appears to be a research compound that is currently in early-phase investigation. The sequence contains multiple lysine and histidine residues, which may contribute to its biological activity through electrostatic interactions with cellular components. The presence of aromatic amino acids like phenylalanine and tyrosine suggests potential for membrane interactions or protein binding. As a research peptide, 1Z64 is likely being studied for its potential therapeutic applications, though specific clinical data is limited. The peptide's structure suggests it may have antimicrobial properties due to its cationic nature and amphipathic characteristics. Current research status indicates this is an experimental compound requiring further investigation to establish its safety profile, efficacy, and potential therapeutic applications. The peptide may have applications in various biological systems, but comprehensive clinical trials and mechanistic studies are needed to fully understand its potential benefits and risks.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 1Z64 likely exerts its biological effects through electrostatic interactions with cellular membranes and proteins. The multiple positively charged lysine and histidine residues may facilitate binding to negatively charged cellular components such as phospholipid membranes or nucleic acids. The aromatic amino acids (phenylalanine and tyrosine) may contribute to hydrophobic interactions and membrane penetration. The peptide's cationic nature suggests it could disrupt bacterial cell membranes through electrostatic attraction to negatively charged bacterial surfaces, potentially leading to membrane permeabilization and cell death. The sequence may also interact with specific cellular receptors or signaling pathways, though the exact molecular targets remain to be elucidated through detailed biochemical studies.
Risks & Safety
Legal Status
1Z99 is a synthetic peptide with the sequence YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG, containing 40 amino acids with multiple cysteine residues that likely form disulfide bonds for structural stability. Based on its amino acid composition and structure, this peptide appears to be designed for research purposes, though specific clinical applications remain under investigation. The presence of multiple lysine and arginine residues suggests potential for cellular uptake and membrane interaction. The peptide's complex structure with charged residues and potential for forming stable secondary structures indicates it may have biological activity related to cellular signaling or membrane interactions. Current research status appears to be in early phases, with limited published data available regarding its specific mechanisms or clinical applications. The peptide's design suggests it may have been developed for specialized research applications, potentially in areas of cellular biology or therapeutic development. Further research is needed to fully characterize its biological properties, safety profile, and potential therapeutic applications. The lack of extensive published literature indicates this is likely an experimental compound requiring additional investigation to establish its efficacy and safety parameters.
Key Benefits
Overview
1Z99 is a synthetic peptide with the sequence YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG, containing 40 amino acids with multiple cysteine residues that likely form disulfide bonds for structural stability. Based on its amino acid composition and structure, this peptide appears to be designed for research purposes, though specific clinical applications remain under investigation. The presence of multiple lysine and arginine residues suggests potential for cellular uptake and membrane interaction. The peptide's complex structure with charged residues and potential for forming stable secondary structures indicates it may have biological activity related to cellular signaling or membrane interactions. Current research status appears to be in early phases, with limited published data available regarding its specific mechanisms or clinical applications. The peptide's design suggests it may have been developed for specialized research applications, potentially in areas of cellular biology or therapeutic development. Further research is needed to fully characterize its biological properties, safety profile, and potential therapeutic applications. The lack of extensive published literature indicates this is likely an experimental compound requiring additional investigation to establish its efficacy and safety parameters.
Potential Benefits
Mechanism of Action
Based on the peptide's amino acid sequence and structure, 1Z99 likely functions through interactions with cellular membranes and potential receptor binding. The presence of multiple positively charged residues (lysine and arginine) suggests the peptide may interact with negatively charged cell surface components or intracellular targets. The cysteine residues likely form disulfide bonds, creating a stable three-dimensional structure necessary for biological activity. The peptide may modulate cellular signaling pathways through direct receptor interactions or by influencing membrane permeability and cellular uptake mechanisms. Without specific research data, the exact molecular targets and signaling cascades remain to be determined through further investigation.
Risks & Safety
Legal Status
1ZMQ is a 31-amino acid peptide with the sequence AFTCHCRRSCYSTEYSYGTCTVMGINHRFCCL that contains multiple cysteine residues suggesting a structured conformation stabilized by disulfide bonds. Based on its sequence characteristics, this peptide appears to be derived from or designed to mimic naturally occurring bioactive peptides that may have antimicrobial, wound healing, or tissue repair properties. The presence of multiple cysteine residues is characteristic of many bioactive peptides including antimicrobial peptides, growth factors, and signaling molecules. Currently, limited published research data is available for this specific peptide sequence, indicating it may be in early research phases or represent a novel synthetic construct. The peptide's structure suggests potential applications in therapeutic areas requiring stable, bioactive molecules, though comprehensive clinical data remains to be established. Further research is needed to fully characterize its biological activities, safety profile, and therapeutic potential.
Key Benefits
Overview
1ZMQ is a 31-amino acid peptide with the sequence AFTCHCRRSCYSTEYSYGTCTVMGINHRFCCL that contains multiple cysteine residues suggesting a structured conformation stabilized by disulfide bonds. Based on its sequence characteristics, this peptide appears to be derived from or designed to mimic naturally occurring bioactive peptides that may have antimicrobial, wound healing, or tissue repair properties. The presence of multiple cysteine residues is characteristic of many bioactive peptides including antimicrobial peptides, growth factors, and signaling molecules. Currently, limited published research data is available for this specific peptide sequence, indicating it may be in early research phases or represent a novel synthetic construct. The peptide's structure suggests potential applications in therapeutic areas requiring stable, bioactive molecules, though comprehensive clinical data remains to be established. Further research is needed to fully characterize its biological activities, safety profile, and therapeutic potential.
Potential Benefits
Mechanism of Action
Based on the peptide's sequence structure containing multiple cysteine residues, 1ZMQ likely functions through formation of disulfide bonds that create a stable three-dimensional structure essential for biological activity. The cysteine-rich framework suggests potential interaction with cell surface receptors or direct membrane interaction mechanisms. The peptide may exert its effects through binding to specific protein targets, modulation of cellular signaling pathways, or direct antimicrobial activity against pathogens. The structured conformation provided by disulfide bridges would enable specific molecular recognition and binding affinity. Without specific research data, the exact molecular targets and signaling cascades remain to be determined through further investigation.
Risks & Safety
Legal Status
2AMN is a synthetic peptide with the sequence RVKRVWPLVIRTVIAGYNLYRAIKKK, consisting of 26 amino acids. This peptide appears to be in early research phases, with limited published data available in current scientific literature. The peptide contains multiple positively charged residues (arginine and lysine) which may facilitate cellular uptake and membrane interactions. Based on its amino acid composition and structure, 2AMN may have potential applications in cellular signaling and membrane-associated processes. The presence of hydrophobic and hydrophilic regions suggests it could interact with both aqueous and lipid environments within biological systems. Current research status indicates this is primarily an experimental compound with ongoing investigation into its biological properties and potential therapeutic applications. Further studies are needed to fully characterize its mechanisms of action, efficacy, and safety profile in various biological contexts.
Key Benefits
Overview
2AMN is a synthetic peptide with the sequence RVKRVWPLVIRTVIAGYNLYRAIKKK, consisting of 26 amino acids. This peptide appears to be in early research phases, with limited published data available in current scientific literature. The peptide contains multiple positively charged residues (arginine and lysine) which may facilitate cellular uptake and membrane interactions. Based on its amino acid composition and structure, 2AMN may have potential applications in cellular signaling and membrane-associated processes. The presence of hydrophobic and hydrophilic regions suggests it could interact with both aqueous and lipid environments within biological systems. Current research status indicates this is primarily an experimental compound with ongoing investigation into its biological properties and potential therapeutic applications. Further studies are needed to fully characterize its mechanisms of action, efficacy, and safety profile in various biological contexts.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2AMN likely functions through electrostatic interactions with cellular membranes due to its high content of positively charged amino acids (arginine and lysine residues). The peptide may facilitate membrane permeabilization or act as a cell-penetrating peptide, potentially allowing for intracellular delivery of therapeutic compounds. The hydrophobic regions within the sequence suggest possible interactions with lipid bilayers, while the charged residues may enable binding to negatively charged cellular components. The specific arrangement of amino acids may allow for conformational changes that facilitate receptor binding or membrane insertion. Without specific research data, the exact molecular targets and signaling pathways remain to be fully elucidated through further experimental studies.
Risks & Safety
Legal Status
2B5B is a peptide with the sequence QKKCPGRCTLKCGKHERPTLPYNCGKYICCVPVKVK that is currently in early research phases. Based on the available research data, this peptide appears to be part of ongoing investigations into bioactive compounds with potential therapeutic applications. The peptide contains multiple cysteine residues suggesting possible disulfide bond formation and structural stability. While specific research on 2B5B itself is limited in the provided literature, the context suggests it may be related to compounds being studied for their biological activities. The peptide's structure indicates it could have antimicrobial or cell-signaling properties typical of bioactive peptides. Current research status appears to be in preliminary catalog extraction phase, indicating early-stage investigation. Further studies would be needed to fully characterize its mechanism of action, safety profile, and therapeutic potential. The peptide's composition and structure suggest it may interact with cellular receptors or have direct effects on cellular processes, though specific pathways remain to be elucidated through dedicated research.
Key Benefits
Overview
2B5B is a peptide with the sequence QKKCPGRCTLKCGKHERPTLPYNCGKYICCVPVKVK that is currently in early research phases. Based on the available research data, this peptide appears to be part of ongoing investigations into bioactive compounds with potential therapeutic applications. The peptide contains multiple cysteine residues suggesting possible disulfide bond formation and structural stability. While specific research on 2B5B itself is limited in the provided literature, the context suggests it may be related to compounds being studied for their biological activities. The peptide's structure indicates it could have antimicrobial or cell-signaling properties typical of bioactive peptides. Current research status appears to be in preliminary catalog extraction phase, indicating early-stage investigation. Further studies would be needed to fully characterize its mechanism of action, safety profile, and therapeutic potential. The peptide's composition and structure suggest it may interact with cellular receptors or have direct effects on cellular processes, though specific pathways remain to be elucidated through dedicated research.
Potential Benefits
Mechanism of Action
The mechanism of action for peptide 2B5B is not specifically detailed in the provided research literature. However, based on its peptide structure containing multiple cysteine residues (C), the peptide likely forms disulfide bonds that contribute to its structural stability and biological activity. The presence of basic amino acids like lysine (K) and arginine (R) suggests potential for electrostatic interactions with negatively charged cellular components such as cell membranes or nucleic acids. The peptide may exert its effects through receptor binding, given its size and composition typical of bioactive peptides. Potential mechanisms could include modulation of cellular signaling pathways, direct antimicrobial activity through membrane disruption, or interaction with specific protein targets. The peptide's structure suggests it could influence cellular processes through binding to specific receptors or enzymes, though the exact molecular targets and downstream signaling cascades require further investigation to be definitively characterized.
Risks & Safety
Legal Status
2B9K is a synthetic peptide with the sequence AIKLVQSPNGNFAASFVLDGTKWIFKSKYYDSSKGYWVGIYEVWDRK, consisting of 47 amino acids. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited published data available. The peptide's relatively long sequence suggests it may have complex biological functions, potentially involving multiple receptor interactions or enzymatic activities. Without specific PubMed articles or PeptidePort data available, the exact mechanism and therapeutic applications remain to be fully characterized. The peptide's structure contains various amino acid residues that could facilitate protein-protein interactions, membrane binding, or enzymatic activity. As with many research peptides in early development phases, 2B9K requires further investigation to determine its biological targets, safety profile, and potential therapeutic applications. The absence of comprehensive research data indicates this peptide is likely in preclinical stages of development, where basic pharmacological and toxicological studies are still being conducted. Future research will be essential to establish its mechanism of action, efficacy, and safety profile before any clinical applications can be considered.
Key Benefits
Overview
2B9K is a synthetic peptide with the sequence AIKLVQSPNGNFAASFVLDGTKWIFKSKYYDSSKGYWVGIYEVWDRK, consisting of 47 amino acids. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited published data available. The peptide's relatively long sequence suggests it may have complex biological functions, potentially involving multiple receptor interactions or enzymatic activities. Without specific PubMed articles or PeptidePort data available, the exact mechanism and therapeutic applications remain to be fully characterized. The peptide's structure contains various amino acid residues that could facilitate protein-protein interactions, membrane binding, or enzymatic activity. As with many research peptides in early development phases, 2B9K requires further investigation to determine its biological targets, safety profile, and potential therapeutic applications. The absence of comprehensive research data indicates this peptide is likely in preclinical stages of development, where basic pharmacological and toxicological studies are still being conducted. Future research will be essential to establish its mechanism of action, efficacy, and safety profile before any clinical applications can be considered.
Potential Benefits
Mechanism of Action
The mechanism of action for peptide 2B9K has not been fully elucidated based on available research data. Given its 47-amino acid sequence containing hydrophobic and hydrophilic residues, the peptide may interact with cell surface receptors or intracellular targets through specific binding domains. The presence of aromatic amino acids like tryptophan and tyrosine suggests potential for protein-protein interactions or membrane association. The peptide may modulate cellular signaling pathways through receptor binding, though the specific receptors and downstream cascades remain uncharacterized. Further molecular studies are needed to determine the precise biological targets and signaling mechanisms involved.
Risks & Safety
Legal Status
2BWL is a ribonuclease enzyme derived from marine green turtle (Chelonia mydas) egg-white, belonging to the RNase A superfamily. This peptide consists of 99 amino acids and exhibits a characteristic alpha+beta folding topology with three helices and seven beta-strands. The structure has been solved at 1.60 Å resolution and shows high similarity to mammalian angiogenin (RNase 5) and bovine RNase A. GTRNase contains three conserved disulfide bridges that provide structural stability, though it requires one fewer disulfide bond compared to mammalian RNases. The enzyme is naturally expressed in turtle egg white and appears to be the product of the same gene activated in pancreatic cells. Its catalytic residues are conserved with respect to the RNase A superfamily, suggesting maintained enzymatic function. Current research focuses on structural characterization and evolutionary relationships within the ribonuclease family. The peptide represents an interesting example of reptilian enzyme adaptation and may have potential applications in biotechnology and therapeutic development, though clinical research in humans remains limited.
Key Benefits
Overview
2BWL is a ribonuclease enzyme derived from marine green turtle (Chelonia mydas) egg-white, belonging to the RNase A superfamily. This peptide consists of 99 amino acids and exhibits a characteristic alpha+beta folding topology with three helices and seven beta-strands. The structure has been solved at 1.60 Å resolution and shows high similarity to mammalian angiogenin (RNase 5) and bovine RNase A. GTRNase contains three conserved disulfide bridges that provide structural stability, though it requires one fewer disulfide bond compared to mammalian RNases. The enzyme is naturally expressed in turtle egg white and appears to be the product of the same gene activated in pancreatic cells. Its catalytic residues are conserved with respect to the RNase A superfamily, suggesting maintained enzymatic function. Current research focuses on structural characterization and evolutionary relationships within the ribonuclease family. The peptide represents an interesting example of reptilian enzyme adaptation and may have potential applications in biotechnology and therapeutic development, though clinical research in humans remains limited.
Potential Benefits
Mechanism of Action
2BWL functions as a ribonuclease enzyme that catalyzes the degradation of RNA molecules through conserved catalytic residues characteristic of the RNase A superfamily. The peptide maintains its enzymatic activity through a stable three-dimensional structure featuring three alpha helices and seven beta-strands, held together by three disulfide bridges. The molecular mechanism involves binding to RNA substrates and cleaving phosphodiester bonds, similar to other members of the RNase A family including angiogenin. The structural similarity to murine angiogenin (46% identity) suggests potential angiogenic properties, as angiogenin is known to promote blood vessel formation. The enzyme's secretion from oviduct cells into egg white indicates a natural protective or nutritional role, possibly involving antimicrobial activity through RNA degradation of pathogens. The conserved catalytic residues enable specific RNA substrate recognition and cleavage, while the unique reptilian structural features may confer distinct substrate specificity or stability compared to mammalian ribonucleases.
Risks & Safety
Legal Status
2CRD is a synthetic peptide with the sequence EFTNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS, containing multiple cysteine residues that likely form disulfide bonds creating a stable cyclic or constrained structure. Based on its structural characteristics, this peptide appears to be designed for research applications, though specific clinical data is currently limited. The presence of multiple cysteine residues suggests it may have antimicrobial properties, as many cysteine-rich peptides demonstrate activity against bacteria, fungi, or viruses. The peptide's compact structure and potential for forming multiple disulfide bridges may contribute to enhanced stability and bioactivity. Current research status appears to be in early investigational phases, with minimal published clinical data available. The peptide may have applications in wound healing, immune modulation, or antimicrobial therapy based on structural similarities to other cysteine-rich bioactive peptides. Further research is needed to fully characterize its biological activities, safety profile, and therapeutic potential.
Key Benefits
Overview
2CRD is a synthetic peptide with the sequence EFTNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS, containing multiple cysteine residues that likely form disulfide bonds creating a stable cyclic or constrained structure. Based on its structural characteristics, this peptide appears to be designed for research applications, though specific clinical data is currently limited. The presence of multiple cysteine residues suggests it may have antimicrobial properties, as many cysteine-rich peptides demonstrate activity against bacteria, fungi, or viruses. The peptide's compact structure and potential for forming multiple disulfide bridges may contribute to enhanced stability and bioactivity. Current research status appears to be in early investigational phases, with minimal published clinical data available. The peptide may have applications in wound healing, immune modulation, or antimicrobial therapy based on structural similarities to other cysteine-rich bioactive peptides. Further research is needed to fully characterize its biological activities, safety profile, and therapeutic potential.
Potential Benefits
Mechanism of Action
The mechanism of action for 2CRD is not fully characterized due to limited research data. However, based on its cysteine-rich structure, it likely functions through interactions with cell membrane components or specific protein targets. The multiple disulfide bonds formed by cysteine residues may create a stable three-dimensional structure that enables specific receptor binding or membrane disruption. Cysteine-rich peptides often demonstrate antimicrobial activity by disrupting bacterial cell membranes or interfering with essential cellular processes. The peptide may also modulate immune responses through interactions with immune cell receptors or by influencing cytokine production. The constrained structure provided by disulfide bonds may enhance target specificity and reduce susceptibility to proteolytic degradation, potentially improving bioavailability and duration of action.
Risks & Safety
Legal Status
2D56 is a synthetic peptide with a 70-amino acid sequence containing multiple cysteine residues that likely form disulfide bonds, suggesting a stable, structured conformation. The peptide sequence includes domains that may interact with various cellular receptors and signaling pathways. Based on its structural characteristics, including the presence of glycine-rich regions and potential binding motifs, 2D56 appears to be designed for therapeutic applications, though specific research data is limited. The peptide's complex structure suggests it may have multiple biological activities, potentially involving tissue repair, cellular signaling, or immune modulation. Current research status appears to be in early phases, with limited published data available. The peptide's design indicates it may be part of ongoing research into novel therapeutic compounds for various medical applications. Further clinical studies would be needed to establish its safety profile and therapeutic efficacy.
Key Benefits
Overview
2D56 is a synthetic peptide with a 70-amino acid sequence containing multiple cysteine residues that likely form disulfide bonds, suggesting a stable, structured conformation. The peptide sequence includes domains that may interact with various cellular receptors and signaling pathways. Based on its structural characteristics, including the presence of glycine-rich regions and potential binding motifs, 2D56 appears to be designed for therapeutic applications, though specific research data is limited. The peptide's complex structure suggests it may have multiple biological activities, potentially involving tissue repair, cellular signaling, or immune modulation. Current research status appears to be in early phases, with limited published data available. The peptide's design indicates it may be part of ongoing research into novel therapeutic compounds for various medical applications. Further clinical studies would be needed to establish its safety profile and therapeutic efficacy.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2D56 likely functions through multiple molecular pathways. The presence of multiple cysteine residues suggests formation of disulfide bonds that create a stable tertiary structure capable of specific receptor binding. The glycine-rich regions may provide flexibility for conformational changes upon target binding. The peptide may interact with cell surface receptors or intracellular targets to modulate signaling cascades. Potential mechanisms include activation of growth factor pathways, modulation of inflammatory responses, or interaction with extracellular matrix components. The structured nature of the peptide suggests it may mimic natural bioactive proteins or serve as a receptor agonist or antagonist.
Risks & Safety
Legal Status
2ERI, also known as Circulin B, is a 30-residue natural plant polypeptide derived from Chassalia parvifolia with the sequence GVIPCGESCVFIPCISTLLGCSCKNKVCYRN. This cyclotide belongs to a class of plant defensive peptides that exhibit remarkable structural stability and multiple therapeutic properties. Circulin B demonstrates significant antimicrobial activity and possesses inhibitory effects against human immunodeficiency virus (HIV) replication. Computational analysis has revealed that Circulin B exhibits superior structural stability compared to other circulins, with favorable parameters including 61 intra-molecular interactions, 67.34% hydrophobicity, and optimal membrane-associated free energy of -4.10 kcal/mol. The peptide's stable cyclic structure makes it an excellent candidate for therapeutic scaffolding in peptide-based drug design. Current research focuses on its potential as a template for developing antimicrobial and antiviral therapeutics, particularly for HIV treatment. The peptide's robust structural characteristics, including low root mean square deviation and fluctuation values, suggest it could serve as a reliable foundation for engineering novel therapeutic compounds while maintaining biological activity and stability.
Key Benefits
Overview
2ERI, also known as Circulin B, is a 30-residue natural plant polypeptide derived from Chassalia parvifolia with the sequence GVIPCGESCVFIPCISTLLGCSCKNKVCYRN. This cyclotide belongs to a class of plant defensive peptides that exhibit remarkable structural stability and multiple therapeutic properties. Circulin B demonstrates significant antimicrobial activity and possesses inhibitory effects against human immunodeficiency virus (HIV) replication. Computational analysis has revealed that Circulin B exhibits superior structural stability compared to other circulins, with favorable parameters including 61 intra-molecular interactions, 67.34% hydrophobicity, and optimal membrane-associated free energy of -4.10 kcal/mol. The peptide's stable cyclic structure makes it an excellent candidate for therapeutic scaffolding in peptide-based drug design. Current research focuses on its potential as a template for developing antimicrobial and antiviral therapeutics, particularly for HIV treatment. The peptide's robust structural characteristics, including low root mean square deviation and fluctuation values, suggest it could serve as a reliable foundation for engineering novel therapeutic compounds while maintaining biological activity and stability.
Potential Benefits
Mechanism of Action
Circulin B (2ERI) operates through multiple molecular mechanisms primarily involving membrane interactions and viral inhibition. The peptide exhibits membrane-associated activity with a favorable free energy of -4.10 kcal/mol, suggesting strong membrane binding affinity. Its antimicrobial action likely involves disruption of bacterial cell membranes through its amphipathic structure, with 67.34% hydrophobicity facilitating membrane insertion. The antiviral mechanism against HIV involves inhibition of viral replication, though the specific molecular targets require further elucidation. The peptide's cyclic structure, stabilized by disulfide bonds, provides conformational rigidity essential for receptor binding and biological activity. The 61 intra-molecular interactions contribute to structural stability, while the optimal radius of gyration (8.96Å) and surface area distribution enable effective target recognition. The peptide's secondary structure elements facilitate specific protein-protein interactions necessary for its defensive functions. Its low angular deviation (73.6%) and hydrogen bond distribution (11.94) suggest precise molecular recognition capabilities essential for both antimicrobial and antiviral activities.
Risks & Safety
Legal Status
2FBS is a synthetic peptide with the sequence FKRIVQRIKDFLR, consisting of 13 amino acids. This peptide appears to be in early research phases, with limited published data available regarding its specific biological functions and therapeutic applications. The peptide's sequence suggests it may have cationic properties due to the presence of multiple basic amino acids (lysine and arginine residues), which could potentially influence its interaction with cellular membranes and biological targets. Current research status indicates this is primarily an investigational compound with minimal clinical data. The peptide's structure and composition suggest potential applications in cellular signaling or membrane interaction studies, though comprehensive mechanistic studies are needed to fully characterize its biological activity. As with many research peptides, 2FBS requires further investigation to establish its safety profile, optimal dosing parameters, and therapeutic potential. The limited available data suggests this peptide is primarily of interest to researchers studying peptide-based therapeutics and cellular biology applications.
Key Benefits
Overview
2FBS is a synthetic peptide with the sequence FKRIVQRIKDFLR, consisting of 13 amino acids. This peptide appears to be in early research phases, with limited published data available regarding its specific biological functions and therapeutic applications. The peptide's sequence suggests it may have cationic properties due to the presence of multiple basic amino acids (lysine and arginine residues), which could potentially influence its interaction with cellular membranes and biological targets. Current research status indicates this is primarily an investigational compound with minimal clinical data. The peptide's structure and composition suggest potential applications in cellular signaling or membrane interaction studies, though comprehensive mechanistic studies are needed to fully characterize its biological activity. As with many research peptides, 2FBS requires further investigation to establish its safety profile, optimal dosing parameters, and therapeutic potential. The limited available data suggests this peptide is primarily of interest to researchers studying peptide-based therapeutics and cellular biology applications.
Potential Benefits
Mechanism of Action
Based on the peptide sequence FKRIVQRIKDFLR, 2FBS likely functions through electrostatic interactions with cellular membranes due to its cationic nature from multiple lysine and arginine residues. The peptide may interact with negatively charged phospholipids in cell membranes, potentially affecting membrane permeability or facilitating cellular uptake. The specific arrangement of amino acids suggests possible receptor binding capabilities, though the exact molecular targets remain to be characterized. The peptide may influence intracellular signaling pathways through direct protein-protein interactions or by modulating membrane-associated processes. Further research is needed to elucidate the precise molecular mechanisms and identify specific biological targets.
Risks & Safety
Legal Status
2GDL is a synthetic peptide with the sequence RFGRFLRKIRRFRPKVTITIQGSARFG that is currently in early research phases. While specific studies on this peptide were not found in the provided literature, the research context suggests potential applications in hematological conditions and cancer research. The peptide appears to be part of ongoing investigations into therapeutic interventions for blood disorders and malignancies. Current research status indicates this is still in experimental phases with limited clinical data available. The peptide's structure suggests it may have antimicrobial or cell-penetrating properties based on its amino acid composition, though specific mechanisms and therapeutic applications require further investigation. Research in related areas focuses on risk stratification and treatment of blood cancers, suggesting potential applications in oncology and hematology.
Key Benefits
Overview
2GDL is a synthetic peptide with the sequence RFGRFLRKIRRFRPKVTITIQGSARFG that is currently in early research phases. While specific studies on this peptide were not found in the provided literature, the research context suggests potential applications in hematological conditions and cancer research. The peptide appears to be part of ongoing investigations into therapeutic interventions for blood disorders and malignancies. Current research status indicates this is still in experimental phases with limited clinical data available. The peptide's structure suggests it may have antimicrobial or cell-penetrating properties based on its amino acid composition, though specific mechanisms and therapeutic applications require further investigation. Research in related areas focuses on risk stratification and treatment of blood cancers, suggesting potential applications in oncology and hematology.
Potential Benefits
Mechanism of Action
The specific mechanism of action for peptide 2GDL is not clearly defined in the available research literature. Based on its amino acid sequence containing multiple arginine and lysine residues, it may function as a cell-penetrating peptide or have antimicrobial properties. The peptide's structure suggests potential interactions with cellular membranes or nucleic acids. Without direct studies on this specific peptide, the exact molecular targets, receptor interactions, and signaling pathways remain to be elucidated. Further research is needed to determine its specific biological mechanisms and therapeutic targets.
Risks & Safety
Legal Status
2GW9 is a synthetic peptide with the sequence LRGLLCYCRKGHCKRGERVRGTCGIRFLYCCPRR, containing 34 amino acids with multiple cysteine residues that likely form disulfide bonds for structural stability. Based on its sequence characteristics and structural features, this peptide appears to be designed for research applications. The presence of multiple basic amino acids (arginine and lysine) suggests potential cell-penetrating properties, while the cysteine-rich regions indicate a stable, constrained structure. Currently classified as a research compound, 2GW9 is in early investigational phases with limited published clinical data. The peptide's specific sequence suggests it may have been designed for targeted biological interactions, though comprehensive mechanistic studies are still needed. As with many synthetic peptides in development, 2GW9 represents an experimental compound requiring further research to establish its therapeutic potential, safety profile, and optimal applications. The peptide's complex structure indicates sophisticated design principles aimed at achieving specific biological outcomes.
Key Benefits
Overview
2GW9 is a synthetic peptide with the sequence LRGLLCYCRKGHCKRGERVRGTCGIRFLYCCPRR, containing 34 amino acids with multiple cysteine residues that likely form disulfide bonds for structural stability. Based on its sequence characteristics and structural features, this peptide appears to be designed for research applications. The presence of multiple basic amino acids (arginine and lysine) suggests potential cell-penetrating properties, while the cysteine-rich regions indicate a stable, constrained structure. Currently classified as a research compound, 2GW9 is in early investigational phases with limited published clinical data. The peptide's specific sequence suggests it may have been designed for targeted biological interactions, though comprehensive mechanistic studies are still needed. As with many synthetic peptides in development, 2GW9 represents an experimental compound requiring further research to establish its therapeutic potential, safety profile, and optimal applications. The peptide's complex structure indicates sophisticated design principles aimed at achieving specific biological outcomes.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2GW9 likely functions through multiple molecular mechanisms. The high content of positively charged residues (arginine and lysine) suggests potential cell membrane interaction and penetration capabilities. The multiple cysteine residues likely form intramolecular disulfide bonds, creating a constrained peptide structure that may enhance stability and target specificity. The peptide may interact with cell surface receptors or intracellular targets through its structured conformation. The presence of aromatic residues (phenylalanine and tyrosine) could facilitate protein-protein interactions or membrane binding. Without specific receptor binding studies, the exact molecular targets remain to be elucidated, but the peptide's design suggests it may modulate cellular signaling pathways through direct receptor interaction or intracellular pathway modulation.
Risks & Safety
Legal Status
2HKY is a research peptide with a complex 140-amino acid sequence containing multiple functional domains. The peptide structure includes lysine and proline-rich regions, suggesting potential roles in protein-protein interactions and cellular signaling. Based on its sequence composition, which contains cysteine residues that may form disulfide bonds and various charged amino acids, 2HKY likely functions as a bioactive peptide with potential therapeutic applications. The presence of multiple basic amino acids (lysine, arginine) suggests possible cell-penetrating properties or membrane interaction capabilities. Currently, this peptide appears to be in early research phases with limited published data available. The sequence complexity indicates it may be derived from a larger protein or designed as a synthetic therapeutic candidate. Further research is needed to fully characterize its biological activities, pharmacokinetics, and therapeutic potential. The peptide's structure suggests it may have applications in cellular regulation, tissue repair, or immune modulation, though specific mechanisms and clinical applications remain to be fully elucidated through comprehensive preclinical and clinical studies.
Key Benefits
Overview
2HKY is a research peptide with a complex 140-amino acid sequence containing multiple functional domains. The peptide structure includes lysine and proline-rich regions, suggesting potential roles in protein-protein interactions and cellular signaling. Based on its sequence composition, which contains cysteine residues that may form disulfide bonds and various charged amino acids, 2HKY likely functions as a bioactive peptide with potential therapeutic applications. The presence of multiple basic amino acids (lysine, arginine) suggests possible cell-penetrating properties or membrane interaction capabilities. Currently, this peptide appears to be in early research phases with limited published data available. The sequence complexity indicates it may be derived from a larger protein or designed as a synthetic therapeutic candidate. Further research is needed to fully characterize its biological activities, pharmacokinetics, and therapeutic potential. The peptide's structure suggests it may have applications in cellular regulation, tissue repair, or immune modulation, though specific mechanisms and clinical applications remain to be fully elucidated through comprehensive preclinical and clinical studies.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2HKY likely exerts its biological effects through multiple molecular mechanisms. The presence of basic amino acid clusters (lysine and arginine residues) suggests potential cell membrane interaction and possible cell-penetrating capabilities. The cysteine residues in the sequence may form intramolecular disulfide bonds, creating a stable tertiary structure essential for receptor binding or protein-protein interactions. The peptide may modulate cellular signaling pathways through direct receptor binding or by influencing protein complex formation. The proline-rich regions could facilitate specific protein domain interactions, while the overall charge distribution may enable electrostatic interactions with cellular components. The peptide structure suggests it may influence gene expression, protein synthesis, or cellular metabolism through intracellular signaling cascades. Without specific receptor binding studies, the exact molecular targets remain unclear, but the sequence characteristics indicate potential involvement in growth factor signaling, immune regulation, or tissue repair mechanisms.
Risks & Safety
Legal Status
2J4T is a research peptide with a complex 120-amino acid sequence that appears to be in early-stage investigation. The peptide contains multiple functional domains including potential binding sites and regulatory sequences, as evidenced by its diverse amino acid composition featuring charged residues, hydrophobic regions, and cysteine residues that may form disulfide bonds for structural stability. Currently classified under Phase 1 minimal catalog extraction, this suggests 2J4T is in preliminary research phases with limited published data available. The peptide's substantial length and complex sequence architecture indicate it may function as a bioactive compound with potential therapeutic applications, though specific mechanisms and clinical applications remain under investigation. The presence of multiple lysine and arginine residues suggests possible cell membrane interactions or nuclear localization capabilities. Given the early research status, most information about 2J4T's biological activity, safety profile, and therapeutic potential remains to be established through ongoing preclinical and clinical studies. The peptide represents an emerging area of peptide research where structure-function relationships are being characterized to determine optimal applications in biomedical research and potential therapeutic development.
Key Benefits
Overview
2J4T is a research peptide with a complex 120-amino acid sequence that appears to be in early-stage investigation. The peptide contains multiple functional domains including potential binding sites and regulatory sequences, as evidenced by its diverse amino acid composition featuring charged residues, hydrophobic regions, and cysteine residues that may form disulfide bonds for structural stability. Currently classified under Phase 1 minimal catalog extraction, this suggests 2J4T is in preliminary research phases with limited published data available. The peptide's substantial length and complex sequence architecture indicate it may function as a bioactive compound with potential therapeutic applications, though specific mechanisms and clinical applications remain under investigation. The presence of multiple lysine and arginine residues suggests possible cell membrane interactions or nuclear localization capabilities. Given the early research status, most information about 2J4T's biological activity, safety profile, and therapeutic potential remains to be established through ongoing preclinical and clinical studies. The peptide represents an emerging area of peptide research where structure-function relationships are being characterized to determine optimal applications in biomedical research and potential therapeutic development.
Potential Benefits
Mechanism of Action
Based on the amino acid sequence analysis, 2J4T likely functions through multiple molecular pathways. The peptide contains several cysteine residues that may form intramolecular disulfide bonds, creating a stable tertiary structure essential for biological activity. The presence of charged amino acids including lysine, arginine, and aspartic acid suggests potential electrostatic interactions with cell surface receptors or intracellular targets. The peptide may modulate cellular signaling cascades through direct receptor binding or by influencing protein-protein interactions. Hydrophobic regions within the sequence could facilitate membrane penetration or binding to lipophilic targets. The complex sequence architecture suggests 2J4T may act as a multifunctional peptide capable of engaging multiple biological pathways simultaneously, though specific receptor targets and downstream signaling mechanisms require further characterization through detailed biochemical studies.
Risks & Safety
Legal Status
2JMY is a synthetic antimicrobial peptide with the sequence KWKLFKKIGAVLKVL, consisting of 15 amino acids. This peptide belongs to the class of cationic antimicrobial peptides (CAMPs) that are designed to combat bacterial infections through membrane disruption mechanisms. The peptide contains multiple lysine residues which contribute to its positive charge, enabling electrostatic interactions with negatively charged bacterial membranes. Currently in early research phases, 2JMY represents part of ongoing efforts to develop novel antimicrobial agents in response to growing antibiotic resistance concerns. The peptide's amphipathic nature, with both hydrophobic and hydrophilic regions, allows it to integrate into bacterial cell membranes and disrupt their integrity. While specific clinical data for 2JMY is limited, similar antimicrobial peptides have shown promise in preclinical studies for treating various bacterial infections. The research focus appears to be on understanding its spectrum of antimicrobial activity, optimal dosing parameters, and potential therapeutic applications. As with many antimicrobial peptides, 2JMY may offer advantages over traditional antibiotics including reduced likelihood of resistance development and broad-spectrum activity against both gram-positive and gram-negative bacteria.
Key Benefits
Overview
2JMY is a synthetic antimicrobial peptide with the sequence KWKLFKKIGAVLKVL, consisting of 15 amino acids. This peptide belongs to the class of cationic antimicrobial peptides (CAMPs) that are designed to combat bacterial infections through membrane disruption mechanisms. The peptide contains multiple lysine residues which contribute to its positive charge, enabling electrostatic interactions with negatively charged bacterial membranes. Currently in early research phases, 2JMY represents part of ongoing efforts to develop novel antimicrobial agents in response to growing antibiotic resistance concerns. The peptide's amphipathic nature, with both hydrophobic and hydrophilic regions, allows it to integrate into bacterial cell membranes and disrupt their integrity. While specific clinical data for 2JMY is limited, similar antimicrobial peptides have shown promise in preclinical studies for treating various bacterial infections. The research focus appears to be on understanding its spectrum of antimicrobial activity, optimal dosing parameters, and potential therapeutic applications. As with many antimicrobial peptides, 2JMY may offer advantages over traditional antibiotics including reduced likelihood of resistance development and broad-spectrum activity against both gram-positive and gram-negative bacteria.
Potential Benefits
Mechanism of Action
2JMY functions as a cationic antimicrobial peptide through electrostatic and hydrophobic interactions with bacterial cell membranes. The peptide's multiple positively charged lysine residues enable initial binding to negatively charged phospholipids and lipopolysaccharides on bacterial cell surfaces. Following membrane binding, the amphipathic structure allows the peptide to insert into the lipid bilayer, forming pores or causing membrane destabilization through carpet-like mechanisms. This membrane disruption leads to leakage of cellular contents, loss of membrane potential, and ultimately bacterial cell death. The hydrophobic residues (leucine, valine, isoleucine) facilitate membrane insertion while the cationic residues maintain selectivity for bacterial over mammalian cells. The peptide may also have intracellular targets, potentially interfering with DNA replication, protein synthesis, or enzymatic processes once membrane permeabilization occurs. The rapid bactericidal action and membrane-targeting mechanism reduce the likelihood of resistance development compared to antibiotics that target specific proteins or metabolic pathways.
Risks & Safety
Legal Status
2jni is a synthetic peptide with the sequence RWCVYAYVRIRGVLVRYRRCW, consisting of 21 amino acids. This peptide contains multiple cysteine residues that likely form disulfide bonds, contributing to its structural stability. The sequence includes several positively charged residues (arginine and lysine analogs) which may facilitate cellular uptake and membrane interactions. Currently, there is limited published research available on this specific peptide, suggesting it may be in early stages of development or investigation. The peptide's structure suggests potential applications in cellular signaling or membrane-related functions, though specific mechanisms and therapeutic applications require further research validation. As with many synthetic peptides in development, 2jni represents part of ongoing efforts to develop novel therapeutic compounds with specific biological activities. The lack of extensive published data indicates this peptide may be proprietary or under investigation in preclinical studies. Further research is needed to establish its safety profile, efficacy, and potential therapeutic applications.
Key Benefits
Overview
2jni is a synthetic peptide with the sequence RWCVYAYVRIRGVLVRYRRCW, consisting of 21 amino acids. This peptide contains multiple cysteine residues that likely form disulfide bonds, contributing to its structural stability. The sequence includes several positively charged residues (arginine and lysine analogs) which may facilitate cellular uptake and membrane interactions. Currently, there is limited published research available on this specific peptide, suggesting it may be in early stages of development or investigation. The peptide's structure suggests potential applications in cellular signaling or membrane-related functions, though specific mechanisms and therapeutic applications require further research validation. As with many synthetic peptides in development, 2jni represents part of ongoing efforts to develop novel therapeutic compounds with specific biological activities. The lack of extensive published data indicates this peptide may be proprietary or under investigation in preclinical studies. Further research is needed to establish its safety profile, efficacy, and potential therapeutic applications.
Potential Benefits
Mechanism of Action
Based on the amino acid sequence of 2jni, the peptide likely functions through membrane interactions facilitated by its positively charged residues (arginine) and hydrophobic regions. The presence of cysteine residues suggests the formation of disulfide bonds that stabilize the peptide structure, potentially creating a specific conformational arrangement necessary for biological activity. The peptide may interact with cell surface receptors or membrane components through electrostatic interactions. However, without specific research data, the exact molecular targets, receptor binding affinities, and downstream signaling pathways remain to be elucidated through further investigation.
Risks & Safety
Legal Status
2JOB is a research peptide with a 100-amino acid sequence that appears to be in early-stage investigation. Based on its designation as a research compound, it likely represents a synthetic or modified peptide designed for specific biological applications. The peptide's relatively long sequence suggests it may function as a bioactive protein fragment or engineered therapeutic candidate. Currently classified in Phase 1 minimal catalog extraction, indicating limited published research data is available. The peptide's structure contains multiple functional domains that could potentially interact with various biological targets. As with many research peptides, 2JOB is likely being evaluated for therapeutic potential in areas such as tissue repair, metabolic regulation, or cellular signaling modulation. The lack of extensive published literature suggests this compound is in preliminary research phases, with potential applications yet to be fully characterized through clinical studies.
Key Benefits
Overview
2JOB is a research peptide with a 100-amino acid sequence that appears to be in early-stage investigation. Based on its designation as a research compound, it likely represents a synthetic or modified peptide designed for specific biological applications. The peptide's relatively long sequence suggests it may function as a bioactive protein fragment or engineered therapeutic candidate. Currently classified in Phase 1 minimal catalog extraction, indicating limited published research data is available. The peptide's structure contains multiple functional domains that could potentially interact with various biological targets. As with many research peptides, 2JOB is likely being evaluated for therapeutic potential in areas such as tissue repair, metabolic regulation, or cellular signaling modulation. The lack of extensive published literature suggests this compound is in preliminary research phases, with potential applications yet to be fully characterized through clinical studies.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2JOB likely functions through protein-protein interactions and receptor binding mechanisms. The presence of multiple amino acid motifs suggests potential interaction with cell surface receptors or intracellular signaling pathways. The peptide may modulate cellular processes through direct binding to target proteins or by influencing gene expression patterns. Specific receptor interactions and downstream signaling cascades remain to be fully elucidated due to limited research data. The peptide's bioactivity likely depends on conformational stability and binding affinity to specific molecular targets within cellular systems.
Risks & Safety
Legal Status
2jos is a 22-amino acid peptide with the sequence FFHHIFRGIVHVGKTIHRLVTG. Currently classified as a research peptide, 2jos appears to be in early-stage investigation with limited published data available in major scientific databases. The peptide's specific biological targets and therapeutic applications remain largely undefined, suggesting it may be an experimental compound undergoing preliminary characterization. Without extensive clinical or preclinical studies, the peptide's safety profile, efficacy, and optimal dosing parameters have not been established. The amino acid composition includes multiple histidine residues and hydrophobic amino acids, which may influence its stability and bioavailability. As with many research peptides, 2jos likely requires further investigation to determine its potential therapeutic value, mechanism of action, and clinical applications. The current research status indicates this peptide is in Phase 1 minimal catalog extraction, meaning comprehensive data collection and analysis are still needed to fully understand its biological properties and potential medical applications.
Key Benefits
Overview
2jos is a 22-amino acid peptide with the sequence FFHHIFRGIVHVGKTIHRLVTG. Currently classified as a research peptide, 2jos appears to be in early-stage investigation with limited published data available in major scientific databases. The peptide's specific biological targets and therapeutic applications remain largely undefined, suggesting it may be an experimental compound undergoing preliminary characterization. Without extensive clinical or preclinical studies, the peptide's safety profile, efficacy, and optimal dosing parameters have not been established. The amino acid composition includes multiple histidine residues and hydrophobic amino acids, which may influence its stability and bioavailability. As with many research peptides, 2jos likely requires further investigation to determine its potential therapeutic value, mechanism of action, and clinical applications. The current research status indicates this peptide is in Phase 1 minimal catalog extraction, meaning comprehensive data collection and analysis are still needed to fully understand its biological properties and potential medical applications.
Potential Benefits
Mechanism of Action
The specific mechanism of action for peptide 2jos has not been well-characterized in available literature. Based on its amino acid sequence containing multiple histidine residues (FFHHIFRGIVHVGKTIHRLVTG), the peptide may interact with metal ions or exhibit pH-dependent conformational changes. The presence of hydrophobic amino acids like phenylalanine and isoleucine suggests potential membrane interactions or protein-protein binding capabilities. Without specific receptor binding studies or pathway analysis, the exact molecular targets remain unknown. The peptide may function through direct receptor binding, enzyme modulation, or cellular signaling pathway activation, but these mechanisms require experimental validation through targeted research studies.
Risks & Safety
Legal Status
2JPJ is a synthetic peptide with the sequence GTWDDIGQGIGRVAYWVGKALGNLSDVNQASRINRKKKH that is currently in early research phases. This 38-amino acid peptide contains multiple functional domains, including what appears to be a cell-penetrating sequence at the C-terminus (RKKKH) which may facilitate cellular uptake. The peptide's structure suggests potential bioactive properties, though comprehensive clinical data remains limited. The presence of aromatic residues (tryptophan, tyrosine) and charged regions indicates possible membrane interactions and biological activity. Current research status indicates this peptide is in Phase 1 minimal catalog extraction, suggesting it is an experimental compound undergoing initial characterization. Without extensive published research, the peptide's specific therapeutic applications and mechanisms remain to be fully elucidated. The peptide's design and sequence composition suggest it may have been engineered for specific biological functions, potentially related to cellular signaling or therapeutic delivery applications.
Key Benefits
Overview
2JPJ is a synthetic peptide with the sequence GTWDDIGQGIGRVAYWVGKALGNLSDVNQASRINRKKKH that is currently in early research phases. This 38-amino acid peptide contains multiple functional domains, including what appears to be a cell-penetrating sequence at the C-terminus (RKKKH) which may facilitate cellular uptake. The peptide's structure suggests potential bioactive properties, though comprehensive clinical data remains limited. The presence of aromatic residues (tryptophan, tyrosine) and charged regions indicates possible membrane interactions and biological activity. Current research status indicates this peptide is in Phase 1 minimal catalog extraction, suggesting it is an experimental compound undergoing initial characterization. Without extensive published research, the peptide's specific therapeutic applications and mechanisms remain to be fully elucidated. The peptide's design and sequence composition suggest it may have been engineered for specific biological functions, potentially related to cellular signaling or therapeutic delivery applications.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2JPJ likely functions through multiple molecular mechanisms. The C-terminal lysine and arginine-rich region (RKKKH) suggests cell-penetrating peptide properties, facilitating membrane translocation through electrostatic interactions with negatively charged cell membranes. The aromatic residues (tryptophan and tyrosine) may contribute to membrane binding and protein-protein interactions. The peptide's structure indicates potential receptor binding capabilities, though specific targets have not been definitively identified. The presence of glycine residues provides structural flexibility, while the overall sequence composition suggests possible involvement in cellular signaling pathways. Without specific receptor binding studies, the exact molecular targets and downstream signaling cascades remain speculative.
Risks & Safety
Legal Status
2JR3 is a synthetic peptide with the sequence DDTPSSRCGSGGWGPCLPIVDLLCIVHVTVGCSGGFGCCRIG, containing 41 amino acids with multiple cysteine residues that likely form disulfide bonds for structural stability. Based on its sequence characteristics, this peptide appears to be designed for research purposes, potentially targeting specific biological pathways or serving as a molecular probe. The presence of multiple glycine residues suggests flexibility in certain regions, while the cysteine-rich domains indicate a structured conformation. Currently, 2JR3 appears to be in early research phases with limited published data available. The peptide's specific biological targets and therapeutic applications remain under investigation. Without extensive clinical data, its primary use is likely confined to laboratory research settings where its unique sequence properties can be studied for potential therapeutic development. The peptide's design suggests it may interact with specific receptors or biological targets, though comprehensive mechanistic studies are needed to fully characterize its biological activity and potential therapeutic applications.
Key Benefits
Overview
2JR3 is a synthetic peptide with the sequence DDTPSSRCGSGGWGPCLPIVDLLCIVHVTVGCSGGFGCCRIG, containing 41 amino acids with multiple cysteine residues that likely form disulfide bonds for structural stability. Based on its sequence characteristics, this peptide appears to be designed for research purposes, potentially targeting specific biological pathways or serving as a molecular probe. The presence of multiple glycine residues suggests flexibility in certain regions, while the cysteine-rich domains indicate a structured conformation. Currently, 2JR3 appears to be in early research phases with limited published data available. The peptide's specific biological targets and therapeutic applications remain under investigation. Without extensive clinical data, its primary use is likely confined to laboratory research settings where its unique sequence properties can be studied for potential therapeutic development. The peptide's design suggests it may interact with specific receptors or biological targets, though comprehensive mechanistic studies are needed to fully characterize its biological activity and potential therapeutic applications.
Potential Benefits
Mechanism of Action
The mechanism of action for 2JR3 is not well-characterized in available literature. Based on its amino acid sequence containing multiple cysteine residues, the peptide likely forms a stable tertiary structure through disulfide bond formation. The presence of charged residues (aspartic acid) at the N-terminus may facilitate binding to specific receptor sites or cellular targets. The peptide's structure suggests it may interact with cell surface receptors or intracellular targets through specific binding domains. The glycine-rich regions may provide conformational flexibility necessary for target recognition and binding. Without specific research data, the exact molecular pathways, receptor interactions, and downstream signaling cascades remain to be elucidated through further investigation.
Risks & Safety
Legal Status
2JR8 is a synthetic peptide with the sequence GKIPVKAIKQAGKVIGKGLRAINIAGTTHDVVSFFRPKKKKH that appears to be in early research phases. Based on its structural characteristics and amino acid composition, this peptide contains multiple lysine residues and arginine residues, suggesting potential for cellular uptake and membrane interaction. The peptide's sequence includes regions that may facilitate protein-protein interactions and cellular signaling. Currently, there is limited published research available on this specific peptide, indicating it may be a novel compound or research tool in development. The peptide's design suggests potential applications in cellular research, though specific therapeutic targets and mechanisms remain to be fully elucidated. Further investigation is needed to determine its biological activity, safety profile, and potential therapeutic applications. The current research status appears to be in preliminary phases with minimal catalog extraction completed.
Key Benefits
Overview
2JR8 is a synthetic peptide with the sequence GKIPVKAIKQAGKVIGKGLRAINIAGTTHDVVSFFRPKKKKH that appears to be in early research phases. Based on its structural characteristics and amino acid composition, this peptide contains multiple lysine residues and arginine residues, suggesting potential for cellular uptake and membrane interaction. The peptide's sequence includes regions that may facilitate protein-protein interactions and cellular signaling. Currently, there is limited published research available on this specific peptide, indicating it may be a novel compound or research tool in development. The peptide's design suggests potential applications in cellular research, though specific therapeutic targets and mechanisms remain to be fully elucidated. Further investigation is needed to determine its biological activity, safety profile, and potential therapeutic applications. The current research status appears to be in preliminary phases with minimal catalog extraction completed.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2JR8 contains multiple positively charged residues (lysine and arginine) that may facilitate cellular membrane interaction and uptake. The peptide structure suggests potential for protein-protein interactions through its diverse amino acid composition. The presence of hydrophobic and hydrophilic regions may allow for membrane association and cellular internalization. However, specific receptor targets, signaling pathways, and molecular mechanisms have not been established in available research data. The peptide may function through direct cellular uptake mechanisms or membrane-mediated signaling, but detailed mechanistic studies are required to confirm specific biological pathways and molecular targets.
Risks & Safety
Legal Status
2jsb is a synthetic peptide with the sequence RWCVYAYVRVRGVLVRYRRCW, containing 20 amino acids with multiple arginine and cysteine residues. The peptide structure suggests potential antimicrobial and cell-penetrating properties based on its high content of positively charged arginine residues and cysteine residues that may form disulfide bonds for structural stability. The presence of aromatic amino acids (tyrosine and tryptophan) along with the cationic nature indicates possible membrane-interacting capabilities. Currently, this peptide appears to be in early research phases with limited published data available. The specific sequence pattern suggests it may have been designed for therapeutic applications, potentially in antimicrobial therapy or as a delivery vehicle for other therapeutic agents. Further research is needed to fully characterize its biological activities, safety profile, and therapeutic potential. The peptide's unique composition and structure warrant investigation for various biomedical applications.
Key Benefits
Overview
2jsb is a synthetic peptide with the sequence RWCVYAYVRVRGVLVRYRRCW, containing 20 amino acids with multiple arginine and cysteine residues. The peptide structure suggests potential antimicrobial and cell-penetrating properties based on its high content of positively charged arginine residues and cysteine residues that may form disulfide bonds for structural stability. The presence of aromatic amino acids (tyrosine and tryptophan) along with the cationic nature indicates possible membrane-interacting capabilities. Currently, this peptide appears to be in early research phases with limited published data available. The specific sequence pattern suggests it may have been designed for therapeutic applications, potentially in antimicrobial therapy or as a delivery vehicle for other therapeutic agents. Further research is needed to fully characterize its biological activities, safety profile, and therapeutic potential. The peptide's unique composition and structure warrant investigation for various biomedical applications.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2jsb likely functions through electrostatic interactions with negatively charged cell membranes due to its high arginine content. The multiple arginine residues provide strong positive charges that can interact with phospholipid bilayers, potentially leading to membrane permeabilization or cell penetration. The cysteine residues may form intramolecular disulfide bonds, providing structural stability and defining the peptide's three-dimensional conformation. The aromatic amino acids (tryptophan and tyrosine) may facilitate membrane insertion through hydrophobic interactions. This combination of properties suggests the peptide may disrupt microbial cell membranes or facilitate cellular uptake of therapeutic cargo through membrane translocation mechanisms.
Risks & Safety
Legal Status
2K6O is a synthetic peptide with the sequence LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES, consisting of 36 amino acids. This peptide appears to be a research compound that is currently in early-phase investigation, as indicated by its minimal catalog extraction status. The peptide's sequence contains multiple basic amino acids (lysine and arginine residues) which may contribute to its biological activity through electrostatic interactions with cellular membranes or proteins. Given the presence of aromatic residues (phenylalanine) and the overall composition, 2K6O may have potential applications in cellular signaling or membrane interaction studies. However, comprehensive research data is currently limited, and the peptide remains in experimental phases of development. The specific biological targets and therapeutic applications of 2K6O require further investigation through controlled studies to establish its safety profile, efficacy, and potential clinical applications. As with many research peptides, 2K6O represents an area of ongoing scientific inquiry with potential implications for various biological processes, though definitive conclusions about its mechanisms and benefits await more extensive research and clinical validation.
Key Benefits
Overview
2K6O is a synthetic peptide with the sequence LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES, consisting of 36 amino acids. This peptide appears to be a research compound that is currently in early-phase investigation, as indicated by its minimal catalog extraction status. The peptide's sequence contains multiple basic amino acids (lysine and arginine residues) which may contribute to its biological activity through electrostatic interactions with cellular membranes or proteins. Given the presence of aromatic residues (phenylalanine) and the overall composition, 2K6O may have potential applications in cellular signaling or membrane interaction studies. However, comprehensive research data is currently limited, and the peptide remains in experimental phases of development. The specific biological targets and therapeutic applications of 2K6O require further investigation through controlled studies to establish its safety profile, efficacy, and potential clinical applications. As with many research peptides, 2K6O represents an area of ongoing scientific inquiry with potential implications for various biological processes, though definitive conclusions about its mechanisms and benefits await more extensive research and clinical validation.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2K6O likely functions through electrostatic interactions with cellular membranes and proteins due to its high content of positively charged amino acids (lysine and arginine). The peptide may interact with negatively charged phospholipids in cell membranes, potentially affecting membrane permeability or facilitating cellular uptake. The presence of aromatic phenylalanine residues suggests possible protein-protein interactions through π-π stacking or hydrophobic interactions. The peptide's structure may enable it to modulate cellular signaling pathways, though specific receptor targets have not been definitively identified. The mechanism likely involves direct binding to cellular components, potentially influencing intracellular processes or membrane dynamics. However, detailed mechanistic studies are needed to fully elucidate the specific molecular pathways and biological targets involved in 2K6O's activity.
Risks & Safety
Legal Status
2KB8 is a synthetic peptide with the sequence KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY that is currently in early research phases. Limited published research data is available for this specific peptide sequence, indicating it may be a novel or experimental compound under investigation. The peptide contains 38 amino acids and includes cysteine residues that may form disulfide bonds, potentially contributing to structural stability. Based on its sequence characteristics and the presence of various amino acid motifs, 2KB8 may have potential applications in tissue repair and regenerative medicine, though comprehensive clinical data is not yet available. The peptide's specific biological targets and therapeutic mechanisms remain to be fully elucidated through ongoing research. Current understanding is primarily based on sequence analysis and preliminary studies. As with many experimental peptides, 2KB8 represents an area of active investigation where researchers are exploring potential therapeutic applications. The limited available data suggests this peptide may have relevance in cellular signaling pathways, though definitive conclusions about its efficacy and safety profile require further clinical investigation and peer-reviewed research studies.
Key Benefits
Overview
2KB8 is a synthetic peptide with the sequence KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY that is currently in early research phases. Limited published research data is available for this specific peptide sequence, indicating it may be a novel or experimental compound under investigation. The peptide contains 38 amino acids and includes cysteine residues that may form disulfide bonds, potentially contributing to structural stability. Based on its sequence characteristics and the presence of various amino acid motifs, 2KB8 may have potential applications in tissue repair and regenerative medicine, though comprehensive clinical data is not yet available. The peptide's specific biological targets and therapeutic mechanisms remain to be fully elucidated through ongoing research. Current understanding is primarily based on sequence analysis and preliminary studies. As with many experimental peptides, 2KB8 represents an area of active investigation where researchers are exploring potential therapeutic applications. The limited available data suggests this peptide may have relevance in cellular signaling pathways, though definitive conclusions about its efficacy and safety profile require further clinical investigation and peer-reviewed research studies.
Potential Benefits
Mechanism of Action
The mechanism of action for 2KB8 is not well-established in current literature due to limited research data. Based on sequence analysis, the peptide contains multiple amino acid residues that could potentially interact with cellular receptors or signaling pathways. The presence of cysteine residues suggests possible disulfide bond formation, which may contribute to peptide stability and receptor binding affinity. The sequence includes hydrophobic and hydrophilic regions that could facilitate membrane interactions or protein-protein binding. Potential mechanisms may involve modulation of cellular signaling cascades, though specific receptor targets have not been definitively identified. The peptide's structure suggests it may influence tissue repair processes through unknown molecular pathways. Further research is needed to elucidate the precise biological mechanisms and identify specific molecular targets.
Risks & Safety
Legal Status
2KEF refers to the Protein Data Bank (PDB) structure identifier for hepcidin-25, a 25-amino acid peptide hormone that serves as the master regulator of iron homeostasis in the human body. With the sequence DTHFPICIFCCGCCHRSKCGMCCKT, hepcidin-25 is the bioactive form of hepcidin, distinguished from other naturally occurring N-truncated isoforms (hepcidin-20, -22, -24) that appear to be inactive in iron metabolism. This peptide is primarily produced by hepatocytes in the liver and plays a crucial role in controlling iron absorption, distribution, and storage throughout the body. Current research focuses heavily on developing accurate analytical methods for quantifying hepcidin-25 in clinical samples, as its measurement is essential for diagnosing and monitoring iron-related disorders. The peptide presents analytical challenges due to its 'sticky' character and tendency to interact with laboratory surfaces, requiring specialized techniques such as silanized vials and optimized LC-MS/MS methods for reliable quantification. Hepcidin-25 levels serve as important biomarkers for various conditions including iron deficiency anemia, hemochromatosis, and chronic inflammatory diseases, making accurate measurement critical for clinical applications.
Key Benefits
Overview
2KEF refers to the Protein Data Bank (PDB) structure identifier for hepcidin-25, a 25-amino acid peptide hormone that serves as the master regulator of iron homeostasis in the human body. With the sequence DTHFPICIFCCGCCHRSKCGMCCKT, hepcidin-25 is the bioactive form of hepcidin, distinguished from other naturally occurring N-truncated isoforms (hepcidin-20, -22, -24) that appear to be inactive in iron metabolism. This peptide is primarily produced by hepatocytes in the liver and plays a crucial role in controlling iron absorption, distribution, and storage throughout the body. Current research focuses heavily on developing accurate analytical methods for quantifying hepcidin-25 in clinical samples, as its measurement is essential for diagnosing and monitoring iron-related disorders. The peptide presents analytical challenges due to its 'sticky' character and tendency to interact with laboratory surfaces, requiring specialized techniques such as silanized vials and optimized LC-MS/MS methods for reliable quantification. Hepcidin-25 levels serve as important biomarkers for various conditions including iron deficiency anemia, hemochromatosis, and chronic inflammatory diseases, making accurate measurement critical for clinical applications.
Potential Benefits
Mechanism of Action
Hepcidin-25 functions as the central regulator of iron homeostasis by binding to and inducing the degradation of ferroportin, the only known cellular iron exporter. When hepcidin levels are elevated, it causes internalization and degradation of ferroportin in iron-absorbing enterocytes, iron-recycling macrophages, and iron-storing hepatocytes. This mechanism effectively blocks iron absorption from the intestine and iron release from cellular stores, leading to decreased serum iron levels. The peptide's structure, characterized by multiple disulfide bonds formed by its eight cysteine residues, creates a stable beta-hairpin conformation essential for its biological activity. Hepcidin expression is regulated by multiple signaling pathways including the BMP-SMAD pathway (responding to iron stores), the JAK-STAT pathway (responding to inflammation), and the TMPRSS6-mediated pathway (responding to iron deficiency). The peptide's sticky character and tendency to adhere to surfaces reflects its hydrophobic regions and complex tertiary structure, which also contribute to its specific receptor binding and biological stability in physiological conditions.
Risks & Safety
Legal Status
2KET is a synthetic peptide with the sequence GRFKRFRKKFKKLFKKLSPVIPLLHLG, containing 26 amino acids. This peptide appears to be a research compound that is currently in early phases of investigation. The sequence contains multiple lysine and arginine residues, suggesting potential cell-penetrating properties due to its cationic nature. The peptide's structure includes both hydrophilic and hydrophobic regions, which may facilitate membrane interactions and cellular uptake. Limited research data is currently available for 2KET, indicating it is likely an experimental peptide undergoing preliminary characterization studies. The presence of multiple basic amino acids in the sequence suggests it may have antimicrobial properties or cell membrane interaction capabilities. Further research is needed to fully elucidate its biological functions, therapeutic potential, and safety profile. As with many research peptides, 2KET represents an area of ongoing scientific investigation where mechanisms of action and clinical applications are still being determined through preclinical studies.
Key Benefits
Overview
2KET is a synthetic peptide with the sequence GRFKRFRKKFKKLFKKLSPVIPLLHLG, containing 26 amino acids. This peptide appears to be a research compound that is currently in early phases of investigation. The sequence contains multiple lysine and arginine residues, suggesting potential cell-penetrating properties due to its cationic nature. The peptide's structure includes both hydrophilic and hydrophobic regions, which may facilitate membrane interactions and cellular uptake. Limited research data is currently available for 2KET, indicating it is likely an experimental peptide undergoing preliminary characterization studies. The presence of multiple basic amino acids in the sequence suggests it may have antimicrobial properties or cell membrane interaction capabilities. Further research is needed to fully elucidate its biological functions, therapeutic potential, and safety profile. As with many research peptides, 2KET represents an area of ongoing scientific investigation where mechanisms of action and clinical applications are still being determined through preclinical studies.
Potential Benefits
Mechanism of Action
Based on the amino acid sequence of 2KET, the peptide likely functions through electrostatic interactions with negatively charged cell membranes due to its high content of positively charged residues (lysine and arginine). The cationic nature of the peptide may enable it to penetrate cell membranes through direct interaction with phospholipid bilayers. The peptide may disrupt bacterial cell walls or membranes through charge-based interactions, potentially leading to antimicrobial effects. The hydrophobic regions within the sequence could facilitate insertion into lipid membranes, while the hydrophilic portions maintain aqueous solubility. Without specific research data, the exact molecular targets and signaling pathways remain to be determined through further investigation.
Risks & Safety
Legal Status
2KSG is a synthetic peptide with the sequence SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL, consisting of 48 amino acids. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited published data available. The peptide's sequence suggests potential structural properties that may influence cellular interactions, though specific mechanisms and therapeutic applications remain largely unexplored in the current literature. As a research-grade peptide, 2KSG requires further investigation to establish its biological activity, safety profile, and potential therapeutic applications. The absence of comprehensive PubMed research and clinical data indicates that this compound is in preliminary research phases, with most information derived from basic structural analysis. Given the limited research status, any potential applications or benefits remain speculative and require validation through controlled studies. The peptide's development status suggests it may be of interest for basic research purposes, but lacks the extensive characterization needed for therapeutic applications. Further research is needed to determine its biological targets, pharmacokinetics, and safety profile before any clinical applications can be considered.
Key Benefits
Overview
2KSG is a synthetic peptide with the sequence SSLLEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL, consisting of 48 amino acids. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited published data available. The peptide's sequence suggests potential structural properties that may influence cellular interactions, though specific mechanisms and therapeutic applications remain largely unexplored in the current literature. As a research-grade peptide, 2KSG requires further investigation to establish its biological activity, safety profile, and potential therapeutic applications. The absence of comprehensive PubMed research and clinical data indicates that this compound is in preliminary research phases, with most information derived from basic structural analysis. Given the limited research status, any potential applications or benefits remain speculative and require validation through controlled studies. The peptide's development status suggests it may be of interest for basic research purposes, but lacks the extensive characterization needed for therapeutic applications. Further research is needed to determine its biological targets, pharmacokinetics, and safety profile before any clinical applications can be considered.
Potential Benefits
Mechanism of Action
The mechanism of action for peptide 2KSG remains largely uncharacterized due to limited research data. Based on its amino acid sequence composition, the peptide contains multiple lysine and glycine residues, which may influence its structural conformation and potential protein-protein interactions. The presence of charged amino acids suggests possible electrostatic interactions with cellular targets, though specific receptor binding or enzymatic activity has not been documented. Without published research on its biological targets, signaling pathways, or cellular effects, the precise molecular mechanisms remain speculative. The peptide's length and sequence composition suggest it may function through direct protein interactions or membrane-associated processes, but these hypotheses require experimental validation through biochemical and cellular studies.
Risks & Safety
Legal Status
2L1Q is a 39-amino acid peptide with the sequence MTPFWRGVSLRPIGASCRDDSECITRLCRKRRCSLSVAQE. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited publicly available data. The peptide's structure suggests potential bioactive properties, though comprehensive clinical research and mechanistic studies are still needed to fully characterize its therapeutic potential. As with many research peptides, 2L1Q may have applications in various biological processes, but its specific targets, efficacy, and safety profile require further investigation. The peptide's relatively short sequence and unique composition indicate it may interact with specific biological pathways, though the exact nature of these interactions remains to be elucidated through systematic research. Current understanding is limited to basic structural information, and more extensive preclinical and clinical studies would be necessary to determine its therapeutic value and potential applications in human health.
Key Benefits
Overview
2L1Q is a 39-amino acid peptide with the sequence MTPFWRGVSLRPIGASCRDDSECITRLCRKRRCSLSVAQE. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited publicly available data. The peptide's structure suggests potential bioactive properties, though comprehensive clinical research and mechanistic studies are still needed to fully characterize its therapeutic potential. As with many research peptides, 2L1Q may have applications in various biological processes, but its specific targets, efficacy, and safety profile require further investigation. The peptide's relatively short sequence and unique composition indicate it may interact with specific biological pathways, though the exact nature of these interactions remains to be elucidated through systematic research. Current understanding is limited to basic structural information, and more extensive preclinical and clinical studies would be necessary to determine its therapeutic value and potential applications in human health.
Potential Benefits
Mechanism of Action
The mechanism of action for 2L1Q is not well-characterized due to limited research data. Based on its peptide structure and sequence composition, it likely interacts with specific cellular receptors or signaling pathways, though the exact molecular targets remain undefined. The peptide may modulate intracellular signaling cascades through receptor binding or direct interaction with cellular components. Further research is needed to elucidate the specific biological pathways, receptor interactions, and downstream effects that characterize this peptide's mechanism of action.
Risks & Safety
Legal Status
2L5M is a synthetic peptide with the sequence GFKRIVQRIKDFLRNLV, consisting of 17 amino acids. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited published data available. The peptide's sequence suggests potential bioactive properties, though comprehensive clinical studies are lacking. As with many synthetic peptides in early research phases, 2L5M may have therapeutic potential that requires further investigation to establish its safety profile, efficacy, and optimal applications. The peptide's amino acid composition includes basic residues (lysine, arginine) and hydrophobic residues (phenylalanine, leucine, valine) which may contribute to membrane interactions or protein binding capabilities. Without extensive published research, the peptide's specific mechanisms and clinical applications remain largely theoretical. Current understanding is based primarily on structural analysis and comparison to similar peptide sequences. Further research is needed to establish definitive therapeutic benefits, safety parameters, and regulatory approval pathways.
Key Benefits
Overview
2L5M is a synthetic peptide with the sequence GFKRIVQRIKDFLRNLV, consisting of 17 amino acids. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited published data available. The peptide's sequence suggests potential bioactive properties, though comprehensive clinical studies are lacking. As with many synthetic peptides in early research phases, 2L5M may have therapeutic potential that requires further investigation to establish its safety profile, efficacy, and optimal applications. The peptide's amino acid composition includes basic residues (lysine, arginine) and hydrophobic residues (phenylalanine, leucine, valine) which may contribute to membrane interactions or protein binding capabilities. Without extensive published research, the peptide's specific mechanisms and clinical applications remain largely theoretical. Current understanding is based primarily on structural analysis and comparison to similar peptide sequences. Further research is needed to establish definitive therapeutic benefits, safety parameters, and regulatory approval pathways.
Potential Benefits
Mechanism of Action
Based on the peptide sequence GFKRIVQRIKDFLRNLV, 2L5M likely functions through direct protein-protein interactions or membrane binding mechanisms. The presence of multiple basic amino acids (lysine and arginine) suggests potential for electrostatic interactions with negatively charged cellular components or receptor binding sites. The hydrophobic residues may facilitate membrane penetration or hydrophobic pocket binding. Without specific research data, the exact molecular targets and signaling pathways remain undefined. The peptide may modulate cellular processes through receptor activation, enzyme inhibition, or direct cellular uptake mechanisms typical of bioactive peptides.
Risks & Safety
Legal Status
2L7S is a 51-amino acid peptide with the sequence YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGY. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited published data available. The peptide contains cysteine residues suggesting potential disulfide bond formation, which may contribute to structural stability and biological activity. Based on its amino acid composition and length, 2L7S appears to be a synthetic or modified peptide designed for research purposes. The presence of charged residues (lysine, arginine, aspartic acid) and aromatic amino acids (tyrosine, phenylalanine) suggests potential for protein-protein interactions and membrane binding capabilities. Without specific research data, the exact biological targets and mechanisms remain to be elucidated. The peptide's structure suggests it may interact with cellular receptors or signaling pathways, though specific applications require further investigation. As an early-phase research peptide, 2L7S represents the preliminary stages of peptide development where basic characterization and initial biological screening are typically conducted to determine therapeutic potential and safety profiles.
Key Benefits
Overview
2L7S is a 51-amino acid peptide with the sequence YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGY. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited published data available. The peptide contains cysteine residues suggesting potential disulfide bond formation, which may contribute to structural stability and biological activity. Based on its amino acid composition and length, 2L7S appears to be a synthetic or modified peptide designed for research purposes. The presence of charged residues (lysine, arginine, aspartic acid) and aromatic amino acids (tyrosine, phenylalanine) suggests potential for protein-protein interactions and membrane binding capabilities. Without specific research data, the exact biological targets and mechanisms remain to be elucidated. The peptide's structure suggests it may interact with cellular receptors or signaling pathways, though specific applications require further investigation. As an early-phase research peptide, 2L7S represents the preliminary stages of peptide development where basic characterization and initial biological screening are typically conducted to determine therapeutic potential and safety profiles.
Potential Benefits
Mechanism of Action
The mechanism of action for 2L7S is not well-characterized due to limited available research data. Based on its amino acid sequence, the peptide likely functions through protein-protein interactions facilitated by its charged and aromatic residues. The presence of cysteine residues suggests potential for disulfide bond formation, which could stabilize the peptide structure and enhance binding affinity to target receptors. The peptide may interact with cell surface receptors or intracellular signaling molecules through electrostatic interactions mediated by its lysine, arginine, and aspartic acid residues. Tyrosine and phenylalanine residues could contribute to hydrophobic interactions and membrane association. Without specific binding studies or functional assays, the exact molecular targets and downstream signaling pathways remain unknown. The peptide's length and composition suggest it may modulate cellular processes through receptor binding, enzyme inhibition, or protein complex formation, but these mechanisms require experimental validation.
Risks & Safety
Legal Status
2LA2 is a synthetic peptide with the sequence RWKIFKKIEKVGRNVRDGIIKAGPAVAVVGQAATVVK, currently in Phase 1 minimal catalog extraction status. This 38-amino acid peptide contains multiple positively charged residues (arginine, lysine) and hydrophobic regions, suggesting potential membrane-interacting or cell-penetrating properties. The peptide's structure includes several key motifs that may facilitate cellular uptake and biological activity. Current research on 2LA2 is limited, with the peptide appearing to be in early investigational stages. The presence of basic amino acids and the overall composition suggest it may have antimicrobial properties or cell-penetrating capabilities similar to other cationic peptides. However, comprehensive studies on its specific biological mechanisms, therapeutic applications, and safety profile are not yet available in the current literature. The peptide's design and sequence characteristics indicate it may be engineered for specific biological functions, though detailed research findings and clinical applications remain to be established through further investigation.
Key Benefits
Overview
2LA2 is a synthetic peptide with the sequence RWKIFKKIEKVGRNVRDGIIKAGPAVAVVGQAATVVK, currently in Phase 1 minimal catalog extraction status. This 38-amino acid peptide contains multiple positively charged residues (arginine, lysine) and hydrophobic regions, suggesting potential membrane-interacting or cell-penetrating properties. The peptide's structure includes several key motifs that may facilitate cellular uptake and biological activity. Current research on 2LA2 is limited, with the peptide appearing to be in early investigational stages. The presence of basic amino acids and the overall composition suggest it may have antimicrobial properties or cell-penetrating capabilities similar to other cationic peptides. However, comprehensive studies on its specific biological mechanisms, therapeutic applications, and safety profile are not yet available in the current literature. The peptide's design and sequence characteristics indicate it may be engineered for specific biological functions, though detailed research findings and clinical applications remain to be established through further investigation.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2LA2 likely functions through electrostatic interactions with negatively charged cell membranes due to its high content of positively charged residues (arginine and lysine). The peptide may act as a cell-penetrating peptide, facilitating cellular uptake through membrane disruption or receptor-mediated endocytosis. The hydrophobic regions within the sequence suggest potential for membrane insertion and pore formation. The peptide's cationic nature may enable it to interact with bacterial cell walls or biofilms, potentially disrupting membrane integrity. The specific arrangement of charged and hydrophobic residues may allow for conformational changes upon membrane contact, leading to antimicrobial activity or enhanced cellular permeability. However, detailed mechanistic studies are needed to confirm these proposed pathways.
Risks & Safety
Legal Status
2LG4 is a synthetic peptide with the sequence AACSDRAHGHICESFKSFCKDSGRNGVKLRANCKKTCGLC, containing 39 amino acids with multiple cysteine residues suggesting potential disulfide bond formation for structural stability. Based on its amino acid composition and sequence characteristics, this peptide appears to be designed for research applications, though specific clinical data is currently limited. The presence of multiple cysteine residues indicates it may have a complex three-dimensional structure that could be important for its biological activity. The peptide contains various charged and hydrophobic residues that may facilitate interactions with cellular receptors or other biological targets. Current research status appears to be in early investigational phases, with minimal published data available regarding its specific therapeutic applications or mechanisms. The peptide's structure suggests it may have potential applications in areas requiring stable, bioactive compounds, though comprehensive clinical validation remains to be established.
Key Benefits
Overview
2LG4 is a synthetic peptide with the sequence AACSDRAHGHICESFKSFCKDSGRNGVKLRANCKKTCGLC, containing 39 amino acids with multiple cysteine residues suggesting potential disulfide bond formation for structural stability. Based on its amino acid composition and sequence characteristics, this peptide appears to be designed for research applications, though specific clinical data is currently limited. The presence of multiple cysteine residues indicates it may have a complex three-dimensional structure that could be important for its biological activity. The peptide contains various charged and hydrophobic residues that may facilitate interactions with cellular receptors or other biological targets. Current research status appears to be in early investigational phases, with minimal published data available regarding its specific therapeutic applications or mechanisms. The peptide's structure suggests it may have potential applications in areas requiring stable, bioactive compounds, though comprehensive clinical validation remains to be established.
Potential Benefits
Mechanism of Action
The mechanism of action for 2LG4 is not well-established in current literature. Based on its structural characteristics, the peptide likely functions through specific receptor binding interactions facilitated by its complex amino acid sequence. The multiple cysteine residues suggest formation of disulfide bonds that create a stable tertiary structure necessary for biological activity. The peptide may interact with cellular signaling pathways through receptor-mediated mechanisms, though the specific targets and downstream effects require further investigation. The presence of charged residues like arginine and aspartic acid may facilitate electrostatic interactions with target proteins or cell surface receptors.
Risks & Safety
Legal Status
2LMF is a synthetic peptide with the sequence LLGDFFRKSKEKIGKEFKRIVQR, consisting of 23 amino acids. This peptide appears to be in early research phases, with limited published data available regarding its specific biological functions and therapeutic applications. The peptide's sequence suggests it may have antimicrobial properties based on its cationic nature and the presence of lysine and arginine residues, which are common features in antimicrobial peptides. The peptide contains both hydrophobic and hydrophilic regions, indicating potential membrane-active properties. Current research status appears to be in preliminary stages, with minimal catalog extraction completed as part of Phase 1 studies. Without extensive clinical data, the peptide's full therapeutic potential remains to be established through further research and development. The peptide's structure suggests it may interact with bacterial membranes or cellular targets, though specific mechanisms require further investigation.
Key Benefits
Overview
2LMF is a synthetic peptide with the sequence LLGDFFRKSKEKIGKEFKRIVQR, consisting of 23 amino acids. This peptide appears to be in early research phases, with limited published data available regarding its specific biological functions and therapeutic applications. The peptide's sequence suggests it may have antimicrobial properties based on its cationic nature and the presence of lysine and arginine residues, which are common features in antimicrobial peptides. The peptide contains both hydrophobic and hydrophilic regions, indicating potential membrane-active properties. Current research status appears to be in preliminary stages, with minimal catalog extraction completed as part of Phase 1 studies. Without extensive clinical data, the peptide's full therapeutic potential remains to be established through further research and development. The peptide's structure suggests it may interact with bacterial membranes or cellular targets, though specific mechanisms require further investigation.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2LMF likely functions through electrostatic interactions with negatively charged bacterial cell membranes due to its cationic residues (lysine and arginine). The peptide may disrupt membrane integrity through pore formation or membrane permeabilization mechanisms common to antimicrobial peptides. The hydrophobic regions (leucine and phenylalanine residues) may facilitate membrane insertion, while the charged residues provide selectivity for bacterial over mammalian cells. The peptide may also interact with intracellular targets following membrane translocation, potentially interfering with essential cellular processes such as DNA replication, protein synthesis, or enzymatic functions.
Risks & Safety
Legal Status
2LMU is a synthetic peptide with the sequence MKTILRFVAGYDIASHKKKTGGYPWERGKA that is currently in early research phases. Limited data is available about this specific peptide, as it appears to be a research compound that has not been extensively studied in published literature. The peptide consists of 30 amino acids and may have potential therapeutic applications based on its structural composition, though comprehensive clinical data is lacking. The designation '2LMU' suggests it may be a laboratory identifier or research code rather than a commercially available therapeutic peptide. Current understanding of this peptide is minimal, with most information being derived from basic structural analysis rather than functional studies. Further research would be needed to establish its biological activity, safety profile, and potential therapeutic applications. The peptide's sequence contains various amino acids that could potentially interact with biological systems, but without specific studies, its mechanism of action and clinical relevance remain largely theoretical.
Key Benefits
Overview
2LMU is a synthetic peptide with the sequence MKTILRFVAGYDIASHKKKTGGYPWERGKA that is currently in early research phases. Limited data is available about this specific peptide, as it appears to be a research compound that has not been extensively studied in published literature. The peptide consists of 30 amino acids and may have potential therapeutic applications based on its structural composition, though comprehensive clinical data is lacking. The designation '2LMU' suggests it may be a laboratory identifier or research code rather than a commercially available therapeutic peptide. Current understanding of this peptide is minimal, with most information being derived from basic structural analysis rather than functional studies. Further research would be needed to establish its biological activity, safety profile, and potential therapeutic applications. The peptide's sequence contains various amino acids that could potentially interact with biological systems, but without specific studies, its mechanism of action and clinical relevance remain largely theoretical.
Potential Benefits
Mechanism of Action
The mechanism of action for peptide 2LMU is not well-established due to limited research data. Based on its amino acid sequence composition, the peptide may interact with cellular receptors or signaling pathways, though specific molecular targets have not been identified. The presence of basic amino acids like lysine and arginine in the sequence suggests potential for electrostatic interactions with negatively charged cellular components. Without published studies detailing receptor binding, enzymatic activity, or cellular uptake mechanisms, the precise biological pathways affected by this peptide remain speculative. Further research would be required to elucidate specific receptor interactions, downstream signaling cascades, and cellular responses.
Risks & Safety
Legal Status
2LR5 is a synthetic peptide with the sequence GFGCPFNENECHAHCLSIGRKFGFCAGPLRATCTCGKQ that appears to be in early research phases. Based on its structural characteristics, this peptide contains multiple cysteine residues suggesting potential disulfide bond formation, which is common in bioactive peptides with therapeutic applications. The presence of charged amino acids and the overall sequence composition indicates it may have biological activity related to cellular signaling or receptor interactions. Currently, there is limited published research available on this specific peptide, indicating it may be a novel compound under investigation or in early development stages. The peptide's structure suggests potential applications in therapeutic areas, though comprehensive clinical data is not yet available. Further research is needed to fully characterize its biological properties, safety profile, and therapeutic potential. The peptide represents an area of ongoing scientific interest in peptide-based therapeutics.
Key Benefits
Overview
2LR5 is a synthetic peptide with the sequence GFGCPFNENECHAHCLSIGRKFGFCAGPLRATCTCGKQ that appears to be in early research phases. Based on its structural characteristics, this peptide contains multiple cysteine residues suggesting potential disulfide bond formation, which is common in bioactive peptides with therapeutic applications. The presence of charged amino acids and the overall sequence composition indicates it may have biological activity related to cellular signaling or receptor interactions. Currently, there is limited published research available on this specific peptide, indicating it may be a novel compound under investigation or in early development stages. The peptide's structure suggests potential applications in therapeutic areas, though comprehensive clinical data is not yet available. Further research is needed to fully characterize its biological properties, safety profile, and therapeutic potential. The peptide represents an area of ongoing scientific interest in peptide-based therapeutics.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2LR5 contains multiple cysteine residues that likely form disulfide bonds, creating a stable three-dimensional structure typical of bioactive peptides. The presence of charged residues (arginine and lysine) suggests potential for electrostatic interactions with cellular receptors or binding proteins. The peptide may interact with specific cell surface receptors or intracellular targets to modulate signaling pathways. The glycine residues provide structural flexibility, while the aromatic phenylalanine residues may contribute to hydrophobic interactions with target proteins. Without specific research data, the exact molecular targets and signaling cascades remain to be elucidated through further investigation.
Risks & Safety
Legal Status
2LR7 is a synthetic peptide with the sequence RKCNFLCKLKEKLRTVITSHIDKVLRPQG that is currently in early research phases. Limited data is available about this specific peptide, suggesting it may be an experimental compound under investigation for potential therapeutic applications. The peptide's structure contains multiple basic amino acids (lysine and arginine) which may facilitate cellular uptake and membrane interactions. Given its designation as a research peptide, 2LR7 likely represents a novel therapeutic candidate being evaluated for various biological activities. The peptide's specific sequence suggests it may have been designed for particular receptor interactions or cellular targeting mechanisms. Current research status appears to be in preliminary stages with minimal published data available. Further investigation is needed to fully characterize its biological properties, safety profile, and potential therapeutic applications. The peptide may be part of ongoing drug discovery efforts aimed at developing new treatments for various medical conditions.
Key Benefits
Overview
2LR7 is a synthetic peptide with the sequence RKCNFLCKLKEKLRTVITSHIDKVLRPQG that is currently in early research phases. Limited data is available about this specific peptide, suggesting it may be an experimental compound under investigation for potential therapeutic applications. The peptide's structure contains multiple basic amino acids (lysine and arginine) which may facilitate cellular uptake and membrane interactions. Given its designation as a research peptide, 2LR7 likely represents a novel therapeutic candidate being evaluated for various biological activities. The peptide's specific sequence suggests it may have been designed for particular receptor interactions or cellular targeting mechanisms. Current research status appears to be in preliminary stages with minimal published data available. Further investigation is needed to fully characterize its biological properties, safety profile, and potential therapeutic applications. The peptide may be part of ongoing drug discovery efforts aimed at developing new treatments for various medical conditions.
Potential Benefits
Mechanism of Action
The mechanism of action for peptide 2LR7 is not well-characterized due to limited available research data. Based on its amino acid sequence containing multiple positively charged residues (lysine and arginine), the peptide may interact with negatively charged cellular membranes or specific receptor sites. The presence of cysteine residues suggests potential for disulfide bond formation, which could contribute to structural stability and specific binding conformations. The peptide may modulate cellular signaling pathways through receptor binding or direct cellular uptake mechanisms. Without specific research data, the exact molecular targets and downstream signaling cascades remain to be determined through further investigation.
Risks & Safety
Legal Status
2LXO is a peptide with the sequence GIINTLQKYYCRVRGAICHPVFCPRRYKQIGTCGLPGTKCCKKP that is currently in early research phases. Based on its structural characteristics and amino acid composition, this peptide appears to contain multiple cysteine residues suggesting potential disulfide bond formation and structural stability. The presence of basic amino acids like lysine and arginine may indicate potential for cellular membrane interactions or receptor binding. Currently, there is limited published research available on this specific peptide sequence, indicating it may be a novel or proprietary compound under investigation. The peptide's complex structure with 43 amino acids suggests it may have multiple functional domains. Without extensive clinical data, the peptide remains in experimental stages with potential applications yet to be fully characterized. Further research is needed to establish its biological activity, safety profile, and therapeutic potential.
Key Benefits
Overview
2LXO is a peptide with the sequence GIINTLQKYYCRVRGAICHPVFCPRRYKQIGTCGLPGTKCCKKP that is currently in early research phases. Based on its structural characteristics and amino acid composition, this peptide appears to contain multiple cysteine residues suggesting potential disulfide bond formation and structural stability. The presence of basic amino acids like lysine and arginine may indicate potential for cellular membrane interactions or receptor binding. Currently, there is limited published research available on this specific peptide sequence, indicating it may be a novel or proprietary compound under investigation. The peptide's complex structure with 43 amino acids suggests it may have multiple functional domains. Without extensive clinical data, the peptide remains in experimental stages with potential applications yet to be fully characterized. Further research is needed to establish its biological activity, safety profile, and therapeutic potential.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2LXO likely functions through protein-protein interactions facilitated by its multiple cysteine residues which can form disulfide bonds for structural stability. The presence of charged amino acids including lysine, arginine, and tyrosine suggests potential for receptor binding or enzyme interactions. The peptide may modulate cellular signaling pathways through direct binding to specific receptors or by influencing protein conformational changes. However, without specific research data, the exact molecular mechanisms remain to be elucidated through further biochemical and pharmacological studies.
Risks & Safety
Legal Status
2LYF is a synthetic peptide with the sequence GFCRCLCRRGVCRCICTR, characterized by multiple cysteine residues that likely form disulfide bonds creating a stable, constrained structure. This peptide appears to be in early research phases with limited published data available. The high cysteine content suggests it may have antimicrobial properties, as many cysteine-rich peptides demonstrate activity against bacteria, fungi, or other pathogens. The specific sequence and structure may confer unique biological activities, though comprehensive studies are needed to fully characterize its mechanisms and therapeutic potential. Current research status appears to be in preliminary stages, with minimal catalog extraction completed. The peptide's compact, disulfide-stabilized structure is typical of bioactive peptides that can resist enzymatic degradation and maintain biological activity in physiological conditions. Further investigation is required to determine its specific targets, optimal dosing, safety profile, and clinical applications.
Key Benefits
Overview
2LYF is a synthetic peptide with the sequence GFCRCLCRRGVCRCICTR, characterized by multiple cysteine residues that likely form disulfide bonds creating a stable, constrained structure. This peptide appears to be in early research phases with limited published data available. The high cysteine content suggests it may have antimicrobial properties, as many cysteine-rich peptides demonstrate activity against bacteria, fungi, or other pathogens. The specific sequence and structure may confer unique biological activities, though comprehensive studies are needed to fully characterize its mechanisms and therapeutic potential. Current research status appears to be in preliminary stages, with minimal catalog extraction completed. The peptide's compact, disulfide-stabilized structure is typical of bioactive peptides that can resist enzymatic degradation and maintain biological activity in physiological conditions. Further investigation is required to determine its specific targets, optimal dosing, safety profile, and clinical applications.
Potential Benefits
Mechanism of Action
Based on the cysteine-rich sequence of 2LYF, the peptide likely functions through formation of multiple disulfide bonds that create a stable, constrained three-dimensional structure. This structural stability may enable specific binding to target receptors or proteins. The peptide may interact with microbial cell membranes or specific cellular targets through electrostatic interactions and hydrogen bonding. The arginine residues in the sequence could facilitate cellular uptake or membrane interaction through positive charge interactions with negatively charged cell surfaces. The mechanism may involve disruption of pathogen membranes, modulation of immune responses, or specific receptor-mediated signaling pathways, though detailed mechanistic studies are needed for confirmation.
Risks & Safety
Legal Status
2MAA (2-methoxyacetic acid) is not a peptide but rather a metabolic compound with the sequence FLPLIGRVLSGIL. Based on the research data, 2MAA appears in multiple biological contexts. It is identified as a metabolite associated with beta-ketothiolase deficiency, a rare metabolic disorder affecting ketone and isoleucine metabolism. In this context, elevated urinary excretion of 2MAA serves as a diagnostic marker for the condition. Additionally, 2MAA is the active metabolite of ethylene glycol monomethyl ether (EGME), an industrial compound that demonstrates significant developmental toxicity. Research shows 2MAA can disrupt limb development through alterations in acetylation programming, affecting histone modifications and cellular processes. The compound has also been investigated for bioelectronic applications, where it forms nanoscale biofilms with cytochrome f for potential use in biosensing devices. Current research focuses on understanding its role as both a metabolic biomarker and a developmental toxin, with limited therapeutic applications identified.
Key Benefits
Overview
2MAA (2-methoxyacetic acid) is not a peptide but rather a metabolic compound with the sequence FLPLIGRVLSGIL. Based on the research data, 2MAA appears in multiple biological contexts. It is identified as a metabolite associated with beta-ketothiolase deficiency, a rare metabolic disorder affecting ketone and isoleucine metabolism. In this context, elevated urinary excretion of 2MAA serves as a diagnostic marker for the condition. Additionally, 2MAA is the active metabolite of ethylene glycol monomethyl ether (EGME), an industrial compound that demonstrates significant developmental toxicity. Research shows 2MAA can disrupt limb development through alterations in acetylation programming, affecting histone modifications and cellular processes. The compound has also been investigated for bioelectronic applications, where it forms nanoscale biofilms with cytochrome f for potential use in biosensing devices. Current research focuses on understanding its role as both a metabolic biomarker and a developmental toxin, with limited therapeutic applications identified.
Potential Benefits
Mechanism of Action
2MAA exerts its biological effects primarily through disruption of acetylation programming and cellular signaling pathways. As a metabolite in beta-ketothiolase deficiency, it accumulates due to impaired ketone and isoleucine metabolism. In developmental toxicity studies, 2MAA induces hyperacetylation of histones H3K9 and H4K12, disrupting normal gene expression patterns. The compound significantly increases acetylation of the tumor suppressor protein p53 at lysine 379, leading to activation of cell cycle arrest mechanisms through increased p21 expression. 2MAA also triggers apoptotic pathways by inducing caspase-3 cleavage. These molecular changes result in altered cellular programming that disrupts normal developmental processes. In bioelectronic applications, 2MAA functions as a self-assembling layer that facilitates cytochrome f attachment to gold surfaces, creating biofilms with electrochemical properties suitable for biosensing applications.
Risks & Safety
Legal Status
2MAG (2-monoacylglycerol) is a bioactive lipid molecule that plays crucial roles in cellular signaling and metabolism. As an endocannabinoid and lipid mediator, 2MAG is involved in various physiological processes including energy metabolism, thermogenesis, and neural signaling. The molecule is primarily regulated by the enzyme ABHD6 (α/β-hydrolase domain 6), which hydrolyzes monoacylglycerols and controls their signaling functions. Research has demonstrated 2MAG's involvement in insulin secretion, adipose tissue browning, food intake regulation, and neurotransmission. The compound serves as a substrate for multiple cellular targets including PPARα, GPR119, and CB1/2 receptors, enabling diverse signaling pathways. Current research focuses on understanding 2MAG's therapeutic potential in metabolic diseases, obesity, diabetes, and neurological conditions. Studies have shown that modulation of 2MAG levels through ABHD6 inhibition can enhance cold tolerance and adaptive thermogenesis, suggesting potential applications in metabolic health and energy expenditure regulation.
Key Benefits
Overview
2MAG (2-monoacylglycerol) is a bioactive lipid molecule that plays crucial roles in cellular signaling and metabolism. As an endocannabinoid and lipid mediator, 2MAG is involved in various physiological processes including energy metabolism, thermogenesis, and neural signaling. The molecule is primarily regulated by the enzyme ABHD6 (α/β-hydrolase domain 6), which hydrolyzes monoacylglycerols and controls their signaling functions. Research has demonstrated 2MAG's involvement in insulin secretion, adipose tissue browning, food intake regulation, and neurotransmission. The compound serves as a substrate for multiple cellular targets including PPARα, GPR119, and CB1/2 receptors, enabling diverse signaling pathways. Current research focuses on understanding 2MAG's therapeutic potential in metabolic diseases, obesity, diabetes, and neurological conditions. Studies have shown that modulation of 2MAG levels through ABHD6 inhibition can enhance cold tolerance and adaptive thermogenesis, suggesting potential applications in metabolic health and energy expenditure regulation.
Potential Benefits
Mechanism of Action
2MAG functions through multiple signaling pathways and receptor interactions. It acts as an endocannabinoid that binds to CB1/2 receptors, influencing neurotransmission and metabolic processes. The molecule activates PPARα in adipocytes, leading to enhanced expression and activity of glycerolipid/free fatty acid (GL/FFA) cycle enzymes, which promotes thermogenic metabolism. 2MAG also interacts with GPR119 receptors and mammalian unc13-1 (Munc13-1), contributing to insulin secretion regulation. The compound's levels are controlled by ABHD6, which hydrolyzes monoacylglycerols to terminate their signaling. When ABHD6 is inhibited, nuclear 2MAG levels increase, particularly in visceral white adipose tissue during cold stress. This elevation triggers a metabolic signaling network involving MAG/PPARα/GL/FFA cycling, which enhances both lipolysis and lipogenesis simultaneously. The molecule also participates in intestinal lipid absorption and transport, where it is re-esterified to form triacylglycerols and incorporated into chylomicrons for lymphatic transport.
Risks & Safety
Legal Status
2MLT is a synthetic peptide with the sequence GIGAVLKVLTTGLPALISWIKRKRQQ, consisting of 26 amino acids. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited published data available. The peptide's sequence suggests potential membrane-interacting properties due to its hydrophobic and cationic regions, which may influence cellular uptake and biological activity. The presence of basic amino acids like lysine and arginine at the C-terminus indicates possible cell-penetrating capabilities. Without extensive clinical research data, the peptide's specific therapeutic applications and mechanisms remain largely theoretical. The compound appears to be in preliminary research phases, with its safety profile, efficacy, and optimal dosing protocols yet to be fully established through comprehensive studies. Further research is needed to determine its potential therapeutic applications and clinical utility.
Key Benefits
Overview
2MLT is a synthetic peptide with the sequence GIGAVLKVLTTGLPALISWIKRKRQQ, consisting of 26 amino acids. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited published data available. The peptide's sequence suggests potential membrane-interacting properties due to its hydrophobic and cationic regions, which may influence cellular uptake and biological activity. The presence of basic amino acids like lysine and arginine at the C-terminus indicates possible cell-penetrating capabilities. Without extensive clinical research data, the peptide's specific therapeutic applications and mechanisms remain largely theoretical. The compound appears to be in preliminary research phases, with its safety profile, efficacy, and optimal dosing protocols yet to be fully established through comprehensive studies. Further research is needed to determine its potential therapeutic applications and clinical utility.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2MLT likely functions through membrane interaction mechanisms. The peptide contains hydrophobic residues (glycine, isoleucine, valine, leucine, alanine) that may facilitate membrane insertion, while the cationic C-terminal region (lysine and arginine residues) could enable electrostatic interactions with negatively charged cell membranes. The amphipathic nature of the sequence suggests potential cell-penetrating peptide properties, allowing cellular uptake and intracellular delivery. The specific receptor interactions and downstream signaling pathways remain undefined due to limited research data. The peptide may modulate cellular processes through direct membrane effects or intracellular target engagement, though the exact molecular targets and biological pathways require further investigation.
Risks & Safety
Legal Status
2MVE is a synthetic peptide with the sequence VFQFLGKIIHHVGNFVHGFSHVF that is currently in early research phases. Limited data is available regarding this specific peptide, suggesting it may be an experimental compound under investigation for potential therapeutic applications. The peptide's sequence contains 23 amino acids with multiple hydrophobic residues including phenylalanine, leucine, and valine, which may influence its membrane interactions and biological activity. Given the presence of histidine residues and the overall composition, 2MVE may have potential applications in cellular signaling or membrane-related processes. The peptide appears to be in minimal catalog extraction phase, indicating that comprehensive research data is still being compiled. Without extensive published research, the full therapeutic potential and safety profile remain to be established through future clinical investigations.
Key Benefits
Overview
2MVE is a synthetic peptide with the sequence VFQFLGKIIHHVGNFVHGFSHVF that is currently in early research phases. Limited data is available regarding this specific peptide, suggesting it may be an experimental compound under investigation for potential therapeutic applications. The peptide's sequence contains 23 amino acids with multiple hydrophobic residues including phenylalanine, leucine, and valine, which may influence its membrane interactions and biological activity. Given the presence of histidine residues and the overall composition, 2MVE may have potential applications in cellular signaling or membrane-related processes. The peptide appears to be in minimal catalog extraction phase, indicating that comprehensive research data is still being compiled. Without extensive published research, the full therapeutic potential and safety profile remain to be established through future clinical investigations.
Potential Benefits
Mechanism of Action
Based on the amino acid sequence of 2MVE, the peptide likely interacts with cellular membranes due to its hydrophobic residues including phenylalanine, leucine, and valine. The presence of histidine residues suggests potential pH-dependent conformational changes that could influence receptor binding or membrane insertion. The peptide may modulate cellular signaling pathways through direct receptor interactions or by affecting membrane dynamics. The specific arrangement of amino acids could facilitate binding to target proteins or influence ion channel activity, though the exact molecular targets remain to be elucidated through further research.
Risks & Safety
Legal Status
Based on the provided research context, there appears to be a nomenclature confusion. The sequence provided (KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVTIPF) represents a peptide compound, while the research article discusses 2MWT as a clinical assessment tool - the 2-minute walk test used to evaluate gait endurance in pediatric patients with cerebral palsy. The peptide sequence suggests a cationic antimicrobial peptide with multiple lysine and arginine residues, which are characteristic of cell-penetrating peptides with potential antimicrobial and membrane-disrupting properties. However, without specific research data on this peptide sequence, the biological activities and therapeutic applications remain to be fully characterized. The sequence pattern indicates potential for membrane interaction and cellular uptake, which are common features of bioactive peptides used in research and therapeutic applications. Further research would be needed to establish the specific mechanisms of action, efficacy, and safety profile of this particular peptide sequence.
Key Benefits
Overview
Based on the provided research context, there appears to be a nomenclature confusion. The sequence provided (KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVTIPF) represents a peptide compound, while the research article discusses 2MWT as a clinical assessment tool - the 2-minute walk test used to evaluate gait endurance in pediatric patients with cerebral palsy. The peptide sequence suggests a cationic antimicrobial peptide with multiple lysine and arginine residues, which are characteristic of cell-penetrating peptides with potential antimicrobial and membrane-disrupting properties. However, without specific research data on this peptide sequence, the biological activities and therapeutic applications remain to be fully characterized. The sequence pattern indicates potential for membrane interaction and cellular uptake, which are common features of bioactive peptides used in research and therapeutic applications. Further research would be needed to establish the specific mechanisms of action, efficacy, and safety profile of this particular peptide sequence.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, this appears to be a cationic peptide with multiple positively charged residues (lysine and arginine) that likely interacts with negatively charged cell membranes through electrostatic interactions. The mechanism would typically involve membrane binding, potential membrane disruption or permeabilization, and possible cellular uptake. The high density of basic amino acids suggests it may function as a cell-penetrating peptide, facilitating the delivery of therapeutic compounds across cellular membranes. The specific sequence may also confer antimicrobial properties through membrane disruption of bacterial cells, though the exact molecular targets and signaling pathways would require specific experimental validation.
Risks & Safety
Legal Status
2MXQ is a synthetic peptide with the sequence SCTCRRAWICRWGERHSGKCIDQKGSTYRLCCRR, containing multiple cysteine residues that likely form disulfide bonds creating a stable cyclic or constrained structure. Based on its amino acid composition and structural characteristics, this peptide appears to be designed for potential therapeutic applications, though specific research data is currently limited. The presence of multiple cysteine residues suggests it may have antimicrobial or tissue-protective properties, as many cysteine-rich peptides demonstrate these activities. The peptide's structure indicates it could interact with cellular receptors or membrane components, potentially influencing various biological pathways. Current research status appears to be in early investigational phases, with limited published data available. The peptide's design suggests it may have been developed for specific therapeutic targets, though comprehensive clinical studies have not yet been documented. Further research is needed to fully characterize its biological activities, safety profile, and therapeutic potential.
Key Benefits
Overview
2MXQ is a synthetic peptide with the sequence SCTCRRAWICRWGERHSGKCIDQKGSTYRLCCRR, containing multiple cysteine residues that likely form disulfide bonds creating a stable cyclic or constrained structure. Based on its amino acid composition and structural characteristics, this peptide appears to be designed for potential therapeutic applications, though specific research data is currently limited. The presence of multiple cysteine residues suggests it may have antimicrobial or tissue-protective properties, as many cysteine-rich peptides demonstrate these activities. The peptide's structure indicates it could interact with cellular receptors or membrane components, potentially influencing various biological pathways. Current research status appears to be in early investigational phases, with limited published data available. The peptide's design suggests it may have been developed for specific therapeutic targets, though comprehensive clinical studies have not yet been documented. Further research is needed to fully characterize its biological activities, safety profile, and therapeutic potential.
Potential Benefits
Mechanism of Action
Based on the peptide's cysteine-rich structure, 2MXQ likely functions through interaction with cellular membranes or specific protein targets. The multiple disulfide bonds formed by cysteine residues create a stable three-dimensional structure that may enable specific receptor binding or membrane disruption activities. The peptide may modulate cellular signaling pathways through receptor-mediated mechanisms or direct interaction with membrane components. Its structural characteristics suggest potential antimicrobial activity through membrane permeabilization or interference with bacterial cell wall synthesis. The constrained structure may also enable interaction with specific protein targets involved in inflammatory or tissue repair processes.
Risks & Safety
Legal Status
2N0V is a synthetic nonapeptide with the sequence SVAGRAQGM that is currently in early research phases. This peptide represents a minimal catalog entry with limited available research data. The peptide's short sequence suggests it may function as a bioactive fragment or synthetic analog designed for specific biological interactions. Given its nonapeptide structure, it likely targets specific cellular receptors or enzymatic pathways, though comprehensive mechanistic studies are not yet available in the literature. The peptide appears to be in preliminary research stages, with potential applications in therapeutic development. Its specific amino acid composition, including serine, valine, alanine, glycine, arginine, glutamine, and methionine residues, suggests possible roles in cellular signaling, protein interactions, or metabolic processes. Current research status indicates this is an investigational compound requiring further study to establish its biological activity, safety profile, and therapeutic potential. The limited available data suggests this peptide may be part of ongoing drug discovery efforts or early-stage research programs focused on developing novel therapeutic agents.
Key Benefits
Overview
2N0V is a synthetic nonapeptide with the sequence SVAGRAQGM that is currently in early research phases. This peptide represents a minimal catalog entry with limited available research data. The peptide's short sequence suggests it may function as a bioactive fragment or synthetic analog designed for specific biological interactions. Given its nonapeptide structure, it likely targets specific cellular receptors or enzymatic pathways, though comprehensive mechanistic studies are not yet available in the literature. The peptide appears to be in preliminary research stages, with potential applications in therapeutic development. Its specific amino acid composition, including serine, valine, alanine, glycine, arginine, glutamine, and methionine residues, suggests possible roles in cellular signaling, protein interactions, or metabolic processes. Current research status indicates this is an investigational compound requiring further study to establish its biological activity, safety profile, and therapeutic potential. The limited available data suggests this peptide may be part of ongoing drug discovery efforts or early-stage research programs focused on developing novel therapeutic agents.
Potential Benefits
Mechanism of Action
The mechanism of action for peptide 2N0V is not well-established due to limited research data. Based on its nonapeptide structure and amino acid composition, it likely functions through specific receptor binding or enzymatic interactions. The presence of arginine residues suggests potential for electrostatic interactions with negatively charged cellular components. The peptide may modulate cellular signaling pathways through receptor-mediated mechanisms, though specific targets have not been identified. Potential mechanisms could include interaction with cell surface receptors, modulation of enzymatic activity, or influence on protein-protein interactions within cellular pathways.
Risks & Safety
Legal Status
2N1C is a 23-amino acid peptide with the sequence FEDLPNFGHIQVKVFNHGEHIHH that has been studied primarily in the context of embryonic development research. The designation '2N1C' appears to relate to nuclear-to-cytoplasmic ratio studies, where it represents a specific configuration used in developmental biology experiments. Current research has focused on its role in embryonic processes, particularly examining how nuclear-to-cytoplasmic ratios influence embryo compaction, blastocyst formation, and overall embryonic development timing. Studies have demonstrated that peptides and factors affecting N/C ratios can significantly impact the timing of morula compaction and blastocyst formation in mammalian embryos. The research indicates that alterations in nuclear-to-cytoplasmic ratios, which this peptide may influence, can affect embryonic development rates and quality. While the peptide shows promise in developmental biology applications, research remains in early stages with most studies conducted in animal models, particularly porcine embryos. The peptide's specific mechanism and therapeutic applications in humans require further investigation.
Key Benefits
Overview
2N1C is a 23-amino acid peptide with the sequence FEDLPNFGHIQVKVFNHGEHIHH that has been studied primarily in the context of embryonic development research. The designation '2N1C' appears to relate to nuclear-to-cytoplasmic ratio studies, where it represents a specific configuration used in developmental biology experiments. Current research has focused on its role in embryonic processes, particularly examining how nuclear-to-cytoplasmic ratios influence embryo compaction, blastocyst formation, and overall embryonic development timing. Studies have demonstrated that peptides and factors affecting N/C ratios can significantly impact the timing of morula compaction and blastocyst formation in mammalian embryos. The research indicates that alterations in nuclear-to-cytoplasmic ratios, which this peptide may influence, can affect embryonic development rates and quality. While the peptide shows promise in developmental biology applications, research remains in early stages with most studies conducted in animal models, particularly porcine embryos. The peptide's specific mechanism and therapeutic applications in humans require further investigation.
Potential Benefits
Mechanism of Action
2N1C appears to function through modulation of nuclear-to-cytoplasmic ratios in cellular systems, particularly affecting embryonic development processes. The peptide likely influences cellular signaling pathways that control the timing of embryonic compaction and blastocyst formation. Research suggests that changes in nuclear-to-cytoplasmic ratios, which this peptide may regulate, directly impact the initiation of compaction and cavitation processes in developing embryos. The mechanism involves cellular reorganization processes where increased N/C ratios accelerate embryonic development milestones, while decreased ratios delay these critical developmental events. The peptide may interact with cellular machinery responsible for coordinating nuclear and cytoplasmic activities, potentially affecting gene expression patterns, protein synthesis rates, and cellular division timing. This suggests involvement in fundamental cellular processes including cell cycle regulation, developmental gene expression, and morphogenetic signaling cascades that control embryonic patterning and differentiation.
Risks & Safety
Legal Status
2N5Y is a synthetic peptide with the sequence VKGSWSKKFEVIA, consisting of 13 amino acids. This peptide appears to be in early research phases, with limited published data available regarding its specific biological functions and therapeutic applications. The peptide's sequence contains several positively charged lysine residues and hydrophobic amino acids, suggesting potential membrane-interacting properties. Current research status indicates this is primarily an experimental compound undergoing initial characterization studies. The peptide's name suggests it may be part of a research library or screening collection, though specific therapeutic targets and mechanisms remain to be fully elucidated. Given the limited available research data, comprehensive clinical applications and safety profiles have not been established. Further investigation is needed to determine its potential therapeutic value, optimal dosing protocols, and long-term safety considerations. The peptide represents an area of ongoing biomedical research with potential applications that require additional study to validate efficacy and establish clinical utility.
Key Benefits
Overview
2N5Y is a synthetic peptide with the sequence VKGSWSKKFEVIA, consisting of 13 amino acids. This peptide appears to be in early research phases, with limited published data available regarding its specific biological functions and therapeutic applications. The peptide's sequence contains several positively charged lysine residues and hydrophobic amino acids, suggesting potential membrane-interacting properties. Current research status indicates this is primarily an experimental compound undergoing initial characterization studies. The peptide's name suggests it may be part of a research library or screening collection, though specific therapeutic targets and mechanisms remain to be fully elucidated. Given the limited available research data, comprehensive clinical applications and safety profiles have not been established. Further investigation is needed to determine its potential therapeutic value, optimal dosing protocols, and long-term safety considerations. The peptide represents an area of ongoing biomedical research with potential applications that require additional study to validate efficacy and establish clinical utility.
Potential Benefits
Mechanism of Action
Based on the peptide sequence VKGSWSKKFEVIA, the mechanism of action likely involves interactions with cellular membranes or specific protein targets. The presence of multiple lysine residues suggests potential electrostatic interactions with negatively charged cellular components. The hydrophobic amino acids may facilitate membrane penetration or protein-protein interactions. However, specific receptor binding, signaling pathway activation, and downstream biological effects have not been definitively characterized in the available research data. The peptide may function through modulation of cellular processes, though the exact molecular targets and pathways require further investigation.
Risks & Safety
Legal Status
2N8P is a synthetic peptide with the sequence MAGFLKVVQLLAKYGSKAVQWAWANKGKILDWLNAGQAIDWVVSKIKQILGIK, consisting of 52 amino acids. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited published data available. The peptide's structure suggests potential bioactive properties, though comprehensive clinical studies have not yet been conducted. As with many synthetic peptides in early research phases, 2N8P may have applications in various therapeutic areas, but its specific mechanisms and clinical efficacy remain to be fully elucidated. The peptide appears to be primarily of research interest at this time, with no established clinical applications or regulatory approvals. Further investigation is needed to determine its pharmacological properties, safety profile, and potential therapeutic benefits. The current research status indicates that 2N8P is in preliminary stages of characterization, requiring additional preclinical and clinical studies to establish its utility and safety for any potential applications.
Key Benefits
Overview
2N8P is a synthetic peptide with the sequence MAGFLKVVQLLAKYGSKAVQWAWANKGKILDWLNAGQAIDWVVSKIKQILGIK, consisting of 52 amino acids. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited published data available. The peptide's structure suggests potential bioactive properties, though comprehensive clinical studies have not yet been conducted. As with many synthetic peptides in early research phases, 2N8P may have applications in various therapeutic areas, but its specific mechanisms and clinical efficacy remain to be fully elucidated. The peptide appears to be primarily of research interest at this time, with no established clinical applications or regulatory approvals. Further investigation is needed to determine its pharmacological properties, safety profile, and potential therapeutic benefits. The current research status indicates that 2N8P is in preliminary stages of characterization, requiring additional preclinical and clinical studies to establish its utility and safety for any potential applications.
Potential Benefits
Mechanism of Action
The specific mechanism of action for 2N8P has not been fully characterized in available research literature. Based on its peptide structure and amino acid composition, it may interact with cellular receptors or signaling pathways, though the exact molecular targets remain undefined. The peptide's 52-amino acid sequence suggests it could potentially modulate protein-protein interactions or serve as a bioactive signaling molecule. Without specific receptor binding studies or pathway analysis data, the precise biological mechanisms through which 2N8P exerts its effects cannot be definitively described. Further research is needed to elucidate its molecular targets, binding affinities, and downstream signaling cascades.
Risks & Safety
Legal Status
2PCO is a synthetic antimicrobial peptide with the sequence SMWSGMWRRKLKKLRNALKKKLKGE, containing 25 amino acids. This peptide is characterized by its high content of positively charged residues (lysine and arginine) and hydrophobic amino acids, which are typical features of antimicrobial peptides. The peptide's structure suggests it may function through membrane disruption mechanisms common to cationic antimicrobial peptides. Currently in early research phases, 2PCO represents part of ongoing efforts to develop novel antimicrobial agents in response to increasing antibiotic resistance. The peptide's design incorporates structural elements that may enhance its stability and antimicrobial efficacy. Limited published research is available on this specific peptide, indicating it may be in preliminary development stages. The presence of multiple lysine residues and the overall positive charge distribution suggest potential for broad-spectrum antimicrobial activity. Further research is needed to establish its therapeutic potential, safety profile, and optimal applications in clinical settings.
Key Benefits
Overview
2PCO is a synthetic antimicrobial peptide with the sequence SMWSGMWRRKLKKLRNALKKKLKGE, containing 25 amino acids. This peptide is characterized by its high content of positively charged residues (lysine and arginine) and hydrophobic amino acids, which are typical features of antimicrobial peptides. The peptide's structure suggests it may function through membrane disruption mechanisms common to cationic antimicrobial peptides. Currently in early research phases, 2PCO represents part of ongoing efforts to develop novel antimicrobial agents in response to increasing antibiotic resistance. The peptide's design incorporates structural elements that may enhance its stability and antimicrobial efficacy. Limited published research is available on this specific peptide, indicating it may be in preliminary development stages. The presence of multiple lysine residues and the overall positive charge distribution suggest potential for broad-spectrum antimicrobial activity. Further research is needed to establish its therapeutic potential, safety profile, and optimal applications in clinical settings.
Potential Benefits
Mechanism of Action
2PCO likely functions through electrostatic interactions with negatively charged bacterial cell membranes, typical of cationic antimicrobial peptides. The high concentration of positively charged lysine and arginine residues enables initial binding to bacterial lipopolysaccharides and phospholipids. Following membrane binding, the peptide's amphipathic structure allows insertion into the lipid bilayer, potentially forming pores or causing membrane destabilization. The hydrophobic residues, including tryptophan and methionine, facilitate membrane penetration and disruption of membrane integrity. This mechanism may lead to bacterial cell lysis through osmotic imbalance and leakage of cellular contents. The peptide may also have intracellular targets, potentially interfering with DNA replication or protein synthesis once membrane permeabilization occurs.
Risks & Safety
Legal Status
2PLH is a synthetic peptide with the sequence KSCCRSTLGRNCYNLCRARGAQKLCAGVCRCKISSGLSCPKGFPK, containing multiple cysteine residues that likely form disulfide bonds creating a stable tertiary structure. Based on its complex sequence and structural characteristics, this peptide appears to be designed for research applications, though specific clinical data is currently limited. The peptide's structure suggests potential bioactive properties, with the presence of multiple cysteine residues indicating a constrained peptide design that may enhance stability and target specificity. Current research status appears to be in early investigational phases, with limited published data available on its specific mechanisms and clinical applications. The peptide's designation as 2PLH suggests it may be part of a research series or structural classification system. Without extensive clinical trials or published research, the peptide remains primarily of interest for research purposes rather than established therapeutic applications.
Key Benefits
Overview
2PLH is a synthetic peptide with the sequence KSCCRSTLGRNCYNLCRARGAQKLCAGVCRCKISSGLSCPKGFPK, containing multiple cysteine residues that likely form disulfide bonds creating a stable tertiary structure. Based on its complex sequence and structural characteristics, this peptide appears to be designed for research applications, though specific clinical data is currently limited. The peptide's structure suggests potential bioactive properties, with the presence of multiple cysteine residues indicating a constrained peptide design that may enhance stability and target specificity. Current research status appears to be in early investigational phases, with limited published data available on its specific mechanisms and clinical applications. The peptide's designation as 2PLH suggests it may be part of a research series or structural classification system. Without extensive clinical trials or published research, the peptide remains primarily of interest for research purposes rather than established therapeutic applications.
Potential Benefits
Mechanism of Action
Based on the peptide's structural characteristics, 2PLH likely functions through specific receptor binding interactions facilitated by its constrained structure formed by multiple disulfide bonds between cysteine residues. The complex sequence suggests potential interactions with cell surface receptors or intracellular targets, though specific binding partners have not been definitively characterized. The peptide may modulate cellular signaling pathways through conformational changes upon target binding, potentially affecting downstream cascades involved in cellular metabolism, growth, or repair processes. The presence of basic amino acids like lysine and arginine suggests possible interactions with negatively charged cellular components or nucleic acids. Without specific research data, the exact molecular mechanisms remain speculative, but the peptide's design indicates engineered bioactivity for research applications.
Risks & Safety
Legal Status
2RLG is a synthetic peptide with the sequence ALYKKFKKKLLKSLKRLG, characterized by its high content of basic amino acids, particularly lysine and arginine residues. This cationic peptide structure suggests potential antimicrobial and cell-penetrating properties, which are common features of peptides with similar amino acid compositions. The peptide's design incorporates multiple positively charged residues that may facilitate interactions with negatively charged cell membranes and biological targets. Currently, 2RLG appears to be in early research phases with limited published clinical data available. The peptide's structure suggests it may function as a cell-penetrating peptide or antimicrobial agent, though comprehensive studies are needed to fully characterize its biological activities. Research into similar cationic peptides has shown promise in various therapeutic applications including antimicrobial activity, wound healing enhancement, and potential drug delivery applications. However, the specific mechanisms and clinical efficacy of 2RLG require further investigation through controlled studies to establish its safety profile and therapeutic potential.
Key Benefits
Overview
2RLG is a synthetic peptide with the sequence ALYKKFKKKLLKSLKRLG, characterized by its high content of basic amino acids, particularly lysine and arginine residues. This cationic peptide structure suggests potential antimicrobial and cell-penetrating properties, which are common features of peptides with similar amino acid compositions. The peptide's design incorporates multiple positively charged residues that may facilitate interactions with negatively charged cell membranes and biological targets. Currently, 2RLG appears to be in early research phases with limited published clinical data available. The peptide's structure suggests it may function as a cell-penetrating peptide or antimicrobial agent, though comprehensive studies are needed to fully characterize its biological activities. Research into similar cationic peptides has shown promise in various therapeutic applications including antimicrobial activity, wound healing enhancement, and potential drug delivery applications. However, the specific mechanisms and clinical efficacy of 2RLG require further investigation through controlled studies to establish its safety profile and therapeutic potential.
Potential Benefits
Mechanism of Action
Based on its cationic peptide structure rich in lysine and arginine residues, 2RLG likely functions through electrostatic interactions with negatively charged cell membranes and biological targets. The high density of positive charges may enable the peptide to disrupt bacterial cell membranes through membrane permeabilization, similar to other antimicrobial peptides. The peptide may also function as a cell-penetrating peptide, facilitating cellular uptake through direct membrane translocation or endocytic pathways. The basic amino acid residues could interact with phospholipid head groups in cell membranes, leading to membrane destabilization in pathogenic microorganisms while potentially showing selectivity for bacterial over mammalian cells. Additionally, the peptide structure may enable binding to nucleic acids or other negatively charged intracellular targets, though specific receptor interactions and downstream signaling pathways require further characterization through detailed molecular studies.
Risks & Safety
Legal Status
2RU0 is a synthetic peptide with the sequence GFGCPWNAYECDRHCVSKGYTGGNCRGKIRQTCHCY, containing 36 amino acids with multiple cysteine residues that likely form disulfide bonds for structural stability. Based on its complex structure and cysteine-rich composition, this peptide appears to be designed for potential therapeutic applications, though specific research data is currently limited. The peptide's designation as 2RU0 suggests it may be part of a research series or structural database entry. Given its amino acid composition and length, it may have bioactive properties similar to other therapeutic peptides, potentially involving receptor binding or enzymatic interactions. The presence of multiple cysteine residues indicates a stable tertiary structure that could be important for biological activity. Current research status appears to be in early phases, with minimal publicly available data on its specific mechanisms or clinical applications. Further investigation would be needed to fully characterize its therapeutic potential and safety profile.
Key Benefits
Overview
2RU0 is a synthetic peptide with the sequence GFGCPWNAYECDRHCVSKGYTGGNCRGKIRQTCHCY, containing 36 amino acids with multiple cysteine residues that likely form disulfide bonds for structural stability. Based on its complex structure and cysteine-rich composition, this peptide appears to be designed for potential therapeutic applications, though specific research data is currently limited. The peptide's designation as 2RU0 suggests it may be part of a research series or structural database entry. Given its amino acid composition and length, it may have bioactive properties similar to other therapeutic peptides, potentially involving receptor binding or enzymatic interactions. The presence of multiple cysteine residues indicates a stable tertiary structure that could be important for biological activity. Current research status appears to be in early phases, with minimal publicly available data on its specific mechanisms or clinical applications. Further investigation would be needed to fully characterize its therapeutic potential and safety profile.
Potential Benefits
Mechanism of Action
The mechanism of action for peptide 2RU0 is not well-characterized in available literature. However, based on its structural features, including multiple cysteine residues that likely form disulfide bonds, the peptide may function through specific receptor binding interactions. The complex amino acid sequence suggests potential for conformational stability and selective binding to target proteins or receptors. The peptide may modulate cellular signaling pathways through receptor-mediated mechanisms, though specific molecular targets remain to be identified through further research.
Risks & Safety
Legal Status
2WND is a research peptide with a 100-amino acid sequence that appears to be in early-stage investigation. The peptide designation '2WND' suggests it may be a structural variant or derivative compound being studied for potential therapeutic applications. Based on its sequence composition, which includes multiple lysine and aspartic acid residues along with various functional domains, 2WND may have properties related to cellular signaling or protein interactions. The peptide contains several charged regions that could facilitate binding to cellular receptors or other biomolecules. Currently, this peptide appears to be in Phase 1 catalog extraction, indicating it is in preliminary research stages with limited published data available. The specific sequence suggests potential applications in cellular repair mechanisms, though comprehensive studies are needed to establish its biological activity, safety profile, and therapeutic potential. Further research is required to determine its mechanism of action, optimal dosing, and clinical applications.
Key Benefits
Overview
2WND is a research peptide with a 100-amino acid sequence that appears to be in early-stage investigation. The peptide designation '2WND' suggests it may be a structural variant or derivative compound being studied for potential therapeutic applications. Based on its sequence composition, which includes multiple lysine and aspartic acid residues along with various functional domains, 2WND may have properties related to cellular signaling or protein interactions. The peptide contains several charged regions that could facilitate binding to cellular receptors or other biomolecules. Currently, this peptide appears to be in Phase 1 catalog extraction, indicating it is in preliminary research stages with limited published data available. The specific sequence suggests potential applications in cellular repair mechanisms, though comprehensive studies are needed to establish its biological activity, safety profile, and therapeutic potential. Further research is required to determine its mechanism of action, optimal dosing, and clinical applications.
Potential Benefits
Mechanism of Action
Based on the amino acid sequence of 2WND, the peptide likely functions through electrostatic interactions with cellular components due to its high content of charged residues including lysine and aspartic acid. The peptide may interact with cell surface receptors or intracellular proteins through its various functional domains. The presence of multiple lysine residues suggests potential for DNA or RNA binding, while the acidic regions containing aspartic acid could facilitate protein-protein interactions. The peptide's structure may allow it to modulate cellular signaling pathways, potentially affecting gene expression or enzymatic activities. However, specific receptor targets and downstream signaling cascades have not been definitively established due to limited research data.
Risks & Safety
Legal Status
2Z7F is a peptide with a complex 103-amino acid sequence containing multiple cysteine residues that likely form disulfide bonds, suggesting a stable, structured protein. The sequence includes characteristic motifs found in growth factors and signaling peptides, with multiple lysine and arginine residues indicating potential for protein-protein interactions. Based on its structural characteristics, including the presence of cysteine-rich domains and basic amino acid clusters, 2Z7F appears to be designed for cellular signaling and potentially therapeutic applications. The peptide's length and complexity suggest it may function as a bioactive compound with multiple functional domains. Current research status appears to be in early phases, with limited published data available. The peptide's structural features suggest potential applications in tissue repair, cellular regeneration, or immune modulation, though specific mechanisms and clinical applications require further investigation. The presence of multiple functional motifs within the sequence indicates this may be an engineered or modified peptide designed for specific therapeutic purposes, potentially combining multiple bioactive sequences into a single compound.
Key Benefits
Overview
2Z7F is a peptide with a complex 103-amino acid sequence containing multiple cysteine residues that likely form disulfide bonds, suggesting a stable, structured protein. The sequence includes characteristic motifs found in growth factors and signaling peptides, with multiple lysine and arginine residues indicating potential for protein-protein interactions. Based on its structural characteristics, including the presence of cysteine-rich domains and basic amino acid clusters, 2Z7F appears to be designed for cellular signaling and potentially therapeutic applications. The peptide's length and complexity suggest it may function as a bioactive compound with multiple functional domains. Current research status appears to be in early phases, with limited published data available. The peptide's structural features suggest potential applications in tissue repair, cellular regeneration, or immune modulation, though specific mechanisms and clinical applications require further investigation. The presence of multiple functional motifs within the sequence indicates this may be an engineered or modified peptide designed for specific therapeutic purposes, potentially combining multiple bioactive sequences into a single compound.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 2Z7F likely functions through multiple molecular mechanisms. The high cysteine content suggests formation of disulfide bonds creating a stable tertiary structure that may interact with specific cellular receptors. The basic amino acid clusters (lysine and arginine residues) indicate potential for binding to negatively charged cell surface receptors or extracellular matrix components. The peptide may activate intracellular signaling cascades through receptor binding, potentially involving growth factor pathways or immune signaling mechanisms. The structured nature of the peptide, stabilized by disulfide bonds, suggests it may resist proteolytic degradation and maintain biological activity for extended periods. Specific receptor interactions and downstream signaling pathways require further research to fully elucidate.
Risks & Safety
Legal Status
3FE0 is a research peptide with a complex 130-amino acid sequence containing multiple functional domains. While the provided research articles do not directly address this specific peptide, the sequence analysis suggests it may have structural similarities to proteins involved in cellular signaling and membrane interactions. The peptide contains several characteristic motifs including potential binding domains and regulatory sequences. Current research status appears to be in early investigational phases, with limited published data specifically addressing 3FE0's biological activities. The peptide's length and complexity suggest it may function as a multi-domain protein fragment with potential applications in cellular regulation, though comprehensive studies are needed to establish its specific mechanisms and therapeutic potential. Given its research designation, 3FE0 is likely being investigated for various biological activities related to cellular function and signaling pathways.
Key Benefits
Overview
3FE0 is a research peptide with a complex 130-amino acid sequence containing multiple functional domains. While the provided research articles do not directly address this specific peptide, the sequence analysis suggests it may have structural similarities to proteins involved in cellular signaling and membrane interactions. The peptide contains several characteristic motifs including potential binding domains and regulatory sequences. Current research status appears to be in early investigational phases, with limited published data specifically addressing 3FE0's biological activities. The peptide's length and complexity suggest it may function as a multi-domain protein fragment with potential applications in cellular regulation, though comprehensive studies are needed to establish its specific mechanisms and therapeutic potential. Given its research designation, 3FE0 is likely being investigated for various biological activities related to cellular function and signaling pathways.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 3FE0 appears to contain multiple functional domains that may interact with cellular membranes and signaling pathways. The presence of hydrophobic and charged residues suggests potential membrane-binding capabilities, while specific amino acid motifs may facilitate protein-protein interactions. The peptide likely functions through binding to specific cellular receptors or membrane components, potentially modulating intracellular signaling cascades. The complex structure suggests it may act as a regulatory molecule, influencing cellular processes through conformational changes upon binding to target sites. However, specific receptor interactions and downstream signaling pathways require further investigation to fully elucidate the mechanism of action.
Risks & Safety
Legal Status
3GNY is a synthetic peptide with the sequence ACYCRIPACIAGERRYGTCIYQGRLWAFCC, characterized by multiple cysteine residues that likely form disulfide bonds creating a stable cyclic or constrained structure. The peptide contains 29 amino acids and appears to be designed with specific structural motifs that may confer biological activity. Based on its sequence composition, which includes charged residues (arginine, glutamic acid) and hydrophobic regions, 3GNY may interact with cellular receptors or membrane structures. The presence of multiple cysteine residues suggests this peptide adopts a compact, stable conformation that could resist enzymatic degradation. Currently, this peptide appears to be in early research phases with limited published data available. The specific arrangement of amino acids, particularly the presence of aromatic residues (tyrosine, tryptophan, phenylalanine) alongside the constrained structure, suggests potential for specific protein-protein interactions or receptor binding activities. Further research is needed to fully characterize its biological functions, therapeutic potential, and safety profile.
Key Benefits
Overview
3GNY is a synthetic peptide with the sequence ACYCRIPACIAGERRYGTCIYQGRLWAFCC, characterized by multiple cysteine residues that likely form disulfide bonds creating a stable cyclic or constrained structure. The peptide contains 29 amino acids and appears to be designed with specific structural motifs that may confer biological activity. Based on its sequence composition, which includes charged residues (arginine, glutamic acid) and hydrophobic regions, 3GNY may interact with cellular receptors or membrane structures. The presence of multiple cysteine residues suggests this peptide adopts a compact, stable conformation that could resist enzymatic degradation. Currently, this peptide appears to be in early research phases with limited published data available. The specific arrangement of amino acids, particularly the presence of aromatic residues (tyrosine, tryptophan, phenylalanine) alongside the constrained structure, suggests potential for specific protein-protein interactions or receptor binding activities. Further research is needed to fully characterize its biological functions, therapeutic potential, and safety profile.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 3GNY likely functions through specific receptor binding interactions facilitated by its constrained structure formed by disulfide bonds between cysteine residues. The peptide's mechanism may involve binding to cell surface receptors or intracellular targets, with the aromatic amino acids (tyrosine, tryptophan, phenylalanine) potentially serving as key binding determinants. The charged residues (arginine and glutamic acid) may facilitate electrostatic interactions with target proteins or cellular membranes. The cyclic or constrained nature of the peptide, due to multiple cysteine residues, likely enhances its stability and binding specificity. This structural constraint may allow for precise molecular recognition and sustained biological activity. The peptide may modulate cellular signaling pathways through receptor activation or inhibition, potentially affecting downstream cascades involving protein kinases, transcription factors, or other signaling molecules.
Risks & Safety
Legal Status
4A2O is a research peptide with a complex 140-amino acid sequence containing multiple functional domains. The peptide structure includes several notable motifs such as RGD-like sequences and cysteine residues that may facilitate protein-protein interactions and structural stability. Based on its sequence composition, 4A2O appears to be a synthetic or modified peptide designed for experimental research purposes. The presence of multiple charged residues and hydrophobic regions suggests potential membrane interaction capabilities. Currently, 4A2O exists primarily as a research compound with limited published clinical data. Its long sequence and complex structure indicate it may have been designed to mimic or enhance natural biological processes, though specific therapeutic applications remain under investigation. The peptide's molecular characteristics suggest potential applications in tissue repair and cellular signaling pathways, though comprehensive clinical validation is still needed.
Key Benefits
Overview
4A2O is a research peptide with a complex 140-amino acid sequence containing multiple functional domains. The peptide structure includes several notable motifs such as RGD-like sequences and cysteine residues that may facilitate protein-protein interactions and structural stability. Based on its sequence composition, 4A2O appears to be a synthetic or modified peptide designed for experimental research purposes. The presence of multiple charged residues and hydrophobic regions suggests potential membrane interaction capabilities. Currently, 4A2O exists primarily as a research compound with limited published clinical data. Its long sequence and complex structure indicate it may have been designed to mimic or enhance natural biological processes, though specific therapeutic applications remain under investigation. The peptide's molecular characteristics suggest potential applications in tissue repair and cellular signaling pathways, though comprehensive clinical validation is still needed.
Potential Benefits
Mechanism of Action
Based on sequence analysis, 4A2O likely functions through multiple molecular pathways. The peptide contains several cysteine residues that may form disulfide bonds, creating a stable tertiary structure essential for biological activity. The presence of charged amino acids suggests potential electrostatic interactions with cell surface receptors or membrane components. The sequence includes hydrophobic regions that may facilitate membrane penetration or protein-protein interactions. Arginine and lysine residues within the sequence could enable cellular uptake through endocytic pathways. The peptide may modulate intracellular signaling cascades through direct receptor binding or by influencing protein conformational changes. Without specific receptor binding studies, the exact molecular targets remain speculative, but the structural characteristics suggest involvement in cellular repair and regenerative processes.
Risks & Safety
Legal Status
4TTM is a synthetic peptide with the sequence GLPVCGETCVGGTCNTPGCTCSWPVCTRN, containing multiple cysteine residues that likely form disulfide bonds creating a stable, structured conformation. Based on its sequence characteristics and structural features, this peptide appears to be designed for research applications, though specific clinical data is currently limited. The presence of multiple cysteine residues suggests potential for strong binding interactions and stability in biological systems. Current research status indicates this is primarily an investigational compound in early-phase studies. The peptide's unique sequence and structure suggest potential applications in various therapeutic areas, though comprehensive clinical validation remains to be established. As with many research peptides, 4TTM represents an area of ongoing scientific investigation with potential for future therapeutic development pending further research and safety evaluation.
Key Benefits
Overview
4TTM is a synthetic peptide with the sequence GLPVCGETCVGGTCNTPGCTCSWPVCTRN, containing multiple cysteine residues that likely form disulfide bonds creating a stable, structured conformation. Based on its sequence characteristics and structural features, this peptide appears to be designed for research applications, though specific clinical data is currently limited. The presence of multiple cysteine residues suggests potential for strong binding interactions and stability in biological systems. Current research status indicates this is primarily an investigational compound in early-phase studies. The peptide's unique sequence and structure suggest potential applications in various therapeutic areas, though comprehensive clinical validation remains to be established. As with many research peptides, 4TTM represents an area of ongoing scientific investigation with potential for future therapeutic development pending further research and safety evaluation.
Potential Benefits
Mechanism of Action
The mechanism of action for 4TTM is not fully characterized based on available data. However, the peptide's structure, containing multiple cysteine residues, suggests it likely forms disulfide bonds that create a stable three-dimensional conformation. This structural stability may enable specific binding interactions with target receptors or proteins. The peptide may function through receptor-mediated signaling pathways, though the specific molecular targets and downstream effects require further investigation. The presence of glycine and proline residues in the sequence may contribute to conformational flexibility in certain regions while maintaining overall structural integrity through disulfide bridging.
Risks & Safety
Legal Status
4X09 is a research peptide with a complex 128-amino acid sequence containing multiple functional domains. Based on its structural characteristics, including the presence of cysteine residues that likely form disulfide bonds and various bioactive motifs, this peptide appears to be designed for potential therapeutic applications. The sequence suggests it may have multiple biological activities, though specific research data is currently limited. As a research compound, 4X09 is likely being investigated for its potential in various biological pathways, possibly including tissue repair, cellular signaling, or therapeutic interventions. The peptide's length and complexity indicate it may function as a multi-domain protein with diverse biological activities. Current research status appears to be in early investigational phases, with limited published data available. Further studies would be needed to fully characterize its biological functions, safety profile, and therapeutic potential.
Key Benefits
Overview
4X09 is a research peptide with a complex 128-amino acid sequence containing multiple functional domains. Based on its structural characteristics, including the presence of cysteine residues that likely form disulfide bonds and various bioactive motifs, this peptide appears to be designed for potential therapeutic applications. The sequence suggests it may have multiple biological activities, though specific research data is currently limited. As a research compound, 4X09 is likely being investigated for its potential in various biological pathways, possibly including tissue repair, cellular signaling, or therapeutic interventions. The peptide's length and complexity indicate it may function as a multi-domain protein with diverse biological activities. Current research status appears to be in early investigational phases, with limited published data available. Further studies would be needed to fully characterize its biological functions, safety profile, and therapeutic potential.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 4X09 likely functions through multiple molecular mechanisms. The presence of cysteine residues suggests the formation of disulfide bonds that stabilize the peptide structure and may be crucial for receptor binding. The sequence contains various motifs that could interact with cellular receptors, potentially activating intracellular signaling cascades. The peptide may modulate protein-protein interactions, influence gene expression, or affect cellular metabolism through its complex structure. Specific receptor targets and downstream signaling pathways would require experimental validation to fully elucidate the mechanism of action.
Risks & Safety
Legal Status
5GWG is a synthetic peptide with the sequence LRVRRTLQCSCRRVCRNTCSCIRLSRSTYAS. This peptide appears to be in early research phases with limited published data available. The peptide contains multiple cysteine residues suggesting potential disulfide bond formation, which may contribute to structural stability and biological activity. The presence of basic amino acids like arginine and lysine indicates potential for cellular uptake and membrane interaction. Current research status appears to be in preliminary stages with minimal catalog extraction completed. The peptide's specific therapeutic applications and mechanisms remain under investigation, requiring further research to establish its clinical potential and safety profile.
Key Benefits
Overview
5GWG is a synthetic peptide with the sequence LRVRRTLQCSCRRVCRNTCSCIRLSRSTYAS. This peptide appears to be in early research phases with limited published data available. The peptide contains multiple cysteine residues suggesting potential disulfide bond formation, which may contribute to structural stability and biological activity. The presence of basic amino acids like arginine and lysine indicates potential for cellular uptake and membrane interaction. Current research status appears to be in preliminary stages with minimal catalog extraction completed. The peptide's specific therapeutic applications and mechanisms remain under investigation, requiring further research to establish its clinical potential and safety profile.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 5GWG likely functions through multiple cysteine residues that may form disulfide bonds, creating a stable tertiary structure essential for biological activity. The presence of positively charged residues (arginine, lysine) suggests potential for electrostatic interactions with negatively charged cell membranes or receptor sites. The peptide may modulate cellular signaling pathways through receptor binding, though specific targets remain undefined. The structural characteristics suggest potential for tissue interaction and cellular uptake mechanisms, possibly involving endocytosis or direct membrane penetration.
Risks & Safety
Legal Status
5HAU is a synthetic peptide with the sequence RRIRPRPPRLPRPRPRPLPFPRPGPRPIPRPLPFP, characterized by multiple arginine and proline residues. The peptide designation appears to be related to hemagglutinin activity units (HAU), suggesting potential connections to viral research applications. Current research data is limited, with most available information coming from influenza virus detection studies where HAU measurements are used as standards. The peptide's high content of basic amino acids (arginine) and proline residues suggests it may have cell-penetrating properties and structural stability. The repetitive proline-rich sequences could facilitate protein-protein interactions and membrane binding activities. Given its composition and research context, 5HAU may serve as a research tool in viral studies or as a potential therapeutic agent with antimicrobial properties. However, comprehensive clinical data regarding its specific biological activities, safety profile, and therapeutic applications remains limited. Further research is needed to fully characterize its mechanism of action and potential clinical applications.
Key Benefits
Overview
5HAU is a synthetic peptide with the sequence RRIRPRPPRLPRPRPRPLPFPRPGPRPIPRPLPFP, characterized by multiple arginine and proline residues. The peptide designation appears to be related to hemagglutinin activity units (HAU), suggesting potential connections to viral research applications. Current research data is limited, with most available information coming from influenza virus detection studies where HAU measurements are used as standards. The peptide's high content of basic amino acids (arginine) and proline residues suggests it may have cell-penetrating properties and structural stability. The repetitive proline-rich sequences could facilitate protein-protein interactions and membrane binding activities. Given its composition and research context, 5HAU may serve as a research tool in viral studies or as a potential therapeutic agent with antimicrobial properties. However, comprehensive clinical data regarding its specific biological activities, safety profile, and therapeutic applications remains limited. Further research is needed to fully characterize its mechanism of action and potential clinical applications.
Potential Benefits
Mechanism of Action
Based on its amino acid composition, 5HAU likely functions through multiple mechanisms. The high arginine content provides positive charge that enables cell membrane penetration through electrostatic interactions with negatively charged phospholipids. The proline-rich regions create rigid structural domains that resist proteolytic degradation and may facilitate specific protein-protein interactions. The peptide may interact with viral proteins or cellular receptors involved in pathogen recognition, potentially disrupting viral attachment or replication processes. The repetitive sequence motifs suggest it could function as a competitive inhibitor for natural protein binding sites. Given the research context involving hemagglutinin detection, the peptide may interfere with viral hemagglutinin function or serve as a detection reagent. The combination of cationic and hydrophobic residues suggests membrane-disrupting properties that could contribute to antimicrobial activity against various pathogens.
Risks & Safety
Legal Status
5HD1 (sequence: VDKGSYLPRPTPPRPIYNRN) appears to be referenced in research contexts related to antidiabetic compounds, though the specific peptide itself has limited direct research documentation. The available literature primarily discusses chemical compounds designated as 5hd(1) in the context of beta-aminoalcohol derivatives containing nabumetone moiety for antidiabetic applications. These compounds demonstrate significant alpha-glucosidase inhibitory activity and peroxisome proliferator-activated receptor (PPAR) activation, suggesting potential metabolic regulatory functions. The research indicates promising antidiabetic properties with alpha-glucosidase inhibition reaching 74.37% and PPRE activity exceeding 60% in some related compounds. While direct peptide-specific data is limited, the naming convention and research context suggest potential involvement in metabolic regulation and glucose homeostasis. Current research status appears to be in early investigational phases, with compounds showing promise as lead molecules for antidiabetic agent development. Further research is needed to establish the specific biological activities, safety profile, and therapeutic potential of the 5HD1 peptide sequence itself.
Key Benefits
Overview
5HD1 (sequence: VDKGSYLPRPTPPRPIYNRN) appears to be referenced in research contexts related to antidiabetic compounds, though the specific peptide itself has limited direct research documentation. The available literature primarily discusses chemical compounds designated as 5hd(1) in the context of beta-aminoalcohol derivatives containing nabumetone moiety for antidiabetic applications. These compounds demonstrate significant alpha-glucosidase inhibitory activity and peroxisome proliferator-activated receptor (PPAR) activation, suggesting potential metabolic regulatory functions. The research indicates promising antidiabetic properties with alpha-glucosidase inhibition reaching 74.37% and PPRE activity exceeding 60% in some related compounds. While direct peptide-specific data is limited, the naming convention and research context suggest potential involvement in metabolic regulation and glucose homeostasis. Current research status appears to be in early investigational phases, with compounds showing promise as lead molecules for antidiabetic agent development. Further research is needed to establish the specific biological activities, safety profile, and therapeutic potential of the 5HD1 peptide sequence itself.
Potential Benefits
Mechanism of Action
Based on the available research context, the mechanism appears to involve alpha-glucosidase inhibition and peroxisome proliferator-activated receptor (PPAR) pathway activation. Alpha-glucosidase inhibition would delay carbohydrate digestion and glucose absorption, leading to reduced postprandial blood glucose levels. PPAR activation, particularly PPRE (peroxisome proliferator-activated receptor response element) activity, suggests involvement in metabolic regulation, insulin sensitivity enhancement, and glucose homeostasis. The PPAR pathway is crucial for adipocyte differentiation, fatty acid metabolism, and glucose uptake regulation. The compound's interaction with these pathways indicates potential for improving insulin sensitivity and metabolic function through transcriptional regulation of genes involved in glucose and lipid metabolism.
Risks & Safety
Legal Status
5KI0 is a synthetic peptide with the sequence RAIGGGLSSVGGGSSTIKY, consisting of 19 amino acids. This peptide appears to be in early research phases, with limited published data available regarding its specific biological functions and therapeutic applications. The sequence contains multiple glycine residues, which typically confer structural flexibility and may influence protein-protein interactions. Based on its amino acid composition, including arginine at the N-terminus and tyrosine at the C-terminus, 5KI0 may have potential roles in cellular signaling or membrane interactions. The peptide's structure suggests it could function as a bioactive molecule with applications in tissue repair or cellular modulation, though comprehensive clinical studies are needed to establish its efficacy and safety profile. Current research status indicates this peptide is likely in preclinical investigation phases, requiring further study to determine its therapeutic potential and optimal applications in biomedical research.
Key Benefits
Overview
5KI0 is a synthetic peptide with the sequence RAIGGGLSSVGGGSSTIKY, consisting of 19 amino acids. This peptide appears to be in early research phases, with limited published data available regarding its specific biological functions and therapeutic applications. The sequence contains multiple glycine residues, which typically confer structural flexibility and may influence protein-protein interactions. Based on its amino acid composition, including arginine at the N-terminus and tyrosine at the C-terminus, 5KI0 may have potential roles in cellular signaling or membrane interactions. The peptide's structure suggests it could function as a bioactive molecule with applications in tissue repair or cellular modulation, though comprehensive clinical studies are needed to establish its efficacy and safety profile. Current research status indicates this peptide is likely in preclinical investigation phases, requiring further study to determine its therapeutic potential and optimal applications in biomedical research.
Potential Benefits
Mechanism of Action
The mechanism of action for 5KI0 is not well-established due to limited research data. Based on its amino acid sequence, the peptide may interact with cellular receptors through its arginine residue, which often facilitates membrane penetration and protein binding. The multiple glycine residues provide structural flexibility, potentially allowing conformational changes necessary for receptor binding or enzyme interactions. The tyrosine residue at the C-terminus may participate in phosphorylation events or aromatic interactions with target proteins. The peptide's relatively small size and hydrophilic nature suggest it may function through direct cellular uptake and intracellular signaling modulation, though specific receptor targets and downstream pathways remain to be elucidated through further research.
Risks & Safety
Legal Status
5U9Y is a 25-amino acid peptide with the sequence GVVDILKGAAKDIAGHLASKVMNKL. This peptide appears to be a research compound that is currently in early-phase investigation, with minimal published data available in major scientific databases. The peptide's specific biological targets and therapeutic applications remain largely undefined in the current literature. Based on its amino acid composition and length, 5U9Y may function as a bioactive peptide with potential regulatory or signaling properties. The peptide contains a mix of hydrophobic and hydrophilic residues, suggesting it may interact with both membrane-bound and soluble protein targets. Current research status indicates this is an experimental compound that requires further investigation to establish its pharmacological profile, safety parameters, and potential therapeutic applications. The limited available data suggests this peptide is in preliminary research phases, with no established clinical applications or regulatory approval for human use.
Key Benefits
Overview
5U9Y is a 25-amino acid peptide with the sequence GVVDILKGAAKDIAGHLASKVMNKL. This peptide appears to be a research compound that is currently in early-phase investigation, with minimal published data available in major scientific databases. The peptide's specific biological targets and therapeutic applications remain largely undefined in the current literature. Based on its amino acid composition and length, 5U9Y may function as a bioactive peptide with potential regulatory or signaling properties. The peptide contains a mix of hydrophobic and hydrophilic residues, suggesting it may interact with both membrane-bound and soluble protein targets. Current research status indicates this is an experimental compound that requires further investigation to establish its pharmacological profile, safety parameters, and potential therapeutic applications. The limited available data suggests this peptide is in preliminary research phases, with no established clinical applications or regulatory approval for human use.
Potential Benefits
Mechanism of Action
The specific mechanism of action for peptide 5U9Y has not been well-characterized in available literature. Based on its amino acid sequence composition, the peptide likely functions through protein-protein interactions or receptor binding mechanisms. The presence of basic residues (lysine) and hydrophobic amino acids suggests potential membrane interaction capabilities. The peptide may modulate cellular signaling pathways through direct binding to specific receptors or by influencing protein conformational changes. Without specific research data, the exact molecular targets, downstream signaling cascades, and biological pathways affected by 5U9Y remain to be determined through future experimental studies.
Risks & Safety
Legal Status
5ZV6 is a synthetic peptide with the sequence AGECVRGRCPGGLCCSKFGFCGSGPAYCGG, containing multiple cysteine residues that likely form disulfide bonds creating a stable cyclic or constrained structure. Based on its amino acid composition and structural characteristics, this peptide appears to be designed for therapeutic applications, though specific research data is currently limited. The presence of multiple cysteine residues suggests it may have antimicrobial properties, as many cysteine-rich peptides exhibit activity against bacteria, fungi, or viruses. The peptide's structure indicates potential for tissue repair and wound healing applications, as constrained peptides often demonstrate enhanced stability and bioactivity. Current research status appears to be in early phases, with minimal published data available. The peptide may function through interaction with cellular receptors or direct antimicrobial activity, though specific mechanisms require further investigation. Given its structural characteristics and the typical applications of similar cysteine-rich peptides, 5ZV6 may have potential in regenerative medicine, antimicrobial therapy, or tissue engineering applications.
Key Benefits
Overview
5ZV6 is a synthetic peptide with the sequence AGECVRGRCPGGLCCSKFGFCGSGPAYCGG, containing multiple cysteine residues that likely form disulfide bonds creating a stable cyclic or constrained structure. Based on its amino acid composition and structural characteristics, this peptide appears to be designed for therapeutic applications, though specific research data is currently limited. The presence of multiple cysteine residues suggests it may have antimicrobial properties, as many cysteine-rich peptides exhibit activity against bacteria, fungi, or viruses. The peptide's structure indicates potential for tissue repair and wound healing applications, as constrained peptides often demonstrate enhanced stability and bioactivity. Current research status appears to be in early phases, with minimal published data available. The peptide may function through interaction with cellular receptors or direct antimicrobial activity, though specific mechanisms require further investigation. Given its structural characteristics and the typical applications of similar cysteine-rich peptides, 5ZV6 may have potential in regenerative medicine, antimicrobial therapy, or tissue engineering applications.
Potential Benefits
Mechanism of Action
Based on the peptide's cysteine-rich structure, 5ZV6 likely functions through multiple mechanisms. The disulfide bonds formed by the cysteine residues create a constrained structure that enhances stability and may facilitate specific receptor binding. The peptide may interact with cell surface receptors to trigger intracellular signaling cascades involved in tissue repair and regeneration. The presence of glycine residues provides structural flexibility, while charged amino acids like arginine may facilitate cellular uptake or membrane interaction. If antimicrobial, the peptide could disrupt bacterial cell membranes or interfere with essential cellular processes. The constrained structure may also allow for specific protein-protein interactions that modulate inflammatory responses or promote healing processes. Without specific research data, the exact molecular targets and pathways remain to be elucidated through further investigation.
Risks & Safety
Legal Status
6CWS is a peptide sequence consisting of 128 amino acids with a complex structure that includes multiple cysteine residues, suggesting potential disulfide bond formation for structural stability. The sequence contains various functional domains including histidine-rich regions and lysine-arginine clusters that may facilitate cellular interactions and membrane penetration. Currently, this peptide appears to be in early research phases with limited published data available. The presence of specific amino acid motifs suggests potential applications in cellular signaling, protein-protein interactions, or therapeutic interventions. The peptide's structure indicates it may have bioactive properties, though comprehensive clinical studies are needed to establish its safety profile and therapeutic efficacy. Research into this peptide is still emerging, and its full biological significance and potential applications remain to be fully characterized through systematic investigation.
Key Benefits
Overview
6CWS is a peptide sequence consisting of 128 amino acids with a complex structure that includes multiple cysteine residues, suggesting potential disulfide bond formation for structural stability. The sequence contains various functional domains including histidine-rich regions and lysine-arginine clusters that may facilitate cellular interactions and membrane penetration. Currently, this peptide appears to be in early research phases with limited published data available. The presence of specific amino acid motifs suggests potential applications in cellular signaling, protein-protein interactions, or therapeutic interventions. The peptide's structure indicates it may have bioactive properties, though comprehensive clinical studies are needed to establish its safety profile and therapeutic efficacy. Research into this peptide is still emerging, and its full biological significance and potential applications remain to be fully characterized through systematic investigation.
Potential Benefits
Mechanism of Action
Based on the amino acid sequence analysis, 6CWS likely functions through multiple molecular mechanisms. The presence of cysteine residues suggests formation of disulfide bonds that stabilize the peptide structure and may facilitate receptor binding. The histidine-rich regions could enable pH-dependent conformational changes and metal ion coordination. Lysine and arginine clusters may promote cellular uptake through electrostatic interactions with negatively charged cell membranes. The peptide may modulate intracellular signaling pathways through protein-protein interactions, potentially affecting gene expression, enzyme activity, or cellular metabolism. However, specific receptor targets and detailed molecular pathways require further investigation to fully elucidate the mechanism of action.
Risks & Safety
Legal Status
6FKR is a synthetic peptide with the sequence RRIRFRPPYLPRPGRRPRFPPPFPIPRIPRIP, characterized by its high content of arginine and proline residues. This 31-amino acid peptide contains multiple positively charged arginine residues, which may facilitate cellular uptake and membrane interactions. The peptide's structure suggests potential cell-penetrating properties due to its cationic nature. Currently, 6FKR appears to be in early research phases with limited published data available. The high arginine content is reminiscent of cell-penetrating peptides (CPPs) that are known for their ability to cross cellular membranes and deliver therapeutic cargo. The proline residues may contribute to structural rigidity and stability. Without extensive published research, the specific biological targets and therapeutic applications remain largely undefined. The peptide may have potential applications in drug delivery, cellular research, or as a research tool for studying membrane permeability. Further investigation is needed to establish its safety profile, efficacy, and optimal applications. The current research status indicates this is primarily an experimental compound requiring additional preclinical and clinical studies to determine its therapeutic potential and establish proper usage protocols.
Key Benefits
Overview
6FKR is a synthetic peptide with the sequence RRIRFRPPYLPRPGRRPRFPPPFPIPRIPRIP, characterized by its high content of arginine and proline residues. This 31-amino acid peptide contains multiple positively charged arginine residues, which may facilitate cellular uptake and membrane interactions. The peptide's structure suggests potential cell-penetrating properties due to its cationic nature. Currently, 6FKR appears to be in early research phases with limited published data available. The high arginine content is reminiscent of cell-penetrating peptides (CPPs) that are known for their ability to cross cellular membranes and deliver therapeutic cargo. The proline residues may contribute to structural rigidity and stability. Without extensive published research, the specific biological targets and therapeutic applications remain largely undefined. The peptide may have potential applications in drug delivery, cellular research, or as a research tool for studying membrane permeability. Further investigation is needed to establish its safety profile, efficacy, and optimal applications. The current research status indicates this is primarily an experimental compound requiring additional preclinical and clinical studies to determine its therapeutic potential and establish proper usage protocols.
Potential Benefits
Mechanism of Action
Based on the peptide's amino acid composition, 6FKR likely functions through electrostatic interactions with negatively charged cellular membranes due to its high arginine content. The multiple arginine residues may enable the peptide to interact with cell surface proteoglycans and phospholipids, potentially facilitating membrane translocation. The cationic nature of the peptide suggests it may utilize endocytic pathways for cellular entry, similar to other arginine-rich cell-penetrating peptides. The proline residues may provide structural constraints that influence the peptide's conformation and stability. Without specific research data, the exact molecular targets and signaling pathways remain speculative, but the peptide may interact with membrane receptors or intracellular components following cellular uptake.
Risks & Safety
Legal Status
6GIL is a synthetic peptide with the sequence LLPIVGNLLKSLL, consisting of 13 amino acids. This peptide is currently in early research phases with minimal published data available in major scientific databases. The peptide's structure suggests potential bioactive properties, though comprehensive clinical studies are limited. Based on its amino acid composition, which includes leucine residues that are commonly associated with muscle protein synthesis and cellular signaling, 6GIL may have applications in tissue repair and regenerative medicine. The peptide's hydrophobic nature, indicated by the presence of multiple leucine and isoleucine residues, suggests it may interact with cellular membranes or protein structures. Current research status indicates this is primarily an experimental compound with ongoing investigations into its biological activities. The lack of extensive published research means that most applications and effects remain theoretical or based on preliminary studies. Further research is needed to establish definitive mechanisms of action, therapeutic applications, and safety profiles. As with many research peptides, 6GIL represents an area of active investigation in peptide therapeutics, though clinical applications remain to be fully established through rigorous scientific validation.
Key Benefits
Overview
6GIL is a synthetic peptide with the sequence LLPIVGNLLKSLL, consisting of 13 amino acids. This peptide is currently in early research phases with minimal published data available in major scientific databases. The peptide's structure suggests potential bioactive properties, though comprehensive clinical studies are limited. Based on its amino acid composition, which includes leucine residues that are commonly associated with muscle protein synthesis and cellular signaling, 6GIL may have applications in tissue repair and regenerative medicine. The peptide's hydrophobic nature, indicated by the presence of multiple leucine and isoleucine residues, suggests it may interact with cellular membranes or protein structures. Current research status indicates this is primarily an experimental compound with ongoing investigations into its biological activities. The lack of extensive published research means that most applications and effects remain theoretical or based on preliminary studies. Further research is needed to establish definitive mechanisms of action, therapeutic applications, and safety profiles. As with many research peptides, 6GIL represents an area of active investigation in peptide therapeutics, though clinical applications remain to be fully established through rigorous scientific validation.
Potential Benefits
Mechanism of Action
The mechanism of action for 6GIL is not well-established due to limited research data. Based on its amino acid sequence containing multiple leucine residues, the peptide may interact with leucine-sensing pathways involved in protein synthesis and cellular metabolism. The hydrophobic nature of the sequence suggests potential membrane interactions or binding to hydrophobic protein domains. The peptide may influence mTOR signaling pathways, which are activated by leucine and play crucial roles in cell growth, protein synthesis, and tissue repair. The presence of glycine and asparagine residues may provide flexibility and hydrogen bonding capabilities, potentially affecting protein-protein interactions. Without specific receptor binding studies or pathway analysis from published research, the exact molecular mechanisms remain speculative and require further investigation to establish definitive biological targets and signaling cascades.
Risks & Safety
Legal Status
6GS3 is a synthetic peptide with the sequence GVGDLIRKAVSVIKNIV, consisting of 17 amino acids. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited publicly available data. The peptide's sequence suggests potential bioactive properties, though comprehensive clinical studies and mechanistic research remain to be conducted. As with many synthetic peptides in early research phases, 6GS3 may have applications in various therapeutic areas, but its specific targets, efficacy, and safety profile require further investigation. The peptide's structure indicates it may interact with cellular receptors or signaling pathways, though the exact mechanisms remain to be elucidated. Given the limited research data currently available, 6GS3 should be considered an experimental compound requiring additional preclinical and clinical studies to establish its therapeutic potential, optimal dosing, and safety parameters. Further research is needed to determine its specific applications and validate any potential benefits.
Key Benefits
Overview
6GS3 is a synthetic peptide with the sequence GVGDLIRKAVSVIKNIV, consisting of 17 amino acids. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited publicly available data. The peptide's sequence suggests potential bioactive properties, though comprehensive clinical studies and mechanistic research remain to be conducted. As with many synthetic peptides in early research phases, 6GS3 may have applications in various therapeutic areas, but its specific targets, efficacy, and safety profile require further investigation. The peptide's structure indicates it may interact with cellular receptors or signaling pathways, though the exact mechanisms remain to be elucidated. Given the limited research data currently available, 6GS3 should be considered an experimental compound requiring additional preclinical and clinical studies to establish its therapeutic potential, optimal dosing, and safety parameters. Further research is needed to determine its specific applications and validate any potential benefits.
Potential Benefits
Mechanism of Action
The mechanism of action for 6GS3 has not been fully elucidated due to limited research data. Based on its peptide structure (GVGDLIRKAVSVIKNIV), it likely functions through receptor-mediated pathways common to bioactive peptides. The sequence suggests potential interactions with cell surface receptors or intracellular targets, which may trigger downstream signaling cascades. Like other synthetic peptides, 6GS3 may modulate cellular processes through binding to specific protein targets, potentially influencing gene expression, protein synthesis, or enzymatic activities. The peptide may also interact with membrane receptors to initiate intracellular signaling pathways that could affect cellular metabolism, growth factors, or inflammatory mediators. However, without specific research data, the exact molecular targets, binding affinities, and downstream effects remain speculative and require experimental validation.
Risks & Safety
Legal Status
6HN9 is a synthetic peptide with the sequence GFWSSVWDGAKNVGTAIIKNAKVCVYAVCVSHK, currently in early research phases. Limited published data is available regarding this specific peptide sequence, suggesting it may be a novel or proprietary compound under investigation. The peptide appears to be designed for potential therapeutic applications, though specific mechanisms and clinical outcomes remain largely undocumented in peer-reviewed literature. Based on its structural characteristics and amino acid composition, 6HN9 may have applications in tissue repair, cellular signaling, or metabolic processes. The presence of multiple cysteine residues suggests potential for disulfide bond formation, which could contribute to structural stability and biological activity. Current research status indicates this peptide is in preliminary investigation phases, with minimal catalog extraction completed. Further research is needed to establish definitive therapeutic applications, safety profiles, and efficacy data. The peptide's development appears to be in early stages, requiring comprehensive preclinical and clinical studies to determine its full therapeutic potential and appropriate medical applications.
Key Benefits
Overview
6HN9 is a synthetic peptide with the sequence GFWSSVWDGAKNVGTAIIKNAKVCVYAVCVSHK, currently in early research phases. Limited published data is available regarding this specific peptide sequence, suggesting it may be a novel or proprietary compound under investigation. The peptide appears to be designed for potential therapeutic applications, though specific mechanisms and clinical outcomes remain largely undocumented in peer-reviewed literature. Based on its structural characteristics and amino acid composition, 6HN9 may have applications in tissue repair, cellular signaling, or metabolic processes. The presence of multiple cysteine residues suggests potential for disulfide bond formation, which could contribute to structural stability and biological activity. Current research status indicates this peptide is in preliminary investigation phases, with minimal catalog extraction completed. Further research is needed to establish definitive therapeutic applications, safety profiles, and efficacy data. The peptide's development appears to be in early stages, requiring comprehensive preclinical and clinical studies to determine its full therapeutic potential and appropriate medical applications.
Potential Benefits
Mechanism of Action
The mechanism of action for 6HN9 remains largely undefined due to limited available research data. Based on its amino acid sequence composition, the peptide likely interacts with specific cellular receptors or signaling pathways. The presence of hydrophobic residues (phenylalanine, tryptophan, valine) suggests potential membrane interactions or protein-protein binding capabilities. The multiple cysteine residues may form disulfide bridges, contributing to conformational stability and receptor binding specificity. The peptide may modulate cellular processes through direct receptor activation, enzyme inhibition, or interference with protein complexes. Without specific research data, the exact molecular targets, downstream signaling cascades, and biological pathways affected by 6HN9 cannot be definitively established. Further investigation is required to elucidate the precise mechanisms by which this peptide exerts its biological effects.
Risks & Safety
Legal Status
6MJV is a synthetic peptide with the sequence KKCWNGGRCRKKCKENEKPIGYCRNGKKCCVN, containing multiple cysteine residues that likely form disulfide bonds creating a stable cyclic or constrained structure. The peptide appears to be a research compound currently in early phase development, as indicated by its minimal catalog status. Based on its structural characteristics, including the presence of basic amino acids (lysine and arginine) and the constrained architecture from potential disulfide bridging, 6MJV may have antimicrobial or cell-penetrating properties. The peptide's design suggests it could interact with cellular membranes or specific protein targets, though detailed mechanistic studies are limited. Current research status indicates this is an experimental compound with potential therapeutic applications that require further investigation to establish safety, efficacy, and optimal dosing protocols. The peptide's unique sequence and structure make it a candidate for various biomedical applications, though comprehensive clinical data remains to be established.
Key Benefits
Overview
6MJV is a synthetic peptide with the sequence KKCWNGGRCRKKCKENEKPIGYCRNGKKCCVN, containing multiple cysteine residues that likely form disulfide bonds creating a stable cyclic or constrained structure. The peptide appears to be a research compound currently in early phase development, as indicated by its minimal catalog status. Based on its structural characteristics, including the presence of basic amino acids (lysine and arginine) and the constrained architecture from potential disulfide bridging, 6MJV may have antimicrobial or cell-penetrating properties. The peptide's design suggests it could interact with cellular membranes or specific protein targets, though detailed mechanistic studies are limited. Current research status indicates this is an experimental compound with potential therapeutic applications that require further investigation to establish safety, efficacy, and optimal dosing protocols. The peptide's unique sequence and structure make it a candidate for various biomedical applications, though comprehensive clinical data remains to be established.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 6MJV likely functions through multiple mechanisms related to its structural features. The presence of multiple cysteine residues suggests formation of disulfide bonds that create a constrained, stable peptide structure capable of specific protein-protein interactions. The basic amino acids (lysine and arginine) may facilitate electrostatic interactions with negatively charged cellular components or membranes. The peptide may act as a cell-penetrating peptide due to its cationic nature, potentially allowing cellular uptake and intracellular target engagement. The constrained structure could enable specific receptor binding or enzyme inhibition through conformational complementarity. Without specific research data, the exact molecular targets and signaling pathways remain to be elucidated through detailed biochemical and pharmacological studies.
Risks & Safety
Legal Status
6MK8 is a synthetic peptide with the sequence GLSLLLSLGLKLL, consisting of 13 amino acids. This peptide appears to be in early research phases, with limited published data available regarding its specific biological functions and therapeutic applications. The peptide's sequence contains multiple leucine residues and hydrophobic amino acids, which may suggest potential membrane-interacting properties or antimicrobial characteristics. Currently classified as a research compound, 6MK8 requires further investigation to establish its primary mechanisms of action, therapeutic potential, and safety profile. The peptide's structure suggests it may have applications in areas such as antimicrobial research, tissue repair, or cellular membrane interactions, though comprehensive clinical studies are needed to validate these potential applications. As with many experimental peptides, 6MK8 represents an area of ongoing scientific interest where researchers are working to understand its biological activity and potential therapeutic value. The limited available data indicates this peptide is still in preliminary research stages, requiring extensive preclinical and clinical evaluation before any therapeutic applications can be established.
Key Benefits
Overview
6MK8 is a synthetic peptide with the sequence GLSLLLSLGLKLL, consisting of 13 amino acids. This peptide appears to be in early research phases, with limited published data available regarding its specific biological functions and therapeutic applications. The peptide's sequence contains multiple leucine residues and hydrophobic amino acids, which may suggest potential membrane-interacting properties or antimicrobial characteristics. Currently classified as a research compound, 6MK8 requires further investigation to establish its primary mechanisms of action, therapeutic potential, and safety profile. The peptide's structure suggests it may have applications in areas such as antimicrobial research, tissue repair, or cellular membrane interactions, though comprehensive clinical studies are needed to validate these potential applications. As with many experimental peptides, 6MK8 represents an area of ongoing scientific interest where researchers are working to understand its biological activity and potential therapeutic value. The limited available data indicates this peptide is still in preliminary research stages, requiring extensive preclinical and clinical evaluation before any therapeutic applications can be established.
Potential Benefits
Mechanism of Action
Based on the peptide sequence GLSLLLSLGLKLL, 6MK8 likely functions through membrane interaction mechanisms due to its high content of hydrophobic amino acids, particularly leucine residues. The peptide may interact with cellular membranes through hydrophobic interactions, potentially affecting membrane permeability or stability. The presence of glycine residues may provide structural flexibility, allowing the peptide to adopt conformations suitable for membrane insertion or receptor binding. The peptide may exert antimicrobial effects by disrupting bacterial cell membranes or interfering with membrane-associated processes. Additionally, the sequence suggests potential for protein-protein interactions or binding to hydrophobic domains of cellular receptors. However, specific receptor targets, signaling pathways, and detailed molecular mechanisms require further research to be definitively established.
Risks & Safety
Legal Status
6NM2 is a synthetic octapeptide with the sequence WWWLRKIW, characterized by multiple tryptophan residues and basic amino acids. Currently in Phase 1 research status with minimal catalog extraction completed. The peptide's unique structure, featuring three consecutive tryptophan residues followed by leucine, arginine, lysine, isoleucine, and tryptophan, suggests potential for membrane interactions and cellular penetration. The high tryptophan content may facilitate protein-protein interactions and membrane binding properties. While specific biological mechanisms remain under investigation, the peptide's composition indicates potential applications in cellular signaling, membrane stabilization, and therapeutic delivery systems. The presence of positively charged residues (arginine and lysine) combined with hydrophobic tryptophan residues creates an amphipathic structure that could enable cell membrane penetration and intracellular targeting. Current research is in early stages, with limited published data available on specific biological activities, therapeutic applications, or clinical outcomes. Further investigation is needed to fully characterize its pharmacological properties, safety profile, and potential therapeutic applications in various biological systems.
Key Benefits
Overview
6NM2 is a synthetic octapeptide with the sequence WWWLRKIW, characterized by multiple tryptophan residues and basic amino acids. Currently in Phase 1 research status with minimal catalog extraction completed. The peptide's unique structure, featuring three consecutive tryptophan residues followed by leucine, arginine, lysine, isoleucine, and tryptophan, suggests potential for membrane interactions and cellular penetration. The high tryptophan content may facilitate protein-protein interactions and membrane binding properties. While specific biological mechanisms remain under investigation, the peptide's composition indicates potential applications in cellular signaling, membrane stabilization, and therapeutic delivery systems. The presence of positively charged residues (arginine and lysine) combined with hydrophobic tryptophan residues creates an amphipathic structure that could enable cell membrane penetration and intracellular targeting. Current research is in early stages, with limited published data available on specific biological activities, therapeutic applications, or clinical outcomes. Further investigation is needed to fully characterize its pharmacological properties, safety profile, and potential therapeutic applications in various biological systems.
Potential Benefits
Mechanism of Action
Based on the peptide sequence WWWLRKIW, the mechanism of action likely involves membrane interaction through the multiple tryptophan residues, which are known for their ability to anchor into lipid bilayers and facilitate membrane penetration. The positively charged arginine and lysine residues may enable electrostatic interactions with negatively charged cell surface components, potentially facilitating cellular uptake. The amphipathic nature of the peptide, with hydrophobic tryptophan residues and hydrophilic charged amino acids, suggests it may function as a cell-penetrating peptide or membrane-active compound. The tryptophan residues could also participate in protein-protein interactions through π-π stacking and hydrophobic interactions. However, specific receptor targets, signaling pathways, and downstream biological effects have not been clearly established in the available research data. The peptide may modulate cellular processes through direct membrane effects, intracellular delivery of bioactive compounds, or interaction with specific protein targets that remain to be identified.
Risks & Safety
Legal Status
6SIG is a synthetic peptide with the sequence MAAFMKLIQFLATKGQKYVSLAWKHKGTILKWINAGQSFEWIYKQIKKLWA, currently in early research phases. Limited published research data is available for this specific peptide sequence, indicating it may be an experimental or proprietary compound under investigation. The peptide appears to be designed for potential therapeutic applications, though its exact mechanism and clinical efficacy remain to be fully established. As with many research peptides, 6SIG likely targets specific cellular pathways or receptor systems, but comprehensive studies demonstrating its safety and efficacy in humans are lacking. The peptide's relatively long sequence suggests it may have complex biological activity and potentially multiple target sites. Current research status appears to be in preliminary stages, with minimal catalog extraction completed. Further investigation through controlled studies would be necessary to determine its therapeutic potential, optimal dosing, and safety profile. The peptide represents part of the expanding field of synthetic peptide therapeutics, which aim to modulate biological processes with greater specificity than traditional small molecule drugs.
Key Benefits
Overview
6SIG is a synthetic peptide with the sequence MAAFMKLIQFLATKGQKYVSLAWKHKGTILKWINAGQSFEWIYKQIKKLWA, currently in early research phases. Limited published research data is available for this specific peptide sequence, indicating it may be an experimental or proprietary compound under investigation. The peptide appears to be designed for potential therapeutic applications, though its exact mechanism and clinical efficacy remain to be fully established. As with many research peptides, 6SIG likely targets specific cellular pathways or receptor systems, but comprehensive studies demonstrating its safety and efficacy in humans are lacking. The peptide's relatively long sequence suggests it may have complex biological activity and potentially multiple target sites. Current research status appears to be in preliminary stages, with minimal catalog extraction completed. Further investigation through controlled studies would be necessary to determine its therapeutic potential, optimal dosing, and safety profile. The peptide represents part of the expanding field of synthetic peptide therapeutics, which aim to modulate biological processes with greater specificity than traditional small molecule drugs.
Potential Benefits
Mechanism of Action
Based on the available sequence data, 6SIG appears to be a synthetic peptide designed to interact with specific cellular targets, though the exact molecular mechanism remains unclear due to limited research data. The peptide's 50-amino acid sequence suggests it may function through receptor binding or protein-protein interactions. Like other therapeutic peptides, it likely works by modulating cellular signaling pathways, potentially affecting gene expression, enzyme activity, or membrane transport processes. The peptide may bind to specific receptors on target cells, triggering downstream signaling cascades that result in therapeutic effects. Without specific research data, the precise molecular targets, binding affinity, and downstream effects cannot be definitively characterized. The mechanism likely involves selective interaction with biological targets to produce desired therapeutic outcomes while minimizing off-target effects.
Risks & Safety
Legal Status
7T9Q is a synthetic peptide with the sequence SYYSTLQCRNNHGHCRRLCFHGEQWIGNCNGRHQHCCK, containing 38 amino acids with multiple cysteine residues suggesting potential disulfide bond formation for structural stability. Based on its complex structure and cysteine-rich composition, this peptide appears to be designed for potential therapeutic applications, though specific research data is currently limited. The presence of multiple cysteine residues indicates it may have a stable tertiary structure that could interact with specific biological targets. Current research status appears to be in early phases, with minimal published data available in major databases. The peptide's structure suggests it may have been designed for specific receptor interactions or as a potential therapeutic agent, though comprehensive clinical data is not yet available. Further research is needed to fully characterize its biological activity, safety profile, and therapeutic potential.
Key Benefits
Overview
7T9Q is a synthetic peptide with the sequence SYYSTLQCRNNHGHCRRLCFHGEQWIGNCNGRHQHCCK, containing 38 amino acids with multiple cysteine residues suggesting potential disulfide bond formation for structural stability. Based on its complex structure and cysteine-rich composition, this peptide appears to be designed for potential therapeutic applications, though specific research data is currently limited. The presence of multiple cysteine residues indicates it may have a stable tertiary structure that could interact with specific biological targets. Current research status appears to be in early phases, with minimal published data available in major databases. The peptide's structure suggests it may have been designed for specific receptor interactions or as a potential therapeutic agent, though comprehensive clinical data is not yet available. Further research is needed to fully characterize its biological activity, safety profile, and therapeutic potential.
Potential Benefits
Mechanism of Action
Based on the peptide's structure containing multiple cysteine residues, 7T9Q likely forms disulfide bonds that create a stable three-dimensional structure capable of specific protein-protein interactions. The cysteine-rich nature suggests it may function through receptor binding mechanisms, potentially modulating cellular signaling pathways. The specific amino acid sequence may allow for targeted interactions with cell surface receptors or intracellular proteins, though the exact molecular targets remain to be fully characterized. The peptide's structure indicates it may influence cellular processes through conformational changes upon binding to target proteins.
Risks & Safety
Legal Status
7YOA is a synthetic peptide with the sequence LRDLVCYCRTRGCKRRERMNGTCRRGHLMHTLCCR, containing 34 amino acids. This peptide features multiple cysteine residues that likely form disulfide bonds, creating a stable cyclic or constrained structure. The presence of basic amino acids like arginine and lysine suggests potential for cellular uptake and membrane interactions. Currently classified as a research compound, 7YOA appears to be in early investigational phases with limited published clinical data. The peptide's structure suggests it may have antimicrobial properties, given its cationic nature and potential membrane-disrupting capabilities. Its complex sequence and multiple cysteine residues indicate it may have been designed for specific receptor binding or enzymatic interactions. As with many research peptides, 7YOA requires further investigation to fully characterize its biological activities, therapeutic potential, and safety profile. The peptide represents part of ongoing efforts to develop novel therapeutic compounds through peptide engineering and design.
Key Benefits
Overview
7YOA is a synthetic peptide with the sequence LRDLVCYCRTRGCKRRERMNGTCRRGHLMHTLCCR, containing 34 amino acids. This peptide features multiple cysteine residues that likely form disulfide bonds, creating a stable cyclic or constrained structure. The presence of basic amino acids like arginine and lysine suggests potential for cellular uptake and membrane interactions. Currently classified as a research compound, 7YOA appears to be in early investigational phases with limited published clinical data. The peptide's structure suggests it may have antimicrobial properties, given its cationic nature and potential membrane-disrupting capabilities. Its complex sequence and multiple cysteine residues indicate it may have been designed for specific receptor binding or enzymatic interactions. As with many research peptides, 7YOA requires further investigation to fully characterize its biological activities, therapeutic potential, and safety profile. The peptide represents part of ongoing efforts to develop novel therapeutic compounds through peptide engineering and design.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, 7YOA likely functions through multiple molecular mechanisms. The high content of positively charged residues (arginine and lysine) suggests electrostatic interactions with negatively charged cellular membranes or receptors. The multiple cysteine residues indicate formation of disulfide bonds, creating a constrained peptide structure that may enhance binding specificity and stability. The peptide may interact with cell surface receptors or penetrate cellular membranes due to its cationic nature. The presence of aromatic residues could facilitate hydrophobic interactions with membrane components or protein binding sites. The structured nature of the peptide, stabilized by disulfide bonds, may allow for specific recognition of target proteins or receptors, potentially modulating cellular signaling pathways related to immune function, antimicrobial activity, or tissue repair processes.
Risks & Safety
Legal Status
7YSS is a synthetic peptide with the sequence WLRRIKAWLRRIKA, characterized by its cationic and amphipathic properties due to the presence of multiple arginine and lysine residues alongside tryptophan and leucine. Based on its structural composition, this peptide appears to belong to the class of cell-penetrating peptides (CPPs) or antimicrobial peptides (AMPs). The sequence contains repeated motifs that suggest potential membrane-interacting capabilities. The peptide's design incorporates positively charged amino acids that may facilitate cellular uptake and membrane permeabilization. Current research status appears to be in early phases, with limited published data available. The peptide's structure suggests it may have applications in drug delivery, antimicrobial therapy, or cellular research applications. The presence of tryptophan residues may contribute to membrane binding affinity, while the basic amino acids could enhance cellular penetration. Further research is needed to fully characterize its biological activities, safety profile, and therapeutic potential. The peptide represents an area of ongoing investigation in peptide therapeutics and biotechnology applications.
Key Benefits
Overview
7YSS is a synthetic peptide with the sequence WLRRIKAWLRRIKA, characterized by its cationic and amphipathic properties due to the presence of multiple arginine and lysine residues alongside tryptophan and leucine. Based on its structural composition, this peptide appears to belong to the class of cell-penetrating peptides (CPPs) or antimicrobial peptides (AMPs). The sequence contains repeated motifs that suggest potential membrane-interacting capabilities. The peptide's design incorporates positively charged amino acids that may facilitate cellular uptake and membrane permeabilization. Current research status appears to be in early phases, with limited published data available. The peptide's structure suggests it may have applications in drug delivery, antimicrobial therapy, or cellular research applications. The presence of tryptophan residues may contribute to membrane binding affinity, while the basic amino acids could enhance cellular penetration. Further research is needed to fully characterize its biological activities, safety profile, and therapeutic potential. The peptide represents an area of ongoing investigation in peptide therapeutics and biotechnology applications.
Potential Benefits
Mechanism of Action
Based on the peptide sequence WLRRIKAWLRRIKA, 7YSS likely functions through electrostatic interactions with negatively charged cell membranes. The multiple positively charged residues (arginine and lysine) facilitate initial binding to phospholipid bilayers, while tryptophan residues may anchor into the membrane interface. The peptide may disrupt membrane integrity through pore formation or membrane permeabilization mechanisms. As a potential cell-penetrating peptide, it could facilitate translocation across cellular barriers via endocytic pathways or direct membrane penetration. The amphipathic nature suggests it may adopt secondary structures that interact with lipid bilayers, potentially leading to membrane destabilization in target cells. If functioning as an antimicrobial agent, it would likely target bacterial cell walls and membranes, disrupting essential cellular processes. The repeated sequence motifs may enhance binding affinity and biological activity through multivalent interactions.
Risks & Safety
Legal Status
7ZWJ is a synthetic peptide with the sequence SKKSKPGDGIRGKGVRG, consisting of 17 amino acids. This peptide contains multiple lysine and arginine residues, giving it a highly cationic (positively charged) nature. The sequence includes several basic amino acids that may facilitate cellular uptake and membrane interactions. Currently, there is limited published research specifically on this peptide designation, suggesting it may be in early research phases or represent a proprietary compound. The peptide's structure suggests potential applications in cellular delivery systems or as a cell-penetrating peptide due to its high positive charge density. The presence of glycine residues may provide structural flexibility, while the lysine-rich regions could enable interactions with negatively charged cellular components such as DNA, RNA, or cell membranes. Without extensive clinical data, the peptide's therapeutic potential remains largely theoretical, based on its structural characteristics and similarity to other cationic peptides used in research applications.
Key Benefits
Overview
7ZWJ is a synthetic peptide with the sequence SKKSKPGDGIRGKGVRG, consisting of 17 amino acids. This peptide contains multiple lysine and arginine residues, giving it a highly cationic (positively charged) nature. The sequence includes several basic amino acids that may facilitate cellular uptake and membrane interactions. Currently, there is limited published research specifically on this peptide designation, suggesting it may be in early research phases or represent a proprietary compound. The peptide's structure suggests potential applications in cellular delivery systems or as a cell-penetrating peptide due to its high positive charge density. The presence of glycine residues may provide structural flexibility, while the lysine-rich regions could enable interactions with negatively charged cellular components such as DNA, RNA, or cell membranes. Without extensive clinical data, the peptide's therapeutic potential remains largely theoretical, based on its structural characteristics and similarity to other cationic peptides used in research applications.
Potential Benefits
Mechanism of Action
Based on its amino acid composition, 7ZWJ likely functions through electrostatic interactions with negatively charged cellular components. The high concentration of positively charged lysine and arginine residues suggests the peptide may interact with cell membranes, potentially facilitating membrane permeabilization or cellular uptake. The cationic nature could enable binding to nucleic acids (DNA/RNA) or negatively charged proteins. The peptide may function as a cell-penetrating peptide, utilizing the arginine and lysine residues to traverse cellular membranes through energy-dependent or independent pathways. Glycine residues within the sequence may provide conformational flexibility, allowing the peptide to adapt its structure for optimal binding interactions. The mechanism likely involves initial electrostatic attraction to the cell surface, followed by membrane interaction and potential internalization through endocytic pathways or direct membrane translocation.
Risks & Safety
Legal Status
8B1L is a synthetic peptide with the sequence FLGMLLHGVGHAIHGLIHGKQNVE, consisting of 24 amino acids. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited published data available. The peptide's sequence contains multiple hydrophobic amino acids including phenylalanine, leucine, and glycine, along with histidine residues that may contribute to its biological activity. Based on its amino acid composition and structure, 8B1L may have potential applications in cellular signaling and membrane interactions. The presence of histidine residues suggests possible metal-binding capabilities or pH-dependent conformational changes. As a research peptide, 8B1L requires further investigation to fully characterize its biological functions, therapeutic potential, and safety profile. Current research status indicates this compound is in preliminary stages of development with minimal clinical or preclinical data publicly available. The peptide's specific mechanism of action, target receptors, and therapeutic applications remain to be fully elucidated through comprehensive research studies.
Key Benefits
Overview
8B1L is a synthetic peptide with the sequence FLGMLLHGVGHAIHGLIHGKQNVE, consisting of 24 amino acids. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited published data available. The peptide's sequence contains multiple hydrophobic amino acids including phenylalanine, leucine, and glycine, along with histidine residues that may contribute to its biological activity. Based on its amino acid composition and structure, 8B1L may have potential applications in cellular signaling and membrane interactions. The presence of histidine residues suggests possible metal-binding capabilities or pH-dependent conformational changes. As a research peptide, 8B1L requires further investigation to fully characterize its biological functions, therapeutic potential, and safety profile. Current research status indicates this compound is in preliminary stages of development with minimal clinical or preclinical data publicly available. The peptide's specific mechanism of action, target receptors, and therapeutic applications remain to be fully elucidated through comprehensive research studies.
Potential Benefits
Mechanism of Action
Based on the amino acid sequence of 8B1L, the peptide likely functions through membrane interactions and potential receptor binding. The sequence contains multiple hydrophobic residues (phenylalanine, leucine, glycine) that may facilitate membrane penetration or lipid interactions. The presence of histidine residues suggests potential metal coordination or pH-sensitive conformational changes that could modulate biological activity. The peptide may interact with cellular membranes through hydrophobic interactions, potentially affecting membrane permeability or stability. Glycine residues provide structural flexibility, while the overall sequence composition suggests possible antimicrobial or cell-penetrating properties. Without specific research data, the exact molecular targets and signaling pathways remain speculative, but the peptide structure indicates potential for cellular uptake and intracellular effects.
Risks & Safety
Legal Status
8DYN is a research peptide with the sequence GHSVDRIPEYFGPPGLPGPVLFYS that appears to be under investigation for its potential therapeutic applications. While specific direct research on 8DYN itself is limited in the provided literature, the research context suggests involvement in vascular and endothelial cell functions. The available studies focus on endothelial cell mechanisms, particularly involving PECAM-1 targeting and thrombomodulin regulation in brain microvascular endothelial cells. These research areas indicate potential applications in vascular health, blood-brain barrier function, and endothelial cell regulation. The peptide appears to be in early research phases, with studies examining cellular uptake mechanisms, flow-mediated endocytosis, and endothelial cell responses to various stimuli. Current research suggests potential roles in vascular targeting, drug delivery systems, and endothelial cell modulation. The peptide's therapeutic potential may relate to cardiovascular health, neuroprotection, and vascular integrity maintenance, though more specific research on 8DYN itself would be needed to fully characterize its mechanisms and clinical applications.
Key Benefits
Overview
8DYN is a research peptide with the sequence GHSVDRIPEYFGPPGLPGPVLFYS that appears to be under investigation for its potential therapeutic applications. While specific direct research on 8DYN itself is limited in the provided literature, the research context suggests involvement in vascular and endothelial cell functions. The available studies focus on endothelial cell mechanisms, particularly involving PECAM-1 targeting and thrombomodulin regulation in brain microvascular endothelial cells. These research areas indicate potential applications in vascular health, blood-brain barrier function, and endothelial cell regulation. The peptide appears to be in early research phases, with studies examining cellular uptake mechanisms, flow-mediated endocytosis, and endothelial cell responses to various stimuli. Current research suggests potential roles in vascular targeting, drug delivery systems, and endothelial cell modulation. The peptide's therapeutic potential may relate to cardiovascular health, neuroprotection, and vascular integrity maintenance, though more specific research on 8DYN itself would be needed to fully characterize its mechanisms and clinical applications.
Potential Benefits
Mechanism of Action
Based on the research context, 8DYN appears to function through endothelial cell-mediated mechanisms. The related research indicates involvement in PECAM-1 (CD31) targeting pathways, which are crucial for endothelial cell adhesion and signaling. The mechanism likely involves interaction with endothelial cell surface receptors, potentially modulating endocytosis pathways mediated by RhoA/ROCK and Src Family Kinases. The peptide may influence thrombomodulin regulation, which is critical for blood vessel homeostasis and anti-coagulant activity. Flow shear stress appears to modulate the activity through cholesterol-rich plasmalemma domains, suggesting membrane-mediated signaling. The mechanism may involve differential regulation of endothelial cells in response to biomechanical and humoral signals, potentially affecting blood-brain barrier integrity and cerebrovascular endothelium function. The peptide's action appears to be epitope-specific and flow-dependent, suggesting a sophisticated targeting mechanism that responds to local hemodynamic conditions.
Risks & Safety
Legal Status
8TFV is a synthetic peptide with the sequence GSKKPVPIIYCNRRTGKCQRM that is currently in early research phases. Limited published data is available regarding this specific peptide sequence, indicating it may be a novel or experimental compound under investigation. The peptide contains 21 amino acids and includes cysteine residues that may form disulfide bonds, potentially contributing to structural stability. Based on its sequence composition, which includes basic amino acids (lysine, arginine) and hydrophobic residues, it may interact with cellular membranes or specific protein targets. The presence of proline residues suggests potential structural rigidity in certain regions. Without extensive published research, the exact biological targets and therapeutic applications remain to be fully characterized. Current understanding is primarily based on sequence analysis and preliminary research phases, with comprehensive clinical data yet to be established.
Key Benefits
Overview
8TFV is a synthetic peptide with the sequence GSKKPVPIIYCNRRTGKCQRM that is currently in early research phases. Limited published data is available regarding this specific peptide sequence, indicating it may be a novel or experimental compound under investigation. The peptide contains 21 amino acids and includes cysteine residues that may form disulfide bonds, potentially contributing to structural stability. Based on its sequence composition, which includes basic amino acids (lysine, arginine) and hydrophobic residues, it may interact with cellular membranes or specific protein targets. The presence of proline residues suggests potential structural rigidity in certain regions. Without extensive published research, the exact biological targets and therapeutic applications remain to be fully characterized. Current understanding is primarily based on sequence analysis and preliminary research phases, with comprehensive clinical data yet to be established.
Potential Benefits
Mechanism of Action
The mechanism of action for 8TFV is not well-established in current literature. Based on sequence analysis, the peptide contains positively charged residues (lysine and arginine) that may facilitate interaction with negatively charged cellular components such as membrane phospholipids or nucleic acids. The presence of cysteine residues suggests potential for disulfide bond formation, which could stabilize the peptide structure and influence its binding affinity to target receptors. The hydrophobic amino acids in the sequence may enable membrane penetration or protein-protein interactions. Without specific receptor binding studies or pathway analysis available in the research data, the precise molecular targets and downstream signaling cascades remain to be elucidated through further investigation.
Risks & Safety
Legal Status
Abaecin is a natural antimicrobial peptide (AMP) rich in proline, originally derived from bees and serving as an important component of their innate humoral immunity. With the sequence YVPLPNVPQPGRRPFPTFPGQGPFNPKIKWPQGY, this peptide demonstrates broad-spectrum antibacterial activity, particularly against Gram-negative bacteria. Unlike traditional antimicrobials, abaecin exhibits unique potentiating properties, showing minimal activity when used alone but significantly enhancing the efficacy of pore-forming peptides from various species. Recent research has expanded beyond its antimicrobial properties, revealing therapeutic potential for inflammatory bowel conditions. Studies demonstrate that abaecin can alleviate ulcerative colitis in mice by modulating inflammatory signaling pathways, reducing pro-inflammatory cytokines, and improving intestinal microbial composition. The peptide's mechanism involves interaction with bacterial chaperone proteins like DnaK and enhancement of membrane permeabilization when combined with other antimicrobial agents. This synergistic approach represents a promising strategy for addressing multidrug-resistant pathogens. Current research focuses on optimizing expression systems for therapeutic production and exploring combination therapies that could overcome antibiotic resistance while maintaining safety profiles.
Key Benefits
Overview
Abaecin is a natural antimicrobial peptide (AMP) rich in proline, originally derived from bees and serving as an important component of their innate humoral immunity. With the sequence YVPLPNVPQPGRRPFPTFPGQGPFNPKIKWPQGY, this peptide demonstrates broad-spectrum antibacterial activity, particularly against Gram-negative bacteria. Unlike traditional antimicrobials, abaecin exhibits unique potentiating properties, showing minimal activity when used alone but significantly enhancing the efficacy of pore-forming peptides from various species. Recent research has expanded beyond its antimicrobial properties, revealing therapeutic potential for inflammatory bowel conditions. Studies demonstrate that abaecin can alleviate ulcerative colitis in mice by modulating inflammatory signaling pathways, reducing pro-inflammatory cytokines, and improving intestinal microbial composition. The peptide's mechanism involves interaction with bacterial chaperone proteins like DnaK and enhancement of membrane permeabilization when combined with other antimicrobial agents. This synergistic approach represents a promising strategy for addressing multidrug-resistant pathogens. Current research focuses on optimizing expression systems for therapeutic production and exploring combination therapies that could overcome antibiotic resistance while maintaining safety profiles.
Potential Benefits
Mechanism of Action
Abaecin operates through a unique dual-mechanism approach involving direct bacterial targeting and synergistic enhancement of other antimicrobial agents. The peptide binds efficiently to specific intracellular targets, particularly the bacterial chaperone DnaK, an evolutionarily conserved central organizer of the bacterial chaperone network. However, abaecin shows minimal standalone antibacterial activity against Gram-negative bacteria like E. coli, requiring membrane compromise by pore-forming peptides to access intracellular targets. When combined with pore-forming peptides such as hymenoptaecin, cecropin A, or stomoxyn, abaecin significantly enhances membrane permeabilization and reduces minimal inhibitory concentrations. In inflammatory conditions, abaecin modulates key signaling pathways including NF-κB and MAPK, reducing phosphorylation of inflammatory proteins and decreasing production of pro-inflammatory cytokines IL-1β, IL-6, TNF-α, and IFN-γ. The peptide also promotes intestinal barrier function and beneficially alters gut microbiome composition. This multi-target approach allows abaecin to function both as an antimicrobial agent and an anti-inflammatory modulator, making it effective against both pathogenic bacteria and inflammatory processes.
Risks & Safety
Legal Status
ABI74602 is a synthetic peptide with the sequence SRWPSPGRPRPFPGRPNPIFRPRPCICVRQPCPCDTY, containing 37 amino acids. This peptide features multiple proline and arginine residues, along with cysteine residues that likely form disulfide bonds contributing to its structural stability. The presence of arginine-rich sequences suggests potential cell-penetrating properties, while the proline residues may confer resistance to proteolytic degradation. Currently classified as a research compound, ABI74602 appears to be in early investigational stages with limited published clinical data. The peptide's unique sequence composition, particularly the abundance of basic amino acids and the presence of cysteine bridges, suggests it may have applications in cellular signaling, tissue repair, or therapeutic delivery systems. However, comprehensive mechanistic studies and clinical trials are needed to fully elucidate its biological functions and therapeutic potential. The peptide's structural characteristics indicate it may interact with cellular membranes or specific protein targets, though specific receptor interactions remain to be definitively established through rigorous scientific investigation.
Key Benefits
Overview
ABI74602 is a synthetic peptide with the sequence SRWPSPGRPRPFPGRPNPIFRPRPCICVRQPCPCDTY, containing 37 amino acids. This peptide features multiple proline and arginine residues, along with cysteine residues that likely form disulfide bonds contributing to its structural stability. The presence of arginine-rich sequences suggests potential cell-penetrating properties, while the proline residues may confer resistance to proteolytic degradation. Currently classified as a research compound, ABI74602 appears to be in early investigational stages with limited published clinical data. The peptide's unique sequence composition, particularly the abundance of basic amino acids and the presence of cysteine bridges, suggests it may have applications in cellular signaling, tissue repair, or therapeutic delivery systems. However, comprehensive mechanistic studies and clinical trials are needed to fully elucidate its biological functions and therapeutic potential. The peptide's structural characteristics indicate it may interact with cellular membranes or specific protein targets, though specific receptor interactions remain to be definitively established through rigorous scientific investigation.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, ABI74602 likely functions through multiple molecular mechanisms. The arginine-rich regions (GRPRPFPGRPNPIFRPRP) suggest cell-penetrating peptide properties, potentially facilitating cellular uptake through electrostatic interactions with negatively charged cell membrane components. The multiple proline residues may create rigid structural domains that resist enzymatic degradation while maintaining bioactive conformations. The cysteine residues at positions likely form intramolecular disulfide bonds, stabilizing the peptide's three-dimensional structure and potentially creating binding domains for specific cellular targets. The peptide may interact with cell surface receptors or intracellular signaling pathways once internalized. The presence of aromatic phenylalanine residues could facilitate protein-protein interactions through π-π stacking or hydrophobic interactions. Without specific receptor binding studies, the exact molecular targets remain speculative, but the peptide's composition suggests potential involvement in cellular signaling cascades, possibly related to growth factors, wound healing pathways, or tissue regeneration mechanisms.
Risks & Safety
Legal Status
Acetyl Hexapeptide-3, commonly known as Argireline, is a synthetic cosmetic peptide widely recognized as a topical alternative to botulinum toxin (Botox) for anti-aging applications. This hexapeptide consists of six amino acids and has a molecular weight of 889 Da. It functions by inhibiting acetylcholine release at neuromuscular junctions, leading to reduced muscle contractions and subsequent smoothing of expression lines and wrinkles. The peptide has gained significant attention in the cosmeceutical industry due to its ability to provide anti-wrinkle effects without the invasiveness of injectable treatments. Research demonstrates its effectiveness in facial rejuvenation protocols, often used as an adjunct to other cosmetic procedures to reduce the frequency of botulinum toxin injections needed. Due to its hydrophilic nature and relatively large molecular weight, skin penetration can be challenging, leading to innovative delivery methods including microneedle patches and iontophoresis. Studies have shown that Acetyl Hexapeptide-3 not only reduces wrinkle formation but also provides additional benefits such as enhanced skin hydration, improved collagen synthesis, and antioxidant effects. The peptide has demonstrated a favorable safety profile in topical applications and is widely incorporated into anti-aging skincare formulations targeting expression lines around the eyes and forehead.
Key Benefits
Overview
Acetyl Hexapeptide-3, commonly known as Argireline, is a synthetic cosmetic peptide widely recognized as a topical alternative to botulinum toxin (Botox) for anti-aging applications. This hexapeptide consists of six amino acids and has a molecular weight of 889 Da. It functions by inhibiting acetylcholine release at neuromuscular junctions, leading to reduced muscle contractions and subsequent smoothing of expression lines and wrinkles. The peptide has gained significant attention in the cosmeceutical industry due to its ability to provide anti-wrinkle effects without the invasiveness of injectable treatments. Research demonstrates its effectiveness in facial rejuvenation protocols, often used as an adjunct to other cosmetic procedures to reduce the frequency of botulinum toxin injections needed. Due to its hydrophilic nature and relatively large molecular weight, skin penetration can be challenging, leading to innovative delivery methods including microneedle patches and iontophoresis. Studies have shown that Acetyl Hexapeptide-3 not only reduces wrinkle formation but also provides additional benefits such as enhanced skin hydration, improved collagen synthesis, and antioxidant effects. The peptide has demonstrated a favorable safety profile in topical applications and is widely incorporated into anti-aging skincare formulations targeting expression lines around the eyes and forehead.
Potential Benefits
Mechanism of Action
Acetyl Hexapeptide-3 works by inhibiting the release of acetylcholine at neuromuscular junctions, specifically targeting the SNARE complex involved in neurotransmitter release. The peptide interferes with the formation or stability of the SNARE complex, which is essential for vesicle fusion and acetylcholine release from nerve terminals. By reducing acetylcholine availability, the peptide decreases muscle contractions that contribute to the formation of expression lines and dynamic wrinkles. Additionally, the peptide demonstrates antioxidant properties by upregulating superoxide dismutase 2 (SOD2), an important antioxidant enzyme that protects cells from oxidative stress. Research indicates that the peptide preferentially accumulates around sensory neurons when applied topically, suggesting targeted cellular uptake. The mechanism also involves stimulation of type I collagen synthesis, contributing to improved skin structure and elasticity. The peptide's effects on catecholamine content suggest additional neurochemical modulation beyond acetylcholine inhibition. When delivered through advanced methods like microneedles, convective solvent flow contributes to enhanced transdermal delivery, allowing the peptide to reach deeper skin layers where it can interact with target cells more effectively.
Risks & Safety
Legal Status
Alloferon 1 is a 13-amino acid insect-derived peptide (HGVSGHGQHGVHG) originally isolated from the blood of experimentally infected blow flies (Calliphora vicina). This bioactive peptide demonstrates significant immunomodulatory, anti-inflammatory, antiviral, and antitumor properties through its ability to stimulate natural killer (NK) cell activity and interferon synthesis. Research has shown Alloferon 1's therapeutic potential extends beyond immune modulation to include bone health applications, particularly in treating estrogen deficiency-induced osteoporosis by dampening inflammatory signaling pathways. The peptide exhibits anti-inflammatory effects through suppression of cytokines including TNF-α, IL-1β, IL-18, and MCP1, while also demonstrating antinociceptive properties in central nervous system studies. Current research focuses on its application in cancer therapy, where it shows moderate tumoristatic and tumoricidal activities, particularly when combined with conventional chemotherapy. Alloferon 1 is currently used clinically for treating persistent viral infections and is being investigated for broader therapeutic applications including inflammatory diseases and cancer treatment.
Key Benefits
Overview
Alloferon 1 is a 13-amino acid insect-derived peptide (HGVSGHGQHGVHG) originally isolated from the blood of experimentally infected blow flies (Calliphora vicina). This bioactive peptide demonstrates significant immunomodulatory, anti-inflammatory, antiviral, and antitumor properties through its ability to stimulate natural killer (NK) cell activity and interferon synthesis. Research has shown Alloferon 1's therapeutic potential extends beyond immune modulation to include bone health applications, particularly in treating estrogen deficiency-induced osteoporosis by dampening inflammatory signaling pathways. The peptide exhibits anti-inflammatory effects through suppression of cytokines including TNF-α, IL-1β, IL-18, and MCP1, while also demonstrating antinociceptive properties in central nervous system studies. Current research focuses on its application in cancer therapy, where it shows moderate tumoristatic and tumoricidal activities, particularly when combined with conventional chemotherapy. Alloferon 1 is currently used clinically for treating persistent viral infections and is being investigated for broader therapeutic applications including inflammatory diseases and cancer treatment.
Potential Benefits
Mechanism of Action
Alloferon 1 exerts its biological effects through multiple molecular pathways. The peptide primarily functions as an immunomodulator by stimulating natural killer (NK) cell cytotoxic activity and enhancing interferon synthesis in both animal and human models. Its anti-inflammatory mechanism involves dampening the NLRP3/caspase-1/IL-1β/IL-18 signaling pathway, effectively suppressing inflammasome activation and reducing inflammatory cytokine expression. The peptide coordinates with metal ions, particularly zinc and copper, through its multiple histidine residues, which may influence its biological activity and stability. In bone metabolism, Alloferon 1 prevents estrogen deficiency-induced bone loss by modulating inflammatory cytokines and restoring bone microstructure. The peptide demonstrates antinociceptive effects through central nervous system pathways, though the exact mechanisms remain under investigation. Its antitumor activity appears to involve both direct cytotoxic effects and immune system enhancement, making it effective in combination therapies. The peptide's ability to reduce neutrophil influx and vascular permeability contributes to its anti-inflammatory properties in acute inflammatory conditions.
Risks & Safety
Legal Status
Alpha-MSH (α-melanocyte-stimulating hormone) is a 13-amino acid neuropeptide hormone with the sequence SYSMEHFRWGKPV, derived from the precursor protein proopiomelanocortin (POMC). This endogenous melanocortin agonist plays crucial roles in multiple physiological processes including appetite regulation, melanogenesis, immune modulation, and neuroendocrine signaling. Alpha-MSH primarily acts through melanocortin receptors, particularly MC3R, MC4R, and MC5R, to exert its diverse biological effects. In the central nervous system, it functions as a potent anorexigenic peptide, suppressing food intake and increasing energy expenditure through hypothalamic pathways. The peptide also demonstrates significant immunomodulatory properties, influencing myelopoiesis, inflammation, and immune cell function. Recent research has revealed its involvement in tumor immunity, with elevated levels correlating with immunosuppression in cancer patients. Alpha-MSH exhibits age-dependent effects on appetite regulation, with varying responsiveness across different life stages. The peptide's synthetic analogue, bremelanotide, has received FDA approval for treating hypoactive sexual desire disorder in premenopausal women, highlighting its therapeutic potential. Current research continues to explore its applications in cancer immunotherapy, metabolic disorders, and inflammatory conditions, positioning alpha-MSH as a significant target for various therapeutic interventions.
Key Benefits
Overview
Alpha-MSH (α-melanocyte-stimulating hormone) is a 13-amino acid neuropeptide hormone with the sequence SYSMEHFRWGKPV, derived from the precursor protein proopiomelanocortin (POMC). This endogenous melanocortin agonist plays crucial roles in multiple physiological processes including appetite regulation, melanogenesis, immune modulation, and neuroendocrine signaling. Alpha-MSH primarily acts through melanocortin receptors, particularly MC3R, MC4R, and MC5R, to exert its diverse biological effects. In the central nervous system, it functions as a potent anorexigenic peptide, suppressing food intake and increasing energy expenditure through hypothalamic pathways. The peptide also demonstrates significant immunomodulatory properties, influencing myelopoiesis, inflammation, and immune cell function. Recent research has revealed its involvement in tumor immunity, with elevated levels correlating with immunosuppression in cancer patients. Alpha-MSH exhibits age-dependent effects on appetite regulation, with varying responsiveness across different life stages. The peptide's synthetic analogue, bremelanotide, has received FDA approval for treating hypoactive sexual desire disorder in premenopausal women, highlighting its therapeutic potential. Current research continues to explore its applications in cancer immunotherapy, metabolic disorders, and inflammatory conditions, positioning alpha-MSH as a significant target for various therapeutic interventions.
Potential Benefits
Mechanism of Action
Alpha-MSH exerts its biological effects primarily through binding to melanocortin receptors (MC3R, MC4R, and MC5R) expressed on target cells. In the hypothalamus, α-MSH binds to MC3/4 receptors on neurons to suppress appetite and increase energy expenditure via sympathetic nervous system activation. The peptide modulates the JAK/STAT and NF-κB signaling pathways, particularly in immune cells like group 2 innate lymphoid cells (ILC2s), where it attenuates their inflammatory function through MC5R interaction. In melanogenesis, α-MSH activates cAMP-dependent pathways leading to CREB phosphorylation and MITF (microphthalmia-associated transcription factor) expression, promoting melanin production. The peptide influences bone marrow progenitors through MC5R to promote myelopoiesis and myeloid cell accumulation. Alpha-MSH also interacts with other appetite-regulating peptides, enhancing anorexigenic hormone transmission (like dopamine) while antagonizing orexigenic factors such as agouti-related protein and neuropeptide Y. The hypothalamic-pituitary axis responds to various stimuli by increasing α-MSH production, which then acts systemically to coordinate metabolic, immune, and neuroendocrine responses. Its effects on sexual function involve modulation of brain pathways through MC4R activation, influencing neural circuits involved in sexual response and desire.
Risks & Safety
Legal Status
Amylin, human, amide is a 37-amino acid peptide hormone naturally produced by pancreatic beta cells alongside insulin. Also known as islet amyloid polypeptide (IAPP), amylin plays a crucial role in glucose homeostasis and metabolic regulation. The peptide functions as a neuroendocrine hormone that complements insulin's effects by slowing gastric emptying, promoting satiety, and suppressing postprandial glucagon secretion. Amylin's unique structure includes a disulfide bridge between cysteine residues at positions 2 and 7, which is essential for its biological activity. In healthy individuals, amylin is co-secreted with insulin in response to nutrient intake, helping to fine-tune glucose metabolism and prevent postprandial glucose spikes. The amide form represents a stabilized version of the natural hormone. Research has focused on amylin's therapeutic potential for diabetes management and metabolic disorders, as well as its role in pancreatic islet function. However, amylin is also associated with pathological conditions, particularly in type 2 diabetes where it can form toxic amyloid deposits in pancreatic islets, contributing to beta cell dysfunction and disease progression.
Key Benefits
Overview
Amylin, human, amide is a 37-amino acid peptide hormone naturally produced by pancreatic beta cells alongside insulin. Also known as islet amyloid polypeptide (IAPP), amylin plays a crucial role in glucose homeostasis and metabolic regulation. The peptide functions as a neuroendocrine hormone that complements insulin's effects by slowing gastric emptying, promoting satiety, and suppressing postprandial glucagon secretion. Amylin's unique structure includes a disulfide bridge between cysteine residues at positions 2 and 7, which is essential for its biological activity. In healthy individuals, amylin is co-secreted with insulin in response to nutrient intake, helping to fine-tune glucose metabolism and prevent postprandial glucose spikes. The amide form represents a stabilized version of the natural hormone. Research has focused on amylin's therapeutic potential for diabetes management and metabolic disorders, as well as its role in pancreatic islet function. However, amylin is also associated with pathological conditions, particularly in type 2 diabetes where it can form toxic amyloid deposits in pancreatic islets, contributing to beta cell dysfunction and disease progression.
Potential Benefits
Mechanism of Action
Amylin exerts its biological effects primarily through binding to amylin receptors, which are G-protein coupled receptors formed by the calcitonin receptor in combination with receptor activity-modifying proteins (RAMPs). Upon receptor binding, amylin activates adenylyl cyclase, leading to increased cyclic adenosine monophosphate (cAMP) levels and subsequent activation of protein kinase A signaling pathways. In the gastrointestinal system, amylin slows gastric emptying by acting on receptors in the area postrema and nucleus tractus solitarius in the brainstem. The peptide promotes satiety through central nervous system pathways, particularly in the hypothalamus, where it modulates feeding behavior and energy homeostasis. Amylin also suppresses glucagon secretion from pancreatic alpha cells through both direct and indirect mechanisms, helping to prevent excessive hepatic glucose production during fed states. At the molecular level, the peptide's tendency to aggregate and form amyloid fibrils represents a pathological mechanism that can lead to cellular toxicity and inflammation in pancreatic islets.
Risks & Safety
Legal Status
Andropin is a synthetic antimicrobial peptide with the sequence VFIDILDKVENAIHNAAQVGIGFAKPFEKLINPK that has demonstrated significant therapeutic potential against parasitic infections, particularly leishmaniasis. Research has shown that Andropin exhibits selective activity against intracellular forms of Leishmania parasites, including L. panamensis and L. major, which cause cutaneous leishmaniasis affecting millions worldwide. The peptide shows a selectivity index of 4 against intracellular L. panamensis, indicating its ability to target parasites while minimizing damage to host cells. Unlike some other antimicrobial peptides that work against free-living parasite forms, Andropin's unique mechanism specifically targets the intracellular stages of infection, making it particularly valuable for treating established infections. This selectivity for intracellular parasites suggests potential applications beyond leishmaniasis treatment. Current research positions Andropin as a promising therapeutic tool for both New and Old World cutaneous leishmaniasis, addressing the critical need for new treatment options given the adverse reactions, emerging resistance, and lack of vaccines associated with current antileishmanial drugs. The peptide represents part of ongoing efforts to develop antimicrobial molecules with both direct pathogen-killing properties and immunomodulatory activities.
Key Benefits
Overview
Andropin is a synthetic antimicrobial peptide with the sequence VFIDILDKVENAIHNAAQVGIGFAKPFEKLINPK that has demonstrated significant therapeutic potential against parasitic infections, particularly leishmaniasis. Research has shown that Andropin exhibits selective activity against intracellular forms of Leishmania parasites, including L. panamensis and L. major, which cause cutaneous leishmaniasis affecting millions worldwide. The peptide shows a selectivity index of 4 against intracellular L. panamensis, indicating its ability to target parasites while minimizing damage to host cells. Unlike some other antimicrobial peptides that work against free-living parasite forms, Andropin's unique mechanism specifically targets the intracellular stages of infection, making it particularly valuable for treating established infections. This selectivity for intracellular parasites suggests potential applications beyond leishmaniasis treatment. Current research positions Andropin as a promising therapeutic tool for both New and Old World cutaneous leishmaniasis, addressing the critical need for new treatment options given the adverse reactions, emerging resistance, and lack of vaccines associated with current antileishmanial drugs. The peptide represents part of ongoing efforts to develop antimicrobial molecules with both direct pathogen-killing properties and immunomodulatory activities.
Potential Benefits
Mechanism of Action
Andropin functions as an antimicrobial peptide with selective activity against intracellular parasitic forms. The peptide specifically targets Leishmania parasites that have invaded dendritic cells, demonstrating unique selectivity for intracellular rather than extracellular parasite forms. This mechanism suggests that Andropin may interact with specific cellular components or pathways that are only accessible or relevant when parasites are within host cells. The peptide's antimicrobial activity likely involves disruption of parasite cellular membranes or interference with essential metabolic processes within the intracellular environment. Unlike broad-spectrum antimicrobial peptides that affect both free-living and intracellular forms, Andropin's selective mechanism allows it to target established infections while potentially preserving beneficial microorganisms and reducing cytotoxicity to host cells. The peptide's activity against both L. panamensis and L. major suggests it targets conserved mechanisms across different Leishmania species, making it broadly applicable for leishmaniasis treatment.
Risks & Safety
Legal Status
Apidaecin IA is an antimicrobial peptide (AMP) with the sequence GNNRPVYIPQPRPPHPRI that represents a promising alternative to conventional antibiotics for treating drug-resistant infections. Originally derived from natural sources, this peptide has gained significant attention in synthetic biology research due to its potent antimicrobial properties. Recent research has focused on developing cost-effective production methods using genetically modified yeast systems, particularly Pichia pastoris, to overcome the traditionally high manufacturing costs associated with AMPs. The peptide has demonstrated bioactivity against Escherichia coli and other bacterial pathogens. Current research emphasizes scaling up production through bioreactor systems using fusion protein approaches that leverage the stability properties of human serum albumin. This innovative manufacturing approach could revolutionize AMP production and make these therapeutic peptides more accessible for clinical applications. Apidaecin IA is currently in the research phase, with studies focusing on optimizing production methods and evaluating its therapeutic potential against antibiotic-resistant bacterial infections.
Key Benefits
Overview
Apidaecin IA is an antimicrobial peptide (AMP) with the sequence GNNRPVYIPQPRPPHPRI that represents a promising alternative to conventional antibiotics for treating drug-resistant infections. Originally derived from natural sources, this peptide has gained significant attention in synthetic biology research due to its potent antimicrobial properties. Recent research has focused on developing cost-effective production methods using genetically modified yeast systems, particularly Pichia pastoris, to overcome the traditionally high manufacturing costs associated with AMPs. The peptide has demonstrated bioactivity against Escherichia coli and other bacterial pathogens. Current research emphasizes scaling up production through bioreactor systems using fusion protein approaches that leverage the stability properties of human serum albumin. This innovative manufacturing approach could revolutionize AMP production and make these therapeutic peptides more accessible for clinical applications. Apidaecin IA is currently in the research phase, with studies focusing on optimizing production methods and evaluating its therapeutic potential against antibiotic-resistant bacterial infections.
Potential Benefits
Mechanism of Action
Apidaecin IA functions as an antimicrobial peptide that targets bacterial pathogens through direct interaction with bacterial cell membranes and intracellular components. The peptide's cationic nature allows it to bind to negatively charged bacterial cell surfaces, leading to membrane disruption and cell death. The research indicates that the peptide maintains its bioactivity when produced through recombinant fusion protein systems, suggesting that its antimicrobial mechanism remains intact even after purification from fusion constructs. The peptide likely works by penetrating bacterial cell walls and interfering with essential cellular processes, though the specific molecular targets and signaling pathways affected require further investigation. The fusion protein approach used in production leverages human serum albumin's stability properties to protect the peptide during manufacturing while maintaining its biological activity against target organisms like Escherichia coli.
Risks & Safety
Legal Status
Apidaecin IB is a proline-rich antimicrobial peptide consisting of 18 amino acids (GNNRPVYIPQPRPPHPRL) naturally produced by insects. This cationic peptide demonstrates potent antibacterial activity, particularly against gram-negative bacteria including Escherichia coli and Pseudomonas aeruginosa. Unlike traditional antibiotics that target cell walls, apidaecin IB employs unique mechanisms involving disruption of essential bacterial proteins and cellular processes. Research has shown its effectiveness can be enhanced through conjugation with photosensitizers, creating broad-spectrum antibacterial agents effective under light activation. The peptide's non-toxic nature to human and animal cells makes it a promising candidate for novel antibiotic development. Current research focuses on understanding its complex mechanisms of action, including effects on bacterial membrane proteins, chaperone systems, and lipopolysaccharide biosynthesis. Studies indicate apidaecin IB causes significant alterations in bacterial protein expression, particularly affecting essential cellular maintenance systems. Its proline-rich structure contributes to its stability and unique mode of action, distinguishing it from conventional antimicrobial agents.
Key Benefits
Overview
Apidaecin IB is a proline-rich antimicrobial peptide consisting of 18 amino acids (GNNRPVYIPQPRPPHPRL) naturally produced by insects. This cationic peptide demonstrates potent antibacterial activity, particularly against gram-negative bacteria including Escherichia coli and Pseudomonas aeruginosa. Unlike traditional antibiotics that target cell walls, apidaecin IB employs unique mechanisms involving disruption of essential bacterial proteins and cellular processes. Research has shown its effectiveness can be enhanced through conjugation with photosensitizers, creating broad-spectrum antibacterial agents effective under light activation. The peptide's non-toxic nature to human and animal cells makes it a promising candidate for novel antibiotic development. Current research focuses on understanding its complex mechanisms of action, including effects on bacterial membrane proteins, chaperone systems, and lipopolysaccharide biosynthesis. Studies indicate apidaecin IB causes significant alterations in bacterial protein expression, particularly affecting essential cellular maintenance systems. Its proline-rich structure contributes to its stability and unique mode of action, distinguishing it from conventional antimicrobial agents.
Potential Benefits
Mechanism of Action
Apidaecin IB operates through multiple sophisticated mechanisms targeting essential bacterial cellular processes. The peptide disrupts bacterial membrane protein profiles, specifically causing overproduction of cell division protease ftsH, an essential regulator of membrane lipid homeostasis. This overexpression leads to intensified degradation of UDP-3-O-acyl-N-acetylglucosamine deacetylase, which catalyzes the first committed step in lipid A biosynthesis of lipopolysaccharides (LPS). This cascade results in unbalanced biosynthesis of LPS and phospholipids, compromising bacterial membrane integrity. Additionally, apidaecin IB significantly decreases production of the essential chaperonin system GroEL-GroES, which is the only essential chaperone system in E. coli cytoplasm under all growth conditions. This disruption impairs proper protein folding and cellular maintenance. When conjugated with photosensitizers like porphyrin compounds, the peptide gains photodynamic properties, enabling light-activated antimicrobial effects that enhance its broad-spectrum activity against both gram-positive and gram-negative bacteria.
Risks & Safety
Legal Status
APSUNMC-P001 is a synthetic peptide with the sequence WLSRARKSMWEQAADIAFEEQMDIMWR, currently in early research phases. This 26-amino acid peptide appears to be a research compound developed for potential therapeutic applications, though specific clinical data is limited. The peptide's sequence contains several charged residues and hydrophobic regions that may facilitate cellular interactions and membrane penetration. Given its designation as a research peptide, APSUNMC-P001 is likely being investigated for various biological activities including potential anti-inflammatory, neuroprotective, or tissue repair properties. The peptide's structure suggests it may interact with cellular receptors or signaling pathways, though the exact mechanisms remain under investigation. Current research status indicates this is an experimental compound with minimal published data available, requiring further studies to establish its safety profile, efficacy, and therapeutic potential. As with many research peptides, APSUNMC-P001 represents an early-stage investigational compound that may hold promise for future therapeutic development pending comprehensive preclinical and clinical evaluation.
Key Benefits
Overview
APSUNMC-P001 is a synthetic peptide with the sequence WLSRARKSMWEQAADIAFEEQMDIMWR, currently in early research phases. This 26-amino acid peptide appears to be a research compound developed for potential therapeutic applications, though specific clinical data is limited. The peptide's sequence contains several charged residues and hydrophobic regions that may facilitate cellular interactions and membrane penetration. Given its designation as a research peptide, APSUNMC-P001 is likely being investigated for various biological activities including potential anti-inflammatory, neuroprotective, or tissue repair properties. The peptide's structure suggests it may interact with cellular receptors or signaling pathways, though the exact mechanisms remain under investigation. Current research status indicates this is an experimental compound with minimal published data available, requiring further studies to establish its safety profile, efficacy, and therapeutic potential. As with many research peptides, APSUNMC-P001 represents an early-stage investigational compound that may hold promise for future therapeutic development pending comprehensive preclinical and clinical evaluation.
Potential Benefits
Mechanism of Action
The mechanism of action for APSUNMC-P001 is not well-established due to limited research data. Based on its peptide structure containing both positively charged residues (arginine, lysine) and hydrophobic amino acids, it may interact with cell membrane receptors or penetrate cellular membranes to influence intracellular signaling pathways. The presence of tryptophan residues suggests potential for protein-protein interactions or membrane binding. The peptide may modulate inflammatory cascades, cellular repair mechanisms, or growth factor signaling, though specific receptor targets and downstream pathways have not been definitively characterized. Further research is needed to elucidate the precise molecular mechanisms by which this peptide exerts its biological effects.
Risks & Safety
Legal Status
APSUNMC-P002 is a synthetic peptide with the sequence NSHNFNYRFEWQFSRCADKK that is currently in early research phases. This 20-amino acid peptide appears to be part of a research catalog, though specific therapeutic applications and mechanisms are not yet fully characterized in published literature. The peptide contains several notable structural features including aromatic residues (phenylalanine, tyrosine, tryptophan) and a cysteine residue that may contribute to its biological activity through disulfide bonding or metal coordination. Given its designation as a research compound, APSUNMC-P002 is likely being investigated for potential therapeutic applications, though comprehensive clinical data is not yet available. The peptide's structure suggests it may interact with cellular receptors or enzymes, potentially influencing various biological pathways. Current research status indicates this is an experimental compound requiring further investigation to establish safety profiles, efficacy, and optimal therapeutic applications. As with many research-stage peptides, its development may focus on areas such as tissue repair, neuroprotection, or metabolic regulation, though specific targets remain to be definitively established through peer-reviewed research.
Key Benefits
Overview
APSUNMC-P002 is a synthetic peptide with the sequence NSHNFNYRFEWQFSRCADKK that is currently in early research phases. This 20-amino acid peptide appears to be part of a research catalog, though specific therapeutic applications and mechanisms are not yet fully characterized in published literature. The peptide contains several notable structural features including aromatic residues (phenylalanine, tyrosine, tryptophan) and a cysteine residue that may contribute to its biological activity through disulfide bonding or metal coordination. Given its designation as a research compound, APSUNMC-P002 is likely being investigated for potential therapeutic applications, though comprehensive clinical data is not yet available. The peptide's structure suggests it may interact with cellular receptors or enzymes, potentially influencing various biological pathways. Current research status indicates this is an experimental compound requiring further investigation to establish safety profiles, efficacy, and optimal therapeutic applications. As with many research-stage peptides, its development may focus on areas such as tissue repair, neuroprotection, or metabolic regulation, though specific targets remain to be definitively established through peer-reviewed research.
Potential Benefits
Mechanism of Action
The mechanism of action for APSUNMC-P002 is not yet fully elucidated in published research. Based on its peptide structure containing aromatic amino acids (phenylalanine, tyrosine, tryptophan) and a cysteine residue, it may interact with cellular receptors through specific binding domains. The presence of charged residues (lysine, aspartic acid) suggests potential electrostatic interactions with target proteins or cell surface receptors. The peptide may modulate intracellular signaling pathways, potentially affecting protein synthesis, cellular metabolism, or gene expression. Without specific research data, the exact molecular targets and downstream effects remain speculative and require further investigation through controlled studies.
Risks & Safety
Legal Status
APSUNMC-P003 is a synthetic peptide with the amino acid sequence FIMNFEYDMTKH that is currently in early research phases. This 12-amino acid peptide represents a novel compound being investigated for potential therapeutic applications, though comprehensive clinical data remains limited. The peptide's unique sequence suggests it may interact with specific biological pathways, potentially offering benefits in areas such as cellular repair, immune modulation, and tissue regeneration. As with many research peptides, APSUNMC-P003 is being studied for its bioactivity profile and safety characteristics. Current research status indicates this is an experimental compound requiring further investigation to fully understand its mechanisms of action, therapeutic potential, and safety profile. The peptide's development appears to be in preliminary stages, with ongoing studies needed to establish its efficacy and clinical applications. Given the limited available data, this peptide should be considered an investigational compound with potential but unproven therapeutic benefits.
Key Benefits
Overview
APSUNMC-P003 is a synthetic peptide with the amino acid sequence FIMNFEYDMTKH that is currently in early research phases. This 12-amino acid peptide represents a novel compound being investigated for potential therapeutic applications, though comprehensive clinical data remains limited. The peptide's unique sequence suggests it may interact with specific biological pathways, potentially offering benefits in areas such as cellular repair, immune modulation, and tissue regeneration. As with many research peptides, APSUNMC-P003 is being studied for its bioactivity profile and safety characteristics. Current research status indicates this is an experimental compound requiring further investigation to fully understand its mechanisms of action, therapeutic potential, and safety profile. The peptide's development appears to be in preliminary stages, with ongoing studies needed to establish its efficacy and clinical applications. Given the limited available data, this peptide should be considered an investigational compound with potential but unproven therapeutic benefits.
Potential Benefits
Mechanism of Action
The specific mechanism of action for APSUNMC-P003 has not been fully elucidated due to limited research data. Based on its peptide structure and sequence FIMNFEYDMTKH, it likely functions through receptor-mediated signaling pathways common to bioactive peptides. The peptide may interact with cell surface receptors or intracellular targets to modulate various biological processes. Potential mechanisms could include activation of growth factor pathways, modulation of inflammatory cascades, or interaction with tissue repair mechanisms. The specific amino acid composition suggests possible involvement in protein-protein interactions or enzyme modulation, though detailed molecular studies are needed to confirm these hypotheses.
Risks & Safety
Legal Status
APSUNMC-P004 is a synthetic peptide with the sequence TPLKHPVIRLDPQK that is currently in early research phases. This 14-amino acid peptide appears to be part of a research catalog, though specific therapeutic applications and mechanisms are still being investigated. The peptide's sequence contains several basic amino acids (lysine, histidine, arginine) which may contribute to its biological activity through interactions with cellular membranes or proteins. Given its designation as a research peptide, APSUNMC-P004 is likely being evaluated for various therapeutic applications, though comprehensive clinical data is not yet available. The peptide's structure suggests potential for cellular uptake and biological activity, making it a candidate for further investigation in areas such as tissue repair, cellular signaling, or therapeutic intervention. Current research status indicates this is an experimental compound requiring further study to establish safety, efficacy, and optimal applications. As with many research peptides, initial investigations typically focus on basic pharmacokinetics, cellular interactions, and preliminary biological effects before advancing to more specific therapeutic applications.
Key Benefits
Overview
APSUNMC-P004 is a synthetic peptide with the sequence TPLKHPVIRLDPQK that is currently in early research phases. This 14-amino acid peptide appears to be part of a research catalog, though specific therapeutic applications and mechanisms are still being investigated. The peptide's sequence contains several basic amino acids (lysine, histidine, arginine) which may contribute to its biological activity through interactions with cellular membranes or proteins. Given its designation as a research peptide, APSUNMC-P004 is likely being evaluated for various therapeutic applications, though comprehensive clinical data is not yet available. The peptide's structure suggests potential for cellular uptake and biological activity, making it a candidate for further investigation in areas such as tissue repair, cellular signaling, or therapeutic intervention. Current research status indicates this is an experimental compound requiring further study to establish safety, efficacy, and optimal applications. As with many research peptides, initial investigations typically focus on basic pharmacokinetics, cellular interactions, and preliminary biological effects before advancing to more specific therapeutic applications.
Potential Benefits
Mechanism of Action
The mechanism of action for APSUNMC-P004 is currently under investigation. Based on its amino acid sequence containing positively charged residues (lysine, histidine, arginine), the peptide likely interacts with negatively charged cellular components such as membrane phospholipids or specific protein receptors. The presence of hydrophobic amino acids (leucine, valine, proline) suggests potential for membrane penetration or protein-protein interactions. The peptide may modulate cellular signaling pathways through receptor binding or direct intracellular effects. Given its research status, the specific molecular targets and downstream signaling cascades activated by APSUNMC-P004 remain to be fully characterized through ongoing studies.
Risks & Safety
Legal Status
Argireline, also known as Acetyl Hexapeptide-3, is a synthetic peptide that has gained significant attention in the cosmetic industry as a needle-free alternative to Botox injections. This hexapeptide works by inhibiting the release of neurotransmitters at the neuromuscular junction, producing a botox-like effect that reduces facial wrinkles and fine lines. Argireline is commonly used as an active ingredient in dermal ointments and creams for anti-aging purposes. Clinical studies have demonstrated its efficacy in reducing wrinkle depth by up to 48% after 4 weeks of twice-daily treatment. The peptide is considered safer than traditional Botox treatments as it does not require invasive injections. However, its large molecular weight and hydrophilic nature present challenges for skin permeation, leading researchers to develop modified analogues with improved penetration properties. Current research focuses on optimizing its delivery methods and understanding its stability, particularly regarding methionine oxidation. While generally considered safe for topical use, comprehensive toxicity data remains limited in the literature, making ongoing safety evaluation important for its continued cosmetic application.
Key Benefits
Overview
Argireline, also known as Acetyl Hexapeptide-3, is a synthetic peptide that has gained significant attention in the cosmetic industry as a needle-free alternative to Botox injections. This hexapeptide works by inhibiting the release of neurotransmitters at the neuromuscular junction, producing a botox-like effect that reduces facial wrinkles and fine lines. Argireline is commonly used as an active ingredient in dermal ointments and creams for anti-aging purposes. Clinical studies have demonstrated its efficacy in reducing wrinkle depth by up to 48% after 4 weeks of twice-daily treatment. The peptide is considered safer than traditional Botox treatments as it does not require invasive injections. However, its large molecular weight and hydrophilic nature present challenges for skin permeation, leading researchers to develop modified analogues with improved penetration properties. Current research focuses on optimizing its delivery methods and understanding its stability, particularly regarding methionine oxidation. While generally considered safe for topical use, comprehensive toxicity data remains limited in the literature, making ongoing safety evaluation important for its continued cosmetic application.
Potential Benefits
Mechanism of Action
Argireline functions by inhibiting the release of neurotransmitters at the neuromuscular junction, specifically targeting the SNARE complex involved in vesicle fusion and neurotransmitter release. The peptide mimics the N-terminal end of SNAP-25, a protein essential for the formation of the SNARE complex. By competing with SNAP-25, Argireline disrupts the normal assembly of the SNARE complex, preventing the fusion of acetylcholine-containing vesicles with the presynaptic membrane. This inhibition reduces the release of acetylcholine and other neurotransmitters, including glutamate, leading to decreased muscle contractions. The reduced muscle activity results in the relaxation of facial muscles responsible for expression lines and wrinkles. Unlike Botox, which cleaves SNARE proteins permanently, Argireline's inhibition is reversible and does not require injection into muscle tissue. The peptide's zwitterionic form at physiological pH affects its skin permeation properties, which has led to the development of modified analogues with altered charge states to improve topical delivery and efficacy.
Risks & Safety
Legal Status
Bactenecin is a 12-amino acid cyclic antimicrobial peptide (CAMP) containing one intramolecular disulfide bond, originally derived from bovine neutrophils as part of the innate immune response. This cationic peptide exhibits broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains. Bactenecin functions through multiple mechanisms including membrane permeabilization and intracellular targeting of bacterial proteins. Research has shown it can rapidly kill bacteria within 1-2 hours and effectively inhibit biofilm formation. The peptide has served as a foundation for developing synthetic analogs with enhanced activity, such as IDR-1018, which demonstrates immunomodulatory, anti-inflammatory, and wound healing properties. Current research focuses on understanding its precise mechanisms of action, including its ability to bind lipopolysaccharides, disrupt bacterial membranes, and target specific intracellular proteins involved in purine metabolism and transcription. Bactenecin represents a promising alternative to conventional antibiotics, particularly against resistant bacterial infections and biofilm-associated diseases.
Key Benefits
Overview
Bactenecin is a 12-amino acid cyclic antimicrobial peptide (CAMP) containing one intramolecular disulfide bond, originally derived from bovine neutrophils as part of the innate immune response. This cationic peptide exhibits broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains. Bactenecin functions through multiple mechanisms including membrane permeabilization and intracellular targeting of bacterial proteins. Research has shown it can rapidly kill bacteria within 1-2 hours and effectively inhibit biofilm formation. The peptide has served as a foundation for developing synthetic analogs with enhanced activity, such as IDR-1018, which demonstrates immunomodulatory, anti-inflammatory, and wound healing properties. Current research focuses on understanding its precise mechanisms of action, including its ability to bind lipopolysaccharides, disrupt bacterial membranes, and target specific intracellular proteins involved in purine metabolism and transcription. Bactenecin represents a promising alternative to conventional antibiotics, particularly against resistant bacterial infections and biofilm-associated diseases.
Potential Benefits
Mechanism of Action
Bactenecin operates through multiple antimicrobial mechanisms. It exhibits strong binding affinity to bacterial lipopolysaccharides (LPS) and induces perturbation of both outer and inner bacterial membranes. The peptide causes changes in membrane fluidity and permeability, leading to membrane leakage at levels two-fold greater than other antimicrobial peptides. Molecular modeling shows stable and deep insertion into membranes up to 9 Å depth. Bactenecin can form dimers or large β-sheet structures in a concentration-dependent manner, rapidly permeabilizing membranes and causing cytosolic leakage. Beyond membrane disruption, it targets specific intracellular proteins including those involved in purine metabolism, histidine kinase pathways, and arginine decarboxylase - a crucial enzyme for bacterial survival in acidic environments. The peptide also induces negative Gaussian curvature in bacterial membranes, facilitating pore formation, blebbing, and budding mechanisms essential for membrane permeation.
Risks & Safety
Legal Status
Beta-endorphin is a 31-amino acid endogenous opioid peptide derived from pro-opiomelanocortin (POMC) and synthesized primarily in the hypothalamic arcuate nucleus and pituitary gland. As a key hormone of relationship and stress response, beta-endorphin plays crucial roles in pain modulation, emotional regulation, and physiological adaptation. It binds to μ-opioid receptors to generate neuronal hyperpolarization and inhibit nociceptive stimuli, providing natural analgesia. Beyond pain management, beta-endorphin influences reproductive health, labor and birth processes, memory consolidation, and stress response through the hypothalamic-pituitary-adrenal axis. Recent research reveals its involvement in neuroimmune modulation via IL-10 pathways, neuroprotective effects against Alzheimer's disease through amyloid-β interaction, and epigenetic regulation mechanisms. The peptide demonstrates sex-dependent effects on alcohol sensitivity and plays important roles in attachment, bonding, and breastfeeding initiation. Current investigations focus on its therapeutic potential for neuropathic pain, neurodegenerative diseases, and addiction disorders, with emerging evidence suggesting exercise-induced beta-endorphin release may contribute to cognitive protection and overall health benefits.
Key Benefits
Overview
Beta-endorphin is a 31-amino acid endogenous opioid peptide derived from pro-opiomelanocortin (POMC) and synthesized primarily in the hypothalamic arcuate nucleus and pituitary gland. As a key hormone of relationship and stress response, beta-endorphin plays crucial roles in pain modulation, emotional regulation, and physiological adaptation. It binds to μ-opioid receptors to generate neuronal hyperpolarization and inhibit nociceptive stimuli, providing natural analgesia. Beyond pain management, beta-endorphin influences reproductive health, labor and birth processes, memory consolidation, and stress response through the hypothalamic-pituitary-adrenal axis. Recent research reveals its involvement in neuroimmune modulation via IL-10 pathways, neuroprotective effects against Alzheimer's disease through amyloid-β interaction, and epigenetic regulation mechanisms. The peptide demonstrates sex-dependent effects on alcohol sensitivity and plays important roles in attachment, bonding, and breastfeeding initiation. Current investigations focus on its therapeutic potential for neuropathic pain, neurodegenerative diseases, and addiction disorders, with emerging evidence suggesting exercise-induced beta-endorphin release may contribute to cognitive protection and overall health benefits.
Potential Benefits
Mechanism of Action
Beta-endorphin exerts its effects primarily through binding to μ-opioid receptors, causing neuronal hyperpolarization and inhibition of nociceptive stimuli. The peptide is synthesized from pro-opiomelanocortin (POMC) through cleavage by proprotein convertase 1. Its expression is regulated through epigenetic mechanisms involving microRNA-203a-3p, histone deacetylase 9, and NR4A2 transcription factor binding. Beta-endorphin modulates neuroimmune responses through IL-10-mediated pathways, stimulating GLP-1R, GRP40, and α7nAChR receptors, as well as intracellular STAT3 signaling. The peptide provides negative feedback to inhibit the hypothalamic-pituitary-adrenal stress axis and facilitates memory consolidation through endogenous state-dependency mechanisms. In Alzheimer's pathology, beta-endorphin forms protective coronas around amyloid-β aggregates, shielding cellular exposure and suppressing toxicity. The peptide also influences neurotransmitter systems in the brain, modulating chemical transmission and contributing to mood regulation, stress adaptation, and pain perception through complex receptor interactions and downstream signaling cascades.
Risks & Safety
Legal Status
BMAP-28 (Bovine Myeloid Antimicrobial Peptide-28) is a cathelicidin-derived antimicrobial peptide with the sequence GGLRSLGRKILRAWKKYGPIIVPIIRIG. Originally identified as part of bovine innate immunity, BMAP-28 has demonstrated potent antimicrobial activity against a broad spectrum of pathogens including drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and pan-drug-resistant Acinetobacter baumannii. The peptide adopts a helical conformation when bound to lipid membranes and exerts its antimicrobial effects primarily through membrane disruption and interaction with bacterial outer membrane proteins. Beyond direct bacterial killing, BMAP-28 exhibits immunomodulatory properties, influencing cytokine expression and inflammatory pathways in macrophages. Research has also explored its antiparasitic activity against Leishmania major. The peptide's mechanism involves membrane anchoring through specific residues (Ser5, Arg8, Arg12) and subsequent membrane destabilization. Current research focuses on understanding structure-activity relationships, developing analogs with enhanced activity, and exploring its potential as a therapeutic agent against antibiotic-resistant infections. Studies have investigated various forms including D-amino acid and retro-inverso variants to improve stability and efficacy.
Key Benefits
Overview
BMAP-28 (Bovine Myeloid Antimicrobial Peptide-28) is a cathelicidin-derived antimicrobial peptide with the sequence GGLRSLGRKILRAWKKYGPIIVPIIRIG. Originally identified as part of bovine innate immunity, BMAP-28 has demonstrated potent antimicrobial activity against a broad spectrum of pathogens including drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and pan-drug-resistant Acinetobacter baumannii. The peptide adopts a helical conformation when bound to lipid membranes and exerts its antimicrobial effects primarily through membrane disruption and interaction with bacterial outer membrane proteins. Beyond direct bacterial killing, BMAP-28 exhibits immunomodulatory properties, influencing cytokine expression and inflammatory pathways in macrophages. Research has also explored its antiparasitic activity against Leishmania major. The peptide's mechanism involves membrane anchoring through specific residues (Ser5, Arg8, Arg12) and subsequent membrane destabilization. Current research focuses on understanding structure-activity relationships, developing analogs with enhanced activity, and exploring its potential as a therapeutic agent against antibiotic-resistant infections. Studies have investigated various forms including D-amino acid and retro-inverso variants to improve stability and efficacy.
Potential Benefits
Mechanism of Action
BMAP-28 functions through multiple molecular mechanisms centered on membrane interaction and disruption. The peptide adopts an amphipathic helical structure when bound to bacterial membranes, with specific residues Ser5, Arg8, and Arg12 crucial for initial membrane anchoring. Upon contact with bacterial cells, BMAP-28 interacts with outer membrane proteins, particularly OmpA in Acinetobacter baumannii, leading to membrane destabilization and cell content leakage. The peptide's antimicrobial activity depends on maintaining a stable helical conformation that promotes membrane anchoring and subsequent pore formation. In immune cells, BMAP-28 modulates inflammatory responses by activating ERK1/2, p38, and NF-κB pathways while influencing TLR4 signaling. It enhances early proinflammatory cytokine responses (IL-1β, IL-6) while inhibiting the TLR4/TRAM/TRIF pathway and IRF-3 activation, thereby suppressing IFN-β expression. The peptide also binds lipopolysaccharides and lipoteichoic acid, affecting bacterial surface properties. Its mechanism involves selective pathway activation that balances antimicrobial activity with immune modulation, making it effective against both gram-positive and gram-negative bacteria while influencing host immune responses.
Risks & Safety
Legal Status
Bombinin is an antimicrobial peptide originally discovered in the skin secretions of amphibians, particularly from Bombina species (fire-bellied toads). With the sequence GIGALSAKGALKGLAKGLAEHFAN, bombinin represents the first amphibian skin antimicrobial peptide to be identified, specifically from the European yellow-bellied toad (Bombina variegata). This cationic amphipathic α-helical peptide demonstrates broad-spectrum antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, and yeasts. Recent research has expanded understanding of bombinin's therapeutic potential, revealing significant anticancer properties against human hepatoma cells. The peptide is co-encoded with other bioactive peptides like feleucins on precursor proteins, suggesting a complex defensive system in amphibian skin. Current research focuses on bombinin variants from different Bombina species, with studies showing promising results for both anti-infection and anticancer therapy applications. The peptide's natural origin and dual antimicrobial-anticancer activity make it an attractive template for drug development, though research remains in early experimental phases.
Key Benefits
Overview
Bombinin is an antimicrobial peptide originally discovered in the skin secretions of amphibians, particularly from Bombina species (fire-bellied toads). With the sequence GIGALSAKGALKGLAKGLAEHFAN, bombinin represents the first amphibian skin antimicrobial peptide to be identified, specifically from the European yellow-bellied toad (Bombina variegata). This cationic amphipathic α-helical peptide demonstrates broad-spectrum antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, and yeasts. Recent research has expanded understanding of bombinin's therapeutic potential, revealing significant anticancer properties against human hepatoma cells. The peptide is co-encoded with other bioactive peptides like feleucins on precursor proteins, suggesting a complex defensive system in amphibian skin. Current research focuses on bombinin variants from different Bombina species, with studies showing promising results for both anti-infection and anticancer therapy applications. The peptide's natural origin and dual antimicrobial-anticancer activity make it an attractive template for drug development, though research remains in early experimental phases.
Potential Benefits
Mechanism of Action
Bombinin functions through its cationic amphipathic α-helical structure, which enables it to interact with microbial cell membranes. The peptide's positive charge allows it to bind to negatively charged bacterial cell walls and membranes, while its amphipathic nature facilitates membrane disruption and permeabilization. This dual structural feature enables bombinin to target both Gram-positive and Gram-negative bacteria as well as yeasts through membrane-disrupting mechanisms. For its anticancer activity, bombinin demonstrates antiproliferative effects on human hepatoma cells at non-toxic doses, suggesting selective targeting of cancer cells while sparing normal cells. The peptide's secondary structure prediction reveals cationic amphipathic α-helical features that are crucial for both antimicrobial and anticancer activities. The mechanism likely involves membrane interaction and disruption in both microbial and cancer cells, though the specific molecular pathways for anticancer activity require further investigation.
Risks & Safety
Legal Status
Bombinin-like peptide 4 is an antimicrobial peptide with the sequence GIGAAILSAGKSIIKGLANGLAEHF, belonging to the bombinin family of bioactive peptides. These peptides are typically derived from amphibian skin secretions and are characterized by their broad-spectrum antimicrobial properties. Bombinin-like peptides have evolved as part of the innate immune defense system in amphibians, providing protection against bacterial, fungal, and viral pathogens. The peptide's amphipathic structure, containing both hydrophobic and hydrophilic regions, enables it to interact with microbial cell membranes effectively. Current research on bombinin-like peptides focuses on their potential therapeutic applications as novel antimicrobial agents, particularly in an era of increasing antibiotic resistance. The peptide shows promise for wound healing applications due to its antimicrobial properties and potential to promote tissue repair. While specific clinical data for Bombinin-like peptide 4 is limited, related bombinin peptides have demonstrated significant biological activity in laboratory studies, suggesting potential for development as therapeutic agents for infectious diseases and wound care applications.
Key Benefits
Overview
Bombinin-like peptide 4 is an antimicrobial peptide with the sequence GIGAAILSAGKSIIKGLANGLAEHF, belonging to the bombinin family of bioactive peptides. These peptides are typically derived from amphibian skin secretions and are characterized by their broad-spectrum antimicrobial properties. Bombinin-like peptides have evolved as part of the innate immune defense system in amphibians, providing protection against bacterial, fungal, and viral pathogens. The peptide's amphipathic structure, containing both hydrophobic and hydrophilic regions, enables it to interact with microbial cell membranes effectively. Current research on bombinin-like peptides focuses on their potential therapeutic applications as novel antimicrobial agents, particularly in an era of increasing antibiotic resistance. The peptide shows promise for wound healing applications due to its antimicrobial properties and potential to promote tissue repair. While specific clinical data for Bombinin-like peptide 4 is limited, related bombinin peptides have demonstrated significant biological activity in laboratory studies, suggesting potential for development as therapeutic agents for infectious diseases and wound care applications.
Potential Benefits
Mechanism of Action
Bombinin-like peptide 4 likely functions through membrane-disrupting mechanisms typical of antimicrobial peptides. The peptide's amphipathic structure allows it to interact with negatively charged bacterial cell membranes through electrostatic interactions. Upon contact, the peptide inserts into the lipid bilayer, causing membrane permeabilization and eventual cell death. The peptide may also penetrate into bacterial cells to interact with intracellular targets such as DNA, RNA, or essential enzymes. Additionally, bombinin-like peptides may modulate host immune responses by activating immune cells and promoting the release of inflammatory mediators. The peptide's wound healing properties likely involve stimulation of cell proliferation, angiogenesis, and tissue remodeling processes. The specific amino acid sequence of Bombinin-like peptide 4 determines its selectivity for microbial membranes over mammalian cell membranes, contributing to its therapeutic potential.
Risks & Safety
Legal Status
Bovine tracheal antimicrobial peptide is a naturally occurring antimicrobial compound derived from bovine tracheal tissue with the sequence NPVSCVRNKGICVPIRCPGSMKQIGTCVGRAVKCCRKK. This peptide belongs to the family of antimicrobial peptides (AMPs) that serve as part of the innate immune system's first line of defense against pathogens. The peptide contains multiple cysteine residues that likely form disulfide bonds, contributing to its structural stability and antimicrobial activity. As a bovine-derived antimicrobial peptide, it demonstrates broad-spectrum activity against various microorganisms including bacteria, fungi, and potentially viruses. The peptide's tracheal origin suggests it plays a role in protecting respiratory tissues from microbial invasion. Current research status indicates this peptide is primarily studied for its antimicrobial properties and potential therapeutic applications in treating infections. The presence of multiple positively charged residues in its sequence suggests it may interact with negatively charged bacterial membranes, leading to membrane disruption and cell death. While research on this specific peptide appears limited, it represents part of the broader field of antimicrobial peptide research aimed at developing novel therapeutic agents to combat antibiotic-resistant pathogens.
Key Benefits
Overview
Bovine tracheal antimicrobial peptide is a naturally occurring antimicrobial compound derived from bovine tracheal tissue with the sequence NPVSCVRNKGICVPIRCPGSMKQIGTCVGRAVKCCRKK. This peptide belongs to the family of antimicrobial peptides (AMPs) that serve as part of the innate immune system's first line of defense against pathogens. The peptide contains multiple cysteine residues that likely form disulfide bonds, contributing to its structural stability and antimicrobial activity. As a bovine-derived antimicrobial peptide, it demonstrates broad-spectrum activity against various microorganisms including bacteria, fungi, and potentially viruses. The peptide's tracheal origin suggests it plays a role in protecting respiratory tissues from microbial invasion. Current research status indicates this peptide is primarily studied for its antimicrobial properties and potential therapeutic applications in treating infections. The presence of multiple positively charged residues in its sequence suggests it may interact with negatively charged bacterial membranes, leading to membrane disruption and cell death. While research on this specific peptide appears limited, it represents part of the broader field of antimicrobial peptide research aimed at developing novel therapeutic agents to combat antibiotic-resistant pathogens.
Potential Benefits
Mechanism of Action
Bovine tracheal antimicrobial peptide likely functions through membrane-targeting mechanisms characteristic of cationic antimicrobial peptides. The peptide's positively charged residues interact with negatively charged components of microbial cell membranes, including lipopolysaccharides in bacterial outer membranes and phospholipids in cytoplasmic membranes. This electrostatic interaction leads to membrane insertion and pore formation, causing membrane permeabilization and subsequent cell death. The multiple cysteine residues in the sequence suggest the formation of disulfide bonds that stabilize the peptide's three-dimensional structure, enhancing its antimicrobial activity. The peptide may also penetrate into cells and interact with intracellular targets such as DNA, RNA, or essential enzymes, providing additional antimicrobial effects. Its tracheal origin indicates adaptation for protecting respiratory epithelium, suggesting potential interactions with respiratory pathogens and inflammatory mediators. The peptide may modulate immune responses by interacting with pattern recognition receptors or influencing cytokine production, contributing to both direct antimicrobial effects and immune system enhancement.
Risks & Safety
Legal Status
BPC-157 (Body Protection Compound-157) is a stable pentadecapeptide consisting of 15 amino acids, originally isolated from human gastric juice. This synthetic peptide has demonstrated remarkable pleiotropic healing properties across multiple tissue types in preclinical studies. BPC-157 functions as a potent angiomodulatory agent that promotes tissue repair through various mechanisms including angiogenesis, anti-inflammatory effects, and cellular protection. Research has shown consistent positive healing effects for traumatic and systemic injuries affecting tendons, ligaments, skeletal muscle, bone, gastrointestinal tract, and even central nervous system tissues. The peptide exhibits an excellent safety profile in animal studies with minimal reported adverse effects. However, despite over two decades of promising preclinical research, BPC-157 lacks comprehensive clinical trials in humans and remains unapproved by the FDA. Only one small human study has been conducted, showing potential benefits for chronic knee pain. The peptide was temporarily banned by WADA in 2022 but is not currently listed as prohibited. While available through unregulated online sources, the absence of clinical safety data and standardized manufacturing raises concerns about its widespread use outside of research settings.
Key Benefits
Overview
BPC-157 (Body Protection Compound-157) is a stable pentadecapeptide consisting of 15 amino acids, originally isolated from human gastric juice. This synthetic peptide has demonstrated remarkable pleiotropic healing properties across multiple tissue types in preclinical studies. BPC-157 functions as a potent angiomodulatory agent that promotes tissue repair through various mechanisms including angiogenesis, anti-inflammatory effects, and cellular protection. Research has shown consistent positive healing effects for traumatic and systemic injuries affecting tendons, ligaments, skeletal muscle, bone, gastrointestinal tract, and even central nervous system tissues. The peptide exhibits an excellent safety profile in animal studies with minimal reported adverse effects. However, despite over two decades of promising preclinical research, BPC-157 lacks comprehensive clinical trials in humans and remains unapproved by the FDA. Only one small human study has been conducted, showing potential benefits for chronic knee pain. The peptide was temporarily banned by WADA in 2022 but is not currently listed as prohibited. While available through unregulated online sources, the absence of clinical safety data and standardized manufacturing raises concerns about its widespread use outside of research settings.
Potential Benefits
Mechanism of Action
BPC-157 exerts its therapeutic effects through multiple interconnected molecular pathways. The peptide promotes angiogenesis by modulating key growth factors including VEGF (vascular endothelial growth factor), EGF (epidermal growth factor), and FGF (fibroblast growth factor), leading to enhanced blood vessel formation and tissue vascularization. At the cellular level, BPC-157 activates the FAK-paxillin signaling pathway, which is crucial for cell migration, adhesion, and survival. This activation increases phosphorylation of focal adhesion kinase (FAK) and paxillin proteins while promoting F-actin formation in fibroblasts. The peptide enhances cell survival under oxidative stress conditions and accelerates cellular migration in a dose-dependent manner. BPC-157 also modulates the nitric oxide system, demonstrating both L-NAME responsive and non-responsive effects depending on the physiological context. In the central nervous system, it influences dopamine pathways and provides neuroprotective effects. The peptide's angiomodulatory properties optimize vascular responses to injury by affecting endothelial function, clotting mechanisms, vasoconstriction/vasodilation balance, and reducing pathological edema formation. These diverse mechanisms work synergistically to accelerate healing processes across multiple tissue types.
Risks & Safety
Legal Status
Brevinin-2EC is a 34-residue antimicrobial cationic peptide derived from the skin of the frog Rana ridibunda. This disulfide-containing peptide belongs to the brevinin family of antimicrobial peptides, which are naturally occurring defense molecules found in amphibian skin secretions. Brevinin-2EC contains cysteine residues that form disulfide bonds, contributing to its structural stability and biological activity. The peptide has been primarily studied for its antimicrobial properties and has served as an important model compound for developing advanced mass spectrometry sequencing techniques for disulfide-containing peptides. Research has focused on understanding its structure-function relationships and optimizing analytical methods for characterizing similar bioactive peptides. As an antimicrobial cationic peptide, Brevinin-2EC likely exhibits broad-spectrum activity against various pathogens through membrane disruption mechanisms typical of this peptide class. Current research status indicates it remains in the investigational phase, with studies concentrating on structural characterization and analytical methodology development rather than clinical applications. The peptide's natural origin and antimicrobial properties make it a candidate for potential therapeutic development, though extensive research is needed to fully understand its biological activities and safety profile.
Key Benefits
Overview
Brevinin-2EC is a 34-residue antimicrobial cationic peptide derived from the skin of the frog Rana ridibunda. This disulfide-containing peptide belongs to the brevinin family of antimicrobial peptides, which are naturally occurring defense molecules found in amphibian skin secretions. Brevinin-2EC contains cysteine residues that form disulfide bonds, contributing to its structural stability and biological activity. The peptide has been primarily studied for its antimicrobial properties and has served as an important model compound for developing advanced mass spectrometry sequencing techniques for disulfide-containing peptides. Research has focused on understanding its structure-function relationships and optimizing analytical methods for characterizing similar bioactive peptides. As an antimicrobial cationic peptide, Brevinin-2EC likely exhibits broad-spectrum activity against various pathogens through membrane disruption mechanisms typical of this peptide class. Current research status indicates it remains in the investigational phase, with studies concentrating on structural characterization and analytical methodology development rather than clinical applications. The peptide's natural origin and antimicrobial properties make it a candidate for potential therapeutic development, though extensive research is needed to fully understand its biological activities and safety profile.
Potential Benefits
Mechanism of Action
Brevinin-2EC functions as an antimicrobial cationic peptide through electrostatic interactions with negatively charged bacterial cell membranes. The peptide's cationic nature allows it to bind to the anionic components of microbial cell walls and membranes, leading to membrane permeabilization and cell death. The disulfide bonds formed by cysteine residues in the peptide structure contribute to its conformational stability and may be essential for maintaining its antimicrobial activity. The peptide likely adopts a specific three-dimensional structure that facilitates membrane insertion and pore formation. As with other antimicrobial peptides, Brevinin-2EC may also have immunomodulatory effects, potentially stimulating host immune responses while directly targeting pathogens. The peptide's mechanism involves disruption of membrane integrity, leading to leakage of cellular contents and ultimately microbial cell death. The specific structural features, including the disulfide connectivity pattern, play crucial roles in determining the peptide's selectivity for microbial versus mammalian cell membranes.
Risks & Safety
Legal Status
Buforin II is a histone-derived antimicrobial peptide with the sequence TRSSRAGLQFPVGRVHRLLRK that demonstrates unique membrane-translocating properties. Unlike many antimicrobial peptides that disrupt bacterial membranes, Buforin II can readily cross lipid membranes without causing significant membrane permeabilization. This peptide represents a promising alternative to traditional antibiotics due to its targeting of generic bacterial structures, making it more difficult for bacteria to develop drug resistance. The peptide's mechanism involves translocation across bacterial cell membranes and subsequent binding to intracellular DNA targets. Recent computational and experimental research has focused on optimizing Buforin II variants through electrostatic charge modifications, particularly arginine substitutions, to enhance DNA-binding affinity and antimicrobial potency. Molecular dynamics simulations have revealed that the peptide's sole proline residue plays a crucial role in membrane translocation, and the peptide may form transient toroidal pores during membrane crossing. Current research suggests that Buforin II works through a cooperative mechanism involving multiple peptides that can embed deeply into membranes. The peptide's unique combination of membrane translocation capability and intracellular DNA targeting makes it an attractive candidate for antimicrobial drug development, with ongoing studies exploring structure-activity relationships and optimization strategies.
Key Benefits
Overview
Buforin II is a histone-derived antimicrobial peptide with the sequence TRSSRAGLQFPVGRVHRLLRK that demonstrates unique membrane-translocating properties. Unlike many antimicrobial peptides that disrupt bacterial membranes, Buforin II can readily cross lipid membranes without causing significant membrane permeabilization. This peptide represents a promising alternative to traditional antibiotics due to its targeting of generic bacterial structures, making it more difficult for bacteria to develop drug resistance. The peptide's mechanism involves translocation across bacterial cell membranes and subsequent binding to intracellular DNA targets. Recent computational and experimental research has focused on optimizing Buforin II variants through electrostatic charge modifications, particularly arginine substitutions, to enhance DNA-binding affinity and antimicrobial potency. Molecular dynamics simulations have revealed that the peptide's sole proline residue plays a crucial role in membrane translocation, and the peptide may form transient toroidal pores during membrane crossing. Current research suggests that Buforin II works through a cooperative mechanism involving multiple peptides that can embed deeply into membranes. The peptide's unique combination of membrane translocation capability and intracellular DNA targeting makes it an attractive candidate for antimicrobial drug development, with ongoing studies exploring structure-activity relationships and optimization strategies.
Potential Benefits
Mechanism of Action
Buforin II operates through a unique membrane translocation mechanism that allows it to cross bacterial cell membranes without causing significant permeabilization. The peptide's mechanism involves several key steps: first, it interacts with bacterial membranes through electrostatic interactions, facilitated by its positively charged residues. The sole proline residue in the peptide sequence plays a critical structural role, promoting conformational changes in the N-terminal region that facilitate membrane entry. Molecular dynamics simulations indicate that multiple Buforin II peptides work cooperatively to form transient toroidal pores in the membrane, allowing passage into the bacterial cytoplasm. Once inside the cell, the peptide targets intracellular DNA through electrostatic interactions between its positively charged residues and the negatively charged DNA backbone. The peptide's antimicrobial activity depends on both its overall positive charge and the specific distribution of charged residues, with arginine residues being particularly important for DNA binding affinity. The mechanism differs from traditional membrane-disrupting antimicrobials, as Buforin II maintains membrane integrity while achieving intracellular access, making it potentially less likely to trigger resistance mechanisms based on membrane modifications.
Risks & Safety
Legal Status
Buthinin is a 33-amino acid peptide with the sequence SIVPIRCRSNRDCRRFCGFRGGRCTYARQCLCGY, characterized by multiple cysteine residues that likely form disulfide bonds contributing to its structural stability. The peptide appears to belong to a class of bioactive compounds with potential therapeutic applications, though comprehensive research data is currently limited. Based on its structural characteristics and peptide classification, Buthinin may exhibit biological activities similar to other cysteine-rich peptides, which are often involved in cellular signaling, antimicrobial functions, or tissue repair processes. The presence of multiple disulfide bonds suggests potential stability in biological environments, making it a candidate for therapeutic development. Current research status appears to be in early investigational phases, with limited published clinical data available. Further studies are needed to fully characterize its biological mechanisms, therapeutic potential, and safety profile. The peptide's unique sequence and structure warrant continued investigation to determine its specific biological targets and potential clinical applications in various therapeutic areas.
Key Benefits
Overview
Buthinin is a 33-amino acid peptide with the sequence SIVPIRCRSNRDCRRFCGFRGGRCTYARQCLCGY, characterized by multiple cysteine residues that likely form disulfide bonds contributing to its structural stability. The peptide appears to belong to a class of bioactive compounds with potential therapeutic applications, though comprehensive research data is currently limited. Based on its structural characteristics and peptide classification, Buthinin may exhibit biological activities similar to other cysteine-rich peptides, which are often involved in cellular signaling, antimicrobial functions, or tissue repair processes. The presence of multiple disulfide bonds suggests potential stability in biological environments, making it a candidate for therapeutic development. Current research status appears to be in early investigational phases, with limited published clinical data available. Further studies are needed to fully characterize its biological mechanisms, therapeutic potential, and safety profile. The peptide's unique sequence and structure warrant continued investigation to determine its specific biological targets and potential clinical applications in various therapeutic areas.
Potential Benefits
Mechanism of Action
Based on the structural characteristics of Buthinin, its mechanism of action likely involves interaction with specific cellular receptors or signaling pathways through its cysteine-rich framework. The multiple disulfide bonds formed by cysteine residues may create a stable three-dimensional structure that enables specific binding to target proteins or receptors. The peptide may modulate cellular processes through receptor-mediated signaling cascades, potentially affecting gene expression, protein synthesis, or enzymatic activities. The presence of basic amino acids like arginine in the sequence suggests possible interactions with negatively charged cellular components or nucleic acids. Without specific research data, the exact molecular targets and signaling pathways remain to be fully elucidated through future studies.
Risks & Safety
Legal Status
c-Myc peptide (EQKLISEEDL) is a 10-amino acid sequence derived from the c-Myc proto-oncogene protein, specifically corresponding to amino acids 424-434. This peptide serves as a well-characterized substrate for casein kinase II (CK2), a serine-threonine kinase involved in numerous cellular processes including cell cycle regulation, apoptosis, and tumor development. The c-Myc peptide has gained significant importance in biomedical research as both a research tool and potential therapeutic target. Current research demonstrates its utility in peptide microarray manufacturing using catalyst-free click chemistry, enabling efficient immobilization for diagnostic and research applications. Studies have revealed differential CK2 enzyme affinity for this peptide between cancerous and non-cancerous lung tissues, with cancer tissues showing twice the binding affinity despite similar overall enzyme activity levels. The peptide's role in c-Myc protein regulation through phosphorylation may influence dimerization processes critical for oncogenic activity. Additionally, the peptide has been successfully incorporated into DNA bidimensional arrays and used in biotinylation studies, highlighting its versatility as a molecular tool. Its applications extend to immunoassays, protein array analysis, and various biochemical research methodologies, making it valuable for understanding cancer biology and developing diagnostic platforms.
Key Benefits
Overview
c-Myc peptide (EQKLISEEDL) is a 10-amino acid sequence derived from the c-Myc proto-oncogene protein, specifically corresponding to amino acids 424-434. This peptide serves as a well-characterized substrate for casein kinase II (CK2), a serine-threonine kinase involved in numerous cellular processes including cell cycle regulation, apoptosis, and tumor development. The c-Myc peptide has gained significant importance in biomedical research as both a research tool and potential therapeutic target. Current research demonstrates its utility in peptide microarray manufacturing using catalyst-free click chemistry, enabling efficient immobilization for diagnostic and research applications. Studies have revealed differential CK2 enzyme affinity for this peptide between cancerous and non-cancerous lung tissues, with cancer tissues showing twice the binding affinity despite similar overall enzyme activity levels. The peptide's role in c-Myc protein regulation through phosphorylation may influence dimerization processes critical for oncogenic activity. Additionally, the peptide has been successfully incorporated into DNA bidimensional arrays and used in biotinylation studies, highlighting its versatility as a molecular tool. Its applications extend to immunoassays, protein array analysis, and various biochemical research methodologies, making it valuable for understanding cancer biology and developing diagnostic platforms.
Potential Benefits
Mechanism of Action
The c-Myc peptide functions primarily as a substrate for casein kinase II (CK2), undergoing phosphorylation at specific serine residues. This phosphorylation event is crucial for the regulation of the full-length c-Myc protein's biological activity. The mechanism involves CK2 binding to the peptide sequence with varying affinities depending on the cellular context - cancer tissues demonstrate approximately twice the binding affinity (Km = 0.18 μM) compared to normal tissues (Km = 0.33 μM). Upon phosphorylation, the modified peptide influences c-Myc protein dimerization, which is essential for its transcriptional regulatory functions. The peptide can be chemically modified through catalyst-free click chemistry reactions, allowing for covalent attachment to solid surfaces via strain-promoted alkyne-azide cycloaddition (SPAAC). This enables its use in microarray applications where it can interact with various biological samples in heterogeneous assay formats. The peptide also serves as a recognition sequence for specific antibodies and can be conjugated with biotin linkers through activated triple bond donors, facilitating detection and purification processes in research applications.
Risks & Safety
Legal Status
Cecropin A is a 37-residue antimicrobial peptide originally isolated from the cecropia moth (Hyalophora cecropia). This cationic peptide belongs to the cecropin family and has emerged as a promising therapeutic agent with dual antimicrobial and anti-inflammatory properties. Research demonstrates its potent activity against multidrug-resistant Gram-negative bacteria including Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae. Beyond its antimicrobial effects, cecropin A exhibits significant anti-inflammatory activities by suppressing cytokine production and inhibiting key inflammatory pathways including MAPK signaling. The peptide works by selectively targeting bacterial cell membranes while demonstrating protective effects against oxidative stress and apoptosis in mammalian cells. Current research focuses on its potential applications in treating inflammatory diseases, bacterial infections, and conditions associated with oxidative stress. Studies have shown its effectiveness in both in vitro and in vivo models, with particular promise for addressing antibiotic-resistant infections and inflammatory conditions in veterinary medicine. The peptide's mechanism involves membrane permeabilization in bacteria and modulation of cellular signaling pathways in host cells, making it a versatile therapeutic candidate for multiple clinical applications.
Key Benefits
Overview
Cecropin A is a 37-residue antimicrobial peptide originally isolated from the cecropia moth (Hyalophora cecropia). This cationic peptide belongs to the cecropin family and has emerged as a promising therapeutic agent with dual antimicrobial and anti-inflammatory properties. Research demonstrates its potent activity against multidrug-resistant Gram-negative bacteria including Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae. Beyond its antimicrobial effects, cecropin A exhibits significant anti-inflammatory activities by suppressing cytokine production and inhibiting key inflammatory pathways including MAPK signaling. The peptide works by selectively targeting bacterial cell membranes while demonstrating protective effects against oxidative stress and apoptosis in mammalian cells. Current research focuses on its potential applications in treating inflammatory diseases, bacterial infections, and conditions associated with oxidative stress. Studies have shown its effectiveness in both in vitro and in vivo models, with particular promise for addressing antibiotic-resistant infections and inflammatory conditions in veterinary medicine. The peptide's mechanism involves membrane permeabilization in bacteria and modulation of cellular signaling pathways in host cells, making it a versatile therapeutic candidate for multiple clinical applications.
Potential Benefits
Mechanism of Action
Cecropin A exerts its antimicrobial effects through selective interaction with bacterial cell membranes, particularly targeting membrane phospholipids and causing membrane permeabilization of both outer and inner bacterial membranes. The peptide shows strong selectivity for bacterial cell mimetic membranes over mammalian cells. Its anti-inflammatory mechanism involves suppression of the MAPK signaling pathway, specifically inhibiting ERK, JNK, and p38 MAPK pathways, which leads to prevention of COX-2 expression in LPS-stimulated cells. Cecropin A reduces production of inflammatory cytokines including TNF-α, IL-1β, IL-8, MIP-1, and MIP-2. Additionally, it alleviates oxidative stress by downregulating NADPH Oxidase (NOX) while upregulating antioxidant enzymes including catalase (CAT), glutathione peroxidase (GPX), and superoxide dismutase (SOD). The peptide also inhibits apoptosis through suppression of the mitochondrial-dependent apoptotic pathway, specifically the Fas/FasL-caspase-8/-3 pathway, and increases the Bcl-2/Bax ratio, which regulates cell survival.
Risks & Safety
Legal Status
Cecropin P1 is an antimicrobial peptide with the sequence SWLSKTAKKLENSAKKRISEGIAIAIQGGPR that demonstrates potent antibacterial activity and immunomodulatory properties. Originally derived from insect immune systems, this peptide has shown significant promise in food safety applications, aquaculture disease resistance, and biomedical research. Studies demonstrate its effectiveness against pathogenic bacteria like E. coli O157:H7 and Aeromonas salmonicida through membrane disruption mechanisms. The peptide works by forming pores in bacterial cell membranes, leading to cell death. Research has shown enhanced efficacy when combined with ultrasonic treatment, achieving six-log reductions in bacterial populations. In aquaculture applications, transgenic rainbow trout expressing cecropin P1 exhibit enhanced disease resistance against both bacterial and viral pathogens. The peptide also demonstrates immunomodulatory effects, influencing pro-inflammatory gene expression and cytokine signaling in fish gill cells. Current research focuses on optimizing delivery methods, understanding structure-activity relationships, and developing applications in food sterilization and aquaculture. The peptide's ability to interact with lipid membranes through carpet mechanism and pore formation makes it a valuable tool for combating antibiotic-resistant pathogens.
Key Benefits
Overview
Cecropin P1 is an antimicrobial peptide with the sequence SWLSKTAKKLENSAKKRISEGIAIAIQGGPR that demonstrates potent antibacterial activity and immunomodulatory properties. Originally derived from insect immune systems, this peptide has shown significant promise in food safety applications, aquaculture disease resistance, and biomedical research. Studies demonstrate its effectiveness against pathogenic bacteria like E. coli O157:H7 and Aeromonas salmonicida through membrane disruption mechanisms. The peptide works by forming pores in bacterial cell membranes, leading to cell death. Research has shown enhanced efficacy when combined with ultrasonic treatment, achieving six-log reductions in bacterial populations. In aquaculture applications, transgenic rainbow trout expressing cecropin P1 exhibit enhanced disease resistance against both bacterial and viral pathogens. The peptide also demonstrates immunomodulatory effects, influencing pro-inflammatory gene expression and cytokine signaling in fish gill cells. Current research focuses on optimizing delivery methods, understanding structure-activity relationships, and developing applications in food sterilization and aquaculture. The peptide's ability to interact with lipid membranes through carpet mechanism and pore formation makes it a valuable tool for combating antibiotic-resistant pathogens.
Potential Benefits
Mechanism of Action
Cecropin P1 operates through multiple membrane-disrupting mechanisms to achieve antimicrobial activity. The peptide primarily functions via pore formation in bacterial cell membranes, creating transmembrane channels that disrupt cellular integrity and lead to cell death. Studies show the peptide follows a carpet mechanism at higher concentrations, where it aggregates with solubilized lipids on the membrane surface before membrane disruption. The peptide's distribution of planar aromatic residues and charged hydrophilic side-chains determines its orientation and interaction with lipid bilayers. Cecropin P1 exhibits critical concentration-dependent activity, requiring threshold levels for pore formation with lag times that decrease at higher concentrations. The peptide modulates immune responses by altering differential expression patterns of immune-relevant genes, particularly those related to pro-inflammation, acute phase responses, and cytokine signal transduction. It influences cell-cell interactions and transcription factors in epithelial cells. The peptide's interaction with membrane dipole potential affects its channel-forming activity, with the negative pole of the cecropin dipole inserting into the membrane to overcome energy barriers for interfacial accumulation.
Risks & Safety
Legal Status
ChBac5 is an antimicrobial peptide with the sequence RFRPPIRRPPIRPPFNPPFRPPVRPPFRPPFRPPFRPPIGPFP. This peptide belongs to the bactenecin family of antimicrobial compounds, which are naturally occurring defense molecules found in various organisms. The peptide's structure is characterized by multiple arginine and proline residues, which are typical features of antimicrobial peptides that contribute to their membrane-disrupting properties. ChBac5 is primarily studied for its potential therapeutic applications against bacterial infections, particularly in the context of antibiotic-resistant pathogens. The peptide's unique amino acid composition suggests it may have broad-spectrum antimicrobial activity through membrane permeabilization mechanisms. Current research status indicates this peptide is in early investigational phases, with studies focusing on its antimicrobial efficacy, safety profile, and potential clinical applications. The peptide's design incorporates structural elements that may enhance its stability and bioactivity compared to naturally occurring antimicrobial peptides. Research interest in ChBac5 stems from the growing need for novel antimicrobial agents to combat the rising threat of antibiotic resistance in clinical settings.
Key Benefits
Overview
ChBac5 is an antimicrobial peptide with the sequence RFRPPIRRPPIRPPFNPPFRPPVRPPFRPPFRPPFRPPIGPFP. This peptide belongs to the bactenecin family of antimicrobial compounds, which are naturally occurring defense molecules found in various organisms. The peptide's structure is characterized by multiple arginine and proline residues, which are typical features of antimicrobial peptides that contribute to their membrane-disrupting properties. ChBac5 is primarily studied for its potential therapeutic applications against bacterial infections, particularly in the context of antibiotic-resistant pathogens. The peptide's unique amino acid composition suggests it may have broad-spectrum antimicrobial activity through membrane permeabilization mechanisms. Current research status indicates this peptide is in early investigational phases, with studies focusing on its antimicrobial efficacy, safety profile, and potential clinical applications. The peptide's design incorporates structural elements that may enhance its stability and bioactivity compared to naturally occurring antimicrobial peptides. Research interest in ChBac5 stems from the growing need for novel antimicrobial agents to combat the rising threat of antibiotic resistance in clinical settings.
Potential Benefits
Mechanism of Action
ChBac5 functions as an antimicrobial peptide through membrane-disrupting mechanisms typical of cationic antimicrobial peptides. The peptide's high content of positively charged arginine residues allows it to interact electrostatically with negatively charged bacterial cell membranes. Upon contact with bacterial surfaces, ChBac5 likely undergoes conformational changes that facilitate membrane insertion and pore formation. The proline residues in the sequence may contribute to structural flexibility, allowing the peptide to adopt membrane-active conformations. The mechanism involves initial binding to lipopolysaccharides or phospholipids in bacterial membranes, followed by membrane permeabilization that leads to cell death. The peptide may also have intracellular targets, potentially interfering with essential cellular processes once membrane integrity is compromised. The multiple arginine-proline motifs suggest the peptide may form amphipathic structures that can disrupt membrane organization and cause leakage of cellular contents.
Risks & Safety
Legal Status
Chrysophsin-1 is a cationic antimicrobial peptide (AMP) originally isolated from the gills of the red sea bream (Pagrus major). This 25-amino acid amphipathic alpha-helical peptide exhibits broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as fungi. The peptide contains a GXXXXG motif that is crucial for its biological activity and selectivity. Chrysophsin-1 demonstrates remarkable stability in physiological conditions, maintaining activity in the presence of salts, serum, and elevated temperatures. Beyond its antimicrobial properties, research has revealed significant anticancer potential, with the peptide showing cytotoxic effects against various cancer cell lines including cervical, fibrosarcoma, and lymphoma cells. The peptide works primarily through membrane disruption mechanisms, causing pore formation and cell lysis. Recent studies have explored its potential as a multidrug resistance modulator in cancer therapy and its anti-inflammatory properties. Chrysophsin-1 has been successfully incorporated into surface coatings and liposomal formulations for therapeutic applications. The peptide represents a promising candidate for addressing antibiotic resistance and developing novel cancer treatments, with ongoing research focusing on optimizing its selectivity and therapeutic applications.
Key Benefits
Overview
Chrysophsin-1 is a cationic antimicrobial peptide (AMP) originally isolated from the gills of the red sea bream (Pagrus major). This 25-amino acid amphipathic alpha-helical peptide exhibits broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as fungi. The peptide contains a GXXXXG motif that is crucial for its biological activity and selectivity. Chrysophsin-1 demonstrates remarkable stability in physiological conditions, maintaining activity in the presence of salts, serum, and elevated temperatures. Beyond its antimicrobial properties, research has revealed significant anticancer potential, with the peptide showing cytotoxic effects against various cancer cell lines including cervical, fibrosarcoma, and lymphoma cells. The peptide works primarily through membrane disruption mechanisms, causing pore formation and cell lysis. Recent studies have explored its potential as a multidrug resistance modulator in cancer therapy and its anti-inflammatory properties. Chrysophsin-1 has been successfully incorporated into surface coatings and liposomal formulations for therapeutic applications. The peptide represents a promising candidate for addressing antibiotic resistance and developing novel cancer treatments, with ongoing research focusing on optimizing its selectivity and therapeutic applications.
Potential Benefits
Mechanism of Action
Chrysophsin-1 operates through multiple mechanisms centered on membrane disruption and cellular interference. As a cationic amphipathic peptide, it preferentially targets negatively charged bacterial membranes through electrostatic interactions. The peptide inserts into lipid bilayers, forming pores that lead to membrane destabilization, cytoplasmic leakage, and ultimately cell death. In cancer cells, chrysophsin-1 disrupts cell membranes without triggering apoptotic pathways, instead causing direct cytolysis. The peptide modulates multidrug resistance by inhibiting P-glycoprotein and multidrug resistance proteins (MRP1, MRP2), enhancing intracellular accumulation of chemotherapeutic agents like epirubicin. It generates reactive oxygen species (ROS), including H2O2 and superoxide, which contribute to its cytotoxic effects. The peptide also influences gene expression, reducing MDR1, MRP1, and MRP2 mRNA levels while increasing p53, Bax, and Bcl-2 expression. In inflammatory responses, chrysophsin-1 inhibits lipopolysaccharide-induced pro-inflammatory cytokine production, particularly TNF-α. The GXXXXG motif is critical for these activities, with modifications to this sequence significantly altering the peptide's selectivity and potency. Temperature and membrane composition influence its mechanism, with different modes of action observed against Gram-positive versus Gram-negative bacteria.
Risks & Safety
Legal Status
Chrysophsin-2 is an antimicrobial peptide (AMP) naturally found in the red sea bream (Pagrus major) with the amino acid sequence FFGWLIRGAIHAGKAIHGLIHRRRH. It belongs to a family of three chrysophsin isoforms (-1, -2, and -3) that serve as part of the fish's innate immune defense system. Research has shown that chrysophsin-2 is primarily distributed in the gills and stomach tissues of the red sea bream, suggesting its role in protecting these vulnerable entry points from pathogenic microorganisms. The peptide represents one of the naturally occurring antimicrobial compounds that fish have evolved to combat bacterial, fungal, and potentially viral infections. Current research focuses on understanding the tissue distribution patterns and quantification methods for chrysophsin isoforms using advanced analytical techniques like liquid chromatography/electrospray ionization-tandem mass spectrometry. The peptide's strategic localization in respiratory and digestive tissues indicates its importance in maintaining host defense at critical barrier sites. While research is still in early stages, chrysophsin-2 shows promise as a model for understanding natural antimicrobial mechanisms and potentially developing new therapeutic approaches for infectious diseases.
Key Benefits
Overview
Chrysophsin-2 is an antimicrobial peptide (AMP) naturally found in the red sea bream (Pagrus major) with the amino acid sequence FFGWLIRGAIHAGKAIHGLIHRRRH. It belongs to a family of three chrysophsin isoforms (-1, -2, and -3) that serve as part of the fish's innate immune defense system. Research has shown that chrysophsin-2 is primarily distributed in the gills and stomach tissues of the red sea bream, suggesting its role in protecting these vulnerable entry points from pathogenic microorganisms. The peptide represents one of the naturally occurring antimicrobial compounds that fish have evolved to combat bacterial, fungal, and potentially viral infections. Current research focuses on understanding the tissue distribution patterns and quantification methods for chrysophsin isoforms using advanced analytical techniques like liquid chromatography/electrospray ionization-tandem mass spectrometry. The peptide's strategic localization in respiratory and digestive tissues indicates its importance in maintaining host defense at critical barrier sites. While research is still in early stages, chrysophsin-2 shows promise as a model for understanding natural antimicrobial mechanisms and potentially developing new therapeutic approaches for infectious diseases.
Potential Benefits
Mechanism of Action
Chrysophsin-2 functions as an antimicrobial peptide through mechanisms typical of cationic antimicrobial peptides. The peptide likely disrupts bacterial cell membranes through electrostatic interactions between its positively charged residues (particularly the arginine and histidine residues in its sequence) and negatively charged bacterial membrane components. The peptide's amphipathic structure, containing both hydrophobic and hydrophilic regions, allows it to insert into and destabilize microbial membranes, leading to cell lysis and death. Its tissue-specific distribution in gills and stomach suggests it acts as a first-line defense mechanism at mucosal surfaces where pathogens commonly enter the host. The peptide may also have immunomodulatory effects, potentially enhancing local immune responses and supporting the overall antimicrobial defense network in fish tissues.
Risks & Safety
Legal Status
Chrysophsin-3 is a cationic antimicrobial peptide (AMP) with the sequence FIGLLISAGKAIHDLIRRRH, originally derived from the red sea bream (Pagrus major). This 20-amino acid peptide exhibits broad-spectrum bactericidal activity against both Gram-positive and Gram-negative bacteria through membrane disruption mechanisms. Research has demonstrated its effectiveness against various oral pathogens including Streptococcus mutans and Enterococcus faecalis, as well as against Bacillus anthracis in multiple metabolic states. The peptide works by destabilizing bacterial cell membranes through pore formation and membrane permeabilization. Chrysophsin-3 shows particular promise for oral health applications, demonstrating the ability to penetrate and disrupt bacterial biofilms while maintaining relatively low cytotoxicity to human cells at therapeutic concentrations. Current research focuses on understanding its molecular mechanisms of action through advanced techniques including molecular dynamics simulations and quartz crystal microbalance studies. The peptide represents a potential therapeutic candidate for treating bacterial infections, particularly in dental and oral medicine applications.
Key Benefits
Overview
Chrysophsin-3 is a cationic antimicrobial peptide (AMP) with the sequence FIGLLISAGKAIHDLIRRRH, originally derived from the red sea bream (Pagrus major). This 20-amino acid peptide exhibits broad-spectrum bactericidal activity against both Gram-positive and Gram-negative bacteria through membrane disruption mechanisms. Research has demonstrated its effectiveness against various oral pathogens including Streptococcus mutans and Enterococcus faecalis, as well as against Bacillus anthracis in multiple metabolic states. The peptide works by destabilizing bacterial cell membranes through pore formation and membrane permeabilization. Chrysophsin-3 shows particular promise for oral health applications, demonstrating the ability to penetrate and disrupt bacterial biofilms while maintaining relatively low cytotoxicity to human cells at therapeutic concentrations. Current research focuses on understanding its molecular mechanisms of action through advanced techniques including molecular dynamics simulations and quartz crystal microbalance studies. The peptide represents a potential therapeutic candidate for treating bacterial infections, particularly in dental and oral medicine applications.
Potential Benefits
Mechanism of Action
Chrysophsin-3 exerts its antimicrobial effects through membrane disruption mechanisms. As a highly cationic peptide, it initially interacts with negatively charged bacterial cell membranes through electrostatic attraction. The peptide then aggregates at the membrane surface, causing pronounced deformation of lipid bilayers. At sufficient concentrations, chrysophsin-3 inserts into the membrane and forms pores, leading to loss of membrane integrity. Molecular dynamics simulations reveal that peptide aggregation within the membrane center leads to spontaneous pore formation. The mechanism involves lipid protrusions and membrane destabilization at peptide-to-lipid ratios greater than 1:12. Microscopy studies show the formation of membranous blebs and pores on bacterial cell surfaces, with subsequent loss of nucleoid material and dissolution of cytoplasmic contents. The peptide can penetrate protective barriers such as the multilayered protein coats of bacterial spores, enabling killing even in sporulated states. Changes in cellular mechanical properties, including increased elasticity and spring constant, occur due to water and cellular material loss following membrane disruption.
Risks & Safety
Legal Status
CRAMP-1 (Cathelicidin-Related Antimicrobial Peptide-1) is a synthetic antimicrobial peptide with the sequence GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE. This peptide belongs to the cathelicidin family, which represents an important class of host defense peptides found in various mammalian species. CRAMP-1 is characterized by its cationic nature and amphipathic structure, which are essential features for its antimicrobial activity. The peptide demonstrates broad-spectrum antimicrobial properties against bacteria, fungi, and potentially other pathogens. Beyond its direct antimicrobial effects, CRAMP-1 may also possess immunomodulatory properties, helping to regulate immune responses and promote tissue healing. Current research on CRAMP-1 is primarily focused on understanding its antimicrobial mechanisms, potential therapeutic applications in treating infections, and its role in wound healing processes. The peptide's ability to disrupt microbial membranes while potentially supporting host tissue repair makes it an interesting candidate for various biomedical applications. However, research on this specific peptide variant remains limited, and most available data is extrapolated from studies on related cathelicidin peptides and antimicrobial peptides in general.
Key Benefits
Overview
CRAMP-1 (Cathelicidin-Related Antimicrobial Peptide-1) is a synthetic antimicrobial peptide with the sequence GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE. This peptide belongs to the cathelicidin family, which represents an important class of host defense peptides found in various mammalian species. CRAMP-1 is characterized by its cationic nature and amphipathic structure, which are essential features for its antimicrobial activity. The peptide demonstrates broad-spectrum antimicrobial properties against bacteria, fungi, and potentially other pathogens. Beyond its direct antimicrobial effects, CRAMP-1 may also possess immunomodulatory properties, helping to regulate immune responses and promote tissue healing. Current research on CRAMP-1 is primarily focused on understanding its antimicrobial mechanisms, potential therapeutic applications in treating infections, and its role in wound healing processes. The peptide's ability to disrupt microbial membranes while potentially supporting host tissue repair makes it an interesting candidate for various biomedical applications. However, research on this specific peptide variant remains limited, and most available data is extrapolated from studies on related cathelicidin peptides and antimicrobial peptides in general.
Potential Benefits
Mechanism of Action
CRAMP-1 functions primarily through membrane disruption mechanisms typical of cationic antimicrobial peptides. The peptide's positive charge allows it to interact with negatively charged bacterial cell membranes, leading to membrane permeabilization and cell death. The amphipathic structure enables CRAMP-1 to insert into lipid bilayers, forming pores or causing membrane destabilization. Beyond direct antimicrobial activity, the peptide may interact with host immune cells, potentially modulating inflammatory responses through interactions with pattern recognition receptors. CRAMP-1 may also influence wound healing processes by promoting cell migration and tissue repair mechanisms, though specific receptor interactions and signaling pathways for this particular peptide variant require further investigation.
Risks & Safety
Legal Status
Cyclopsychotride A is a cyclic peptide with the sequence SIPCGESCVFIPCTVTALLGCSCKSKVCYKN, containing multiple cysteine residues that likely form disulfide bonds contributing to its structural stability. Based on its name and structural characteristics, this peptide appears to belong to the cyclotide family, which are naturally occurring cyclic peptides known for their exceptional stability and diverse biological activities. Cyclotides typically exhibit antimicrobial, anti-inflammatory, and cytotoxic properties due to their unique cyclic backbone and cystine knot motif. The presence of multiple cysteine residues in Cyclopsychotride A suggests it may possess similar structural features that confer resistance to enzymatic degradation and thermal denaturation. Current research status appears to be in early phases, with limited published data available. The peptide's potential therapeutic applications may include antimicrobial therapy, anti-inflammatory treatments, and possibly anti-cancer research, though comprehensive clinical studies are needed to establish its efficacy and safety profile. Its cyclic nature and cysteine-rich composition suggest it may have enhanced bioavailability and prolonged biological activity compared to linear peptides.
Key Benefits
Overview
Cyclopsychotride A is a cyclic peptide with the sequence SIPCGESCVFIPCTVTALLGCSCKSKVCYKN, containing multiple cysteine residues that likely form disulfide bonds contributing to its structural stability. Based on its name and structural characteristics, this peptide appears to belong to the cyclotide family, which are naturally occurring cyclic peptides known for their exceptional stability and diverse biological activities. Cyclotides typically exhibit antimicrobial, anti-inflammatory, and cytotoxic properties due to their unique cyclic backbone and cystine knot motif. The presence of multiple cysteine residues in Cyclopsychotride A suggests it may possess similar structural features that confer resistance to enzymatic degradation and thermal denaturation. Current research status appears to be in early phases, with limited published data available. The peptide's potential therapeutic applications may include antimicrobial therapy, anti-inflammatory treatments, and possibly anti-cancer research, though comprehensive clinical studies are needed to establish its efficacy and safety profile. Its cyclic nature and cysteine-rich composition suggest it may have enhanced bioavailability and prolonged biological activity compared to linear peptides.
Potential Benefits
Mechanism of Action
Based on structural analysis, Cyclopsychotride A likely functions through membrane interaction mechanisms typical of cyclotides. The peptide's cyclic backbone with disulfide bonds forms a stable cystine knot structure that can interact with cell membranes, potentially disrupting membrane integrity in target cells. The cysteine-rich sequence suggests formation of multiple disulfide bridges that create a rigid, bioactive conformation resistant to proteolytic degradation. The peptide may exert its effects through direct membrane permeabilization, leading to cell death in microbial pathogens or cancer cells. Additionally, it may modulate inflammatory pathways by interfering with cytokine signaling or complement activation. The specific amino acid composition, including hydrophobic and charged residues, likely determines its selectivity for different cell types and its ability to cross biological membranes.
Risks & Safety
Legal Status
DYKDDDDK peptide, commonly known as the FLAG peptide, is an eight-amino acid sequence widely used as an affinity tag in molecular biology and protein research. This synthetic peptide serves as a crucial tool for protein purification, detection, and functional analysis when fused to target proteins. The FLAG tag enables researchers to investigate protein function, localization, and interactions in cases where specific antibodies are unavailable. Recent research has focused on developing high-affinity monoclonal antibodies for FLAG detection, including chimeric antibodies that reduce nonspecific signals in immunohistochemical applications. The peptide is extensively utilized in affinity purification coupled with mass spectrometry (AP-MS) approaches for characterizing protein complexes. This methodology has proven particularly valuable in pluripotent stem cell biology and cancer research, where understanding protein-protein interactions is essential. The FLAG peptide's versatility extends to various detection methods including flow cytometry, immunoprecipitation, and immunohistochemistry. Its applications span across multiple research domains, from basic cellular biology to advanced proteomics studies, making it an indispensable tool in modern biomedical research for protein analysis and complex characterization.
Key Benefits
Overview
DYKDDDDK peptide, commonly known as the FLAG peptide, is an eight-amino acid sequence widely used as an affinity tag in molecular biology and protein research. This synthetic peptide serves as a crucial tool for protein purification, detection, and functional analysis when fused to target proteins. The FLAG tag enables researchers to investigate protein function, localization, and interactions in cases where specific antibodies are unavailable. Recent research has focused on developing high-affinity monoclonal antibodies for FLAG detection, including chimeric antibodies that reduce nonspecific signals in immunohistochemical applications. The peptide is extensively utilized in affinity purification coupled with mass spectrometry (AP-MS) approaches for characterizing protein complexes. This methodology has proven particularly valuable in pluripotent stem cell biology and cancer research, where understanding protein-protein interactions is essential. The FLAG peptide's versatility extends to various detection methods including flow cytometry, immunoprecipitation, and immunohistochemistry. Its applications span across multiple research domains, from basic cellular biology to advanced proteomics studies, making it an indispensable tool in modern biomedical research for protein analysis and complex characterization.
Potential Benefits
Mechanism of Action
The DYKDDDDK peptide functions as a molecular tag through specific antibody-antigen interactions. When fused to target proteins, the FLAG sequence provides a recognition site for high-affinity monoclonal antibodies, enabling selective binding and detection. The mechanism relies on the unique amino acid sequence that forms specific epitopes recognized by anti-FLAG antibodies. In affinity purification processes, the FLAG-tagged protein complexes are captured through antibody binding, allowing for isolation and subsequent mass spectrometry analysis. The peptide facilitates protein complex characterization by maintaining stable and transient protein-protein interactions during purification procedures. Recent developments include chimeric antibodies with human Fc fragments that reduce nonspecific binding while maintaining high sensitivity. The FLAG tag enables investigation of direct and indirect protein interactions within cellular complexes, supporting proteomics-based analysis of molecular functions. This tagging system preserves native protein conformations and interactions, making it suitable for studying physiological and pathological cellular processes across various biological systems.
Risks & Safety
Legal Status
EP5-1 is a pentapeptide with the sequence ACSAG (Alanine-Cysteine-Serine-Alanine-Glycine). This short peptide represents a minimal bioactive sequence that is currently in early research phases. The presence of cysteine in the sequence suggests potential for disulfide bond formation, which could be important for structural stability and biological activity. As a pentapeptide, EP5-1 falls into the category of short bioactive peptides that may have therapeutic potential. However, comprehensive research data on this specific peptide is limited, indicating it is likely in preliminary stages of investigation. The simple amino acid composition suggests it may be designed for specific receptor interactions or as a building block for larger peptide constructs. Current research status appears to be in early catalog extraction phase, with minimal published data available. Further studies would be needed to establish its specific biological targets, therapeutic applications, and safety profile. The peptide's short length may offer advantages in terms of synthesis cost and potential oral bioavailability compared to longer peptide sequences.
Key Benefits
Overview
EP5-1 is a pentapeptide with the sequence ACSAG (Alanine-Cysteine-Serine-Alanine-Glycine). This short peptide represents a minimal bioactive sequence that is currently in early research phases. The presence of cysteine in the sequence suggests potential for disulfide bond formation, which could be important for structural stability and biological activity. As a pentapeptide, EP5-1 falls into the category of short bioactive peptides that may have therapeutic potential. However, comprehensive research data on this specific peptide is limited, indicating it is likely in preliminary stages of investigation. The simple amino acid composition suggests it may be designed for specific receptor interactions or as a building block for larger peptide constructs. Current research status appears to be in early catalog extraction phase, with minimal published data available. Further studies would be needed to establish its specific biological targets, therapeutic applications, and safety profile. The peptide's short length may offer advantages in terms of synthesis cost and potential oral bioavailability compared to longer peptide sequences.
Potential Benefits
Mechanism of Action
The mechanism of action for EP5-1 is not well-established due to limited research data. Based on its pentapeptide structure with sequence ACSAG, the peptide likely interacts with specific cellular receptors or enzymes through its amino acid sequence. The cysteine residue at position 2 may be critical for forming disulfide bonds that stabilize the peptide's bioactive conformation. The serine residue could serve as a phosphorylation site or participate in hydrogen bonding with target proteins. As a short peptide, EP5-1 may function by binding to cell surface receptors, modulating enzyme activity, or influencing protein-protein interactions. The specific molecular targets and signaling pathways remain to be elucidated through further research.
Risks & Safety
Legal Status
Esculentin is a family of antimicrobial peptides (AMPs) derived from frog skin, particularly from the genus Rana. These peptides are among the longest naturally occurring AMPs, with esculentin-1 containing 46 amino acids. Esculentins represent key effectors of innate immunity and have emerged as promising candidates for developing new therapeutic agents. The peptides exhibit broad-spectrum antimicrobial activity, particularly against opportunistic pathogens like Pseudomonas aeruginosa and Candida albicans. Beyond their antimicrobial properties, esculentins demonstrate significant immunomodulatory effects, anti-inflammatory activities, and potential anti-diabetic properties. Research has focused on derivatives like esculentin-1a(1-21)NH2 and esculentin-2CHa analogs, which show enhanced therapeutic potential with reduced cytotoxicity. These peptides work through membrane disruption mechanisms and can bind to lipopolysaccharides, providing both direct antimicrobial effects and anti-inflammatory benefits. Current research explores various delivery methods including nanoparticle conjugation and biomedical device immobilization to improve bioavailability and target specificity. The peptides show promise for treating infectious diseases, diabetes complications, and inflammatory conditions, representing a significant advancement in peptide-based drug development from natural sources.
Key Benefits
Overview
Esculentin is a family of antimicrobial peptides (AMPs) derived from frog skin, particularly from the genus Rana. These peptides are among the longest naturally occurring AMPs, with esculentin-1 containing 46 amino acids. Esculentins represent key effectors of innate immunity and have emerged as promising candidates for developing new therapeutic agents. The peptides exhibit broad-spectrum antimicrobial activity, particularly against opportunistic pathogens like Pseudomonas aeruginosa and Candida albicans. Beyond their antimicrobial properties, esculentins demonstrate significant immunomodulatory effects, anti-inflammatory activities, and potential anti-diabetic properties. Research has focused on derivatives like esculentin-1a(1-21)NH2 and esculentin-2CHa analogs, which show enhanced therapeutic potential with reduced cytotoxicity. These peptides work through membrane disruption mechanisms and can bind to lipopolysaccharides, providing both direct antimicrobial effects and anti-inflammatory benefits. Current research explores various delivery methods including nanoparticle conjugation and biomedical device immobilization to improve bioavailability and target specificity. The peptides show promise for treating infectious diseases, diabetes complications, and inflammatory conditions, representing a significant advancement in peptide-based drug development from natural sources.
Potential Benefits
Mechanism of Action
Esculentins function through multiple molecular mechanisms. Their primary antimicrobial action involves membrane disruption through their amphipathic α-helical structure in membrane-mimetic environments, leading to bacterial cell death. The peptides exhibit lipopolysaccharide (LPS)-binding capabilities, which contributes to their anti-inflammatory effects by neutralizing bacterial endotoxins. Esculentins modulate inflammatory pathways by inhibiting LPS-induced expression of proinflammatory mediators including nitric oxide, interleukin-1β, interleukin-6, and tumor necrosis factor-α, while simultaneously enhancing anti-inflammatory interleukin-10 expression. In metabolic regulation, esculentin derivatives stimulate insulin release and improve insulin sensitivity, promote β-cell proliferation, and suppress pancreatic and circulating glucagon concentrations. The peptides demonstrate antioxidant mechanisms by enhancing total thiol and reduced glutathione levels while reducing oxidative stress markers like hydrogen peroxide and nitric oxide generation. Their immunomodulatory properties involve activation of innate immune responses while preventing excessive inflammatory reactions. The peptides can bind to d-(+)-galacturonic acid and interact with bacterial membrane components, disrupting microbial cell integrity and preventing biofilm formation.
Risks & Safety
Legal Status
Esculentin-1B is a 46-amino acid antimicrobial peptide derived from frog skin that serves as part of the innate immune system. The peptide exhibits broad-spectrum antimicrobial activity, with its N-terminal fragment Esc(1-18) containing the first 18 residues being responsible for most of its biological activity. This fragment demonstrates exceptional antimicrobial properties while maintaining negligible toxicity toward eukaryotic cells, making it an attractive candidate for pharmaceutical development. Structurally, Esc(1-18) adopts an amphipathic helical conformation when interacting with biological membranes, characterized by a distinctive kink at residue G8. The peptide shows preferential binding to negatively charged bacterial membranes over neutral eukaryotic membranes, contributing to its selectivity. Unlike many antimicrobial peptides, Esc(1-18) maintains its activity in biological fluids such as serum, which enhances its therapeutic potential. Current research focuses on understanding its three-dimensional structure, membrane interactions, and mode of action against various pathogens including bacteria and fungi like Candida albicans.
Key Benefits
Overview
Esculentin-1B is a 46-amino acid antimicrobial peptide derived from frog skin that serves as part of the innate immune system. The peptide exhibits broad-spectrum antimicrobial activity, with its N-terminal fragment Esc(1-18) containing the first 18 residues being responsible for most of its biological activity. This fragment demonstrates exceptional antimicrobial properties while maintaining negligible toxicity toward eukaryotic cells, making it an attractive candidate for pharmaceutical development. Structurally, Esc(1-18) adopts an amphipathic helical conformation when interacting with biological membranes, characterized by a distinctive kink at residue G8. The peptide shows preferential binding to negatively charged bacterial membranes over neutral eukaryotic membranes, contributing to its selectivity. Unlike many antimicrobial peptides, Esc(1-18) maintains its activity in biological fluids such as serum, which enhances its therapeutic potential. Current research focuses on understanding its three-dimensional structure, membrane interactions, and mode of action against various pathogens including bacteria and fungi like Candida albicans.
Potential Benefits
Mechanism of Action
Esculentin-1B operates through membrane-targeting mechanisms characteristic of cationic antimicrobial peptides. The peptide binds preferentially to negatively charged bacterial plasma membranes through electrostatic interactions, showing higher affinity for prokaryotic versus eukaryotic membranes. Upon binding, Esc(1-18) undergoes conformational changes, adopting an amphipathic helical structure with a kink at glycine residue 8. The peptide inserts deeply into bacterial membranes, with the N-terminal portion forming the active helical structure while the C-terminal hydrophobic cluster serves as a membrane anchor. This insertion disrupts membrane integrity, leading to membrane permeabilization and ultimately cell death. The peptide's selectivity stems from its preferential interaction with negatively charged phospholipids abundant in bacterial membranes. Against fungal pathogens like Candida albicans, the peptide demonstrates membrane-perturbing effects that kill both yeast and hyphal forms, and can inhibit morphological transitions from yeast to the more virulent hyphal phenotype at sub-inhibitory concentrations.
Risks & Safety
Legal Status
Fabatin-1 is a 47-amino acid peptide with the sequence LLGRCKVKSNRFHGPCLTDTHCSTVCRGEGYKGGDCHGLRRRCMCLC. Based on its structural characteristics, including multiple cysteine residues that likely form disulfide bonds, Fabatin-1 appears to be a cysteine-rich peptide with potential antimicrobial and tissue-protective properties. The peptide's name suggests it may be derived from or related to faba bean (Vicia faba) compounds. Currently classified as being in Phase 1 minimal catalog extraction, this indicates limited research data is available. The presence of multiple cysteine residues and the overall peptide structure suggest it may function as a defensin-like molecule or antimicrobial peptide. Such peptides typically exhibit broad-spectrum antimicrobial activity and may have applications in wound healing and tissue repair. The peptide's compact structure and potential for forming stable disulfide bridges could contribute to its biological stability and activity. Further research is needed to fully characterize its mechanisms of action, therapeutic potential, and safety profile.
Key Benefits
Overview
Fabatin-1 is a 47-amino acid peptide with the sequence LLGRCKVKSNRFHGPCLTDTHCSTVCRGEGYKGGDCHGLRRRCMCLC. Based on its structural characteristics, including multiple cysteine residues that likely form disulfide bonds, Fabatin-1 appears to be a cysteine-rich peptide with potential antimicrobial and tissue-protective properties. The peptide's name suggests it may be derived from or related to faba bean (Vicia faba) compounds. Currently classified as being in Phase 1 minimal catalog extraction, this indicates limited research data is available. The presence of multiple cysteine residues and the overall peptide structure suggest it may function as a defensin-like molecule or antimicrobial peptide. Such peptides typically exhibit broad-spectrum antimicrobial activity and may have applications in wound healing and tissue repair. The peptide's compact structure and potential for forming stable disulfide bridges could contribute to its biological stability and activity. Further research is needed to fully characterize its mechanisms of action, therapeutic potential, and safety profile.
Potential Benefits
Mechanism of Action
Based on the structural analysis of Fabatin-1's amino acid sequence, the peptide likely functions through multiple mechanisms typical of cysteine-rich antimicrobial peptides. The eight cysteine residues in the sequence suggest the formation of disulfide bonds that create a stable, compact structure essential for biological activity. The peptide likely interacts with microbial cell membranes through electrostatic interactions, given the presence of charged residues including lysine and arginine. The mechanism may involve membrane permeabilization of pathogenic microorganisms, leading to cell death. Additionally, the peptide may modulate host immune responses by interacting with pattern recognition receptors or cytokine pathways. The presence of glycine residues may provide structural flexibility, allowing the peptide to adopt conformations necessary for target binding. The peptide may also exhibit tissue-protective effects through antioxidant mechanisms or by promoting cellular repair processes.
Risks & Safety
Legal Status
Fabatin-2 is a synthetic peptide with the sequence LLGRCKVKSNRFNGPCLTDTHCSTVCRGEGYKGGDCHGLRRRCMCLC. Based on its structural characteristics and naming convention, this peptide appears to be part of a research series focused on bioactive compounds. The peptide contains multiple cysteine residues suggesting potential disulfide bond formation, which is common in structurally stable bioactive peptides. Currently in early research phases, Fabatin-2's specific biological targets and therapeutic applications are still being investigated. The peptide's complex structure indicates potential for multiple biological interactions, though comprehensive clinical data remains limited. As with many research peptides, Fabatin-2 represents an experimental compound that requires further investigation to fully understand its therapeutic potential and safety profile.
Key Benefits
Overview
Fabatin-2 is a synthetic peptide with the sequence LLGRCKVKSNRFNGPCLTDTHCSTVCRGEGYKGGDCHGLRRRCMCLC. Based on its structural characteristics and naming convention, this peptide appears to be part of a research series focused on bioactive compounds. The peptide contains multiple cysteine residues suggesting potential disulfide bond formation, which is common in structurally stable bioactive peptides. Currently in early research phases, Fabatin-2's specific biological targets and therapeutic applications are still being investigated. The peptide's complex structure indicates potential for multiple biological interactions, though comprehensive clinical data remains limited. As with many research peptides, Fabatin-2 represents an experimental compound that requires further investigation to fully understand its therapeutic potential and safety profile.
Potential Benefits
Mechanism of Action
Based on the peptide's structural characteristics, Fabatin-2 likely functions through specific receptor binding interactions facilitated by its complex amino acid sequence. The presence of multiple cysteine residues suggests the formation of disulfide bridges that create a stable three-dimensional structure necessary for biological activity. The peptide may interact with cellular receptors or enzymes through its unique sequence motifs, potentially modulating intracellular signaling pathways. Without specific research data, the exact molecular targets and signaling cascades remain to be determined through further investigation.
Risks & Safety
Legal Status
Flagellin22 is a 22-amino acid peptide derived from bacterial flagellin, specifically representing a conserved region of the flagellin protein found in bacterial flagella. With the sequence QVQNTNASSSSFLAGAINSTAI, this peptide corresponds to a portion of the flagellin structure that is recognized by the innate immune system. Flagellin is a major component of bacterial flagella and serves as a pathogen-associated molecular pattern (PAMP) that is detected by Toll-like receptor 5 (TLR5) in mammals. As a research peptide, Flagellin22 is primarily studied for its immunomodulatory properties and potential applications in vaccine development and immune system research. The peptide's ability to activate innate immune responses makes it of interest for understanding host-pathogen interactions and developing novel therapeutic approaches. Current research focuses on its role in immune activation, inflammatory responses, and potential applications in immunotherapy. While research is ongoing, Flagellin22 represents an important tool for studying bacterial recognition mechanisms and immune system function.
Key Benefits
Overview
Flagellin22 is a 22-amino acid peptide derived from bacterial flagellin, specifically representing a conserved region of the flagellin protein found in bacterial flagella. With the sequence QVQNTNASSSSFLAGAINSTAI, this peptide corresponds to a portion of the flagellin structure that is recognized by the innate immune system. Flagellin is a major component of bacterial flagella and serves as a pathogen-associated molecular pattern (PAMP) that is detected by Toll-like receptor 5 (TLR5) in mammals. As a research peptide, Flagellin22 is primarily studied for its immunomodulatory properties and potential applications in vaccine development and immune system research. The peptide's ability to activate innate immune responses makes it of interest for understanding host-pathogen interactions and developing novel therapeutic approaches. Current research focuses on its role in immune activation, inflammatory responses, and potential applications in immunotherapy. While research is ongoing, Flagellin22 represents an important tool for studying bacterial recognition mechanisms and immune system function.
Potential Benefits
Mechanism of Action
Flagellin22 functions as a pathogen-associated molecular pattern (PAMP) that is recognized by Toll-like receptor 5 (TLR5) on immune cells. Upon binding to TLR5, the peptide triggers a cascade of intracellular signaling pathways, including activation of MyD88-dependent pathways that lead to NF-κB activation. This results in the production of pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β. The peptide also stimulates the activation of dendritic cells and macrophages, promoting antigen presentation and adaptive immune responses. Through TLR5 signaling, Flagellin22 can enhance both innate and adaptive immunity, making it a potent immunostimulatory agent.
Risks & Safety
Legal Status
Gastric Inhibitory Peptide (GIP), also known as glucose-dependent insulinotropic polypeptide, is a 42-amino acid incretin hormone naturally produced by K-cells in the duodenum and jejunum of the small intestine. GIP plays a crucial role in glucose homeostasis and metabolic regulation by stimulating insulin secretion in a glucose-dependent manner, meaning it only promotes insulin release when blood glucose levels are elevated. This peptide also inhibits gastric acid secretion and gastric motility, hence its original name. GIP functions through binding to GIP receptors (GIPR), which are G-protein coupled receptors found primarily in pancreatic beta cells, but also in adipose tissue, bone, and brain. The hormone is released postprandially in response to nutrient intake, particularly glucose and fatty acids. In addition to its insulinotropic effects, GIP influences lipid metabolism, bone formation, and may have neuroprotective properties. Research has shown that GIP's actions are impaired in type 2 diabetes, leading to interest in GIP receptor agonists as potential therapeutic agents. The peptide's dual role in glucose regulation and metabolic control makes it an important target for understanding and treating metabolic disorders, obesity, and diabetes.
Key Benefits
Overview
Gastric Inhibitory Peptide (GIP), also known as glucose-dependent insulinotropic polypeptide, is a 42-amino acid incretin hormone naturally produced by K-cells in the duodenum and jejunum of the small intestine. GIP plays a crucial role in glucose homeostasis and metabolic regulation by stimulating insulin secretion in a glucose-dependent manner, meaning it only promotes insulin release when blood glucose levels are elevated. This peptide also inhibits gastric acid secretion and gastric motility, hence its original name. GIP functions through binding to GIP receptors (GIPR), which are G-protein coupled receptors found primarily in pancreatic beta cells, but also in adipose tissue, bone, and brain. The hormone is released postprandially in response to nutrient intake, particularly glucose and fatty acids. In addition to its insulinotropic effects, GIP influences lipid metabolism, bone formation, and may have neuroprotective properties. Research has shown that GIP's actions are impaired in type 2 diabetes, leading to interest in GIP receptor agonists as potential therapeutic agents. The peptide's dual role in glucose regulation and metabolic control makes it an important target for understanding and treating metabolic disorders, obesity, and diabetes.
Potential Benefits
Mechanism of Action
GIP exerts its biological effects by binding to the GIP receptor (GIPR), a G-protein coupled receptor that activates adenylyl cyclase, leading to increased intracellular cyclic adenosine monophosphate (cAMP) levels. In pancreatic beta cells, elevated cAMP activates protein kinase A (PKA), which phosphorylates and activates key enzymes involved in insulin synthesis and secretion. The glucose-dependent nature of GIP's insulinotropic action occurs because glucose metabolism in beta cells is required to depolarize the cell membrane and open voltage-dependent calcium channels, allowing GIP's cAMP-mediated effects to trigger insulin granule exocytosis. GIP also activates the exchange protein directly activated by cAMP (EPAC) pathway, which further enhances insulin secretion. In adipose tissue, GIP promotes lipogenesis and glucose uptake through similar cAMP-dependent mechanisms. The peptide inhibits gastric acid secretion by reducing histamine release from enterochromaffin-like cells and directly inhibiting parietal cell acid production. GIP's effects on bone metabolism involve promoting osteoblast activity and bone formation through GIPR activation in bone tissue.
Risks & Safety
Legal Status
GenScript-P001 is a synthetic peptide with the sequence WFHHGIGKRFQLKTCGIVNIEAHKHYQ, currently in Phase 1 minimal catalog extraction status. This 26-amino acid peptide appears to be a research compound developed by GenScript, a biotechnology company specializing in peptide synthesis and drug discovery. Based on its sequence composition, which includes histidine, glycine, lysine, and other bioactive amino acids, this peptide may have potential therapeutic applications. The presence of multiple charged residues and hydrophobic amino acids suggests it could interact with cellular membranes or specific protein targets. However, comprehensive research data regarding its specific biological functions, therapeutic targets, and clinical applications is currently limited. The peptide's designation as P001 indicates it may be part of a larger research portfolio or screening library. Further investigation through preclinical and clinical studies would be necessary to fully characterize its pharmacological properties, safety profile, and therapeutic potential. Current research status appears to be in early developmental stages with minimal published data available.
Key Benefits
Overview
GenScript-P001 is a synthetic peptide with the sequence WFHHGIGKRFQLKTCGIVNIEAHKHYQ, currently in Phase 1 minimal catalog extraction status. This 26-amino acid peptide appears to be a research compound developed by GenScript, a biotechnology company specializing in peptide synthesis and drug discovery. Based on its sequence composition, which includes histidine, glycine, lysine, and other bioactive amino acids, this peptide may have potential therapeutic applications. The presence of multiple charged residues and hydrophobic amino acids suggests it could interact with cellular membranes or specific protein targets. However, comprehensive research data regarding its specific biological functions, therapeutic targets, and clinical applications is currently limited. The peptide's designation as P001 indicates it may be part of a larger research portfolio or screening library. Further investigation through preclinical and clinical studies would be necessary to fully characterize its pharmacological properties, safety profile, and therapeutic potential. Current research status appears to be in early developmental stages with minimal published data available.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, GenScript-P001 likely exerts its biological effects through direct interaction with cellular receptors or membrane proteins. The presence of positively charged amino acids (lysine, arginine, histidine) suggests potential electrostatic interactions with negatively charged cell surface components. The hydrophobic residues may facilitate membrane penetration or protein-protein interactions. The specific sequence may target particular signaling pathways, though detailed mechanistic studies are needed to confirm the exact molecular targets and downstream effects.
Risks & Safety
Legal Status
GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide that functions as a potent growth hormone secretagogue, primarily acting through the growth hormone secretagogue receptor (GHSR). This peptide stimulates the release of growth hormone from the pituitary gland and activates orexigenic pathways in the hypothalamus. Research demonstrates GHRP-6's versatility across multiple therapeutic applications, including acute kidney injury treatment through metabolic reprogramming, body composition management in hypogonadal males, and neuroprotective effects. The peptide has shown particular promise in enhancing autophagy in skeletal muscle and protecting against drug-induced tissue damage. GHRP-6 works by engaging arcuate nucleus neurons involved in both food intake regulation and growth hormone release, making it valuable for metabolic disorders and regenerative medicine applications. Recent studies have explored novel delivery methods, including hydrogel formulations and intranasal administration, which have demonstrated enhanced bioavailability and targeted tissue effects. The peptide's ability to modulate cellular metabolism, particularly through mTOR-P70 pathway activation, positions it as a significant compound in regenerative medicine and metabolic health research.
Key Benefits
Overview
GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide that functions as a potent growth hormone secretagogue, primarily acting through the growth hormone secretagogue receptor (GHSR). This peptide stimulates the release of growth hormone from the pituitary gland and activates orexigenic pathways in the hypothalamus. Research demonstrates GHRP-6's versatility across multiple therapeutic applications, including acute kidney injury treatment through metabolic reprogramming, body composition management in hypogonadal males, and neuroprotective effects. The peptide has shown particular promise in enhancing autophagy in skeletal muscle and protecting against drug-induced tissue damage. GHRP-6 works by engaging arcuate nucleus neurons involved in both food intake regulation and growth hormone release, making it valuable for metabolic disorders and regenerative medicine applications. Recent studies have explored novel delivery methods, including hydrogel formulations and intranasal administration, which have demonstrated enhanced bioavailability and targeted tissue effects. The peptide's ability to modulate cellular metabolism, particularly through mTOR-P70 pathway activation, positions it as a significant compound in regenerative medicine and metabolic health research.
Potential Benefits
Mechanism of Action
GHRP-6 exerts its effects primarily through binding to the growth hormone secretagogue receptor (GHSR-1a), leading to stimulation of growth hormone release from the pituitary gland. The peptide activates orexigenic neuropeptide Y neurons that co-express agouti-related peptide (AgRP) in the arcuate nucleus of the hypothalamus. Research shows that GHRP-6 engages approximately 63.5% of GHSR mRNA-expressing neurons and 79% of AgRP mRNA-expressing neurons in the arcuate nucleus. The peptide promotes metabolic reprogramming in renal tubular epithelial cells by activating the mTOR-P70 pathway, enhancing cell survival in ischemic conditions. GHRP-6 also demonstrates pro-autophagic effects in skeletal muscle by increasing protein abundances of beclin-1 and LC3 II-to-LC3 I ratio. Additionally, some GHRP-6 analogs may interact with CXCR4 receptors, contributing to their cellular protective effects. The peptide influences metabolic pathways involving spermidine, L-glutamine, and acetyl-CoA, which are crucial for amino acid and fatty acid metabolism.
Risks & Safety
Legal Status
Glucagon (1-29), Human is the full-length, naturally occurring form of glucagon, a critical peptide hormone produced by alpha cells in the pancreatic islets. This 29-amino acid peptide plays a fundamental role in glucose homeostasis and metabolic regulation. Glucagon acts as a counter-regulatory hormone to insulin, primarily functioning to raise blood glucose levels during periods of fasting or hypoglycemia. The peptide is essential for maintaining glucose balance through its effects on hepatic glucose production, glycogenolysis, and gluconeogenesis. In clinical settings, synthetic glucagon is used as an emergency treatment for severe hypoglycemia, particularly in diabetic patients. Beyond its primary glucose-regulating functions, glucagon influences various metabolic processes including lipid metabolism, amino acid utilization, and energy expenditure. Research has explored its potential therapeutic applications in metabolic disorders, obesity management, and diabetes treatment. The peptide's mechanism involves binding to specific glucagon receptors, primarily in the liver, triggering cascades that mobilize glucose stores and stimulate glucose production. Current pharmaceutical developments include glucagon receptor agonists and combination therapies that leverage glucagon's metabolic effects for treating type 2 diabetes and obesity.
Key Benefits
Overview
Glucagon (1-29), Human is the full-length, naturally occurring form of glucagon, a critical peptide hormone produced by alpha cells in the pancreatic islets. This 29-amino acid peptide plays a fundamental role in glucose homeostasis and metabolic regulation. Glucagon acts as a counter-regulatory hormone to insulin, primarily functioning to raise blood glucose levels during periods of fasting or hypoglycemia. The peptide is essential for maintaining glucose balance through its effects on hepatic glucose production, glycogenolysis, and gluconeogenesis. In clinical settings, synthetic glucagon is used as an emergency treatment for severe hypoglycemia, particularly in diabetic patients. Beyond its primary glucose-regulating functions, glucagon influences various metabolic processes including lipid metabolism, amino acid utilization, and energy expenditure. Research has explored its potential therapeutic applications in metabolic disorders, obesity management, and diabetes treatment. The peptide's mechanism involves binding to specific glucagon receptors, primarily in the liver, triggering cascades that mobilize glucose stores and stimulate glucose production. Current pharmaceutical developments include glucagon receptor agonists and combination therapies that leverage glucagon's metabolic effects for treating type 2 diabetes and obesity.
Potential Benefits
Mechanism of Action
Glucagon exerts its biological effects primarily through binding to the glucagon receptor (GCGR), a G-protein coupled receptor predominantly expressed in hepatocytes. Upon receptor binding, glucagon activates adenylyl cyclase via Gs protein coupling, leading to increased intracellular cyclic adenosine monophosphate (cAMP) levels. This elevation in cAMP activates protein kinase A (PKA), which phosphorylates key enzymes involved in glucose metabolism. PKA phosphorylates and inactivates acetyl-CoA carboxylase and activates hormone-sensitive lipase, promoting lipolysis and fatty acid oxidation. Simultaneously, PKA phosphorylates phosphofructokinase-2, reducing glycolysis and promoting gluconeogenesis. The peptide stimulates hepatic glucose production through two primary pathways: glycogenolysis (breakdown of glycogen stores) and gluconeogenesis (synthesis of glucose from non-carbohydrate precursors). Glucagon also influences gene expression by activating CREB (cAMP response element-binding protein), which upregulates gluconeogenic enzymes including phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. Additionally, glucagon affects amino acid metabolism, promoting protein catabolism to provide substrates for gluconeogenesis, and influences ketogenesis during prolonged fasting states.
Risks & Safety
Legal Status
GNCP-1 is a 30-amino acid peptide with the sequence RRCICTTRTCRFPYRRLGTCIFQNRVYTFCC, characterized by multiple cysteine residues that likely form disulfide bonds contributing to its structural stability. Based on its sequence composition and structural features, GNCP-1 appears to be a research peptide that may have potential therapeutic applications. The peptide contains several positively charged residues (arginine and lysine) which could facilitate cellular uptake and membrane interactions. The presence of aromatic residues (phenylalanine and tyrosine) suggests potential for protein-protein interactions or receptor binding. Currently, GNCP-1 appears to be in early research phases with limited published data available. The peptide's compact structure, stabilized by potential disulfide bridges, may contribute to its biological activity and stability in physiological conditions. Further research is needed to fully elucidate its mechanism of action, therapeutic potential, and safety profile. The peptide's unique sequence suggests it may have been designed or discovered for specific biological targets, though comprehensive clinical data remains limited at this time.
Key Benefits
Overview
GNCP-1 is a 30-amino acid peptide with the sequence RRCICTTRTCRFPYRRLGTCIFQNRVYTFCC, characterized by multiple cysteine residues that likely form disulfide bonds contributing to its structural stability. Based on its sequence composition and structural features, GNCP-1 appears to be a research peptide that may have potential therapeutic applications. The peptide contains several positively charged residues (arginine and lysine) which could facilitate cellular uptake and membrane interactions. The presence of aromatic residues (phenylalanine and tyrosine) suggests potential for protein-protein interactions or receptor binding. Currently, GNCP-1 appears to be in early research phases with limited published data available. The peptide's compact structure, stabilized by potential disulfide bridges, may contribute to its biological activity and stability in physiological conditions. Further research is needed to fully elucidate its mechanism of action, therapeutic potential, and safety profile. The peptide's unique sequence suggests it may have been designed or discovered for specific biological targets, though comprehensive clinical data remains limited at this time.
Potential Benefits
Mechanism of Action
Based on the structural characteristics of GNCP-1, the peptide likely exerts its biological effects through specific receptor binding interactions facilitated by its cationic residues and aromatic amino acids. The multiple cysteine residues in the sequence suggest the formation of disulfide bonds that create a constrained, stable three-dimensional structure essential for target recognition. The positively charged arginine residues may enable electrostatic interactions with negatively charged cell surface receptors or facilitate cellular membrane penetration. The aromatic residues (phenylalanine and tyrosine) could participate in π-π stacking interactions or hydrophobic binding pockets of target proteins. The peptide's compact structure may allow it to modulate specific signaling pathways, potentially involving G-protein coupled receptors or other membrane-bound targets. The exact molecular targets and downstream signaling cascades remain to be fully characterized through additional research studies.
Risks & Safety
Legal Status
GNCP-2 is a synthetic peptide with the sequence RRCICTTRTCRFPYRRLGTCLFQNRVYTFCC, containing 30 amino acids with multiple cysteine residues that likely form disulfide bonds for structural stability. Based on its sequence characteristics and naming convention, GNCP-2 appears to be a research peptide that may have been designed for specific biological activities. The peptide contains several basic amino acids (arginine and lysine) which could facilitate cellular uptake or receptor binding. Currently, GNCP-2 appears to be in early research phases with minimal published data available in major scientific databases. The peptide's complex structure with multiple cysteine residues suggests it may have been engineered for stability and specific biological targeting. Without extensive published research, the full therapeutic potential and mechanisms of GNCP-2 remain to be elucidated through further investigation. The peptide represents part of the growing field of synthetic peptide therapeutics that are being developed for various medical applications.
Key Benefits
Overview
GNCP-2 is a synthetic peptide with the sequence RRCICTTRTCRFPYRRLGTCLFQNRVYTFCC, containing 30 amino acids with multiple cysteine residues that likely form disulfide bonds for structural stability. Based on its sequence characteristics and naming convention, GNCP-2 appears to be a research peptide that may have been designed for specific biological activities. The peptide contains several basic amino acids (arginine and lysine) which could facilitate cellular uptake or receptor binding. Currently, GNCP-2 appears to be in early research phases with minimal published data available in major scientific databases. The peptide's complex structure with multiple cysteine residues suggests it may have been engineered for stability and specific biological targeting. Without extensive published research, the full therapeutic potential and mechanisms of GNCP-2 remain to be elucidated through further investigation. The peptide represents part of the growing field of synthetic peptide therapeutics that are being developed for various medical applications.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, GNCP-2 likely functions through receptor-mediated mechanisms due to its complex structure containing multiple disulfide bonds formed by cysteine residues. The presence of basic amino acids such as arginine may facilitate cellular membrane interaction and uptake. The peptide's structure suggests it may interact with specific cell surface receptors or intracellular targets to modulate biological pathways. Without specific research data, the exact molecular mechanisms remain speculative, but the peptide's design indicates potential for targeted biological activity through protein-protein interactions or enzyme modulation.
Risks & Safety
Legal Status
HA Peptide (sequence: YPYDVPDYA) is a hemagglutinin-derived peptide that has emerged as a significant research tool in multiple biomedical applications. Originally identified from influenza hemagglutinin protein, this peptide serves as both an epitope tag for protein research and a functional component in therapeutic applications. Current research demonstrates its utility in vaccine development, particularly for influenza where HA peptide epitopes can activate antibody-dependent cellular cytotoxicity (ADCC) responses. The peptide has shown promise in immunological studies, including HLA-peptide complex formation and T-cell receptor recognition. Additionally, HA peptides are being incorporated into advanced biomaterial systems, such as hyaluronan-peptide hydrogels for tissue engineering applications. These hydrogels exhibit tunable viscoelastic properties and demonstrate cytocompatibility, supporting cell encapsulation and promoting dermal fibroblast spreading. The peptide's role extends to antiviral research, where it serves as a model system for studying viral envelope protein interactions. Current research status indicates active investigation across immunology, biomaterials, and therapeutic development, with particular focus on its potential as a universal vaccine component and tissue engineering scaffold.
Key Benefits
Overview
HA Peptide (sequence: YPYDVPDYA) is a hemagglutinin-derived peptide that has emerged as a significant research tool in multiple biomedical applications. Originally identified from influenza hemagglutinin protein, this peptide serves as both an epitope tag for protein research and a functional component in therapeutic applications. Current research demonstrates its utility in vaccine development, particularly for influenza where HA peptide epitopes can activate antibody-dependent cellular cytotoxicity (ADCC) responses. The peptide has shown promise in immunological studies, including HLA-peptide complex formation and T-cell receptor recognition. Additionally, HA peptides are being incorporated into advanced biomaterial systems, such as hyaluronan-peptide hydrogels for tissue engineering applications. These hydrogels exhibit tunable viscoelastic properties and demonstrate cytocompatibility, supporting cell encapsulation and promoting dermal fibroblast spreading. The peptide's role extends to antiviral research, where it serves as a model system for studying viral envelope protein interactions. Current research status indicates active investigation across immunology, biomaterials, and therapeutic development, with particular focus on its potential as a universal vaccine component and tissue engineering scaffold.
Potential Benefits
Mechanism of Action
HA Peptide functions through multiple molecular mechanisms depending on its application context. In immunological applications, the peptide binds to HLA class II molecules, specifically HLA-DRB1*01:01, where it occupies the peptide binding groove and can be presented to T-cell receptors for immune recognition. The peptide demonstrates stable binding interactions with MHC molecules, facilitating antigen presentation pathways. In vaccine applications, HA peptide epitopes activate antibody-dependent cellular cytotoxicity (ADCC) by serving as targets for cross-reactive antibodies that can recognize conserved regions across different influenza strains. When incorporated into biomaterial systems, HA peptides form supramolecular assemblies through hydrogen bonding between peptide chains, creating β-sheet secondary structures that contribute to hydrogel mechanical properties. The peptide's interaction with hyaluronan creates physically cross-linked networks with tunable viscoelasticity. In antiviral research contexts, HA peptides can bind to lectins like Cyanovirin-N through glycosylation-dependent interactions, with dimannosylated forms showing multivalent binding capabilities. The peptide's conformation and binding properties can be modulated by chemical modifications, allowing for targeted therapeutic applications and controlled release systems.
Risks & Safety
Legal Status
Hadrurin is an antimicrobial peptide derived from scorpion venom, specifically from Heterometrus xanthopus. With the sequence GILDTIKSIASKVWNSKTVQDLKRKGINWVANKLGVSPQAA, this peptide belongs to a class of bioactive compounds found in scorpion venoms alongside other antimicrobial peptides like scorpine and pandinins. Research has demonstrated hadrurin's effectiveness against multidrug-resistant bacterial pathogens, making it a promising candidate for addressing antibiotic resistance challenges. The peptide has shown particular efficacy against both Gram-positive and Gram-negative bacteria, including Bacillus subtilis, Salmonella typhimurium, Pseudomonas aeruginosa, and Enterococcus faecalis. Current research focuses on its antimicrobial properties and potential applications in biosensor development. Hadrurin has been incorporated into fluorescent biosensor systems for rapid bacterial detection, though with mixed results regarding specificity and sensitivity. The peptide represents part of the growing interest in natural antimicrobial compounds as alternatives to conventional antibiotics, particularly given the increasing prevalence of drug-resistant bacterial infections.
Key Benefits
Overview
Hadrurin is an antimicrobial peptide derived from scorpion venom, specifically from Heterometrus xanthopus. With the sequence GILDTIKSIASKVWNSKTVQDLKRKGINWVANKLGVSPQAA, this peptide belongs to a class of bioactive compounds found in scorpion venoms alongside other antimicrobial peptides like scorpine and pandinins. Research has demonstrated hadrurin's effectiveness against multidrug-resistant bacterial pathogens, making it a promising candidate for addressing antibiotic resistance challenges. The peptide has shown particular efficacy against both Gram-positive and Gram-negative bacteria, including Bacillus subtilis, Salmonella typhimurium, Pseudomonas aeruginosa, and Enterococcus faecalis. Current research focuses on its antimicrobial properties and potential applications in biosensor development. Hadrurin has been incorporated into fluorescent biosensor systems for rapid bacterial detection, though with mixed results regarding specificity and sensitivity. The peptide represents part of the growing interest in natural antimicrobial compounds as alternatives to conventional antibiotics, particularly given the increasing prevalence of drug-resistant bacterial infections.
Potential Benefits
Mechanism of Action
Hadrurin functions as an antimicrobial peptide through direct interaction with bacterial cell membranes and cellular components. Like other scorpion venom-derived antimicrobial peptides, hadrurin likely disrupts bacterial membrane integrity through electrostatic interactions between its positively charged residues and negatively charged bacterial membrane components. The peptide's amphipathic structure allows it to insert into bacterial membranes, causing membrane permeabilization and subsequent cell death. Research indicates that hadrurin demonstrates differential activity against various bacterial species, suggesting specific molecular interactions that may involve binding to particular membrane receptors or components. When incorporated into biosensor applications, hadrurin can be engineered as fusion proteins with fluorescent markers, where the peptide domain provides bacterial binding specificity while maintaining its antimicrobial properties. The peptide's mechanism appears to be concentration-dependent, as demonstrated by varying effectiveness at different dilution levels in experimental studies.
Risks & Safety
Legal Status
Hexa-His (HHHHHH) is a hexahistidine peptide tag consisting of six consecutive histidine residues. This peptide is primarily utilized as a purification and detection tool in protein research and biotechnology applications rather than as a therapeutic agent. The research literature demonstrates its widespread use in protein expression systems, particularly for purifying recombinant proteins through immobilized metal affinity chromatography (IMAC). Studies show successful application of hexa-His tags in purifying various proteins including NAMPT (nicotinamide phosphoribosyltransferase), transferrin receptor constructs, starch-binding domains, and prion protein fragments. The tag facilitates protein isolation by binding to metal ions like nickel or cobalt in chromatography columns. While not a therapeutic peptide itself, hexa-His tags are essential tools in producing research-grade proteins for drug development and biological studies. The peptide's utility extends to oligonucleotide purification and functionalization processes, demonstrating versatility in molecular biology applications. Current research status focuses on optimizing purification protocols and developing reversible chemistry approaches for tag removal after purification.
Key Benefits
Overview
Hexa-His (HHHHHH) is a hexahistidine peptide tag consisting of six consecutive histidine residues. This peptide is primarily utilized as a purification and detection tool in protein research and biotechnology applications rather than as a therapeutic agent. The research literature demonstrates its widespread use in protein expression systems, particularly for purifying recombinant proteins through immobilized metal affinity chromatography (IMAC). Studies show successful application of hexa-His tags in purifying various proteins including NAMPT (nicotinamide phosphoribosyltransferase), transferrin receptor constructs, starch-binding domains, and prion protein fragments. The tag facilitates protein isolation by binding to metal ions like nickel or cobalt in chromatography columns. While not a therapeutic peptide itself, hexa-His tags are essential tools in producing research-grade proteins for drug development and biological studies. The peptide's utility extends to oligonucleotide purification and functionalization processes, demonstrating versatility in molecular biology applications. Current research status focuses on optimizing purification protocols and developing reversible chemistry approaches for tag removal after purification.
Potential Benefits
Mechanism of Action
Hexa-His functions through coordination chemistry, where the imidazole rings of the six histidine residues coordinate with divalent metal ions such as nickel, cobalt, or zinc. This metal-histidine interaction forms the basis for immobilized metal affinity chromatography (IMAC) purification. The histidine residues act as electron donors, forming coordinate covalent bonds with metal ions immobilized on chromatography resins. The binding is reversible and can be disrupted by pH changes or imidazole competition, allowing for controlled elution of tagged proteins. In protein expression systems, the hexa-His tag is typically fused to the N-terminal or C-terminal end of target proteins, enabling selective purification from complex cellular lysates. The tag can be removed post-purification using specific proteases like Ulp1 when incorporated into SUMO fusion systems. The mechanism relies on the unique chemical properties of histidine's imidazole side chain, which has a pKa around 6.0, making it positively charged at physiological pH and capable of metal coordination.
Risks & Safety
Legal Status
J9PZR2 is a research peptide with a complex 200+ amino acid sequence that appears to be in early-stage investigation. Based on its structural characteristics and sequence analysis, this peptide contains multiple functional domains that suggest potential biological activity. The peptide sequence includes regions that may interact with cellular receptors and signaling pathways, though specific mechanisms remain under investigation. Current research status indicates this is primarily a research chemical without established clinical applications. The peptide's long sequence suggests it may function as a multi-domain protein or enzyme with diverse biological functions. Limited published research is available on this specific peptide, indicating it is likely in preliminary research phases. The complex structure suggests potential applications in cellular signaling, protein interactions, or enzymatic processes, though specific therapeutic targets have not been definitively established. Further research is needed to fully characterize its biological activity, safety profile, and potential therapeutic applications.
Key Benefits
Overview
J9PZR2 is a research peptide with a complex 200+ amino acid sequence that appears to be in early-stage investigation. Based on its structural characteristics and sequence analysis, this peptide contains multiple functional domains that suggest potential biological activity. The peptide sequence includes regions that may interact with cellular receptors and signaling pathways, though specific mechanisms remain under investigation. Current research status indicates this is primarily a research chemical without established clinical applications. The peptide's long sequence suggests it may function as a multi-domain protein or enzyme with diverse biological functions. Limited published research is available on this specific peptide, indicating it is likely in preliminary research phases. The complex structure suggests potential applications in cellular signaling, protein interactions, or enzymatic processes, though specific therapeutic targets have not been definitively established. Further research is needed to fully characterize its biological activity, safety profile, and potential therapeutic applications.
Potential Benefits
Mechanism of Action
The mechanism of action for J9PZR2 is not well-established due to limited research data. Based on sequence analysis, the peptide appears to contain multiple functional domains that may interact with cellular receptors or participate in protein-protein interactions. The peptide's structure suggests it may function through binding to specific cellular targets, potentially modulating signaling pathways or enzymatic processes. The presence of various amino acid motifs within the sequence indicates possible involvement in cellular recognition, binding, or catalytic activities. Without specific receptor binding studies or pathway analysis, the exact molecular mechanisms remain speculative and require further investigation to determine precise biological targets and downstream effects.
Risks & Safety
Legal Status
Lebocin 1/2 is an antimicrobial peptide with the sequence DLRFLYPRGKLPVPTPPPFNPKPIYIDMGNRY. This peptide belongs to a class of naturally occurring defense molecules that exhibit broad-spectrum antimicrobial activity. Lebocin peptides are characterized by their ability to target various pathogenic microorganisms including bacteria, fungi, and potentially viruses. The peptide's structure contains multiple proline residues and charged amino acids that contribute to its antimicrobial properties. Current research on Lebocin 1/2 is in early phases, with studies focusing on understanding its mechanism of action, spectrum of activity, and potential therapeutic applications. The peptide shows promise as a natural antimicrobial agent that could be developed for treating infections, particularly those caused by antibiotic-resistant organisms. Its unique amino acid composition suggests it may have additional biological activities beyond antimicrobial effects, including potential immune-modulating properties. Further research is needed to fully characterize its therapeutic potential, optimal dosing, and safety profile for human applications.
Key Benefits
Overview
Lebocin 1/2 is an antimicrobial peptide with the sequence DLRFLYPRGKLPVPTPPPFNPKPIYIDMGNRY. This peptide belongs to a class of naturally occurring defense molecules that exhibit broad-spectrum antimicrobial activity. Lebocin peptides are characterized by their ability to target various pathogenic microorganisms including bacteria, fungi, and potentially viruses. The peptide's structure contains multiple proline residues and charged amino acids that contribute to its antimicrobial properties. Current research on Lebocin 1/2 is in early phases, with studies focusing on understanding its mechanism of action, spectrum of activity, and potential therapeutic applications. The peptide shows promise as a natural antimicrobial agent that could be developed for treating infections, particularly those caused by antibiotic-resistant organisms. Its unique amino acid composition suggests it may have additional biological activities beyond antimicrobial effects, including potential immune-modulating properties. Further research is needed to fully characterize its therapeutic potential, optimal dosing, and safety profile for human applications.
Potential Benefits
Mechanism of Action
Lebocin 1/2 exerts its antimicrobial effects through multiple mechanisms typical of antimicrobial peptides. The peptide likely disrupts microbial cell membranes through electrostatic interactions between its positively charged residues and negatively charged components of bacterial cell walls. The peptide's amphipathic structure allows it to insert into lipid bilayers, causing membrane permeabilization and cell death. Additionally, Lebocin 1/2 may penetrate cells and interact with intracellular targets such as DNA, RNA, or essential enzymes, further contributing to its antimicrobial activity. The proline-rich regions in its sequence may facilitate specific protein-protein interactions with microbial targets. The peptide may also modulate host immune responses by activating immune cells and enhancing the body's natural defense mechanisms against pathogens.
Risks & Safety
Legal Status
Lebocin 3 is an antimicrobial peptide with the sequence DLRFLYPRGKLPVPTLPPFNPKPIYIDMGNRY. As a member of the lebocin family, it represents a class of naturally occurring defense peptides that exhibit broad-spectrum antimicrobial activity. These peptides are typically found in insects and other organisms as part of their innate immune defense systems. Lebocin 3 demonstrates potential therapeutic applications due to its ability to combat various pathogens while potentially offering additional biological activities. The peptide's unique amino acid sequence suggests it may interact with microbial membranes and cellular targets to exert its antimicrobial effects. Current research status indicates this peptide is primarily in experimental phases, with studies focusing on understanding its antimicrobial spectrum, mechanism of action, and potential therapeutic applications. The peptide's structure and properties make it a candidate for development as an alternative antimicrobial agent, particularly in an era of increasing antibiotic resistance. Further research is needed to fully characterize its safety profile, efficacy, and optimal therapeutic applications in clinical settings.
Key Benefits
Overview
Lebocin 3 is an antimicrobial peptide with the sequence DLRFLYPRGKLPVPTLPPFNPKPIYIDMGNRY. As a member of the lebocin family, it represents a class of naturally occurring defense peptides that exhibit broad-spectrum antimicrobial activity. These peptides are typically found in insects and other organisms as part of their innate immune defense systems. Lebocin 3 demonstrates potential therapeutic applications due to its ability to combat various pathogens while potentially offering additional biological activities. The peptide's unique amino acid sequence suggests it may interact with microbial membranes and cellular targets to exert its antimicrobial effects. Current research status indicates this peptide is primarily in experimental phases, with studies focusing on understanding its antimicrobial spectrum, mechanism of action, and potential therapeutic applications. The peptide's structure and properties make it a candidate for development as an alternative antimicrobial agent, particularly in an era of increasing antibiotic resistance. Further research is needed to fully characterize its safety profile, efficacy, and optimal therapeutic applications in clinical settings.
Potential Benefits
Mechanism of Action
Lebocin 3 likely functions through multiple antimicrobial mechanisms typical of cationic antimicrobial peptides. The peptide's positively charged regions interact with negatively charged bacterial cell membranes, leading to membrane disruption and permeabilization. This interaction can result in pore formation, membrane depolarization, and ultimately bacterial cell death. The peptide may also penetrate bacterial cells and interact with intracellular targets such as DNA, RNA, or essential enzymes, disrupting vital cellular processes. Additionally, Lebocin 3 may modulate host immune responses by activating immune cells and promoting the release of inflammatory mediators. The peptide's structure allows it to adopt specific conformations that enhance its binding affinity to microbial targets while potentially minimizing interactions with host cell membranes. The antimicrobial activity may also involve interference with bacterial protein synthesis, cell wall synthesis, or metabolic pathways essential for bacterial survival and replication.
Risks & Safety
Legal Status
Mastoparan M is an antimicrobial peptide derived from wasp venoms, characterized by its unique amphipathic short linear alpha-helical structure. With the sequence INLKAIAALAKKLL, this peptide belongs to the mastoparan family of compounds found in wasp venoms, which have captured significant research attention due to their diverse biological effects. Mastoparan M exhibits notable antibiotic properties and demonstrates a range of other biological activities related to its ability to interact with biological membranes. The peptide's amphipathic nature allows it to effectively disrupt microbial cell membranes while maintaining selectivity. Current research focuses on understanding the structure-function relationships of this peptide and its potential development as an innovative treatment against infections. As part of the broader mastoparan family, Mastoparan M represents a promising natural compound for antimicrobial applications, with ongoing studies investigating its therapeutic potential and mechanisms of action against various pathogens.
Key Benefits
Overview
Mastoparan M is an antimicrobial peptide derived from wasp venoms, characterized by its unique amphipathic short linear alpha-helical structure. With the sequence INLKAIAALAKKLL, this peptide belongs to the mastoparan family of compounds found in wasp venoms, which have captured significant research attention due to their diverse biological effects. Mastoparan M exhibits notable antibiotic properties and demonstrates a range of other biological activities related to its ability to interact with biological membranes. The peptide's amphipathic nature allows it to effectively disrupt microbial cell membranes while maintaining selectivity. Current research focuses on understanding the structure-function relationships of this peptide and its potential development as an innovative treatment against infections. As part of the broader mastoparan family, Mastoparan M represents a promising natural compound for antimicrobial applications, with ongoing studies investigating its therapeutic potential and mechanisms of action against various pathogens.
Potential Benefits
Mechanism of Action
Mastoparan M functions through its amphipathic alpha-helical structure, which enables it to interact with biological membranes at varying degrees. The peptide's mechanism involves membrane disruption, where the amphipathic nature allows it to insert into lipid bilayers of microbial cells. The alpha-helical conformation facilitates membrane permeabilization, leading to cell death in target microorganisms. The peptide's ability to selectively interact with bacterial membranes while showing reduced toxicity to mammalian cells is attributed to differences in membrane composition and charge distribution. The antimicrobial activity is primarily achieved through direct membrane disruption rather than specific receptor binding, making it effective against a broad spectrum of microorganisms and reducing the likelihood of resistance development.
Risks & Safety
Legal Status
Matrixyl is a cosmeceutical peptide amphiphile containing the collagen-stimulating pentapeptide KTTKS (lysine-threonine-threonine-lysine-serine) conjugated to a lipid chain, commonly C16. This bioactive compound is widely used in anti-aging skincare formulations for its ability to stimulate collagen production and promote skin repair. Research demonstrates that Matrixyl works through self-assembly into nanotape structures at critical aggregation concentrations, which correlates with its biological activity. The peptide has shown significant efficacy in wound healing applications, particularly in diabetic models, where it promotes tissue regeneration, neovascularization, and collagen deposition. Studies indicate that Matrixyl enhances the revival of hair follicles and blood vessels in the dermis, which are critical markers of effective wound repair. The compound exhibits excellent biocompatibility with dermal fibroblasts and has been used as a positive control in photoaging research. Current research focuses on optimizing its delivery through various lipopeptide formulations, including cycloalkane-based variants that show enhanced wound healing properties. Matrixyl represents a well-established cosmeceutical ingredient with substantial research backing its collagen-stimulating and tissue repair capabilities.
Key Benefits
Overview
Matrixyl is a cosmeceutical peptide amphiphile containing the collagen-stimulating pentapeptide KTTKS (lysine-threonine-threonine-lysine-serine) conjugated to a lipid chain, commonly C16. This bioactive compound is widely used in anti-aging skincare formulations for its ability to stimulate collagen production and promote skin repair. Research demonstrates that Matrixyl works through self-assembly into nanotape structures at critical aggregation concentrations, which correlates with its biological activity. The peptide has shown significant efficacy in wound healing applications, particularly in diabetic models, where it promotes tissue regeneration, neovascularization, and collagen deposition. Studies indicate that Matrixyl enhances the revival of hair follicles and blood vessels in the dermis, which are critical markers of effective wound repair. The compound exhibits excellent biocompatibility with dermal fibroblasts and has been used as a positive control in photoaging research. Current research focuses on optimizing its delivery through various lipopeptide formulations, including cycloalkane-based variants that show enhanced wound healing properties. Matrixyl represents a well-established cosmeceutical ingredient with substantial research backing its collagen-stimulating and tissue repair capabilities.
Potential Benefits
Mechanism of Action
Matrixyl functions through self-assembly of its peptide amphiphile structure into nanotape formations at critical aggregation concentrations, which directly correlates with its biological activity. The KTTKS pentapeptide sequence specifically stimulates collagen production in human dermal and corneal fibroblasts in a concentration-dependent manner. The mechanism involves the peptide's ability to signal fibroblasts to increase collagen synthesis, leading to enhanced tissue repair and regeneration. The lipid conjugation (typically C16) facilitates cellular uptake and membrane interaction, while the peptide component provides the bioactive signal. Research shows that the self-assembly process is crucial for biological activity, as the aggregated structures appear to be more effective at stimulating cellular responses than individual molecules. The compound promotes neovascularization through enhanced expression of vascular markers including α-SMA (vascular smooth muscle cells) and CD31 (vascular endothelial cells). Additionally, Matrixyl influences the extracellular matrix by promoting dense collagen network formation and supporting epidermal regeneration, making it effective for both cosmetic anti-aging applications and therapeutic wound healing.
Risks & Safety
Legal Status
Matrixyl 3000 is a cosmetic peptide complex primarily used in anti-aging skincare formulations. It is designed to stimulate collagen production and support skin matrix repair mechanisms. As consumers increasingly seek effective anti-aging solutions, Matrixyl 3000 has gained attention for its potential to address visible signs of aging through topical application. The peptide works by targeting cellular processes involved in skin regeneration and extracellular matrix synthesis. While research data is limited in the provided sources, Matrixyl 3000 is marketed as a cosmetic ingredient rather than a pharmaceutical compound. Its primary appeal lies in its purported ability to enhance skin appearance and texture through stimulation of natural repair processes. The peptide represents part of the growing trend toward peptide-based cosmetic ingredients that aim to provide anti-aging benefits through targeted biological mechanisms. Current understanding of its mechanisms and benefits continues to evolve as more research becomes available in the cosmetic and dermatological fields.
Key Benefits
Overview
Matrixyl 3000 is a cosmetic peptide complex primarily used in anti-aging skincare formulations. It is designed to stimulate collagen production and support skin matrix repair mechanisms. As consumers increasingly seek effective anti-aging solutions, Matrixyl 3000 has gained attention for its potential to address visible signs of aging through topical application. The peptide works by targeting cellular processes involved in skin regeneration and extracellular matrix synthesis. While research data is limited in the provided sources, Matrixyl 3000 is marketed as a cosmetic ingredient rather than a pharmaceutical compound. Its primary appeal lies in its purported ability to enhance skin appearance and texture through stimulation of natural repair processes. The peptide represents part of the growing trend toward peptide-based cosmetic ingredients that aim to provide anti-aging benefits through targeted biological mechanisms. Current understanding of its mechanisms and benefits continues to evolve as more research becomes available in the cosmetic and dermatological fields.
Potential Benefits
Mechanism of Action
Based on available information, Matrixyl 3000 appears to work by stimulating cellular processes involved in extracellular matrix synthesis and skin repair. The peptide likely targets fibroblast cells in the dermis, promoting the production of collagen, elastin, and other structural proteins that comprise the skin matrix. Through signaling pathways that activate cellular regeneration processes, the peptide may enhance the skin's natural ability to repair and maintain its structural integrity. The mechanism likely involves interaction with cellular receptors that trigger cascades leading to increased protein synthesis and tissue remodeling. However, specific molecular pathways and receptor interactions require further research documentation to provide a complete mechanistic understanding.
Risks & Safety
Legal Status
Matrixyl 3000+ is an advanced cosmetic peptide complex designed for anti-aging applications, particularly in skincare formulations. This peptide represents an evolution in cosmetic science, targeting the fundamental mechanisms of skin aging at the cellular level. As consumers increasingly seek effective anti-aging solutions, Matrixyl 3000+ has emerged as a significant ingredient in the cosmetic industry. The peptide works by stimulating collagen production and supporting the skin's natural repair processes. While specific sequence information is not readily available, this peptide complex is formulated to enhance skin appearance and reduce visible signs of aging. The compound is primarily used in topical applications and represents current research efforts in developing effective anti-aging interventions. Its mechanisms focus on supporting the extracellular matrix and promoting cellular regeneration processes that naturally decline with age. The peptide has gained attention in both research and commercial applications for its potential to address multiple aspects of skin aging, making it a valuable component in modern anti-aging formulations.
Key Benefits
Overview
Matrixyl 3000+ is an advanced cosmetic peptide complex designed for anti-aging applications, particularly in skincare formulations. This peptide represents an evolution in cosmetic science, targeting the fundamental mechanisms of skin aging at the cellular level. As consumers increasingly seek effective anti-aging solutions, Matrixyl 3000+ has emerged as a significant ingredient in the cosmetic industry. The peptide works by stimulating collagen production and supporting the skin's natural repair processes. While specific sequence information is not readily available, this peptide complex is formulated to enhance skin appearance and reduce visible signs of aging. The compound is primarily used in topical applications and represents current research efforts in developing effective anti-aging interventions. Its mechanisms focus on supporting the extracellular matrix and promoting cellular regeneration processes that naturally decline with age. The peptide has gained attention in both research and commercial applications for its potential to address multiple aspects of skin aging, making it a valuable component in modern anti-aging formulations.
Potential Benefits
Mechanism of Action
Matrixyl 3000+ operates through stimulation of extracellular matrix synthesis, particularly targeting collagen production pathways. The peptide complex works by signaling fibroblasts to increase their metabolic activity and enhance the production of structural proteins essential for skin integrity. It likely interacts with cellular receptors involved in tissue repair and regeneration processes, triggering cascades that promote matrix protein synthesis. The mechanism involves activation of specific signaling pathways that regulate collagen, elastin, and other matrix components. By mimicking natural cellular signals, the peptide helps restore the balance between matrix synthesis and degradation that becomes disrupted with aging. The compound may also influence cellular communication processes that coordinate tissue repair and maintenance, supporting the skin's natural ability to maintain structural integrity and appearance.
Risks & Safety
Legal Status
Matrixyl synthe'6 is a synthetic peptide complex primarily used in cosmetic and anti-aging applications. This peptide is designed to stimulate collagen production and support skin matrix regeneration, making it a popular ingredient in skincare formulations targeting signs of aging. As consumers increasingly seek effective anti-aging solutions, Matrixyl synthe'6 has gained attention for its potential to improve skin texture, reduce wrinkles, and enhance overall skin appearance. The peptide works by mimicking natural biological processes involved in skin repair and regeneration. While research data is limited in the provided sources, the peptide appears to focus on dermatological applications rather than systemic therapeutic uses. Its development represents part of the growing field of cosmeceuticals, where peptide technology is applied to skincare products. The 'synthe'6' designation suggests this is part of a series of synthetic Matrixyl peptides, each potentially targeting different aspects of skin aging and repair. Current understanding of its mechanisms centers around its ability to influence cellular processes related to extracellular matrix formation and maintenance, though more comprehensive research would be needed to fully characterize its biological activities and therapeutic potential.
Key Benefits
Overview
Matrixyl synthe'6 is a synthetic peptide complex primarily used in cosmetic and anti-aging applications. This peptide is designed to stimulate collagen production and support skin matrix regeneration, making it a popular ingredient in skincare formulations targeting signs of aging. As consumers increasingly seek effective anti-aging solutions, Matrixyl synthe'6 has gained attention for its potential to improve skin texture, reduce wrinkles, and enhance overall skin appearance. The peptide works by mimicking natural biological processes involved in skin repair and regeneration. While research data is limited in the provided sources, the peptide appears to focus on dermatological applications rather than systemic therapeutic uses. Its development represents part of the growing field of cosmeceuticals, where peptide technology is applied to skincare products. The 'synthe'6' designation suggests this is part of a series of synthetic Matrixyl peptides, each potentially targeting different aspects of skin aging and repair. Current understanding of its mechanisms centers around its ability to influence cellular processes related to extracellular matrix formation and maintenance, though more comprehensive research would be needed to fully characterize its biological activities and therapeutic potential.
Potential Benefits
Mechanism of Action
Based on the limited available data, Matrixyl synthe'6 appears to function through stimulation of extracellular matrix components, particularly collagen synthesis. The peptide likely works by binding to specific cellular receptors that trigger intracellular signaling cascades involved in tissue repair and regeneration. This may involve activation of fibroblasts, the primary cells responsible for collagen production in the skin. The mechanism probably includes upregulation of genes encoding for collagen types I and III, as well as other structural proteins like elastin and fibronectin. The peptide may also influence the activity of matrix metalloproteinases (MMPs), enzymes that break down collagen, potentially reducing their activity to preserve existing collagen structures. Additionally, it may stimulate the production of glycosaminoglycans, which help maintain skin hydration and structure. The synthetic nature of the peptide allows for enhanced stability and bioavailability compared to natural peptides, potentially improving its effectiveness in topical applications.
Risks & Safety
Legal Status
mBD-1 (mouse beta-defensin-1) is a cationic antimicrobial peptide belonging to the beta-defensin family, with the sequence DQYKCLQHGGFCLRSSCPSNTKLQGTCKPDKPNCCKS. Beta-defensins are naturally occurring peptides that serve as key components of innate immunity, defending epithelial surfaces throughout the body including the urinary tract, respiratory system, and other mucosal barriers. mBD-1 is constitutively expressed in various tissues and plays a role in host defense against pathogens, particularly viruses and bacteria. Research has shown that mBD-1 is expressed in bladder and ureter tissues, with protein localization in the urothelium. Unlike other beta-defensins that are upregulated during infection, mBD-1 maintains relatively stable expression levels even during inflammatory responses. Studies using mBD-1 knockout mice have revealed its protective role against viral infections, particularly influenza, where deficient mice showed increased mortality and enhanced inflammatory responses. While mBD-1 may not directly inhibit viral replication, it appears to modulate immune responses and protect against pathogenesis through alternative mechanisms. Current research focuses on understanding its role in innate immunity, viral defense, and tissue protection.
Key Benefits
Overview
mBD-1 (mouse beta-defensin-1) is a cationic antimicrobial peptide belonging to the beta-defensin family, with the sequence DQYKCLQHGGFCLRSSCPSNTKLQGTCKPDKPNCCKS. Beta-defensins are naturally occurring peptides that serve as key components of innate immunity, defending epithelial surfaces throughout the body including the urinary tract, respiratory system, and other mucosal barriers. mBD-1 is constitutively expressed in various tissues and plays a role in host defense against pathogens, particularly viruses and bacteria. Research has shown that mBD-1 is expressed in bladder and ureter tissues, with protein localization in the urothelium. Unlike other beta-defensins that are upregulated during infection, mBD-1 maintains relatively stable expression levels even during inflammatory responses. Studies using mBD-1 knockout mice have revealed its protective role against viral infections, particularly influenza, where deficient mice showed increased mortality and enhanced inflammatory responses. While mBD-1 may not directly inhibit viral replication, it appears to modulate immune responses and protect against pathogenesis through alternative mechanisms. Current research focuses on understanding its role in innate immunity, viral defense, and tissue protection.
Potential Benefits
Mechanism of Action
mBD-1 functions as a cationic antimicrobial peptide that interacts with microbial membranes through electrostatic interactions. Its positive charge allows it to bind to negatively charged bacterial and viral components, potentially disrupting membrane integrity. In immune cells such as plasmacytoid dendritic cells and monocytes, mBD-1 expression increases in response to viral challenge, suggesting a role in early innate immune responses. The peptide appears to bridge innate and adaptive immunity by modulating immune cell function rather than directly killing pathogens. During viral infections, mBD-1 may prevent viral replication in immune cells while allowing controlled infection in epithelial cells. The mechanism involves differential expression patterns where immune cells upregulate mBD-1 production while epithelial cells may downregulate expression during infection. This selective modulation suggests mBD-1 acts as an immune regulatory molecule that helps maintain tissue homeostasis during pathogen challenge. The peptide's protective effects against influenza pathogenesis occur through mechanisms independent of direct viral inhibition, likely involving modulation of inflammatory responses and immune cell recruitment.
Risks & Safety
Legal Status
MCF (GLPALISWIKRKRQQ) is a 15-amino acid peptide sequence that appears to be studied in the context of biomedical research. Based on the available research data, MCF is primarily referenced in relation to malignant catarrhal fever virus studies and cancer cell line research, particularly involving MCF-7 breast cancer cells. The peptide contains basic amino acids (lysine and arginine) which may contribute to cell membrane interactions and potential therapeutic applications. Current research suggests involvement in cellular processes related to disease mechanisms and drug resistance pathways. The peptide's structure includes hydrophobic and charged residues that could facilitate cellular uptake and biological activity. Research is still in early phases, with limited clinical data available. The peptide shows potential for various therapeutic applications based on its amino acid composition and preliminary research findings, though more comprehensive studies are needed to fully characterize its biological effects and therapeutic potential.
Key Benefits
Overview
MCF (GLPALISWIKRKRQQ) is a 15-amino acid peptide sequence that appears to be studied in the context of biomedical research. Based on the available research data, MCF is primarily referenced in relation to malignant catarrhal fever virus studies and cancer cell line research, particularly involving MCF-7 breast cancer cells. The peptide contains basic amino acids (lysine and arginine) which may contribute to cell membrane interactions and potential therapeutic applications. Current research suggests involvement in cellular processes related to disease mechanisms and drug resistance pathways. The peptide's structure includes hydrophobic and charged residues that could facilitate cellular uptake and biological activity. Research is still in early phases, with limited clinical data available. The peptide shows potential for various therapeutic applications based on its amino acid composition and preliminary research findings, though more comprehensive studies are needed to fully characterize its biological effects and therapeutic potential.
Potential Benefits
Mechanism of Action
The MCF peptide's mechanism of action appears to involve cellular membrane interactions facilitated by its cationic amino acid residues (lysine and arginine). These positively charged residues likely enable the peptide to interact with negatively charged cell membranes, potentially facilitating cellular uptake. The peptide may influence cellular signaling pathways related to drug resistance mechanisms, as suggested by research involving MCF-7 cell lines. The presence of hydrophobic amino acids (leucine, proline, alanine, isoleucine, tryptophan) suggests potential for membrane integration and intracellular targeting. The peptide may modulate microtubule dynamics and cellular transport mechanisms, as indicated by studies showing effects on drug efflux systems and cellular resistance pathways. Additionally, the peptide structure suggests potential interactions with protein targets involved in cellular proliferation and survival pathways.
Risks & Safety
Legal Status
MDYKDHDGDYKDHDIDYKDDDDK peptide is a synthetic peptide sequence containing multiple FLAG epitope tags (DYKDDDDK) commonly used in molecular biology research. This peptide appears to be designed as a research tool rather than a therapeutic compound, incorporating repeated FLAG tag sequences that are widely utilized for protein purification, detection, and localization studies. The sequence contains multiple tyrosine, aspartic acid, and lysine residues arranged in a specific pattern that facilitates binding to anti-FLAG antibodies. While not primarily developed as a therapeutic peptide, such FLAG-tagged constructs are essential tools in biomedical research for studying protein function, cellular localization, and protein-protein interactions. The peptide's structure suggests it may be used in research applications involving protein expression systems, immunoprecipitation studies, or as a fusion tag for recombinant proteins. Current research status appears to be limited to laboratory applications rather than clinical development, as this type of peptide is typically employed as a research reagent rather than a direct therapeutic intervention.
Key Benefits
Overview
MDYKDHDGDYKDHDIDYKDDDDK peptide is a synthetic peptide sequence containing multiple FLAG epitope tags (DYKDDDDK) commonly used in molecular biology research. This peptide appears to be designed as a research tool rather than a therapeutic compound, incorporating repeated FLAG tag sequences that are widely utilized for protein purification, detection, and localization studies. The sequence contains multiple tyrosine, aspartic acid, and lysine residues arranged in a specific pattern that facilitates binding to anti-FLAG antibodies. While not primarily developed as a therapeutic peptide, such FLAG-tagged constructs are essential tools in biomedical research for studying protein function, cellular localization, and protein-protein interactions. The peptide's structure suggests it may be used in research applications involving protein expression systems, immunoprecipitation studies, or as a fusion tag for recombinant proteins. Current research status appears to be limited to laboratory applications rather than clinical development, as this type of peptide is typically employed as a research reagent rather than a direct therapeutic intervention.
Potential Benefits
Mechanism of Action
The MDYKDHDGDYKDHDIDYKDDDDK peptide functions primarily through its FLAG epitope sequences, which serve as recognition sites for specific anti-FLAG antibodies. The mechanism involves high-affinity binding between the DYKDDDDK sequences and anti-FLAG antibody binding sites, enabling specific detection and purification of tagged proteins. The multiple FLAG tags within the sequence may provide enhanced binding avidity and improved detection sensitivity compared to single FLAG tags. In research applications, this peptide would facilitate protein isolation through immunoaffinity chromatography, enable protein localization studies through immunofluorescence, and support protein quantification through immunoblotting techniques. The peptide's mechanism relies on the specific amino acid sequence recognition rather than traditional receptor-mediated signaling pathways, as it functions primarily as a molecular tag rather than a bioactive signaling molecule.
Risks & Safety
Legal Status
Mj-AMP1 is an antimicrobial peptide with the sequence QCIGNGGRCNENVGPPYCCSGFCLRQPGQGYGYCKNR. Based on its designation as an AMP (Antimicrobial Peptide), this compound belongs to a class of naturally occurring or synthetic molecules that exhibit broad-spectrum antimicrobial activity against bacteria, fungi, and potentially other pathogens. The peptide contains multiple cysteine residues, suggesting the presence of disulfide bonds that likely contribute to its structural stability and biological activity. Antimicrobial peptides like Mj-AMP1 are of significant research interest due to their potential therapeutic applications in treating infections, particularly in an era of increasing antibiotic resistance. These peptides typically work by disrupting microbial cell membranes or interfering with essential cellular processes. While specific research data for Mj-AMP1 is currently limited, antimicrobial peptides in general have shown promise in wound healing applications, immune system modulation, and as alternatives to conventional antibiotics. The research status appears to be in early phases, with ongoing investigations into its antimicrobial spectrum, mechanism of action, and potential therapeutic applications.
Key Benefits
Overview
Mj-AMP1 is an antimicrobial peptide with the sequence QCIGNGGRCNENVGPPYCCSGFCLRQPGQGYGYCKNR. Based on its designation as an AMP (Antimicrobial Peptide), this compound belongs to a class of naturally occurring or synthetic molecules that exhibit broad-spectrum antimicrobial activity against bacteria, fungi, and potentially other pathogens. The peptide contains multiple cysteine residues, suggesting the presence of disulfide bonds that likely contribute to its structural stability and biological activity. Antimicrobial peptides like Mj-AMP1 are of significant research interest due to their potential therapeutic applications in treating infections, particularly in an era of increasing antibiotic resistance. These peptides typically work by disrupting microbial cell membranes or interfering with essential cellular processes. While specific research data for Mj-AMP1 is currently limited, antimicrobial peptides in general have shown promise in wound healing applications, immune system modulation, and as alternatives to conventional antibiotics. The research status appears to be in early phases, with ongoing investigations into its antimicrobial spectrum, mechanism of action, and potential therapeutic applications.
Potential Benefits
Mechanism of Action
Based on its classification as an antimicrobial peptide, Mj-AMP1 likely exerts its effects through membrane disruption mechanisms common to this peptide class. The peptide probably interacts with negatively charged components of microbial cell membranes, such as lipopolysaccharides in bacterial outer membranes. The multiple cysteine residues in its sequence suggest formation of disulfide bonds that create a stable, compact structure capable of membrane insertion. The mechanism likely involves initial electrostatic attraction to the microbial surface, followed by membrane insertion and pore formation, leading to cell lysis. Additionally, some antimicrobial peptides can penetrate cells and interfere with DNA replication, protein synthesis, or enzymatic processes. The peptide may also modulate host immune responses by interacting with immune cells and promoting antimicrobial defense mechanisms.
Risks & Safety
Legal Status
Mj-AMP2 is an antimicrobial peptide with the sequence CIGNGGRCNENVGPPYCCSGFCLRQPNQGYGVCRNR. Based on its classification as an AMP (antimicrobial peptide) and structural characteristics, this peptide likely belongs to a family of naturally occurring defense molecules that provide protection against microbial pathogens. The peptide contains multiple cysteine residues, suggesting the presence of disulfide bonds that contribute to its structural stability and biological activity. Antimicrobial peptides like Mj-AMP2 are typically part of the innate immune system and serve as the first line of defense against bacterial, fungal, and viral infections. These peptides are of significant research interest due to their potential therapeutic applications in treating antibiotic-resistant infections and supporting immune function. The current research status appears to be in early phases, with limited published data available. However, the peptide's structure and classification suggest it may have broad-spectrum antimicrobial properties and potential applications in immune modulation and infection control.
Key Benefits
Overview
Mj-AMP2 is an antimicrobial peptide with the sequence CIGNGGRCNENVGPPYCCSGFCLRQPNQGYGVCRNR. Based on its classification as an AMP (antimicrobial peptide) and structural characteristics, this peptide likely belongs to a family of naturally occurring defense molecules that provide protection against microbial pathogens. The peptide contains multiple cysteine residues, suggesting the presence of disulfide bonds that contribute to its structural stability and biological activity. Antimicrobial peptides like Mj-AMP2 are typically part of the innate immune system and serve as the first line of defense against bacterial, fungal, and viral infections. These peptides are of significant research interest due to their potential therapeutic applications in treating antibiotic-resistant infections and supporting immune function. The current research status appears to be in early phases, with limited published data available. However, the peptide's structure and classification suggest it may have broad-spectrum antimicrobial properties and potential applications in immune modulation and infection control.
Potential Benefits
Mechanism of Action
Based on its classification as an antimicrobial peptide, Mj-AMP2 likely exerts its effects through direct interaction with microbial cell membranes. The peptide's cationic nature and amphipathic structure would allow it to bind to negatively charged bacterial cell walls and membranes, leading to membrane disruption and cell death. The multiple cysteine residues in the sequence suggest formation of disulfide bridges that stabilize the peptide's three-dimensional structure, enhancing its antimicrobial activity. The mechanism may involve pore formation in bacterial membranes, disruption of membrane potential, or interference with essential cellular processes. Additionally, antimicrobial peptides often modulate immune responses by activating immune cells and promoting the release of cytokines and chemokines.
Risks & Safety
Legal Status
Neuropeptide Y (NPY) is a 36-amino acid peptide belonging to the pancreatic polypeptide family and represents one of the most abundant neuropeptides in the central nervous system. It functions as both a neurohormone and neuromodulator, with widespread distribution throughout the brain, particularly in the hypothalamus, amygdala, locus coeruleus, and cerebral cortex. NPY plays crucial roles in regulating food intake, circadian rhythms, stress response, sleep-wake cycles, and bone metabolism. Recent research has revealed its involvement in a brain-gut-bone axis, where it influences bone formation, gut microbiota composition, and metabolic processes. The peptide acts through at least six receptor subtypes, with Y1 and Y2 receptors being particularly well-studied. Current research focuses on its therapeutic potential for conditions including osteoporosis, osteoarthritis, PTSD, chronic pain, and sleep disorders. NPY demonstrates complex, context-dependent effects that can be both beneficial and detrimental depending on the physiological state and location of action.
Key Benefits
Overview
Neuropeptide Y (NPY) is a 36-amino acid peptide belonging to the pancreatic polypeptide family and represents one of the most abundant neuropeptides in the central nervous system. It functions as both a neurohormone and neuromodulator, with widespread distribution throughout the brain, particularly in the hypothalamus, amygdala, locus coeruleus, and cerebral cortex. NPY plays crucial roles in regulating food intake, circadian rhythms, stress response, sleep-wake cycles, and bone metabolism. Recent research has revealed its involvement in a brain-gut-bone axis, where it influences bone formation, gut microbiota composition, and metabolic processes. The peptide acts through at least six receptor subtypes, with Y1 and Y2 receptors being particularly well-studied. Current research focuses on its therapeutic potential for conditions including osteoporosis, osteoarthritis, PTSD, chronic pain, and sleep disorders. NPY demonstrates complex, context-dependent effects that can be both beneficial and detrimental depending on the physiological state and location of action.
Potential Benefits
Mechanism of Action
NPY exerts its effects through binding to specific G-protein coupled receptors (Y1-Y6), with Y1 and Y2 receptors being most prominent. In bone metabolism, NPY activates Y1 receptors on osteocytes, leading to increased bone marrow adipogenesis and decreased osteogenesis through modulation of mesenchymal stem cell differentiation. The peptide operates within a brain-gut-bone axis, where hypothalamic NPY influences gut microbiota composition, intestinal permeability, and systemic inflammation via lipopolysaccharide release. In the nervous system, NPY acts as a neuromodulator in pain pathways, where Y2 receptors on sensory neuron terminals normally inhibit neurotransmitter release. Under hypoxic conditions in cancer cells, NPY activates the Y5 receptor/RhoA pathway, leading to cytokinesis failure and chromosomal instability. The peptide also modulates sleep regulation by acting as a physiological antagonist to corticotropin-releasing hormone and influences stress resilience through complex interactions with the hypothalamic-pituitary-adrenal axis.
Risks & Safety
Legal Status
Nisin is a small, highly modified pentacyclic peptide classified as a Type A lantibiotic, naturally produced by Lactococcus lactis and other Gram-positive bacteria. Discovered nearly a century ago in fermented milk cultures, nisin has served as the paradigm for understanding lantibiotic biosynthesis and post-translational modifications in prokaryotes. Originally developed and widely used as a food preservative, nisin has gained significant attention in biomedical applications due to its potent antimicrobial properties against both Gram-positive and Gram-negative pathogens, including drug-resistant strains like MRSA, Streptococcus pneumoniae, and Clostridium difficile. The peptide undergoes extensive post-translational modifications that create unusual amino acids, contributing to its unique antimicrobial activity. Recent research has expanded nisin's potential beyond food preservation to include therapeutic applications such as cancer treatment, where it exhibits selective cytotoxicity toward cancer cells, immune modulation, and anti-biofilm properties. FDA-approved and generally regarded as safe, nisin represents a promising alternative to conventional antibiotics in the era of increasing antibiotic resistance, with ongoing research exploring bioengineered variants and novel therapeutic applications.
Key Benefits
Overview
Nisin is a small, highly modified pentacyclic peptide classified as a Type A lantibiotic, naturally produced by Lactococcus lactis and other Gram-positive bacteria. Discovered nearly a century ago in fermented milk cultures, nisin has served as the paradigm for understanding lantibiotic biosynthesis and post-translational modifications in prokaryotes. Originally developed and widely used as a food preservative, nisin has gained significant attention in biomedical applications due to its potent antimicrobial properties against both Gram-positive and Gram-negative pathogens, including drug-resistant strains like MRSA, Streptococcus pneumoniae, and Clostridium difficile. The peptide undergoes extensive post-translational modifications that create unusual amino acids, contributing to its unique antimicrobial activity. Recent research has expanded nisin's potential beyond food preservation to include therapeutic applications such as cancer treatment, where it exhibits selective cytotoxicity toward cancer cells, immune modulation, and anti-biofilm properties. FDA-approved and generally regarded as safe, nisin represents a promising alternative to conventional antibiotics in the era of increasing antibiotic resistance, with ongoing research exploring bioengineered variants and novel therapeutic applications.
Potential Benefits
Mechanism of Action
Nisin functions as a lantibiotic through multiple mechanisms involving its unique pentacyclic structure and post-translationally modified amino acids. The peptide targets bacterial cell membranes, causing membrane disruption and cell death in susceptible microorganisms. Its antimicrobial activity is enhanced under acidic conditions (pH 4.0) and involves binding to specific bacterial membrane components. Nisin works synergistically with conventional therapeutic drugs, enhancing their effectiveness. Beyond direct antimicrobial action, nisin exhibits anti-biofilm properties by disrupting established bacterial biofilms, which are often resistant to traditional antibiotics. The peptide also demonstrates immunomodulatory effects, potentially activating adaptive immune responses similar to host-defense peptides. In cancer applications, nisin shows selective cytotoxicity toward malignant cells while sparing normal cells, though the exact mechanism remains under investigation. Recent studies suggest nisin may have affinity for the same receptor used by SARS-CoV-2 to enter human cells, proposing a potential viral blocking mechanism. The peptide's effectiveness is influenced by environmental factors including pH, temperature, and incubation time, with optimal activity observed at lower pH and temperatures.
Risks & Safety
Legal Status
Neuropeptide Y (NPY) is a 36-amino acid peptide from the pancreatic polypeptide family and one of the most abundant neuropeptides in the central nervous system. It functions as both a neurohormone and neuromodulator, widely distributed throughout the brain, particularly in the hypothalamus, amygdala, locus coeruleus, and cerebral cortex. NPY plays crucial roles in regulating feeding behavior, energy homeostasis, stress response, cardiovascular function, and emotional states. The peptide exerts its effects through multiple receptor subtypes (Y1, Y2, Y4, Y5), with Y1 receptors generally mediating anxiolytic effects while Y2 receptors can be anxiogenic. Research demonstrates NPY's involvement in metabolic regulation, including glucose homeostasis and insulin secretion, as well as its neuroprotective properties in stress-related disorders and neurodegenerative diseases. NPY shows promise as an endogenous anticonvulsant and has been investigated for gene therapy applications in epilepsy. The peptide also influences sleep regulation, memory formation, and cardiovascular health, with sympathetic-derived NPY being essential for autonomic physiological functions.
Key Benefits
Overview
Neuropeptide Y (NPY) is a 36-amino acid peptide from the pancreatic polypeptide family and one of the most abundant neuropeptides in the central nervous system. It functions as both a neurohormone and neuromodulator, widely distributed throughout the brain, particularly in the hypothalamus, amygdala, locus coeruleus, and cerebral cortex. NPY plays crucial roles in regulating feeding behavior, energy homeostasis, stress response, cardiovascular function, and emotional states. The peptide exerts its effects through multiple receptor subtypes (Y1, Y2, Y4, Y5), with Y1 receptors generally mediating anxiolytic effects while Y2 receptors can be anxiogenic. Research demonstrates NPY's involvement in metabolic regulation, including glucose homeostasis and insulin secretion, as well as its neuroprotective properties in stress-related disorders and neurodegenerative diseases. NPY shows promise as an endogenous anticonvulsant and has been investigated for gene therapy applications in epilepsy. The peptide also influences sleep regulation, memory formation, and cardiovascular health, with sympathetic-derived NPY being essential for autonomic physiological functions.
Potential Benefits
Mechanism of Action
NPY functions through binding to specific G-protein coupled receptors (Y1, Y2, Y4, Y5) that activate distinct signaling pathways in different tissues. In the hypothalamus, NPY modulates feeding behavior by interacting with POMC neurons and altering leptin responsiveness, particularly through Y2 receptors that become elevated during positive energy balance. NPY inhibits p38/NF-κB-mediated M1 macrophage activation while promoting reparative M2 phenotype, contributing to anti-inflammatory effects. In the sympathetic nervous system, NPY is co-expressed with norepinephrine in 90% of prevertebral sympathetic neurons, modulating cardiovascular and metabolic functions. The peptide influences neuronal excitability and acts as a neuromodulator affecting cellular proliferation, neurogenesis, and synaptic transmission. NPY's anxiolytic effects are mediated primarily through Y1 receptors in the amygdala and prefrontal cortex, while its effects on memory involve Y2 receptor-mediated regulation of hippocampal excitatory transmission. The peptide also modulates mesolimbic dopaminergic release in the nucleus accumbens, affecting reward pathways and addiction behaviors.
Risks & Safety
Legal Status
O15946 is a synthetic peptide with the sequence DLRFWNPREKLPLPTLPPFNPKPIYIDMGNRY, currently in Phase 1 minimal catalog extraction status. This 31-amino acid peptide appears to be a research compound with limited publicly available data regarding its specific biological functions and therapeutic applications. The peptide's sequence suggests it may have bioactive properties, though comprehensive studies detailing its mechanism of action and clinical efficacy remain limited. As with many research peptides, O15946 is likely being investigated for potential therapeutic applications, but its exact targets and pathways require further elucidation. The peptide's current research status indicates it is in early-stage investigation, with minimal characterization data available in public databases. Further research is needed to establish its safety profile, optimal dosing, and potential clinical applications. Given the limited available data, any potential benefits or risks associated with O15946 remain largely theoretical and require validation through controlled studies.
Key Benefits
Overview
O15946 is a synthetic peptide with the sequence DLRFWNPREKLPLPTLPPFNPKPIYIDMGNRY, currently in Phase 1 minimal catalog extraction status. This 31-amino acid peptide appears to be a research compound with limited publicly available data regarding its specific biological functions and therapeutic applications. The peptide's sequence suggests it may have bioactive properties, though comprehensive studies detailing its mechanism of action and clinical efficacy remain limited. As with many research peptides, O15946 is likely being investigated for potential therapeutic applications, but its exact targets and pathways require further elucidation. The peptide's current research status indicates it is in early-stage investigation, with minimal characterization data available in public databases. Further research is needed to establish its safety profile, optimal dosing, and potential clinical applications. Given the limited available data, any potential benefits or risks associated with O15946 remain largely theoretical and require validation through controlled studies.
Potential Benefits
Mechanism of Action
The specific mechanism of action for O15946 remains largely uncharacterized due to limited available research data. Based on its peptide structure and sequence composition, it may interact with specific cellular receptors or signaling pathways, though the exact molecular targets have not been definitively identified. The peptide's 31-amino acid sequence suggests it could potentially modulate protein-protein interactions or serve as a bioactive signaling molecule. Without comprehensive binding studies or functional assays, the precise biological pathways affected by O15946 cannot be determined. Further research is required to elucidate its receptor binding affinity, downstream signaling cascades, and cellular effects.
Risks & Safety
Legal Status
O18495 is a synthetic peptide with the sequence GWLRKAAKSVGKFYYKHKYYIKAAWQIGKHAL, consisting of 32 amino acids. This peptide appears to be in early research phases with limited published data available. Based on its amino acid composition, which includes multiple lysine and tyrosine residues along with aromatic amino acids, O18495 may possess antimicrobial and cell-penetrating properties. The peptide contains several positively charged residues that could facilitate membrane interaction and cellular uptake. The presence of tryptophan and phenylalanine residues suggests potential for protein-protein interactions and membrane binding capabilities. Currently, this peptide appears to be primarily used as a research tool rather than a therapeutic agent. The specific biological targets and mechanisms of action remain largely undefined in the available literature. Further research is needed to fully characterize its pharmacological properties, safety profile, and potential therapeutic applications. The peptide's structure suggests it may have applications in antimicrobial research, drug delivery systems, or as a research probe for studying cellular processes.
Key Benefits
Overview
O18495 is a synthetic peptide with the sequence GWLRKAAKSVGKFYYKHKYYIKAAWQIGKHAL, consisting of 32 amino acids. This peptide appears to be in early research phases with limited published data available. Based on its amino acid composition, which includes multiple lysine and tyrosine residues along with aromatic amino acids, O18495 may possess antimicrobial and cell-penetrating properties. The peptide contains several positively charged residues that could facilitate membrane interaction and cellular uptake. The presence of tryptophan and phenylalanine residues suggests potential for protein-protein interactions and membrane binding capabilities. Currently, this peptide appears to be primarily used as a research tool rather than a therapeutic agent. The specific biological targets and mechanisms of action remain largely undefined in the available literature. Further research is needed to fully characterize its pharmacological properties, safety profile, and potential therapeutic applications. The peptide's structure suggests it may have applications in antimicrobial research, drug delivery systems, or as a research probe for studying cellular processes.
Potential Benefits
Mechanism of Action
The mechanism of action for O18495 is not well-established in current literature. Based on its amino acid sequence, the peptide likely functions through electrostatic interactions with negatively charged cell membranes due to its multiple positively charged lysine residues. The presence of aromatic amino acids including tryptophan, tyrosine, and phenylalanine suggests the peptide may interact with membrane lipids and potentially penetrate cellular barriers. The peptide's cationic nature may enable it to bind to bacterial cell walls or mammalian cell membranes, potentially disrupting membrane integrity or facilitating cellular uptake of other molecules. The specific receptor targets, signaling pathways, and downstream biological effects remain to be fully characterized through additional research studies.
Risks & Safety
Legal Status
OVA Peptide (257-264), with the sequence SIINFEKL, is a well-characterized immunogenic peptide derived from chicken ovalbumin. This octapeptide represents amino acids 257-264 of the ovalbumin protein and serves as a classical model antigen in immunological research. It is particularly significant as a major histocompatibility complex (MHC) class I-restricted epitope that binds to H-2Kb molecules in C57BL/6 mice. The peptide has been extensively used in vaccine development research, cancer immunotherapy studies, and T-cell activation experiments. SIINFEKL is recognized by CD8+ T cells and has become a gold standard for studying antigen presentation, immune responses, and T-cell priming mechanisms. Its well-defined immunogenic properties make it valuable for investigating adaptive immunity, developing immunotherapeutic approaches, and understanding how the immune system recognizes and responds to foreign antigens. The peptide's consistent and predictable immune activation patterns have made it an essential tool in both basic immunology research and translational studies aimed at developing new therapeutic interventions.
Key Benefits
Overview
OVA Peptide (257-264), with the sequence SIINFEKL, is a well-characterized immunogenic peptide derived from chicken ovalbumin. This octapeptide represents amino acids 257-264 of the ovalbumin protein and serves as a classical model antigen in immunological research. It is particularly significant as a major histocompatibility complex (MHC) class I-restricted epitope that binds to H-2Kb molecules in C57BL/6 mice. The peptide has been extensively used in vaccine development research, cancer immunotherapy studies, and T-cell activation experiments. SIINFEKL is recognized by CD8+ T cells and has become a gold standard for studying antigen presentation, immune responses, and T-cell priming mechanisms. Its well-defined immunogenic properties make it valuable for investigating adaptive immunity, developing immunotherapeutic approaches, and understanding how the immune system recognizes and responds to foreign antigens. The peptide's consistent and predictable immune activation patterns have made it an essential tool in both basic immunology research and translational studies aimed at developing new therapeutic interventions.
Potential Benefits
Mechanism of Action
OVA Peptide (257-264) functions through MHC class I antigen presentation pathways. The peptide binds to H-2Kb molecules on antigen-presenting cells, forming stable peptide-MHC complexes that are presented on the cell surface. These complexes are recognized by specific T-cell receptors on CD8+ T lymphocytes, triggering T-cell activation and proliferation. The binding involves specific anchor residues within the SIINFEKL sequence that fit into the peptide-binding groove of the MHC molecule. Upon recognition, activated CD8+ T cells undergo clonal expansion and differentiate into cytotoxic T lymphocytes capable of eliminating cells presenting the same peptide. This process involves multiple signaling cascades including TCR signaling, costimulatory molecule engagement, and cytokine production. The peptide also stimulates memory T-cell formation, providing long-lasting immune protection and recall responses upon re-exposure.
Risks & Safety
Legal Status
Palustrin-1c is an antimicrobial peptide with the sequence ALSILRGLEKLAKMGIALTNCKATKKC, belonging to a family of bioactive peptides originally isolated from amphibian skin secretions. These peptides are part of the innate immune defense system and have evolved as natural antimicrobial agents. Palustrin-1c exhibits broad-spectrum antimicrobial activity against various pathogens including bacteria, fungi, and potentially viruses. The peptide contains characteristic structural features common to antimicrobial peptides, including cationic residues and amphipathic properties that enable membrane disruption in target microorganisms. Current research focuses on understanding its therapeutic potential as an alternative to conventional antibiotics, particularly in the context of increasing antimicrobial resistance. The peptide's natural origin and unique mechanism of action make it an attractive candidate for pharmaceutical development. However, research on Palustrin-1c remains in early stages, with most studies focusing on basic characterization of its antimicrobial properties and structure-activity relationships. Further investigation is needed to fully elucidate its clinical potential and safety profile.
Key Benefits
Overview
Palustrin-1c is an antimicrobial peptide with the sequence ALSILRGLEKLAKMGIALTNCKATKKC, belonging to a family of bioactive peptides originally isolated from amphibian skin secretions. These peptides are part of the innate immune defense system and have evolved as natural antimicrobial agents. Palustrin-1c exhibits broad-spectrum antimicrobial activity against various pathogens including bacteria, fungi, and potentially viruses. The peptide contains characteristic structural features common to antimicrobial peptides, including cationic residues and amphipathic properties that enable membrane disruption in target microorganisms. Current research focuses on understanding its therapeutic potential as an alternative to conventional antibiotics, particularly in the context of increasing antimicrobial resistance. The peptide's natural origin and unique mechanism of action make it an attractive candidate for pharmaceutical development. However, research on Palustrin-1c remains in early stages, with most studies focusing on basic characterization of its antimicrobial properties and structure-activity relationships. Further investigation is needed to fully elucidate its clinical potential and safety profile.
Potential Benefits
Mechanism of Action
Palustrin-1c functions primarily through membrane disruption mechanisms typical of antimicrobial peptides. The peptide's cationic nature allows it to interact with negatively charged bacterial cell membranes through electrostatic attraction. Upon contact, the amphipathic structure enables insertion into the lipid bilayer, leading to membrane permeabilization and subsequent cell death. The peptide may form pores or cause membrane thinning, disrupting cellular integrity and essential metabolic processes. Additionally, Palustrin-1c may have intracellular targets, potentially interfering with DNA synthesis, protein folding, or enzymatic functions once it penetrates the cell membrane. The selective toxicity toward microbial cells over mammalian cells is attributed to differences in membrane composition and charge distribution. The peptide's mechanism may also involve immune system modulation, potentially enhancing host defense responses while directly eliminating pathogens.
Risks & Safety
Legal Status
Palustrin-1d is an antimicrobial peptide derived from amphibian skin secretions, specifically from the frog species Phyllomedusa palustris. With the amino acid sequence ALSILKGLEKLAKMGIALTNCKATKKC, this peptide belongs to the family of host defense peptides that serve as part of the innate immune system in amphibians. Palustrin-1d exhibits broad-spectrum antimicrobial activity against various pathogens including bacteria, fungi, and potentially viruses. Like other antimicrobial peptides from amphibian sources, it likely functions by disrupting microbial cell membranes through electrostatic interactions and membrane permeabilization. The peptide's cationic nature and amphipathic structure are characteristic features that contribute to its antimicrobial properties. Research into amphibian-derived antimicrobial peptides has gained significant interest due to their potential therapeutic applications in treating antibiotic-resistant infections and as templates for developing new antimicrobial agents. However, specific clinical research data for Palustrin-1d remains limited, and most studies focus on its basic antimicrobial characterization and structure-activity relationships. The peptide represents part of the broader research into natural antimicrobial compounds that could address the growing challenge of antimicrobial resistance in clinical settings.
Key Benefits
Overview
Palustrin-1d is an antimicrobial peptide derived from amphibian skin secretions, specifically from the frog species Phyllomedusa palustris. With the amino acid sequence ALSILKGLEKLAKMGIALTNCKATKKC, this peptide belongs to the family of host defense peptides that serve as part of the innate immune system in amphibians. Palustrin-1d exhibits broad-spectrum antimicrobial activity against various pathogens including bacteria, fungi, and potentially viruses. Like other antimicrobial peptides from amphibian sources, it likely functions by disrupting microbial cell membranes through electrostatic interactions and membrane permeabilization. The peptide's cationic nature and amphipathic structure are characteristic features that contribute to its antimicrobial properties. Research into amphibian-derived antimicrobial peptides has gained significant interest due to their potential therapeutic applications in treating antibiotic-resistant infections and as templates for developing new antimicrobial agents. However, specific clinical research data for Palustrin-1d remains limited, and most studies focus on its basic antimicrobial characterization and structure-activity relationships. The peptide represents part of the broader research into natural antimicrobial compounds that could address the growing challenge of antimicrobial resistance in clinical settings.
Potential Benefits
Mechanism of Action
Palustrin-1d functions as an antimicrobial peptide through membrane-disrupting mechanisms typical of cationic host defense peptides. The peptide's positively charged residues interact electrostatically with negatively charged components of microbial cell membranes, including lipopolysaccharides in bacterial outer membranes and phospholipids in cytoplasmic membranes. Upon binding, the amphipathic structure of Palustrin-1d allows it to insert into the lipid bilayer, causing membrane destabilization and permeabilization. This leads to loss of membrane integrity, leakage of cellular contents, and ultimately microbial cell death. The peptide may also have intracellular targets, potentially interfering with DNA synthesis, protein synthesis, or enzymatic processes once it gains entry into the cell. The selectivity for microbial cells over mammalian cells is attributed to differences in membrane composition and transmembrane potential. Additionally, like other antimicrobial peptides, Palustrin-1d may exhibit immunomodulatory effects, potentially enhancing host immune responses while directly combating pathogens.
Risks & Safety
Legal Status
Parathyroid Hormone (PTH) (1-34), Human is a synthetic peptide fragment representing the biologically active N-terminal portion of human parathyroid hormone. This 34-amino acid peptide retains the full biological activity of the complete 84-amino acid PTH molecule and is the primary regulator of calcium and phosphate homeostasis in the human body. PTH (1-34) acts primarily on bone and kidney tissues to maintain serum calcium levels within narrow physiological ranges. The peptide has been extensively studied for its anabolic effects on bone tissue, particularly its ability to stimulate osteoblast activity and promote bone formation when administered intermittently. This unique property distinguishes it from continuous PTH exposure, which typically results in bone resorption. The synthetic version, known pharmaceutically as teriparatide, has been developed as a therapeutic agent for treating severe osteoporosis and other bone-related disorders. Current research focuses on its potential applications in bone healing, fracture repair, and regenerative medicine. The peptide's mechanism involves binding to PTH receptors, activating cyclic adenosine monophosphate (cAMP) signaling pathways, and modulating calcium-regulating hormones. Its clinical significance lies in being one of the few anabolic bone agents available for treating osteoporosis, offering an alternative to anti-resorptive therapies.
Key Benefits
Overview
Parathyroid Hormone (PTH) (1-34), Human is a synthetic peptide fragment representing the biologically active N-terminal portion of human parathyroid hormone. This 34-amino acid peptide retains the full biological activity of the complete 84-amino acid PTH molecule and is the primary regulator of calcium and phosphate homeostasis in the human body. PTH (1-34) acts primarily on bone and kidney tissues to maintain serum calcium levels within narrow physiological ranges. The peptide has been extensively studied for its anabolic effects on bone tissue, particularly its ability to stimulate osteoblast activity and promote bone formation when administered intermittently. This unique property distinguishes it from continuous PTH exposure, which typically results in bone resorption. The synthetic version, known pharmaceutically as teriparatide, has been developed as a therapeutic agent for treating severe osteoporosis and other bone-related disorders. Current research focuses on its potential applications in bone healing, fracture repair, and regenerative medicine. The peptide's mechanism involves binding to PTH receptors, activating cyclic adenosine monophosphate (cAMP) signaling pathways, and modulating calcium-regulating hormones. Its clinical significance lies in being one of the few anabolic bone agents available for treating osteoporosis, offering an alternative to anti-resorptive therapies.
Potential Benefits
Mechanism of Action
PTH (1-34) exerts its biological effects by binding to the parathyroid hormone receptor (PTHR1), a G-protein coupled receptor expressed primarily in bone and kidney tissues. Upon receptor binding, the peptide activates adenylyl cyclase, leading to increased intracellular cyclic adenosine monophosphate (cAMP) levels and subsequent activation of protein kinase A (PKA). This signaling cascade triggers multiple downstream pathways including phosphorylation of cAMP response element-binding protein (CREB) and activation of various transcription factors. In bone tissue, intermittent PTH (1-34) exposure preferentially stimulates osteoblast proliferation, differentiation, and survival while reducing osteoblast apoptosis. The peptide upregulates expression of bone matrix proteins including osteocalcin, type I collagen, and alkaline phosphatase. In kidneys, PTH (1-34) enhances calcium reabsorption in the distal tubules and stimulates 1α-hydroxylase activity, increasing production of active vitamin D (calcitriol). The peptide also modulates phosphate handling by reducing renal phosphate reabsorption. The anabolic versus catabolic effects of PTH depend critically on the pattern of exposure - intermittent administration promotes bone formation, while continuous exposure leads to bone resorption through enhanced osteoclast activity.
Risks & Safety
Legal Status
Penaeidin-2 is an antimicrobial peptide naturally derived from the Pacific white shrimp (Penaeus vannamei) that exhibits broad-spectrum biological activities. Originally identified for its potent antibacterial and antifungal properties, this peptide has emerged as a promising therapeutic agent with significant anticancer potential. The 49-amino acid peptide contains cysteine residues that form disulfide bonds, contributing to its structural stability and biological activity. Recent research has demonstrated that recombinant penaeidin-2 shows selective cytotoxicity against kidney cancer cells while exhibiting minimal toxicity to normal cells. The peptide functions as part of the innate immune system in shrimp, providing protection against various pathogens. Studies have shown that penaeidin-2 expression can be upregulated in response to immune challenges and stress conditions. Its mechanism involves direct interaction with cell membranes, leading to membrane disruption and subsequent cell death in target organisms. The peptide's dual antimicrobial and anticancer properties make it an attractive candidate for therapeutic development, particularly in oncology and infectious disease treatment. Current research focuses on understanding its precise mechanisms of action and optimizing its therapeutic potential through recombinant production methods.
Key Benefits
Overview
Penaeidin-2 is an antimicrobial peptide naturally derived from the Pacific white shrimp (Penaeus vannamei) that exhibits broad-spectrum biological activities. Originally identified for its potent antibacterial and antifungal properties, this peptide has emerged as a promising therapeutic agent with significant anticancer potential. The 49-amino acid peptide contains cysteine residues that form disulfide bonds, contributing to its structural stability and biological activity. Recent research has demonstrated that recombinant penaeidin-2 shows selective cytotoxicity against kidney cancer cells while exhibiting minimal toxicity to normal cells. The peptide functions as part of the innate immune system in shrimp, providing protection against various pathogens. Studies have shown that penaeidin-2 expression can be upregulated in response to immune challenges and stress conditions. Its mechanism involves direct interaction with cell membranes, leading to membrane disruption and subsequent cell death in target organisms. The peptide's dual antimicrobial and anticancer properties make it an attractive candidate for therapeutic development, particularly in oncology and infectious disease treatment. Current research focuses on understanding its precise mechanisms of action and optimizing its therapeutic potential through recombinant production methods.
Potential Benefits
Mechanism of Action
Penaeidin-2 exerts its biological effects primarily through direct interaction with cellular membranes. The peptide targets the plasma membrane as the key site of action, where it binds to and disrupts membrane integrity. In cancer cells, this membrane interaction leads to morphological changes and subsequent cell death through apoptosis induction. The peptide demonstrates selective toxicity, preferentially targeting cancer cells over normal cells, likely due to differences in membrane composition and charge distribution. The antimicrobial activity involves similar membrane-disrupting mechanisms against bacterial and fungal pathogens. Penaeidin-2 contains cationic regions that facilitate electrostatic interactions with negatively charged microbial membranes. The peptide's structure, stabilized by disulfide bonds between cysteine residues, is crucial for its biological activity. In the context of immune function, penaeidin-2 acts as an effector molecule in the innate immune response, with its expression being upregulated during pathogen challenges or stress conditions. The peptide may also interact with specific cellular receptors or signaling pathways involved in apoptosis regulation, though the exact molecular targets require further investigation.
Risks & Safety
Legal Status
Penaeidin-3 is an antimicrobial peptide (AMP) that belongs to the penaeidin family, which plays crucial roles in the innate immune system of penaeid shrimps. This peptide is characterized by a distinctive structure containing an N-terminal proline-rich domain (PRD) and a C-terminal cysteine-rich domain (CRD), with the sequence QVYKGGYTRPIPRPPPFVRPLPGGPIGPYNGCPVSCRGISFSQARSCCSRLGRCCHVGKGYS. Penaeidin-3 has been identified and studied in multiple shrimp species including Fenneropenaeus merguiensis, Fenneropenaeus indicus, Penaeus monodon, and Penaeus vannamei. Research demonstrates that this peptide exhibits broad-spectrum antimicrobial activity against various bacterial pathogens, particularly Gram-positive bacteria like Micrococcus lysodeikticus, and shows variable effectiveness against Gram-negative bacteria such as Vibrio parahaemolyticus. The peptide is constitutively expressed in various tissues including hemocytes, gills, hepatopancreas, and other organs, with expression levels significantly upregulated during bacterial infections. Current research focuses on understanding its role in shrimp immunity, its potential applications in aquaculture disease management, and its structural-functional relationships for developing novel antimicrobial therapeutics.
Key Benefits
Overview
Penaeidin-3 is an antimicrobial peptide (AMP) that belongs to the penaeidin family, which plays crucial roles in the innate immune system of penaeid shrimps. This peptide is characterized by a distinctive structure containing an N-terminal proline-rich domain (PRD) and a C-terminal cysteine-rich domain (CRD), with the sequence QVYKGGYTRPIPRPPPFVRPLPGGPIGPYNGCPVSCRGISFSQARSCCSRLGRCCHVGKGYS. Penaeidin-3 has been identified and studied in multiple shrimp species including Fenneropenaeus merguiensis, Fenneropenaeus indicus, Penaeus monodon, and Penaeus vannamei. Research demonstrates that this peptide exhibits broad-spectrum antimicrobial activity against various bacterial pathogens, particularly Gram-positive bacteria like Micrococcus lysodeikticus, and shows variable effectiveness against Gram-negative bacteria such as Vibrio parahaemolyticus. The peptide is constitutively expressed in various tissues including hemocytes, gills, hepatopancreas, and other organs, with expression levels significantly upregulated during bacterial infections. Current research focuses on understanding its role in shrimp immunity, its potential applications in aquaculture disease management, and its structural-functional relationships for developing novel antimicrobial therapeutics.
Potential Benefits
Mechanism of Action
Penaeidin-3 functions as an antimicrobial peptide through multiple mechanisms involving its unique structural domains. The N-terminal proline-rich domain (PRD) facilitates initial binding to bacterial cell surfaces and may interact with specific bacterial membrane components, while the C-terminal cysteine-rich domain (CRD) containing disulfide bridges provides structural stability and antimicrobial activity. The peptide's mechanism involves direct interaction with bacterial cell membranes, leading to membrane disruption and bacterial cell death. Expression of penaeidin-3 is regulated by transcription factors including Dorsal and Relish, which are key components of the Toll and IMD immune signaling pathways. Upon bacterial infection, these pathways are activated, leading to upregulation of penaeidin-3 transcription. The peptide exhibits differential activity against various bacterial species, suggesting specific molecular interactions with distinct bacterial targets. The alpha-helical secondary structure, particularly in the cysteine-rich domain, is crucial for its antimicrobial function. The peptide's expression is also influenced by environmental factors and developmental stages, indicating complex regulatory mechanisms that optimize immune responses based on physiological conditions.
Risks & Safety
Legal Status
Penetratin is a well-established cell-penetrating peptide (CPP) derived from the homeodomain of the Antennapedia protein in Drosophila melanogaster. Discovered in the early 1990s, it consists of 16 amino acids (RQIKIWFQNRRMKWKK) with a cationic, amphipathic structure that enables effective cellular membrane penetration. As one of the two most widely used CPPs alongside TAT peptide, penetratin has revolutionized drug delivery research by facilitating the intracellular transport of hydrophilic therapeutic compounds that would otherwise struggle to cross biological membranes. The peptide operates through multiple mechanisms including receptor-mediated endocytosis via syndecan-4, direct membrane translocation, and energy-dependent pathways. Its ability to transport various cargoes including insulin, chemotherapeutics, and genetic material has made it a valuable tool in cancer therapy, diabetes treatment, and gene delivery applications. Recent advances include the development of branched variants that show enhanced potency compared to linear forms. Penetratin's broad-spectrum applications span from antimicrobial research to central nervous system drug delivery, making it a cornerstone peptide in the field of therapeutic delivery systems and biomedical research.
Key Benefits
Overview
Penetratin is a well-established cell-penetrating peptide (CPP) derived from the homeodomain of the Antennapedia protein in Drosophila melanogaster. Discovered in the early 1990s, it consists of 16 amino acids (RQIKIWFQNRRMKWKK) with a cationic, amphipathic structure that enables effective cellular membrane penetration. As one of the two most widely used CPPs alongside TAT peptide, penetratin has revolutionized drug delivery research by facilitating the intracellular transport of hydrophilic therapeutic compounds that would otherwise struggle to cross biological membranes. The peptide operates through multiple mechanisms including receptor-mediated endocytosis via syndecan-4, direct membrane translocation, and energy-dependent pathways. Its ability to transport various cargoes including insulin, chemotherapeutics, and genetic material has made it a valuable tool in cancer therapy, diabetes treatment, and gene delivery applications. Recent advances include the development of branched variants that show enhanced potency compared to linear forms. Penetratin's broad-spectrum applications span from antimicrobial research to central nervous system drug delivery, making it a cornerstone peptide in the field of therapeutic delivery systems and biomedical research.
Potential Benefits
Mechanism of Action
Penetratin operates through multiple cellular internalization pathways. The primary mechanism involves receptor-mediated endocytosis through syndecan-4, a transmembrane proteoglycan that binds cationic CPPs via specific interactions between its heparan sulfate chains and the positively charged peptide. This process is mediated by protein kinase C alpha and requires ATP for energy-dependent transport. Additionally, penetratin can utilize direct membrane translocation, where its positive charge interacts with negatively charged cell membranes, allowing direct passage across lipid bilayers. The peptide also employs clathrin-mediated endocytosis and caveolae-dependent pathways. Once internalized, penetratin typically co-localizes with lysosomes and can access both cytoplasm and nucleus. The peptide's amphipathic nature and propensity for α-helical secondary structure facilitate its interaction with cellular membranes and enable conformational changes in different environments. These mechanisms allow penetratin to transport conjugated therapeutic compounds across biological barriers, including the blood-brain barrier, making it effective for central nervous system applications and various drug delivery purposes.
Risks & Safety
Legal Status
PeptidePort-P001 is a synthetic peptide with the sequence MNPWVIMKPLLKFGRMPSYPMVDSPDRS, currently in Phase 1 minimal catalog extraction status. This 27-amino acid peptide appears to be part of an early-stage research catalog, with limited published data available at this time. The peptide's sequence suggests potential bioactive properties, though comprehensive clinical studies have not yet been documented. As with many research peptides in early development phases, PeptidePort-P001 may be designed for investigational purposes to explore various biological pathways and therapeutic applications. The peptide's structure contains both hydrophobic and hydrophilic regions, which could facilitate cellular interactions and membrane permeability. Current research status indicates this compound is likely being evaluated for basic biological activity and safety profiles before advancing to more extensive preclinical and clinical studies. Without published research data, the peptide's specific mechanisms and applications remain to be fully characterized through future studies.
Key Benefits
Overview
PeptidePort-P001 is a synthetic peptide with the sequence MNPWVIMKPLLKFGRMPSYPMVDSPDRS, currently in Phase 1 minimal catalog extraction status. This 27-amino acid peptide appears to be part of an early-stage research catalog, with limited published data available at this time. The peptide's sequence suggests potential bioactive properties, though comprehensive clinical studies have not yet been documented. As with many research peptides in early development phases, PeptidePort-P001 may be designed for investigational purposes to explore various biological pathways and therapeutic applications. The peptide's structure contains both hydrophobic and hydrophilic regions, which could facilitate cellular interactions and membrane permeability. Current research status indicates this compound is likely being evaluated for basic biological activity and safety profiles before advancing to more extensive preclinical and clinical studies. Without published research data, the peptide's specific mechanisms and applications remain to be fully characterized through future studies.
Potential Benefits
Mechanism of Action
Due to limited available research data, the specific mechanism of action for PeptidePort-P001 has not been fully characterized. Based on its peptide structure and sequence composition, it likely interacts with cellular receptors or signaling pathways through standard peptide-protein interactions. The peptide may function through binding to specific membrane receptors, modulating intracellular signaling cascades, or influencing gene expression patterns. Without published studies detailing receptor binding assays or pathway analysis, the exact molecular targets and downstream effects remain to be determined through future research investigations.
Risks & Safety
Legal Status
PeptidePort-P002 is a synthetic peptide with the sequence YRYKQFEWTGLMPVLLVTMPLPKMCM that is currently in early research phases. This 26-amino acid peptide contains several notable structural features including tyrosine and lysine residues at the N-terminus, which may contribute to its biological activity. The peptide also contains hydrophobic regions with leucine, valine, and methionine residues, suggesting potential membrane interactions. Given its sequence composition and structural characteristics, this peptide may have applications in tissue repair and regenerative medicine. The presence of aromatic amino acids and the overall peptide architecture suggest it could interact with cellular receptors or membrane components. However, comprehensive research data is limited, and the peptide appears to be in preliminary investigation stages. Further studies are needed to fully characterize its biological properties, safety profile, and therapeutic potential. The peptide's current classification as a research compound indicates it is not yet approved for clinical use and remains under scientific evaluation.
Key Benefits
Overview
PeptidePort-P002 is a synthetic peptide with the sequence YRYKQFEWTGLMPVLLVTMPLPKMCM that is currently in early research phases. This 26-amino acid peptide contains several notable structural features including tyrosine and lysine residues at the N-terminus, which may contribute to its biological activity. The peptide also contains hydrophobic regions with leucine, valine, and methionine residues, suggesting potential membrane interactions. Given its sequence composition and structural characteristics, this peptide may have applications in tissue repair and regenerative medicine. The presence of aromatic amino acids and the overall peptide architecture suggest it could interact with cellular receptors or membrane components. However, comprehensive research data is limited, and the peptide appears to be in preliminary investigation stages. Further studies are needed to fully characterize its biological properties, safety profile, and therapeutic potential. The peptide's current classification as a research compound indicates it is not yet approved for clinical use and remains under scientific evaluation.
Potential Benefits
Mechanism of Action
Based on the peptide sequence YRYKQFEWTGLMPVLLVTMPLPKMCM, PeptidePort-P002 likely exerts its effects through multiple molecular pathways. The N-terminal tyrosine and lysine residues may facilitate receptor binding or protein-protein interactions. The hydrophobic regions containing leucine, valine, and methionine could enable membrane penetration or lipid interactions. The peptide may modulate cellular signaling cascades through receptor activation or inhibition, potentially affecting growth factor pathways, inflammatory responses, or tissue repair mechanisms. The presence of aromatic amino acids suggests possible interactions with G-protein coupled receptors or other membrane-bound proteins. Without specific research data, the exact molecular targets and signaling pathways remain to be fully elucidated through future studies.
Risks & Safety
Legal Status
PeptidePort-P003 is a synthetic peptide with the sequence HSLLISLESTYFVENFHYWQMTGE, currently in Phase 1 minimal catalog extraction status. This 23-amino acid peptide represents an experimental compound that is being evaluated for its potential therapeutic applications. Due to limited available research data, the peptide's specific biological targets and mechanisms remain under investigation. The peptide's unique sequence suggests it may interact with cellular receptors or signaling pathways, though comprehensive studies are needed to establish its pharmacological profile. As with many research peptides, PeptidePort-P003 is likely being studied for its potential in various therapeutic areas including tissue repair, metabolic regulation, or cellular signaling modulation. The current research status indicates that this peptide is in early-stage development, requiring further preclinical and clinical studies to determine its safety, efficacy, and optimal applications. Given the limited data available, any potential therapeutic benefits remain speculative and require validation through rigorous scientific investigation.
Key Benefits
Overview
PeptidePort-P003 is a synthetic peptide with the sequence HSLLISLESTYFVENFHYWQMTGE, currently in Phase 1 minimal catalog extraction status. This 23-amino acid peptide represents an experimental compound that is being evaluated for its potential therapeutic applications. Due to limited available research data, the peptide's specific biological targets and mechanisms remain under investigation. The peptide's unique sequence suggests it may interact with cellular receptors or signaling pathways, though comprehensive studies are needed to establish its pharmacological profile. As with many research peptides, PeptidePort-P003 is likely being studied for its potential in various therapeutic areas including tissue repair, metabolic regulation, or cellular signaling modulation. The current research status indicates that this peptide is in early-stage development, requiring further preclinical and clinical studies to determine its safety, efficacy, and optimal applications. Given the limited data available, any potential therapeutic benefits remain speculative and require validation through rigorous scientific investigation.
Potential Benefits
Mechanism of Action
The specific mechanism of action for PeptidePort-P003 has not been fully elucidated due to limited research data. Based on its peptide structure and sequence composition, it likely functions through receptor-mediated signaling pathways common to bioactive peptides. The peptide may interact with specific cell surface receptors or intracellular targets, potentially modulating downstream signaling cascades. Like other therapeutic peptides, it may influence cellular processes through binding to G-protein coupled receptors, enzyme modulation, or direct interaction with cellular membranes. The peptide's biological activity would depend on its ability to maintain structural integrity and reach target tissues. Further research is needed to identify specific receptor interactions, binding affinities, and the resulting cellular responses that contribute to its therapeutic effects.
Risks & Safety
Legal Status
Peptides.org-P001 is a synthetic peptide with the sequence RPDRGCELRRD, consisting of 11 amino acids including arginine, proline, aspartic acid, glycine, cysteine, glutamic acid, leucine, and additional arginine and aspartic acid residues. This peptide is currently in Phase 1 minimal catalog extraction status, indicating it is in early research phases with limited comprehensive data available. The presence of cysteine in the sequence suggests potential for disulfide bond formation, which could contribute to structural stability and biological activity. The peptide contains multiple charged residues (arginine, aspartic acid, glutamic acid) that may facilitate cellular interactions and membrane permeability. Given its composition and the presence of basic amino acids, it may have cell-penetrating properties or interact with negatively charged cellular components. Current research status appears to be preliminary, with ongoing evaluation of its biological properties and potential therapeutic applications. The peptide's specific mechanism of action and clinical applications require further investigation through comprehensive preclinical and clinical studies.
Key Benefits
Overview
Peptides.org-P001 is a synthetic peptide with the sequence RPDRGCELRRD, consisting of 11 amino acids including arginine, proline, aspartic acid, glycine, cysteine, glutamic acid, leucine, and additional arginine and aspartic acid residues. This peptide is currently in Phase 1 minimal catalog extraction status, indicating it is in early research phases with limited comprehensive data available. The presence of cysteine in the sequence suggests potential for disulfide bond formation, which could contribute to structural stability and biological activity. The peptide contains multiple charged residues (arginine, aspartic acid, glutamic acid) that may facilitate cellular interactions and membrane permeability. Given its composition and the presence of basic amino acids, it may have cell-penetrating properties or interact with negatively charged cellular components. Current research status appears to be preliminary, with ongoing evaluation of its biological properties and potential therapeutic applications. The peptide's specific mechanism of action and clinical applications require further investigation through comprehensive preclinical and clinical studies.
Potential Benefits
Mechanism of Action
Based on the amino acid sequence RPDRGCELRRD, Peptides.org-P001 likely functions through electrostatic interactions with cellular membranes and proteins due to its charged residues. The arginine residues may facilitate cellular uptake through interaction with negatively charged cell surface components. The cysteine residue could form disulfide bonds contributing to peptide stability or protein interactions. The peptide may modulate cellular signaling pathways through receptor binding or direct protein-protein interactions. The presence of multiple basic residues suggests potential for DNA/RNA binding or interaction with negatively charged intracellular components. Without specific research data, the exact molecular targets and signaling cascades remain to be elucidated through further biochemical and cellular studies.
Risks & Safety
Legal Status
Peptides.org-P002 is a synthetic peptide with the sequence MDWETCEIHTCHIW, currently in Phase 1 minimal catalog extraction status. This 14-amino acid peptide contains cysteine residues that may form disulfide bonds, potentially contributing to structural stability. The presence of tryptophan residues suggests possible interactions with biological membranes or proteins. As a research-stage compound, limited comprehensive data is available regarding its specific biological functions and therapeutic applications. The peptide's unique sequence composition, including hydrophobic and charged residues, indicates potential for diverse biological activities. Current research status suggests it is in early developmental phases with ongoing investigation into its pharmacological properties. The peptide may have applications in various therapeutic areas based on its structural characteristics, though specific mechanisms and clinical efficacy remain to be fully established through comprehensive research studies.
Key Benefits
Overview
Peptides.org-P002 is a synthetic peptide with the sequence MDWETCEIHTCHIW, currently in Phase 1 minimal catalog extraction status. This 14-amino acid peptide contains cysteine residues that may form disulfide bonds, potentially contributing to structural stability. The presence of tryptophan residues suggests possible interactions with biological membranes or proteins. As a research-stage compound, limited comprehensive data is available regarding its specific biological functions and therapeutic applications. The peptide's unique sequence composition, including hydrophobic and charged residues, indicates potential for diverse biological activities. Current research status suggests it is in early developmental phases with ongoing investigation into its pharmacological properties. The peptide may have applications in various therapeutic areas based on its structural characteristics, though specific mechanisms and clinical efficacy remain to be fully established through comprehensive research studies.
Potential Benefits
Mechanism of Action
Based on the peptide sequence MDWETCEIHTCHIW, the mechanism of action likely involves interactions through its cysteine residues, which may form disulfide bonds contributing to structural stability and protein interactions. The tryptophan residues present in the sequence suggest potential for membrane interactions or binding to hydrophobic protein domains. The histidine residues may participate in metal coordination or pH-dependent conformational changes. The peptide's amphipathic nature, containing both hydrophobic and hydrophilic amino acids, suggests it may interact with cell membranes or specific receptor proteins. Without specific research data, the exact molecular targets and signaling pathways remain to be determined through further investigation.
Risks & Safety
Legal Status
PMAP-37 is a 37-amino acid antimicrobial peptide belonging to the cathelicidin family, originally isolated from porcine myeloid marrow. This cationic peptide exhibits broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as antiviral properties. PMAP-37 demonstrates potent bactericidal effects with minimum bactericidal concentrations of 2.5 μM against Bacillus globigii and 5 μM against Escherichia coli. The peptide works by rapidly permeabilizing bacterial cell membranes within 5 minutes and neutralizing endotoxins like lipopolysaccharide (LPS). Beyond direct antimicrobial action, PMAP-37 exhibits immunomodulatory properties by inhibiting nitric oxide production in macrophages and preventing LPS binding to immune cells. Research has focused on developing analogs with enhanced activity through modifications that increase positive charge or hydrophobicity. PMAP-37 shows promise as an alternative to conventional antibiotics, particularly given the rising concern of bacterial resistance. The peptide has demonstrated therapeutic efficacy in animal infection models and maintains stability across various pH conditions and temperatures, making it a viable candidate for clinical applications in treating bacterial infections.
Key Benefits
Overview
PMAP-37 is a 37-amino acid antimicrobial peptide belonging to the cathelicidin family, originally isolated from porcine myeloid marrow. This cationic peptide exhibits broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as antiviral properties. PMAP-37 demonstrates potent bactericidal effects with minimum bactericidal concentrations of 2.5 μM against Bacillus globigii and 5 μM against Escherichia coli. The peptide works by rapidly permeabilizing bacterial cell membranes within 5 minutes and neutralizing endotoxins like lipopolysaccharide (LPS). Beyond direct antimicrobial action, PMAP-37 exhibits immunomodulatory properties by inhibiting nitric oxide production in macrophages and preventing LPS binding to immune cells. Research has focused on developing analogs with enhanced activity through modifications that increase positive charge or hydrophobicity. PMAP-37 shows promise as an alternative to conventional antibiotics, particularly given the rising concern of bacterial resistance. The peptide has demonstrated therapeutic efficacy in animal infection models and maintains stability across various pH conditions and temperatures, making it a viable candidate for clinical applications in treating bacterial infections.
Potential Benefits
Mechanism of Action
PMAP-37 exerts its antimicrobial effects through multiple mechanisms. The peptide rapidly disrupts bacterial cell membranes by permeabilizing both outer and inner membranes within 5 minutes of contact. This membrane disruption is facilitated by the peptide's cationic nature, which allows it to interact with negatively charged bacterial membrane components. PMAP-37 neutralizes the negative charge of bacterial membranes and LPS micellular surfaces through electrostatic interactions. The peptide also demonstrates immunomodulatory activity by inhibiting LPS binding to macrophages and suppressing nitric oxide production in macrophage cell lines stimulated with various endotoxins including LPS, Lipid A, and lipoteichoic acid (LTA). This dual mechanism provides both direct antimicrobial action and indirect pathogen elimination through immune system modulation. The peptide's antiviral activity against porcine epidemic diarrhea virus (PEDV) suggests additional mechanisms of viral neutralization, though the specific pathways are not fully elucidated in the current research.
Risks & Safety
Legal Status
Pn-AMP1 is a hevein-type plant antimicrobial peptide with the sequence QQCGRQASGRLCGNRLCCSQWGYCGSTASYCGAGCQSQCRS that demonstrates potent and broad-spectrum antifungal activity. This naturally occurring peptide belongs to a class of plant defense compounds that show promise as novel therapeutic agents for controlling fungal pathogens. Research has revealed that Pn-AMP1 works through complex interactions with cellular signaling pathways, particularly those involved in alkaline pH stress responses. The peptide's mechanism involves targeting multiple cellular systems including cell wall integrity pathways, calcineurin signaling, and endosomal sorting complexes. Current research status indicates that Pn-AMP1 is being extensively studied using genome-wide screening approaches in model organisms like Saccharomyces cerevisiae to better understand its mode of action. The peptide represents a promising candidate for the development of new antifungal therapeutics, with research focusing on understanding resistance mechanisms and optimizing its therapeutic potential. Its broad-spectrum activity and unique mechanism of action make it an attractive target for pharmaceutical development, particularly in addressing the growing need for novel antimicrobial agents in an era of increasing drug resistance.
Key Benefits
Overview
Pn-AMP1 is a hevein-type plant antimicrobial peptide with the sequence QQCGRQASGRLCGNRLCCSQWGYCGSTASYCGAGCQSQCRS that demonstrates potent and broad-spectrum antifungal activity. This naturally occurring peptide belongs to a class of plant defense compounds that show promise as novel therapeutic agents for controlling fungal pathogens. Research has revealed that Pn-AMP1 works through complex interactions with cellular signaling pathways, particularly those involved in alkaline pH stress responses. The peptide's mechanism involves targeting multiple cellular systems including cell wall integrity pathways, calcineurin signaling, and endosomal sorting complexes. Current research status indicates that Pn-AMP1 is being extensively studied using genome-wide screening approaches in model organisms like Saccharomyces cerevisiae to better understand its mode of action. The peptide represents a promising candidate for the development of new antifungal therapeutics, with research focusing on understanding resistance mechanisms and optimizing its therapeutic potential. Its broad-spectrum activity and unique mechanism of action make it an attractive target for pharmaceutical development, particularly in addressing the growing need for novel antimicrobial agents in an era of increasing drug resistance.
Potential Benefits
Mechanism of Action
Pn-AMP1 exerts its antifungal effects through targeting multiple cellular signaling pathways that coordinate adaptive responses to alkaline pH stress. The peptide interferes with the cell wall integrity (CWI) pathway, which is crucial for maintaining fungal cell structure and viability. It also disrupts the calcineurin/Crz1 signaling cascade, which regulates calcium homeostasis and stress responses. Additionally, Pn-AMP1 affects the Rim101 pathway involved in pH sensing and adaptation, and the SNF1 pathway which controls energy metabolism and stress responses. The peptide also impacts the endosomal sorting complex required for transport (ESCRT complex), which is essential for protein trafficking and membrane dynamics. The primary mechanism appears to involve disruption of cellular pH homeostasis and the associated stress response networks. This multi-target approach makes it difficult for fungi to develop resistance, as multiple critical pathways are simultaneously compromised. The peptide's activity is enhanced under certain pH conditions, suggesting that environmental factors play a role in its mechanism of action.
Risks & Safety
Legal Status
Polyarginine 10R (R10) is a cell-penetrating peptide (CPP) consisting of ten consecutive arginine residues. This cationic peptide belongs to a class of short peptides that can efficiently cross cellular membranes and deliver various cargo molecules into cells. Due to its highly positive charge, R10 interacts with negatively charged cell membrane components, facilitating cellular uptake through multiple endocytic pathways. Polyarginine peptides have gained significant attention in biomedical research as delivery vectors for therapeutic agents, including drugs, proteins, nucleic acids, and nanoparticles. The peptide's ability to penetrate various cell types, including difficult-to-transfect cells, makes it valuable for research applications and potential therapeutic development. Current research focuses on optimizing its delivery efficiency, reducing cytotoxicity, and developing novel therapeutic applications. While primarily used as a research tool, R10 shows promise in drug delivery systems, gene therapy, and regenerative medicine applications. The peptide's mechanism involves both direct membrane translocation and endocytic uptake, though the exact pathways can vary depending on concentration, cell type, and experimental conditions.
Key Benefits
Overview
Polyarginine 10R (R10) is a cell-penetrating peptide (CPP) consisting of ten consecutive arginine residues. This cationic peptide belongs to a class of short peptides that can efficiently cross cellular membranes and deliver various cargo molecules into cells. Due to its highly positive charge, R10 interacts with negatively charged cell membrane components, facilitating cellular uptake through multiple endocytic pathways. Polyarginine peptides have gained significant attention in biomedical research as delivery vectors for therapeutic agents, including drugs, proteins, nucleic acids, and nanoparticles. The peptide's ability to penetrate various cell types, including difficult-to-transfect cells, makes it valuable for research applications and potential therapeutic development. Current research focuses on optimizing its delivery efficiency, reducing cytotoxicity, and developing novel therapeutic applications. While primarily used as a research tool, R10 shows promise in drug delivery systems, gene therapy, and regenerative medicine applications. The peptide's mechanism involves both direct membrane translocation and endocytic uptake, though the exact pathways can vary depending on concentration, cell type, and experimental conditions.
Potential Benefits
Mechanism of Action
Polyarginine 10R functions primarily through electrostatic interactions with negatively charged cell membrane components, particularly heparan sulfate proteoglycans and phospholipids. The peptide's multiple positive charges enable it to bind to the cell surface and initiate cellular uptake through various mechanisms including macropinocytosis, clathrin-mediated endocytosis, and direct membrane translocation. Upon binding, the peptide can induce membrane destabilization and pore formation, allowing passage across the lipid bilayer. The uptake process involves initial binding to cell surface receptors, followed by membrane invagination and internalization. Once inside the cell, the peptide may escape from endosomes through membrane disruption mechanisms, allowing access to the cytoplasm and potentially other cellular compartments. The efficiency of cellular penetration depends on factors such as peptide concentration, cell type, membrane composition, and environmental conditions.
Risks & Safety
Legal Status
Polyarginine 12R is a synthetic cell-penetrating peptide (CPP) consisting of twelve consecutive arginine residues. This peptide belongs to a class of short peptides that can efficiently cross cellular membranes and deliver various cargo molecules into cells. The high positive charge density from the multiple arginine residues enables strong electrostatic interactions with negatively charged cell membrane components, facilitating cellular uptake. Polyarginine peptides have gained significant attention in biomedical research as delivery vehicles for therapeutic molecules, including drugs, proteins, nucleic acids, and nanoparticles. The 12-arginine variant represents an optimized length that balances membrane penetration efficiency with minimal cytotoxicity. Current research focuses on its applications in drug delivery systems, gene therapy, and as a research tool for intracellular delivery of various biomolecules. While primarily used in laboratory settings, polyarginine peptides show promise for therapeutic applications requiring targeted intracellular delivery.
Key Benefits
Overview
Polyarginine 12R is a synthetic cell-penetrating peptide (CPP) consisting of twelve consecutive arginine residues. This peptide belongs to a class of short peptides that can efficiently cross cellular membranes and deliver various cargo molecules into cells. The high positive charge density from the multiple arginine residues enables strong electrostatic interactions with negatively charged cell membrane components, facilitating cellular uptake. Polyarginine peptides have gained significant attention in biomedical research as delivery vehicles for therapeutic molecules, including drugs, proteins, nucleic acids, and nanoparticles. The 12-arginine variant represents an optimized length that balances membrane penetration efficiency with minimal cytotoxicity. Current research focuses on its applications in drug delivery systems, gene therapy, and as a research tool for intracellular delivery of various biomolecules. While primarily used in laboratory settings, polyarginine peptides show promise for therapeutic applications requiring targeted intracellular delivery.
Potential Benefits
Mechanism of Action
Polyarginine 12R functions through electrostatic interactions with negatively charged components of cell membranes, including phospholipids, proteoglycans, and membrane proteins. The peptide's high positive charge density allows it to bind to the cell surface, followed by internalization through multiple pathways including endocytosis, macropinocytosis, and direct membrane translocation. The arginine residues can form hydrogen bonds and electrostatic interactions with membrane phosphates and sulfates. Once internalized, the peptide can escape endosomal compartments through membrane destabilization mechanisms, allowing cargo delivery to the cytoplasm. The guanidinium groups of arginine residues are crucial for membrane interaction and penetration efficiency.
Risks & Safety
Legal Status
Polyarginine 8R (R8) is a cell-penetrating peptide (CPP) consisting of eight consecutive arginine residues. This synthetic peptide belongs to the class of cationic cell-penetrating peptides and has gained significant attention in biomedical research for its ability to facilitate the intracellular delivery of various therapeutic molecules. The peptide's highly positive charge, derived from the guanidinium groups of arginine residues, enables it to interact with negatively charged cell membranes and subsequently penetrate cellular barriers. R8 has been extensively studied as a delivery vehicle for proteins, nucleic acids, drugs, and nanoparticles across various cell types and tissues. Its mechanism of cellular uptake involves both endocytic pathways and direct membrane translocation. The peptide has shown promise in enhancing the bioavailability and therapeutic efficacy of conjugated molecules while maintaining relatively low cytotoxicity at functional concentrations. Current research focuses on optimizing its delivery efficiency, reducing potential immunogenicity, and developing targeted therapeutic applications in areas such as cancer treatment, gene therapy, and regenerative medicine.
Key Benefits
Overview
Polyarginine 8R (R8) is a cell-penetrating peptide (CPP) consisting of eight consecutive arginine residues. This synthetic peptide belongs to the class of cationic cell-penetrating peptides and has gained significant attention in biomedical research for its ability to facilitate the intracellular delivery of various therapeutic molecules. The peptide's highly positive charge, derived from the guanidinium groups of arginine residues, enables it to interact with negatively charged cell membranes and subsequently penetrate cellular barriers. R8 has been extensively studied as a delivery vehicle for proteins, nucleic acids, drugs, and nanoparticles across various cell types and tissues. Its mechanism of cellular uptake involves both endocytic pathways and direct membrane translocation. The peptide has shown promise in enhancing the bioavailability and therapeutic efficacy of conjugated molecules while maintaining relatively low cytotoxicity at functional concentrations. Current research focuses on optimizing its delivery efficiency, reducing potential immunogenicity, and developing targeted therapeutic applications in areas such as cancer treatment, gene therapy, and regenerative medicine.
Potential Benefits
Mechanism of Action
Polyarginine 8R functions through electrostatic interactions between its positively charged arginine residues and negatively charged components of cell membranes, including phospholipids, glycosaminoglycans, and membrane proteins. The peptide's cellular uptake occurs via multiple pathways, including macropinocytosis, clathrin-mediated endocytosis, and caveolin-mediated endocytosis. The guanidinium groups of arginine residues form hydrogen bonds and electrostatic interactions with membrane phosphates and sulfates, facilitating membrane binding and destabilization. Following membrane interaction, R8 can induce temporary membrane permeabilization or invagination, allowing for cytoplasmic delivery of conjugated cargo. The peptide may also interact with cell surface heparan sulfate proteoglycans, which serve as initial binding sites before membrane translocation. Once internalized, R8 can escape endosomal compartments through membrane disruption mechanisms, preventing lysosomal degradation of delivered cargo and ensuring cytoplasmic bioavailability.
Risks & Safety
Legal Status
Polyarginine 9R (9R) is a cell-penetrating peptide (CPP) consisting of nine consecutive arginine residues. This synthetic peptide belongs to a class of short peptides that can efficiently cross cellular membranes and deliver various cargo molecules into cells. The peptide's highly cationic nature, due to the positively charged arginine residues, enables it to interact with negatively charged cell membrane components, facilitating cellular uptake. Polyarginine 9R has gained significant attention in biomedical research as a delivery vehicle for therapeutic agents, including drugs, proteins, nucleic acids, and nanoparticles. Its ability to penetrate various cell types, including difficult-to-transfect cells, makes it valuable for research and potential therapeutic applications. The peptide has been extensively studied for its role in enhancing drug delivery across biological barriers, including the blood-brain barrier. Current research focuses on optimizing its delivery efficiency, reducing potential cytotoxicity, and developing novel therapeutic applications. While primarily used as a research tool, ongoing studies investigate its potential in treating various conditions through improved drug delivery mechanisms.
Key Benefits
Overview
Polyarginine 9R (9R) is a cell-penetrating peptide (CPP) consisting of nine consecutive arginine residues. This synthetic peptide belongs to a class of short peptides that can efficiently cross cellular membranes and deliver various cargo molecules into cells. The peptide's highly cationic nature, due to the positively charged arginine residues, enables it to interact with negatively charged cell membrane components, facilitating cellular uptake. Polyarginine 9R has gained significant attention in biomedical research as a delivery vehicle for therapeutic agents, including drugs, proteins, nucleic acids, and nanoparticles. Its ability to penetrate various cell types, including difficult-to-transfect cells, makes it valuable for research and potential therapeutic applications. The peptide has been extensively studied for its role in enhancing drug delivery across biological barriers, including the blood-brain barrier. Current research focuses on optimizing its delivery efficiency, reducing potential cytotoxicity, and developing novel therapeutic applications. While primarily used as a research tool, ongoing studies investigate its potential in treating various conditions through improved drug delivery mechanisms.
Potential Benefits
Mechanism of Action
Polyarginine 9R functions through electrostatic interactions between its positively charged arginine residues and negatively charged components of cell membranes, particularly heparan sulfate proteoglycans and phospholipids. The peptide initially binds to the cell surface through these ionic interactions, followed by internalization primarily via endocytosis pathways, including macropinocytosis and clathrin-mediated endocytosis. Once internalized, the peptide can escape from endosomal compartments through various mechanisms, including endosomal membrane destabilization and formation of transient pores. The high density of positive charges creates a strong driving force for membrane interaction and penetration. The peptide's mechanism also involves direct membrane translocation under certain conditions, where it can form temporary pores or induce membrane invagination. Its ability to carry cargo molecules relies on either covalent conjugation or non-covalent association, allowing for intracellular delivery of therapeutic agents that would otherwise be unable to cross cellular barriers effectively.
Risks & Safety
Legal Status
Pseudin-2 is an antimicrobial peptide (AMP) naturally isolated from the skin of the South American paradoxical frog Pseudis paradoxa. With the amino acid sequence GLNALKKVFQGIHEAIKLINNHVQ, this 24-residue peptide represents a promising alternative to conventional antibiotics in the fight against antibiotic-resistant pathogens. Pseudin-2 demonstrates potent antimicrobial activity through a dual mechanism of action that involves both membrane disruption and intracellular targeting. The peptide exhibits unique structural properties, existing as aggregates in aqueous solution but dissociating into monomers upon interaction with bacterial lipopolysaccharides. When in contact with biological membranes, pseudin-2 adopts an α-helical conformation that facilitates its antimicrobial function. Current research focuses on understanding its mechanism of action to guide the development of new antibiotic agents. The peptide's ability to form membrane pores and subsequently bind to intracellular RNA makes it particularly effective against both bacterial and fungal pathogens. As antibiotic resistance continues to emerge globally, pseudin-2 represents part of a new class of antimicrobial agents that could provide therapeutic alternatives to traditional antibiotics.
Key Benefits
Overview
Pseudin-2 is an antimicrobial peptide (AMP) naturally isolated from the skin of the South American paradoxical frog Pseudis paradoxa. With the amino acid sequence GLNALKKVFQGIHEAIKLINNHVQ, this 24-residue peptide represents a promising alternative to conventional antibiotics in the fight against antibiotic-resistant pathogens. Pseudin-2 demonstrates potent antimicrobial activity through a dual mechanism of action that involves both membrane disruption and intracellular targeting. The peptide exhibits unique structural properties, existing as aggregates in aqueous solution but dissociating into monomers upon interaction with bacterial lipopolysaccharides. When in contact with biological membranes, pseudin-2 adopts an α-helical conformation that facilitates its antimicrobial function. Current research focuses on understanding its mechanism of action to guide the development of new antibiotic agents. The peptide's ability to form membrane pores and subsequently bind to intracellular RNA makes it particularly effective against both bacterial and fungal pathogens. As antibiotic resistance continues to emerge globally, pseudin-2 represents part of a new class of antimicrobial agents that could provide therapeutic alternatives to traditional antibiotics.
Potential Benefits
Mechanism of Action
Pseudin-2 operates through a sophisticated dual mechanism of antimicrobial action. Initially, the peptide exists in an aggregated state in aqueous environments but undergoes conformational changes upon contact with target pathogens. When interacting with bacterial lipopolysaccharides (LPS), pseudin-2 dissociates into monomeric units, though it does not neutralize LPS in Gram-negative bacteria. Upon contact with biological membranes, the peptide adopts an α-helical secondary structure that is crucial for its antimicrobial activity. The peptide then forms pores in both bacterial and fungal cell membranes, creating channels that disrupt membrane integrity. These pores cause collapse of the membrane potential and allow leakage of intracellular materials, compromising cellular homeostasis. Following pore formation, pseudin-2 enters the cytoplasm where it exhibits high affinity binding to RNA molecules. This intracellular binding interferes with macromolecule synthesis, effectively inhibiting protein production and other essential cellular processes. The combination of membrane disruption and intracellular RNA binding creates a potent antimicrobial effect that makes it difficult for pathogens to develop resistance, as multiple cellular targets are simultaneously compromised.
Risks & Safety
Legal Status
Rabbit neutrophil defensin 2 is an antimicrobial peptide belonging to the defensin family, which represents a crucial component of the innate immune system. Defensins are small, cysteine-rich peptides that serve as natural antibiotics produced by neutrophils and other immune cells. This particular defensin, with the sequence VVCACRRALCLPLERRAGFCRIRGRIHPLCCRR, contains characteristic disulfide bonds that stabilize its structure and contribute to its antimicrobial activity. Neutrophil defensins are stored in azurophilic granules and are released during degranulation in response to microbial invasion or inflammatory stimuli. These peptides play essential roles in host defense by directly killing bacteria, fungi, and some viruses through membrane disruption and other mechanisms. Beyond their antimicrobial properties, defensins also function as immunomodulatory agents, influencing chemotaxis, cytokine production, and adaptive immune responses. Research on rabbit neutrophil defensin 2 is primarily focused on understanding its antimicrobial spectrum, structure-function relationships, and potential therapeutic applications. As a naturally occurring host defense peptide, it represents a promising candidate for developing novel antimicrobial agents, particularly in an era of increasing antibiotic resistance.
Key Benefits
Overview
Rabbit neutrophil defensin 2 is an antimicrobial peptide belonging to the defensin family, which represents a crucial component of the innate immune system. Defensins are small, cysteine-rich peptides that serve as natural antibiotics produced by neutrophils and other immune cells. This particular defensin, with the sequence VVCACRRALCLPLERRAGFCRIRGRIHPLCCRR, contains characteristic disulfide bonds that stabilize its structure and contribute to its antimicrobial activity. Neutrophil defensins are stored in azurophilic granules and are released during degranulation in response to microbial invasion or inflammatory stimuli. These peptides play essential roles in host defense by directly killing bacteria, fungi, and some viruses through membrane disruption and other mechanisms. Beyond their antimicrobial properties, defensins also function as immunomodulatory agents, influencing chemotaxis, cytokine production, and adaptive immune responses. Research on rabbit neutrophil defensin 2 is primarily focused on understanding its antimicrobial spectrum, structure-function relationships, and potential therapeutic applications. As a naturally occurring host defense peptide, it represents a promising candidate for developing novel antimicrobial agents, particularly in an era of increasing antibiotic resistance.
Potential Benefits
Mechanism of Action
Rabbit neutrophil defensin 2 exerts its biological effects primarily through electrostatic interactions with microbial cell membranes. The peptide's cationic nature allows it to bind to negatively charged components of bacterial cell walls and membranes, including lipopolysaccharides in gram-negative bacteria and teichoic acids in gram-positive bacteria. Upon binding, the defensin inserts into the lipid bilayer, forming pores or causing membrane destabilization that leads to cell lysis and death. The peptide's disulfide-stabilized beta-sheet structure is crucial for membrane interaction and antimicrobial activity. Beyond direct antimicrobial effects, defensins modulate immune responses by acting as chemoattractants for immune cells, including T cells, monocytes, and dendritic cells. They can also influence cytokine production and enhance antigen presentation, thereby bridging innate and adaptive immunity. The peptide may also interact with host cell receptors to trigger intracellular signaling pathways involved in inflammation and tissue repair processes.
Risks & Safety
Legal Status
Rabbit neutrophil defensin 3a is an antimicrobial peptide belonging to the defensin family, which represents a crucial component of the innate immune system. Defensins are small, cysteine-rich peptides characterized by their distinctive beta-sheet structure stabilized by disulfide bonds. This particular defensin is derived from rabbit neutrophils, which are white blood cells that serve as the first line of defense against bacterial and fungal infections. The peptide consists of 34 amino acids with a sequence containing multiple cysteine residues that form critical disulfide bridges, contributing to its structural stability and antimicrobial activity. Neutrophil defensins are stored in azurophilic granules and are released during degranulation in response to microbial threats. These peptides exhibit broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, fungi, and some viruses. Beyond their antimicrobial properties, defensins also play roles in immune modulation, wound healing, and tissue repair processes. Current research focuses on understanding their mechanisms of action, potential therapeutic applications, and their role in various disease states. The study of animal defensins like rabbit neutrophil defensin 3a provides insights into evolutionary antimicrobial strategies and may inform the development of novel therapeutic agents for treating antibiotic-resistant infections.
Key Benefits
Overview
Rabbit neutrophil defensin 3a is an antimicrobial peptide belonging to the defensin family, which represents a crucial component of the innate immune system. Defensins are small, cysteine-rich peptides characterized by their distinctive beta-sheet structure stabilized by disulfide bonds. This particular defensin is derived from rabbit neutrophils, which are white blood cells that serve as the first line of defense against bacterial and fungal infections. The peptide consists of 34 amino acids with a sequence containing multiple cysteine residues that form critical disulfide bridges, contributing to its structural stability and antimicrobial activity. Neutrophil defensins are stored in azurophilic granules and are released during degranulation in response to microbial threats. These peptides exhibit broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, fungi, and some viruses. Beyond their antimicrobial properties, defensins also play roles in immune modulation, wound healing, and tissue repair processes. Current research focuses on understanding their mechanisms of action, potential therapeutic applications, and their role in various disease states. The study of animal defensins like rabbit neutrophil defensin 3a provides insights into evolutionary antimicrobial strategies and may inform the development of novel therapeutic agents for treating antibiotic-resistant infections.
Potential Benefits
Mechanism of Action
Rabbit neutrophil defensin 3a exerts its antimicrobial effects primarily through membrane disruption mechanisms. The peptide's cationic nature allows it to interact electrostatically with negatively charged components of microbial cell membranes, including lipopolysaccharides in gram-negative bacteria and teichoic acids in gram-positive bacteria. Upon binding, the defensin inserts into the lipid bilayer, forming pores or causing membrane permeabilization that leads to cell death. The peptide's amphipathic structure, with hydrophobic and hydrophilic regions, facilitates membrane insertion and disruption. Additionally, defensins may interfere with intracellular processes by binding to DNA, inhibiting protein synthesis, or disrupting enzymatic functions once inside the cell. The immune modulatory effects occur through interactions with various immune cell receptors, potentially influencing cytokine production and immune cell activation. The peptide may also promote wound healing through stimulation of epithelial cell migration and proliferation, angiogenesis promotion, and modulation of inflammatory responses at injury sites.
Risks & Safety
Legal Status
Rabbit neutrophil peptide 1 (RNP-1) is a defensin, a class of small cationic antimicrobial peptides that serve as the first line of defense against pathogens and play crucial roles in immune regulation. With the sequence VVCACRRALCLPRERRAGFCRIRGRIHPLCCRR, this peptide belongs to the alpha-defensin family and is naturally produced by neutrophils. Recent research has revealed promising therapeutic applications beyond its antimicrobial properties, particularly in nerve regeneration and tissue repair. A pivotal study demonstrated that a mutated form of RNP-1 (mNP-1) significantly promotes peripheral nerve regeneration following injury, showing efficacy comparable to nerve growth factor (NGF). The peptide enhanced sciatic functional recovery, improved motor nerve conductive velocity, and promoted the formation of myelinated nerve fibers. This suggests that RNP-1 may have dual functions as both an antimicrobial agent and a regenerative therapeutic. Current research status indicates the peptide is in experimental phases, with studies focusing on its potential applications in nerve injury treatment and tissue regeneration. The discovery of its neuroprotective and regenerative properties opens new avenues for therapeutic development, particularly in treating peripheral nerve injuries and potentially other degenerative conditions.
Key Benefits
Overview
Rabbit neutrophil peptide 1 (RNP-1) is a defensin, a class of small cationic antimicrobial peptides that serve as the first line of defense against pathogens and play crucial roles in immune regulation. With the sequence VVCACRRALCLPRERRAGFCRIRGRIHPLCCRR, this peptide belongs to the alpha-defensin family and is naturally produced by neutrophils. Recent research has revealed promising therapeutic applications beyond its antimicrobial properties, particularly in nerve regeneration and tissue repair. A pivotal study demonstrated that a mutated form of RNP-1 (mNP-1) significantly promotes peripheral nerve regeneration following injury, showing efficacy comparable to nerve growth factor (NGF). The peptide enhanced sciatic functional recovery, improved motor nerve conductive velocity, and promoted the formation of myelinated nerve fibers. This suggests that RNP-1 may have dual functions as both an antimicrobial agent and a regenerative therapeutic. Current research status indicates the peptide is in experimental phases, with studies focusing on its potential applications in nerve injury treatment and tissue regeneration. The discovery of its neuroprotective and regenerative properties opens new avenues for therapeutic development, particularly in treating peripheral nerve injuries and potentially other degenerative conditions.
Potential Benefits
Mechanism of Action
Rabbit neutrophil peptide 1 functions through multiple biological pathways. As a defensin, it exhibits antimicrobial activity through its cationic nature, which allows it to interact with negatively charged bacterial cell membranes, leading to membrane disruption and pathogen elimination. In nerve regeneration, the peptide appears to promote neuronal recovery through mechanisms similar to nerve growth factor (NGF). The mutated form (mNP-1) enhances peripheral nerve regeneration by promoting the formation of myelinated nerve fibers, increasing axon diameter, and improving myelin thickness. The peptide likely interacts with cellular receptors involved in nerve growth and repair processes, triggering signaling cascades that promote neuronal survival, axon elongation, and remyelination. The mechanism involves stimulation of Schwann cell proliferation and differentiation, which are essential for proper nerve regeneration. Additionally, as an immune-modulating peptide, RNP-1 may influence inflammatory responses at injury sites, creating a more favorable environment for tissue repair and regeneration.
Risks & Safety
Legal Status
Rabbit neutrophil peptide 3b is an antimicrobial peptide derived from rabbit neutrophils, representing part of the innate immune defense system. With the sequence GRCVCRKQLLCSYRERRIGDCKIRGVRFPFCCPR, this peptide belongs to the defensin family of antimicrobial compounds that play crucial roles in host defense against pathogens. Neutrophil-derived peptides are typically stored in azurophilic granules and released upon neutrophil activation during inflammatory responses. These peptides demonstrate broad-spectrum antimicrobial activity against bacteria, fungi, and some viruses through membrane disruption and other mechanisms. The peptide's cationic nature and disulfide bond structure, evident from its cysteine residues, are characteristic features that contribute to its antimicrobial properties. Current research on rabbit neutrophil peptides focuses on understanding their role in innate immunity, potential therapeutic applications as natural antibiotics, and their contribution to inflammatory processes. While specific clinical data for this particular variant may be limited, related neutrophil peptides have shown promise in wound healing applications and as templates for developing novel antimicrobial therapeutics. The peptide represents an important component of the rabbit immune system's first-line defense mechanisms.
Key Benefits
Overview
Rabbit neutrophil peptide 3b is an antimicrobial peptide derived from rabbit neutrophils, representing part of the innate immune defense system. With the sequence GRCVCRKQLLCSYRERRIGDCKIRGVRFPFCCPR, this peptide belongs to the defensin family of antimicrobial compounds that play crucial roles in host defense against pathogens. Neutrophil-derived peptides are typically stored in azurophilic granules and released upon neutrophil activation during inflammatory responses. These peptides demonstrate broad-spectrum antimicrobial activity against bacteria, fungi, and some viruses through membrane disruption and other mechanisms. The peptide's cationic nature and disulfide bond structure, evident from its cysteine residues, are characteristic features that contribute to its antimicrobial properties. Current research on rabbit neutrophil peptides focuses on understanding their role in innate immunity, potential therapeutic applications as natural antibiotics, and their contribution to inflammatory processes. While specific clinical data for this particular variant may be limited, related neutrophil peptides have shown promise in wound healing applications and as templates for developing novel antimicrobial therapeutics. The peptide represents an important component of the rabbit immune system's first-line defense mechanisms.
Potential Benefits
Mechanism of Action
Rabbit neutrophil peptide 3b functions through multiple antimicrobial mechanisms characteristic of defensin-like peptides. The peptide's cationic charge allows it to interact with negatively charged bacterial cell membranes, leading to membrane disruption and cell death. The presence of multiple cysteine residues suggests disulfide bond formation that stabilizes the peptide's three-dimensional structure, enhancing its antimicrobial potency. Upon release from neutrophil granules during degranulation, the peptide can directly bind to microbial surfaces, insert into lipid bilayers, and form pores or cause membrane permeabilization. Additionally, the peptide may interfere with intracellular processes by binding to DNA or disrupting essential enzymatic functions once inside microbial cells. The peptide likely also modulates immune responses by acting as a chemoattractant for other immune cells and potentially influencing cytokine production. Its arginine-rich regions may facilitate cellular uptake and enhance antimicrobial activity through electrostatic interactions with anionic cellular components.
Risks & Safety
Legal Status
Rabbit neutrophil peptide 4 is an antimicrobial peptide derived from rabbit neutrophils, belonging to the defensin family of host defense peptides. With the sequence VSCTCRRFSCGFGERASGSCTVNGVRHTLCCRR, this cationic peptide contains multiple cysteine residues that form disulfide bonds, creating a stable β-sheet structure characteristic of defensins. Neutrophil-derived peptides like RNP-4 are part of the innate immune system's first line of defense against pathogens. These peptides are stored in neutrophil granules and released upon activation to combat bacterial, fungal, and viral infections. The peptide's cationic nature allows it to interact with negatively charged microbial membranes, leading to membrane disruption and pathogen elimination. Current research on rabbit neutrophil peptides focuses on their antimicrobial spectrum, mechanism of action, and potential therapeutic applications. While specific clinical data for RNP-4 is limited, related neutrophil peptides have shown promise in wound healing applications due to their dual antimicrobial and tissue repair properties. The research status remains primarily preclinical, with studies investigating structure-activity relationships and potential modifications to enhance therapeutic efficacy while reducing cytotoxicity.
Key Benefits
Overview
Rabbit neutrophil peptide 4 is an antimicrobial peptide derived from rabbit neutrophils, belonging to the defensin family of host defense peptides. With the sequence VSCTCRRFSCGFGERASGSCTVNGVRHTLCCRR, this cationic peptide contains multiple cysteine residues that form disulfide bonds, creating a stable β-sheet structure characteristic of defensins. Neutrophil-derived peptides like RNP-4 are part of the innate immune system's first line of defense against pathogens. These peptides are stored in neutrophil granules and released upon activation to combat bacterial, fungal, and viral infections. The peptide's cationic nature allows it to interact with negatively charged microbial membranes, leading to membrane disruption and pathogen elimination. Current research on rabbit neutrophil peptides focuses on their antimicrobial spectrum, mechanism of action, and potential therapeutic applications. While specific clinical data for RNP-4 is limited, related neutrophil peptides have shown promise in wound healing applications due to their dual antimicrobial and tissue repair properties. The research status remains primarily preclinical, with studies investigating structure-activity relationships and potential modifications to enhance therapeutic efficacy while reducing cytotoxicity.
Potential Benefits
Mechanism of Action
Rabbit neutrophil peptide 4 functions through electrostatic interactions with microbial cell membranes. The peptide's cationic charge, conferred by arginine and lysine residues, enables binding to negatively charged phospholipids and lipopolysaccharides on bacterial surfaces. Upon binding, the peptide undergoes conformational changes that allow insertion into the lipid bilayer, forming pores or causing membrane destabilization. The disulfide-stabilized structure provides resistance to proteolytic degradation while maintaining membrane-disrupting activity. Beyond direct antimicrobial effects, the peptide may modulate immune responses by interacting with host cell receptors, potentially influencing cytokine production and inflammatory cascades. The peptide's mechanism likely involves both membrane permeabilization and intracellular targeting of essential cellular processes. Like other defensins, RNP-4 may also exhibit chemotactic properties, recruiting immune cells to infection sites and enhancing overall antimicrobial defense.
Risks & Safety
Legal Status
Rabbit neutrophil peptide 5 is an antimicrobial peptide derived from rabbit neutrophils, belonging to the defensin family of host defense peptides. These peptides are part of the innate immune system's first line of defense against microbial pathogens. The peptide contains 32 amino acids with a characteristic cysteine-rich structure that forms disulfide bonds, creating a stable beta-sheet configuration typical of defensins. Neutrophil-derived peptides like this one are stored in azurophilic granules of neutrophils and are released upon activation during inflammatory responses. The peptide's primary function involves broad-spectrum antimicrobial activity against bacteria, fungi, and potentially viruses through membrane disruption mechanisms. Current research on rabbit neutrophil peptides focuses on understanding their role in innate immunity, potential therapeutic applications as natural antibiotics, and their structure-function relationships. While specific clinical data for rabbit neutrophil peptide 5 is limited, related defensins have shown promise in wound healing applications and as templates for developing novel antimicrobial agents. The peptide represents an important component of the rabbit immune system's antimicrobial arsenal.
Key Benefits
Overview
Rabbit neutrophil peptide 5 is an antimicrobial peptide derived from rabbit neutrophils, belonging to the defensin family of host defense peptides. These peptides are part of the innate immune system's first line of defense against microbial pathogens. The peptide contains 32 amino acids with a characteristic cysteine-rich structure that forms disulfide bonds, creating a stable beta-sheet configuration typical of defensins. Neutrophil-derived peptides like this one are stored in azurophilic granules of neutrophils and are released upon activation during inflammatory responses. The peptide's primary function involves broad-spectrum antimicrobial activity against bacteria, fungi, and potentially viruses through membrane disruption mechanisms. Current research on rabbit neutrophil peptides focuses on understanding their role in innate immunity, potential therapeutic applications as natural antibiotics, and their structure-function relationships. While specific clinical data for rabbit neutrophil peptide 5 is limited, related defensins have shown promise in wound healing applications and as templates for developing novel antimicrobial agents. The peptide represents an important component of the rabbit immune system's antimicrobial arsenal.
Potential Benefits
Mechanism of Action
Rabbit neutrophil peptide 5 functions through electrostatic interactions with negatively charged microbial cell membranes. The peptide's cationic nature allows it to bind to bacterial lipopolysaccharides and phospholipids, leading to membrane permeabilization and cell death. The disulfide-stabilized structure enables the peptide to insert into lipid bilayers, forming pores or causing membrane disruption. Additionally, the peptide may have intracellular targets, potentially interfering with DNA synthesis and protein function once internalized. The mechanism also involves activation of host immune responses, including chemotaxis of immune cells and modulation of inflammatory pathways. The peptide's antimicrobial selectivity is achieved through preferential binding to prokaryotic membranes over eukaryotic cell membranes due to differences in membrane composition and charge distribution.
Risks & Safety
Legal Status
Ref is a hexapeptide with the sequence RRWWRF, currently in Phase 1 minimal catalog extraction status. Based on the research context, this peptide appears to be related to APE1/Ref-1 (Apurinic/apyrimidinic endonuclease 1/Redox factor-1), a multifunctional protein with significant roles in cellular repair, redox regulation, and transcriptional control. APE1/Ref-1 is overexpressed in aggressive cancers and impacts various cellular signaling pathways including NF-κB, HIF1α, STAT3, and AP-1. The protein demonstrates both pro- and anti-atherogenic effects, modulates Wnt/β-catenin signaling in endothelial cells, and plays crucial roles in social memory processing through hippocampal CA2 region interactions. Current research focuses on developing targeted inhibitors like APX3330, which has completed Phase I clinical trials for solid tumors with favorable response rates and minimal toxicity. The peptide's research applications span cardiovascular disease, cancer therapeutics, retinal neovascularization, and neurocognitive functions. While the exact relationship between the Ref peptide and APE1/Ref-1 protein requires further clarification, the associated research suggests potential applications in anti-cancer therapy, cardiovascular protection, and neuroprotective functions.
Key Benefits
Overview
Ref is a hexapeptide with the sequence RRWWRF, currently in Phase 1 minimal catalog extraction status. Based on the research context, this peptide appears to be related to APE1/Ref-1 (Apurinic/apyrimidinic endonuclease 1/Redox factor-1), a multifunctional protein with significant roles in cellular repair, redox regulation, and transcriptional control. APE1/Ref-1 is overexpressed in aggressive cancers and impacts various cellular signaling pathways including NF-κB, HIF1α, STAT3, and AP-1. The protein demonstrates both pro- and anti-atherogenic effects, modulates Wnt/β-catenin signaling in endothelial cells, and plays crucial roles in social memory processing through hippocampal CA2 region interactions. Current research focuses on developing targeted inhibitors like APX3330, which has completed Phase I clinical trials for solid tumors with favorable response rates and minimal toxicity. The peptide's research applications span cardiovascular disease, cancer therapeutics, retinal neovascularization, and neurocognitive functions. While the exact relationship between the Ref peptide and APE1/Ref-1 protein requires further clarification, the associated research suggests potential applications in anti-cancer therapy, cardiovascular protection, and neuroprotective functions.
Potential Benefits
Mechanism of Action
The Ref peptide appears to function through modulation of redox-mediated transcriptional regulatory pathways, particularly targeting APE1/Ref-1 activity. The mechanism involves regulation of key transcription factors including NF-κB, HIF1α, STAT3, and AP-1, which are crucial for tumor development and metastatic growth. In endothelial cells, Ref-1 redox activity modulates canonical Wnt signaling by downregulating Wnt co-receptors LRP5/6 at both mRNA and protein levels, reducing Wnt3a-induced nuclear β-catenin levels and decreasing Wnt transcriptional activity. The protein localizes to nucleus, cytoplasm, and mitochondria, with dynamic regulation based on disease state. In cardiovascular contexts, it suppresses IL-6, TNF-α, and IL-1β-mediated proinflammatory responses, reduces ROS-mediated oxidant activity, and modulates Bax/Bcl-2-mediated vascular calcification and apoptosis. In neural tissue, it affects hippocampal CA2 region function, forming a nexus in disynaptic circuits linking entorhinal cortex input with CA1 output, specifically impacting social memory processing while preserving spatial and contextual memory functions.
Risks & Safety
Legal Status
Royalisin is a 51-amino acid antimicrobial peptide found in royal jelly, the exclusive food source for honeybee queens produced by young nurse bees. With a molecular weight of 5.5 kDa and containing six cysteine residues, royalisin represents one of the key bioactive components responsible for royal jelly's therapeutic properties. This peptide demonstrates potent antibacterial activity, particularly against Gram-positive bacteria, and has been extensively studied for its antimicrobial mechanisms and potential therapeutic applications. Research has shown that royalisin works by disrupting bacterial cell walls and membranes, leading to cell death. Beyond its antimicrobial properties, royalisin has shown promise in cardiovascular health, particularly in detecting and potentially treating atherosclerosis through its ability to bind specifically to oxidized low-density lipoprotein (ox-LDL). The peptide is part of royal jelly's complex bioactive profile that includes anti-inflammatory, immunomodulatory, and anti-aging properties. Current research focuses on understanding its mechanism of action, developing recombinant production methods, and exploring its therapeutic potential in various medical applications including food preservation and pharmaceutical development.
Key Benefits
Overview
Royalisin is a 51-amino acid antimicrobial peptide found in royal jelly, the exclusive food source for honeybee queens produced by young nurse bees. With a molecular weight of 5.5 kDa and containing six cysteine residues, royalisin represents one of the key bioactive components responsible for royal jelly's therapeutic properties. This peptide demonstrates potent antibacterial activity, particularly against Gram-positive bacteria, and has been extensively studied for its antimicrobial mechanisms and potential therapeutic applications. Research has shown that royalisin works by disrupting bacterial cell walls and membranes, leading to cell death. Beyond its antimicrobial properties, royalisin has shown promise in cardiovascular health, particularly in detecting and potentially treating atherosclerosis through its ability to bind specifically to oxidized low-density lipoprotein (ox-LDL). The peptide is part of royal jelly's complex bioactive profile that includes anti-inflammatory, immunomodulatory, and anti-aging properties. Current research focuses on understanding its mechanism of action, developing recombinant production methods, and exploring its therapeutic potential in various medical applications including food preservation and pharmaceutical development.
Potential Benefits
Mechanism of Action
Royalisin exerts its antimicrobial effects primarily through disruption of bacterial cell walls and membranes, particularly in Gram-positive bacteria. The peptide induces membrane permeabilization, leading to leakage of intracellular contents including 260-nm absorbing materials, ultimately resulting in bacterial cell death. Its antibacterial activity is concentration-dependent and involves binding to bacterial cell surfaces, causing structural damage visible through transmission electron microscopy. The peptide's six cysteine residues likely contribute to its structural stability and functional activity. In cardiovascular applications, royalisin demonstrates specific binding affinity to oxidized low-density lipoprotein (ox-LDL) through interaction with major lipid components including lysophosphatidylcholine and oxidized phosphatidylcholine. This binding occurs through specific amino acid sequences, particularly Phe-Lys-Asp and Asp-Lys-Tyr motifs located at positions 41-51 of the peptide. The mechanism involves recognition of oxidized lipid structures, suggesting potential therapeutic applications in atherosclerosis treatment. Royalisin's activity is temperature-sensitive, with reduced efficacy observed at temperatures ranging from 55°C to 85°C, indicating protein denaturation affects its biological function.
Risks & Safety
Legal Status
Rs-AFP2 is a plant defensin peptide originally derived from Raphanus sativus (radish) with potent antifungal properties. This 50-amino acid peptide belongs to the defensin family of antimicrobial proteins that play crucial roles in plant innate immunity. Rs-AFP2 has been extensively studied for its ability to confer resistance against various fungal phytopathogens when expressed in transgenic crops. Research has demonstrated its effectiveness against major agricultural pathogens including Magnaporthe oryzae, Rhizoctonia solani, Bipolaris maydis, and Phaeoisariopsis personata. The peptide has been successfully expressed in multiple crop species including rice, peanut, and maize, showing significant disease resistance without affecting normal plant morphology. Rs-AFP2 exhibits direct antimicrobial activity rather than inducing pathogenesis-related gene expression, making it particularly valuable for agricultural biotechnology applications. Its mechanism involves direct inhibition of fungal growth, with studies showing up to 77% suppression of pathogen growth in controlled conditions. The peptide has been used both individually and in combination with other antimicrobial proteins to create enhanced disease resistance in crops, demonstrating its potential for sustainable agricultural practices and food security applications.
Key Benefits
Overview
Rs-AFP2 is a plant defensin peptide originally derived from Raphanus sativus (radish) with potent antifungal properties. This 50-amino acid peptide belongs to the defensin family of antimicrobial proteins that play crucial roles in plant innate immunity. Rs-AFP2 has been extensively studied for its ability to confer resistance against various fungal phytopathogens when expressed in transgenic crops. Research has demonstrated its effectiveness against major agricultural pathogens including Magnaporthe oryzae, Rhizoctonia solani, Bipolaris maydis, and Phaeoisariopsis personata. The peptide has been successfully expressed in multiple crop species including rice, peanut, and maize, showing significant disease resistance without affecting normal plant morphology. Rs-AFP2 exhibits direct antimicrobial activity rather than inducing pathogenesis-related gene expression, making it particularly valuable for agricultural biotechnology applications. Its mechanism involves direct inhibition of fungal growth, with studies showing up to 77% suppression of pathogen growth in controlled conditions. The peptide has been used both individually and in combination with other antimicrobial proteins to create enhanced disease resistance in crops, demonstrating its potential for sustainable agricultural practices and food security applications.
Potential Benefits
Mechanism of Action
Rs-AFP2 functions as an antimicrobial defensin through direct interaction with fungal pathogens rather than through induction of plant defense pathways. The peptide exhibits its antifungal activity by directly inhibiting the growth and development of target fungi. Unlike some plant defense mechanisms that work by triggering pathogenesis-related (PR) gene expression, Rs-AFP2 operates independently of these pathways, suggesting a direct mode of action against fungal cell structures or essential cellular processes. The defensin likely disrupts fungal cell membrane integrity or interferes with critical metabolic processes necessary for fungal survival and reproduction. When expressed constitutively in transgenic plants, Rs-AFP2 maintains its biological activity and provides continuous protection against invading pathogens. The peptide's effectiveness appears to be concentration-dependent, with expression levels of 0.45-0.53% of total soluble protein being sufficient to confer significant disease resistance. Its mechanism allows for broad-spectrum antifungal activity while maintaining plant health and normal morphological development.
Risks & Safety
Legal Status
Sapecin B is an antimicrobial peptide with the sequence LTCEIDRSLCLLHCRLKGYLRAYCSQQKVCRCVQ that serves as a template for developing novel antibacterial agents. Originally derived from natural sources, this peptide has become the foundation for creating synthetic analogues with enhanced antimicrobial properties. Current research focuses on developing Sapecin B-derived peptides to combat antibiotic-resistant bacterial infections, particularly methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). The peptide demonstrates potent antibacterial activity through membrane disruption mechanisms and has shown promise in both in vitro and in vivo studies. Researchers have successfully created modified versions like mKLK and BF2 that retain the antimicrobial efficacy while improving selectivity and reducing toxicity to mammalian cells. These derivatives exhibit superior biofilm inhibition capabilities and maintain structural stability in human serum, suggesting resistance to proteolytic degradation. The peptide's amphipathic helical structure, with hydrophobic residues confined to one face of the helix, contributes to its membrane-targeting activity. Current research status indicates Sapecin B and its analogues are in preclinical development stages, with studies demonstrating effectiveness against nosocomial infections and biofilm-associated bacterial diseases.
Key Benefits
Overview
Sapecin B is an antimicrobial peptide with the sequence LTCEIDRSLCLLHCRLKGYLRAYCSQQKVCRCVQ that serves as a template for developing novel antibacterial agents. Originally derived from natural sources, this peptide has become the foundation for creating synthetic analogues with enhanced antimicrobial properties. Current research focuses on developing Sapecin B-derived peptides to combat antibiotic-resistant bacterial infections, particularly methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). The peptide demonstrates potent antibacterial activity through membrane disruption mechanisms and has shown promise in both in vitro and in vivo studies. Researchers have successfully created modified versions like mKLK and BF2 that retain the antimicrobial efficacy while improving selectivity and reducing toxicity to mammalian cells. These derivatives exhibit superior biofilm inhibition capabilities and maintain structural stability in human serum, suggesting resistance to proteolytic degradation. The peptide's amphipathic helical structure, with hydrophobic residues confined to one face of the helix, contributes to its membrane-targeting activity. Current research status indicates Sapecin B and its analogues are in preclinical development stages, with studies demonstrating effectiveness against nosocomial infections and biofilm-associated bacterial diseases.
Potential Benefits
Mechanism of Action
Sapecin B functions as a cationic antimicrobial peptide that targets bacterial cell membranes through electrostatic interactions and membrane disruption. The peptide adopts an amphipathic helical structure where hydrophobic residues are concentrated on one face of the helix, facilitating insertion into bacterial lipid bilayers. Upon contact with bacterial membranes, the positively charged peptide interacts with negatively charged phospholipids, leading to membrane permeabilization and cell death. The peptide demonstrates rapid bactericidal activity, killing 99.9% of bacterial cells within 60 minutes of exposure. Its mechanism involves disruption of membrane integrity, which prevents the development of specific resistance mechanisms that bacteria typically develop against conventional antibiotics. The peptide also exhibits potent anti-biofilm activity at sub-MIC concentrations, suggesting additional mechanisms beyond simple membrane disruption. It can inhibit biofilm formation, eradicate existing biofilms, and disperse established bacterial communities. The peptide's self-assembling properties contribute to the formation of β-sheet supramolecular structures that enhance its antimicrobial efficacy. Its stability in human serum indicates resistance to proteolytic degradation, allowing for sustained antimicrobial activity in physiological conditions.
Risks & Safety
Legal Status
Seminalplasmin is a naturally occurring peptide found in seminal plasma with a sequence of 46 amino acids. This peptide belongs to a class of antimicrobial proteins that play important roles in reproductive biology and immune defense. Seminalplasmin exhibits antimicrobial properties and is believed to contribute to the protection of reproductive tissues against bacterial infections. The peptide contains multiple basic amino acid residues, which are characteristic of antimicrobial peptides and contribute to its ability to interact with bacterial cell membranes. Current research on seminalplasmin is limited but suggests potential applications in antimicrobial therapy and reproductive health. The peptide's natural occurrence in seminal fluid indicates its evolutionary importance in maintaining reproductive tract health and protecting against pathogens. Further research is needed to fully elucidate its therapeutic potential and safety profile for clinical applications.
Key Benefits
Overview
Seminalplasmin is a naturally occurring peptide found in seminal plasma with a sequence of 46 amino acids. This peptide belongs to a class of antimicrobial proteins that play important roles in reproductive biology and immune defense. Seminalplasmin exhibits antimicrobial properties and is believed to contribute to the protection of reproductive tissues against bacterial infections. The peptide contains multiple basic amino acid residues, which are characteristic of antimicrobial peptides and contribute to its ability to interact with bacterial cell membranes. Current research on seminalplasmin is limited but suggests potential applications in antimicrobial therapy and reproductive health. The peptide's natural occurrence in seminal fluid indicates its evolutionary importance in maintaining reproductive tract health and protecting against pathogens. Further research is needed to fully elucidate its therapeutic potential and safety profile for clinical applications.
Potential Benefits
Mechanism of Action
Seminalplasmin functions as an antimicrobial peptide through membrane disruption mechanisms typical of cationic antimicrobial peptides. The peptide's positively charged amino acid residues interact with negatively charged bacterial cell membranes, leading to membrane permeabilization and bacterial cell death. The peptide likely adopts an amphipathic structure that allows it to insert into lipid bilayers and form pores or cause membrane destabilization. Additionally, seminalplasmin may interact with intracellular targets after membrane penetration, potentially interfering with bacterial DNA, RNA, or protein synthesis. The peptide's antimicrobial activity is enhanced by its ability to bind to bacterial surface components and disrupt essential cellular processes.
Risks & Safety
Legal Status
So-D7 is a 38-amino acid peptide with the sequence GIFSSRKCKTPSKTFKGYCTRDSNCDTSCRYEGYPAGD. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited publicly available data. The peptide's structure suggests potential bioactive properties, though comprehensive research findings are not yet available in major databases. The presence of cysteine residues in the sequence indicates possible disulfide bond formation, which could contribute to structural stability and biological activity. As with many research peptides, So-D7 likely requires further investigation to fully characterize its mechanisms of action, therapeutic potential, and safety profile. The peptide appears to be in early research phases, with limited clinical or preclinical data currently accessible through standard research channels. Further studies would be needed to establish its pharmacological properties, bioavailability, and potential therapeutic applications. The current status suggests this is primarily a research tool rather than a clinically validated therapeutic agent.
Key Benefits
Overview
So-D7 is a 38-amino acid peptide with the sequence GIFSSRKCKTPSKTFKGYCTRDSNCDTSCRYEGYPAGD. Currently in Phase 1 minimal catalog extraction, this peptide represents an early-stage research compound with limited publicly available data. The peptide's structure suggests potential bioactive properties, though comprehensive research findings are not yet available in major databases. The presence of cysteine residues in the sequence indicates possible disulfide bond formation, which could contribute to structural stability and biological activity. As with many research peptides, So-D7 likely requires further investigation to fully characterize its mechanisms of action, therapeutic potential, and safety profile. The peptide appears to be in early research phases, with limited clinical or preclinical data currently accessible through standard research channels. Further studies would be needed to establish its pharmacological properties, bioavailability, and potential therapeutic applications. The current status suggests this is primarily a research tool rather than a clinically validated therapeutic agent.
Potential Benefits
Mechanism of Action
Based on the peptide sequence analysis, So-D7 contains multiple cysteine residues that likely form disulfide bonds, creating a stable tertiary structure essential for biological activity. The presence of basic amino acids (lysine and arginine) suggests potential interactions with negatively charged cellular components or receptors. The peptide may function through receptor binding mechanisms, though specific target receptors have not been identified in available literature. The structural characteristics indicate possible involvement in cell signaling pathways, potentially through G-protein coupled receptor activation or direct membrane interactions. The peptide's bioactivity likely depends on conformational stability provided by disulfide bridging between cysteine residues.
Risks & Safety
Legal Status
Styelin A is an antimicrobial peptide with the sequence GFGKAFHSVSNFAKKHKTA, belonging to a class of naturally occurring defense molecules. This peptide is characterized by its cationic nature and relatively short chain length of 19 amino acids. Antimicrobial peptides like Styelin A are typically found in various organisms as part of their innate immune defense systems, providing broad-spectrum activity against pathogens including bacteria, fungi, and potentially viruses. The peptide's structure suggests it may function through membrane disruption mechanisms common to cationic antimicrobial peptides. Current research on Styelin A is in early phases, with limited clinical data available. The peptide shows promise as a potential therapeutic agent for infectious diseases and immune system support, though comprehensive safety and efficacy studies are still needed. Its antimicrobial properties make it of particular interest for developing new treatments against antibiotic-resistant pathogens. The research status remains primarily preclinical, with investigations focusing on understanding its spectrum of activity, optimal dosing, and potential therapeutic applications in various infectious disease contexts.
Key Benefits
Overview
Styelin A is an antimicrobial peptide with the sequence GFGKAFHSVSNFAKKHKTA, belonging to a class of naturally occurring defense molecules. This peptide is characterized by its cationic nature and relatively short chain length of 19 amino acids. Antimicrobial peptides like Styelin A are typically found in various organisms as part of their innate immune defense systems, providing broad-spectrum activity against pathogens including bacteria, fungi, and potentially viruses. The peptide's structure suggests it may function through membrane disruption mechanisms common to cationic antimicrobial peptides. Current research on Styelin A is in early phases, with limited clinical data available. The peptide shows promise as a potential therapeutic agent for infectious diseases and immune system support, though comprehensive safety and efficacy studies are still needed. Its antimicrobial properties make it of particular interest for developing new treatments against antibiotic-resistant pathogens. The research status remains primarily preclinical, with investigations focusing on understanding its spectrum of activity, optimal dosing, and potential therapeutic applications in various infectious disease contexts.
Potential Benefits
Mechanism of Action
Styelin A likely functions through electrostatic interactions with negatively charged bacterial cell membranes, characteristic of cationic antimicrobial peptides. The peptide's positive charge allows it to bind to bacterial lipopolysaccharides and phospholipids, leading to membrane destabilization and pore formation. This membrane disruption results in cell lysis and bacterial death. The peptide may also penetrate cells to interact with intracellular targets such as DNA, RNA, or essential enzymes, providing additional antimicrobial effects. Its mechanism likely involves both membrane-active and intracellular pathways, making it effective against a broad spectrum of microorganisms while potentially reducing the likelihood of resistance development compared to conventional antibiotics.
Risks & Safety
Legal Status
Styelin B is a bioactive peptide with the amino acid sequence GFGPAFHSVSNFAKKHKTA. As a relatively understudied peptide, limited comprehensive research data is currently available regarding its specific biological functions and therapeutic applications. The peptide appears to be part of ongoing research investigations, though detailed mechanistic studies and clinical trials remain limited. Current understanding suggests potential bioactive properties that may warrant further investigation. The peptide's structure and sequence suggest it may interact with various biological systems, though specific receptor targets and signaling pathways require additional research to fully elucidate. Given the early stage of research, most information about Styelin B remains preliminary, and comprehensive safety and efficacy profiles have not been fully established through extensive clinical studies.
Key Benefits
Overview
Styelin B is a bioactive peptide with the amino acid sequence GFGPAFHSVSNFAKKHKTA. As a relatively understudied peptide, limited comprehensive research data is currently available regarding its specific biological functions and therapeutic applications. The peptide appears to be part of ongoing research investigations, though detailed mechanistic studies and clinical trials remain limited. Current understanding suggests potential bioactive properties that may warrant further investigation. The peptide's structure and sequence suggest it may interact with various biological systems, though specific receptor targets and signaling pathways require additional research to fully elucidate. Given the early stage of research, most information about Styelin B remains preliminary, and comprehensive safety and efficacy profiles have not been fully established through extensive clinical studies.
Potential Benefits
Mechanism of Action
The specific mechanism of action for Styelin B has not been fully characterized in available research literature. Based on its peptide structure and sequence composition, it likely interacts with cellular receptors and may influence various signaling pathways. The peptide may modulate cellular processes through receptor binding, though specific target receptors have not been definitively identified. Potential mechanisms could involve interaction with cell surface receptors, intracellular signaling cascades, or direct effects on cellular metabolism. Further research is needed to establish the precise molecular targets and downstream signaling pathways affected by Styelin B.
Risks & Safety
Legal Status
Substance P is an 11-amino acid neuropeptide (sequence: RPKPQQFFGLM) belonging to the tachykinin family, encoded by the tachykinin 1 (TAC1) gene. It is widely distributed throughout the central and peripheral nervous systems and is also produced by non-neuronal cells including inflammatory cells, endothelial cells, and immune cells. Substance P primarily exerts its biological effects through binding to the high-affinity neurokinin-1 receptor (NK1R), mediating critical functions in nociception, inflammation, immune response modulation, and tissue repair. Current research demonstrates its involvement in pain transmission, immune cell communication, wound healing, and various pathological processes including fibrotic diseases and cancer progression. The peptide plays a dual role in health and disease - while essential for normal physiological processes like wound healing and immune function, dysregulation of the SP/NK1R system contributes to chronic pain, inflammation, and tumor progression. Recent studies have revealed its protective effects against colitis through anti-inflammatory and anti-ferroptotic mechanisms, as well as its role in respiratory frequency plasticity during development. The therapeutic potential of NK1R antagonists is being actively investigated for treating various conditions including chronic pain, fibrotic diseases, and cancer.
Key Benefits
Overview
Substance P is an 11-amino acid neuropeptide (sequence: RPKPQQFFGLM) belonging to the tachykinin family, encoded by the tachykinin 1 (TAC1) gene. It is widely distributed throughout the central and peripheral nervous systems and is also produced by non-neuronal cells including inflammatory cells, endothelial cells, and immune cells. Substance P primarily exerts its biological effects through binding to the high-affinity neurokinin-1 receptor (NK1R), mediating critical functions in nociception, inflammation, immune response modulation, and tissue repair. Current research demonstrates its involvement in pain transmission, immune cell communication, wound healing, and various pathological processes including fibrotic diseases and cancer progression. The peptide plays a dual role in health and disease - while essential for normal physiological processes like wound healing and immune function, dysregulation of the SP/NK1R system contributes to chronic pain, inflammation, and tumor progression. Recent studies have revealed its protective effects against colitis through anti-inflammatory and anti-ferroptotic mechanisms, as well as its role in respiratory frequency plasticity during development. The therapeutic potential of NK1R antagonists is being actively investigated for treating various conditions including chronic pain, fibrotic diseases, and cancer.
Potential Benefits
Mechanism of Action
Substance P exerts its biological effects primarily through binding to the neurokinin-1 receptor (NK1R), a G-protein coupled receptor. Upon binding, SP activates multiple signaling cascades including the inhibition of the cGAS-STING pathway, which prevents mitochondrial DNA leakage and subsequent inflammatory responses. SP protects mitochondria from damage and directly prevents STING phosphorylation, thereby inhibiting the TBK1-IRF3 signaling pathway. The peptide modulates immune cell proliferation and cytokine production through paracrine and endocrine signaling mechanisms. In mast cells, SP binding to MRGPRX2 receptors triggers degranulation, releasing histamine and mast cell protease 4 (MCPT4) chymase, which promotes vascular permeability. SP also activates sensory neurons through TRPV1 receptors in dorsal root ganglion cells. The peptide influences angiogenesis, cell migration, and apoptosis in various cell types. In the respiratory system, SP induces long-lasting increases in breathing frequency through NK1R-dependent mechanisms. The SP/NK1R system creates feedback loops where SP release can be triggered by various stimuli, leading to sustained cellular responses and potential pathological amplification in disease states.
Risks & Safety
Legal Status
Subtilin is a class I lantibiotic (lanthionine-containing antibiotic peptide) produced by Bacillus subtilis with the sequence WKSESLCTPGCVTGALQTCFLQTLTCNCKISK. It belongs to a family of ribosomally synthesized peptide antibiotics characterized by unusual lanthionine ring structures that provide stability and antimicrobial activity. Subtilin demonstrates potent antibiotic activity against various Gram-positive pathogens, including Staphylococcus aureus and Enterococcus faecalis, with efficacy similar to nisin. The peptide undergoes complex biosynthetic regulation through autoinduction via two-component systems, specifically the SpaRK system in B. subtilis. A critical structural feature is the N-terminal tryptophan residue, which is essential for autoinduction activity. Subtilin can undergo posttranslational succinylation at this tryptophan residue, which dramatically reduces its antimicrobial potency. Production is influenced by environmental factors, particularly glucose concentration and the transition state regulator AbrB. Current research focuses on understanding its biosynthetic mechanisms, optimizing production conditions, and developing it as a potential therapeutic antimicrobial agent. The peptide represents a promising natural antibiotic with specific activity against resistant Gram-positive bacteria.
Key Benefits
Overview
Subtilin is a class I lantibiotic (lanthionine-containing antibiotic peptide) produced by Bacillus subtilis with the sequence WKSESLCTPGCVTGALQTCFLQTLTCNCKISK. It belongs to a family of ribosomally synthesized peptide antibiotics characterized by unusual lanthionine ring structures that provide stability and antimicrobial activity. Subtilin demonstrates potent antibiotic activity against various Gram-positive pathogens, including Staphylococcus aureus and Enterococcus faecalis, with efficacy similar to nisin. The peptide undergoes complex biosynthetic regulation through autoinduction via two-component systems, specifically the SpaRK system in B. subtilis. A critical structural feature is the N-terminal tryptophan residue, which is essential for autoinduction activity. Subtilin can undergo posttranslational succinylation at this tryptophan residue, which dramatically reduces its antimicrobial potency. Production is influenced by environmental factors, particularly glucose concentration and the transition state regulator AbrB. Current research focuses on understanding its biosynthetic mechanisms, optimizing production conditions, and developing it as a potential therapeutic antimicrobial agent. The peptide represents a promising natural antibiotic with specific activity against resistant Gram-positive bacteria.
Potential Benefits
Mechanism of Action
Subtilin exerts its antimicrobial effects through the characteristic mechanism of lantibiotics, utilizing its lanthionine ring structures to disrupt bacterial cell membranes and interfere with cell wall synthesis in Gram-positive bacteria. The peptide's biosynthesis is regulated by a sophisticated autoinduction mechanism involving the two-component system SpaRK in Bacillus subtilis. The N-terminal tryptophan residue is crucial for this autoinduction process, as it specifically activates the histidine kinase SpaK, leading to upregulation of subtilin biosynthesis genes. This autoinduction is highly specific - subtilin cannot activate the nisin regulatory system NisRK due to structural differences, particularly the N-terminal tryptophan. The peptide undergoes posttranslational modifications including the formation of lanthionine bridges and potential succinylation of the N-terminal tryptophan. Succinylation occurs extracellularly or at the cellular membrane through enzymatic catalysis and dramatically reduces antimicrobial activity while preserving autoinduction capability, suggesting these functions operate through different molecular mechanisms. Environmental factors like glucose concentration influence both synthesis and succinylation patterns, with higher glucose levels promoting increased production and reduced succinylation rates.
Risks & Safety
Legal Status
TAT peptide is a cell-penetrating peptide (CPP) derived from the HIV-1 transactivator of transcription (TAT) protein, consisting of 11-13 amino acids with a high proportion of arginine and lysine residues. This peptide has emerged as a powerful molecular shuttle for drug delivery applications due to its unique ability to efficiently cross cellular membranes and deliver various biomolecules including proteins, nucleic acids, and small molecules into cells. TAT peptides work by interacting with lipid bilayers, disrupting membrane organization to facilitate internalization through both endocytic and direct translocation pathways. Recent research has demonstrated significant therapeutic potential, particularly in neurodegenerative diseases like Alzheimer's, where TAT-fusion peptides have shown ability to prevent receptor cleavage, restore synaptic function, and improve cognitive performance in animal models. The peptide's non-immunogenic and minimally toxic nature makes it an attractive tool for systemic drug administration. Current applications span from basic cellular research to advanced therapeutic strategies including cancer treatment, gene therapy, and vaccine development. While numerous preclinical studies show promising results, clinical translation faces challenges related to specificity, efficacy optimization, and delivery mechanisms that researchers continue to address through peptide modifications and enhanced delivery systems.
Key Benefits
Overview
TAT peptide is a cell-penetrating peptide (CPP) derived from the HIV-1 transactivator of transcription (TAT) protein, consisting of 11-13 amino acids with a high proportion of arginine and lysine residues. This peptide has emerged as a powerful molecular shuttle for drug delivery applications due to its unique ability to efficiently cross cellular membranes and deliver various biomolecules including proteins, nucleic acids, and small molecules into cells. TAT peptides work by interacting with lipid bilayers, disrupting membrane organization to facilitate internalization through both endocytic and direct translocation pathways. Recent research has demonstrated significant therapeutic potential, particularly in neurodegenerative diseases like Alzheimer's, where TAT-fusion peptides have shown ability to prevent receptor cleavage, restore synaptic function, and improve cognitive performance in animal models. The peptide's non-immunogenic and minimally toxic nature makes it an attractive tool for systemic drug administration. Current applications span from basic cellular research to advanced therapeutic strategies including cancer treatment, gene therapy, and vaccine development. While numerous preclinical studies show promising results, clinical translation faces challenges related to specificity, efficacy optimization, and delivery mechanisms that researchers continue to address through peptide modifications and enhanced delivery systems.
Potential Benefits
Mechanism of Action
TAT peptide functions as a cell-penetrating peptide through multiple membrane translocation mechanisms. Its cationic nature, due to high arginine and lysine content, enables favorable interactions with negatively charged cell membranes. The peptide disrupts lipid bilayer organization, enhancing membrane permeability and facilitating cellular uptake through both endocytic pathways (including macropinocytosis and receptor-mediated endocytosis) and direct membrane translocation. When fused to therapeutic proteins, TAT enables delivery across cellular barriers that would otherwise be impermeable. In Alzheimer's disease applications, TAT-TrkB fusion peptides specifically prevent amyloid β-triggered cleavage of TrkB-FL receptors, thereby preserving brain-derived neurotrophic factor (BDNF) signaling pathways essential for neuronal survival, differentiation, and synaptic transmission. The peptide can form both covalent and non-covalent complexes with cargo molecules, influencing stability and efficacy. TAT peptides also interact with scaffolding proteins like AKAP79, modulating ion channel activity such as TRPV4 sensitization. The mechanism involves binding to cellular membranes, followed by internalization through vesicular trafficking or direct cytoplasmic delivery, allowing therapeutic cargo to reach intracellular targets and exert biological effects.
Risks & Safety
Legal Status
TAT(49-57) is a cell-penetrating peptide (CPP) derived from the HIV-1 transactivator of transcription protein, with the sequence RKKRRQRRR. This short cationic peptide possesses the remarkable ability to traverse cellular membranes and reach intracellular targets, including the cell nucleus. As a protein transduction domain, TAT(49-57) has gained significant attention in biomedical research for its potential as a drug delivery vehicle. Current research demonstrates its versatility across multiple therapeutic applications, including antimicrobial therapy, cancer treatment, retinal disease management, and vaccine development. Studies show that when conjugated to other therapeutic molecules, TAT(49-57) can enhance their cellular uptake and biological activity. The peptide has been successfully used to deliver acidic FGF to retinal tissue, create antibacterial conjugates effective against both Gram-positive and Gram-negative bacteria, and develop targeted radiotherapy systems using gold nanoparticles. In vaccine applications, TAT(49-57) has shown promise in enhancing immune responses against HPV16-related cancers. The peptide's ability to facilitate intracellular delivery while maintaining the biological function of conjugated molecules makes it a valuable tool in targeted therapy development. Research continues to explore its potential in theranostic applications, combining diagnostic and therapeutic functions in single treatment systems.
Key Benefits
Overview
TAT(49-57) is a cell-penetrating peptide (CPP) derived from the HIV-1 transactivator of transcription protein, with the sequence RKKRRQRRR. This short cationic peptide possesses the remarkable ability to traverse cellular membranes and reach intracellular targets, including the cell nucleus. As a protein transduction domain, TAT(49-57) has gained significant attention in biomedical research for its potential as a drug delivery vehicle. Current research demonstrates its versatility across multiple therapeutic applications, including antimicrobial therapy, cancer treatment, retinal disease management, and vaccine development. Studies show that when conjugated to other therapeutic molecules, TAT(49-57) can enhance their cellular uptake and biological activity. The peptide has been successfully used to deliver acidic FGF to retinal tissue, create antibacterial conjugates effective against both Gram-positive and Gram-negative bacteria, and develop targeted radiotherapy systems using gold nanoparticles. In vaccine applications, TAT(49-57) has shown promise in enhancing immune responses against HPV16-related cancers. The peptide's ability to facilitate intracellular delivery while maintaining the biological function of conjugated molecules makes it a valuable tool in targeted therapy development. Research continues to explore its potential in theranostic applications, combining diagnostic and therapeutic functions in single treatment systems.
Potential Benefits
Mechanism of Action
TAT(49-57) functions as a cell-penetrating peptide through its highly cationic nature, containing multiple arginine and lysine residues that interact with negatively charged cell membrane components. The peptide's mechanism involves direct translocation across cellular membranes without requiring specific receptors, allowing it to reach intracellular compartments including the nucleus. When conjugated to therapeutic molecules, TAT(49-57) acts as a protein transduction domain that facilitates cellular uptake through membrane depolarization. In antimicrobial applications, TAT(49-57) conjugates depolarize bacterial cytoplasmic membranes, disrupting cellular integrity in both Gram-positive and Gram-negative bacteria. The peptide's ability to change interaction modes between conjugated molecules and cell membranes enables broader spectrum activity. In cancer therapy applications, TAT(49-57) delivers therapeutic agents directly to tumor cell nuclei, where radiolabeled conjugates can exert targeted cytotoxic effects through Auger electron emission. For vaccine applications, the peptide enhances antigen presentation and immune cell activation by facilitating intracellular delivery of antigenic peptides and adjuvants like poly(I:C), leading to improved dendritic cell maturation and T-cell responses. The peptide's mechanism preserves the biological activity of conjugated molecules while significantly enhancing their cellular penetration and therapeutic efficacy.
Risks & Safety
Legal Status
Uperin 7.1 is a naturally occurring antimicrobial peptide derived from the skin secretions of Australian frogs, specifically from the Uperoleia genus. With the amino acid sequence GWFDVVKHIASAV, this 13-residue peptide belongs to the family of host defense peptides that serve as part of the innate immune system. Uperin 7.1 exhibits broad-spectrum antimicrobial activity against various pathogens including bacteria, fungi, and potentially viruses. Like other antimicrobial peptides, it likely functions by disrupting microbial cell membranes through electrostatic interactions and membrane permeabilization. The peptide's compact structure and specific amino acid composition contribute to its antimicrobial efficacy while potentially minimizing toxicity to host cells. Current research on Uperin 7.1 is primarily focused on characterizing its antimicrobial spectrum, understanding its mechanism of action, and exploring potential therapeutic applications. As with many amphibian-derived antimicrobial peptides, Uperin 7.1 represents a promising candidate for development of novel antimicrobial agents, particularly in an era of increasing antibiotic resistance. However, research on this specific peptide remains limited, and further studies are needed to fully elucidate its therapeutic potential, safety profile, and clinical applications.
Key Benefits
Overview
Uperin 7.1 is a naturally occurring antimicrobial peptide derived from the skin secretions of Australian frogs, specifically from the Uperoleia genus. With the amino acid sequence GWFDVVKHIASAV, this 13-residue peptide belongs to the family of host defense peptides that serve as part of the innate immune system. Uperin 7.1 exhibits broad-spectrum antimicrobial activity against various pathogens including bacteria, fungi, and potentially viruses. Like other antimicrobial peptides, it likely functions by disrupting microbial cell membranes through electrostatic interactions and membrane permeabilization. The peptide's compact structure and specific amino acid composition contribute to its antimicrobial efficacy while potentially minimizing toxicity to host cells. Current research on Uperin 7.1 is primarily focused on characterizing its antimicrobial spectrum, understanding its mechanism of action, and exploring potential therapeutic applications. As with many amphibian-derived antimicrobial peptides, Uperin 7.1 represents a promising candidate for development of novel antimicrobial agents, particularly in an era of increasing antibiotic resistance. However, research on this specific peptide remains limited, and further studies are needed to fully elucidate its therapeutic potential, safety profile, and clinical applications.
Potential Benefits
Mechanism of Action
Uperin 7.1 likely functions through the typical mechanism of antimicrobial peptides, involving electrostatic attraction to negatively charged microbial cell membranes followed by membrane disruption. The peptide's cationic residues (lysine and histidine) facilitate initial binding to anionic components of bacterial cell walls and membranes, such as lipopolysaccharides in gram-negative bacteria and teichoic acids in gram-positive bacteria. Upon membrane contact, the peptide likely adopts an amphipathic structure that allows insertion into the lipid bilayer. This insertion can lead to membrane permeabilization through various models including barrel-stave, toroidal pore, or carpet mechanisms. The resulting membrane disruption causes leakage of cellular contents, loss of membrane potential, and ultimately cell death. The peptide may also have intracellular targets, potentially interfering with DNA synthesis, protein synthesis, or enzymatic processes once it crosses the compromised membrane. The specific amino acid sequence of Uperin 7.1, particularly the presence of tryptophan and phenylalanine residues, may enhance membrane binding affinity and insertion efficiency. The relatively short length and specific charge distribution of this peptide likely contribute to its selectivity for microbial membranes over mammalian cell membranes.
Risks & Safety
Legal Status
XPF (ERCC4) is a structural endonuclease that forms a heterodimer with ERCC1, creating the ERCC1-XPF nuclease complex critical for DNA repair and genomic stability. This enzyme specifically nicks DNA at junctions between double-stranded and single-stranded DNA when the single strand is oriented 5' to 3' away from the junction. XPF plays essential roles in multiple DNA repair pathways including nucleotide excision repair (NER), base excision repair (BER), interstrand crosslink repair, double-strand break repair, and telomere length regulation. The protein is particularly important in the newly discovered 5'-Gap pathway of long-patch base excision repair. XPF interacts with various proteins including XPA, RPA, SLX4, TRF2, TOP2B, and CTCF to perform its diverse functions. Deficiency in XPF is associated with severe genetic disorders including xeroderma pigmentosum, Cockayne syndrome, Fanconi anemia, and XFE progeria. Current research focuses on its role in transcription-associated DNA damage, R-loop processing, and its potential as a therapeutic target for cancer treatment through DNA repair pathway modulation.
Key Benefits
Overview
XPF (ERCC4) is a structural endonuclease that forms a heterodimer with ERCC1, creating the ERCC1-XPF nuclease complex critical for DNA repair and genomic stability. This enzyme specifically nicks DNA at junctions between double-stranded and single-stranded DNA when the single strand is oriented 5' to 3' away from the junction. XPF plays essential roles in multiple DNA repair pathways including nucleotide excision repair (NER), base excision repair (BER), interstrand crosslink repair, double-strand break repair, and telomere length regulation. The protein is particularly important in the newly discovered 5'-Gap pathway of long-patch base excision repair. XPF interacts with various proteins including XPA, RPA, SLX4, TRF2, TOP2B, and CTCF to perform its diverse functions. Deficiency in XPF is associated with severe genetic disorders including xeroderma pigmentosum, Cockayne syndrome, Fanconi anemia, and XFE progeria. Current research focuses on its role in transcription-associated DNA damage, R-loop processing, and its potential as a therapeutic target for cancer treatment through DNA repair pathway modulation.
Potential Benefits
Mechanism of Action
XPF functions as a structure-specific endonuclease that cleaves DNA at specific junction points, particularly where single-stranded DNA meets double-stranded DNA. The ERCC1-XPF complex recognizes and processes various DNA intermediates by cleaving 3' tails in preparation for further repair processing. In nucleotide excision repair, XPF makes the 5' incision to remove DNA lesions. During base excision repair, it participates in the 5'-Gap pathway for long-patch repair. XPF interacts with topoisomerase II beta (TOP2B) to process R-loops on actively transcribed genes, leading to controlled double-strand break formation and DNA damage response activation. The protein also coordinates with CTCF and cohesin complexes for R-loop-dependent DNA looping during transcription activation. XPF's nuclease activity is regulated through protein-protein interactions and post-translational modifications including SUMOylation, which affects its localization and nuclear condensation state during DNA damage responses.
Risks & Safety
Legal Status
α-Melanocyte-Stimulating Hormone (MSH), amide is a naturally occurring peptide hormone with the sequence SYSMEHFRWGKPV. This peptide is derived from the larger pro-opiomelanocortin (POMC) precursor and belongs to the melanocortin family of peptides. α-MSH primarily functions through activation of melanocortin receptors, particularly MC1R and MC4R, which are distributed throughout various tissues including skin, brain, and immune cells. The peptide plays crucial roles in pigmentation regulation, appetite control, and inflammatory responses. α-MSH has demonstrated significant anti-inflammatory properties and neuroprotective effects in various research models. Its ability to modulate immune responses and promote tissue repair has made it a subject of interest for therapeutic applications. The peptide exhibits potent anti-inflammatory activity through inhibition of nuclear factor-κB (NF-κB) signaling pathways and reduction of pro-inflammatory cytokine production. Current research focuses on its potential applications in treating inflammatory conditions, neurodegenerative diseases, and metabolic disorders. While naturally produced in the body, synthetic versions are being investigated for therapeutic use, though clinical applications remain largely experimental.
Key Benefits
Overview
α-Melanocyte-Stimulating Hormone (MSH), amide is a naturally occurring peptide hormone with the sequence SYSMEHFRWGKPV. This peptide is derived from the larger pro-opiomelanocortin (POMC) precursor and belongs to the melanocortin family of peptides. α-MSH primarily functions through activation of melanocortin receptors, particularly MC1R and MC4R, which are distributed throughout various tissues including skin, brain, and immune cells. The peptide plays crucial roles in pigmentation regulation, appetite control, and inflammatory responses. α-MSH has demonstrated significant anti-inflammatory properties and neuroprotective effects in various research models. Its ability to modulate immune responses and promote tissue repair has made it a subject of interest for therapeutic applications. The peptide exhibits potent anti-inflammatory activity through inhibition of nuclear factor-κB (NF-κB) signaling pathways and reduction of pro-inflammatory cytokine production. Current research focuses on its potential applications in treating inflammatory conditions, neurodegenerative diseases, and metabolic disorders. While naturally produced in the body, synthetic versions are being investigated for therapeutic use, though clinical applications remain largely experimental.
Potential Benefits
Mechanism of Action
α-MSH exerts its biological effects primarily through binding to melanocortin receptors (MCRs), particularly MC1R, MC3R, and MC4R. Upon receptor binding, the peptide activates adenylyl cyclase, leading to increased cyclic adenosine monophosphate (cAMP) levels and subsequent activation of protein kinase A (PKA). This signaling cascade results in phosphorylation of cAMP response element-binding protein (CREB), which regulates transcription of various genes involved in melanogenesis, metabolism, and inflammation. The anti-inflammatory effects are mediated through inhibition of NF-κB activation, reduction of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and other pro-inflammatory mediators. α-MSH also activates anti-inflammatory pathways by inducing IL-10 production and promoting M2 macrophage polarization. In the central nervous system, the peptide modulates hypothalamic circuits controlling appetite and energy expenditure through MC4R activation. The neuroprotective effects involve activation of survival signaling pathways, including PI3K/Akt and ERK1/2, while inhibiting apoptotic cascades and oxidative stress responses.
Risks & Safety
Legal Status
β-Amyloid (1-40) is a 40-amino acid peptide fragment that plays a central role in Alzheimer's disease pathology. This peptide is the most abundant variant of amyloid-beta found in senile plaques, which are characteristic hallmarks of neurodegeneration. Recent research has revealed unexpected properties of β-Amyloid (1-40), including catalytic activity on acetylcholine hydrolysis when formed into fibrils, suggesting potential biocatalytic functions beyond its pathological role. The peptide demonstrates significant membrane-active properties, interacting with lipid membranes in ways that may modulate cellular function. Studies have shown that β-Amyloid (1-40) injections into brain regions like the medial septum cause selective neuronal degeneration, particularly affecting cholinergic and glutamatergic neurons while sparing GABAergic neurons. Interestingly, elevated cerebrospinal fluid concentrations of β-Amyloid (1-40) have been observed in pregnancy complications such as HELLP syndrome, suggesting broader physiological roles. Current research focuses on understanding its aggregation mechanisms, membrane interactions, and potential as a biomarker for various neurological and systemic conditions.
Key Benefits
Overview
β-Amyloid (1-40) is a 40-amino acid peptide fragment that plays a central role in Alzheimer's disease pathology. This peptide is the most abundant variant of amyloid-beta found in senile plaques, which are characteristic hallmarks of neurodegeneration. Recent research has revealed unexpected properties of β-Amyloid (1-40), including catalytic activity on acetylcholine hydrolysis when formed into fibrils, suggesting potential biocatalytic functions beyond its pathological role. The peptide demonstrates significant membrane-active properties, interacting with lipid membranes in ways that may modulate cellular function. Studies have shown that β-Amyloid (1-40) injections into brain regions like the medial septum cause selective neuronal degeneration, particularly affecting cholinergic and glutamatergic neurons while sparing GABAergic neurons. Interestingly, elevated cerebrospinal fluid concentrations of β-Amyloid (1-40) have been observed in pregnancy complications such as HELLP syndrome, suggesting broader physiological roles. Current research focuses on understanding its aggregation mechanisms, membrane interactions, and potential as a biomarker for various neurological and systemic conditions.
Potential Benefits
Mechanism of Action
β-Amyloid (1-40) exerts its effects through multiple molecular mechanisms. When aggregated into fibrils, it exhibits catalytic activity on acetylcholine hydrolysis, functioning as a biocatalyst that may contribute to cholinergic dysfunction in neurological disorders. The peptide demonstrates strong membrane-active properties, interacting directly with lipid membranes and causing structural changes that can be detected through colorimetric assays. Upon injection into neural tissue, β-Amyloid (1-40) selectively targets cholinergic and glutamatergic neurons, causing approximately 50-57% neuronal loss while sparing GABAergic neurons. This selective toxicity disrupts normal neural circuitry, particularly affecting septo-hippocampal pathways crucial for memory formation. The peptide alters firing rates of septal neurons during theta rhythm activities and significantly reduces hippocampal theta rhythm power by approximately 49%. It also markedly reduces the proportion of slow-firing septal neurons correlated to hippocampal theta rhythm by 96%, contributing to memory dysfunction characteristic of Alzheimer's disease.
Risks & Safety
Legal Status
β-Amyloid (1-42), human is a 42-amino acid peptide fragment that represents one of the most studied pathological proteins in neuroscience and Alzheimer's disease research. This peptide is derived from the amyloid precursor protein (APP) through sequential cleavage by β-secretase and γ-secretase enzymes. The Aβ42 variant is particularly significant because it is more prone to aggregation and fibril formation compared to shorter variants like Aβ40. In healthy brains, amyloid-beta peptides are produced at low levels and cleared efficiently, but in Alzheimer's disease, Aβ42 accumulates and forms characteristic amyloid plaques that are hallmarks of the condition. The peptide's tendency to misfold and aggregate into oligomers, protofibrils, and mature fibrils makes it a critical target for understanding neurodegeneration. Current research focuses on its role in synaptic dysfunction, neuroinflammation, and cognitive decline. While primarily studied as a pathological agent, research also investigates its potential physiological functions and therapeutic interventions targeting its production, aggregation, or clearance.
Key Benefits
Overview
β-Amyloid (1-42), human is a 42-amino acid peptide fragment that represents one of the most studied pathological proteins in neuroscience and Alzheimer's disease research. This peptide is derived from the amyloid precursor protein (APP) through sequential cleavage by β-secretase and γ-secretase enzymes. The Aβ42 variant is particularly significant because it is more prone to aggregation and fibril formation compared to shorter variants like Aβ40. In healthy brains, amyloid-beta peptides are produced at low levels and cleared efficiently, but in Alzheimer's disease, Aβ42 accumulates and forms characteristic amyloid plaques that are hallmarks of the condition. The peptide's tendency to misfold and aggregate into oligomers, protofibrils, and mature fibrils makes it a critical target for understanding neurodegeneration. Current research focuses on its role in synaptic dysfunction, neuroinflammation, and cognitive decline. While primarily studied as a pathological agent, research also investigates its potential physiological functions and therapeutic interventions targeting its production, aggregation, or clearance.
Potential Benefits
Mechanism of Action
β-Amyloid (1-42) exerts its effects through multiple pathological mechanisms. The peptide undergoes conformational changes from its initial soluble form to β-sheet-rich structures that aggregate into oligomers and fibrils. These aggregated forms interact with neuronal membranes, disrupting membrane integrity and calcium homeostasis. The peptide can form ion channels or pores in membranes, leading to uncontrolled calcium influx and cellular dysfunction. Aβ42 oligomers bind to synaptic receptors including NMDA and AMPA receptors, interfering with synaptic transmission and plasticity. The peptide also activates microglial cells and astrocytes, triggering neuroinflammatory responses through toll-like receptors and complement pathways. Additionally, Aβ42 promotes oxidative stress by generating reactive oxygen species and interfering with mitochondrial function. It can also interact with tau protein, promoting tau hyperphosphorylation and neurofibrillary tangle formation, creating a cascade of neurodegenerative processes.
Risks & Safety
Legal Status
No peptides match your search. Try different keywords or clear the filter.